US20230310628A1 - Multi-Targeted Multi-Valent Ligand Drug Particles for the Treatment and Prevention of Diseases and Conditions - Google Patents
Multi-Targeted Multi-Valent Ligand Drug Particles for the Treatment and Prevention of Diseases and Conditions Download PDFInfo
- Publication number
- US20230310628A1 US20230310628A1 US18/172,843 US202318172843A US2023310628A1 US 20230310628 A1 US20230310628 A1 US 20230310628A1 US 202318172843 A US202318172843 A US 202318172843A US 2023310628 A1 US2023310628 A1 US 2023310628A1
- Authority
- US
- United States
- Prior art keywords
- valency
- ligand
- receptors
- order
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 462
- 239000002245 particle Substances 0.000 title claims abstract description 252
- 239000003814 drug Substances 0.000 title claims abstract description 161
- 229940079593 drug Drugs 0.000 title claims abstract description 156
- 238000011282 treatment Methods 0.000 title description 2
- 230000006806 disease prevention Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 730
- 108010001857 Cell Surface Receptors Proteins 0.000 claims abstract description 11
- 102000006240 membrane receptors Human genes 0.000 claims abstract 4
- 102000005962 receptors Human genes 0.000 claims description 516
- 230000027455 binding Effects 0.000 claims description 422
- 238000009739 binding Methods 0.000 claims description 422
- 238000000338 in vitro Methods 0.000 claims description 171
- 230000000996 additive effect Effects 0.000 claims description 99
- 239000000654 additive Substances 0.000 claims description 97
- 150000002632 lipids Chemical class 0.000 claims description 90
- 230000002195 synergetic effect Effects 0.000 claims description 79
- 239000002344 surface layer Substances 0.000 claims description 59
- 238000010494 dissociation reaction Methods 0.000 claims description 39
- 230000005593 dissociations Effects 0.000 claims description 39
- 239000012634 fragment Substances 0.000 claims description 36
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 239000000427 antigen Substances 0.000 claims description 29
- 102000036639 antigens Human genes 0.000 claims description 29
- 108091007433 antigens Proteins 0.000 claims description 29
- 239000002202 Polyethylene glycol Substances 0.000 claims description 23
- 229920001223 polyethylene glycol Polymers 0.000 claims description 23
- 230000003993 interaction Effects 0.000 claims description 12
- 239000000232 Lipid Bilayer Substances 0.000 claims description 10
- 230000002209 hydrophobic effect Effects 0.000 claims description 8
- 239000013554 lipid monolayer Substances 0.000 claims description 7
- 102000016979 Other receptors Human genes 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 239000010410 layer Substances 0.000 claims description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 2
- 125000000129 anionic group Chemical group 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 36
- 230000008685 targeting Effects 0.000 abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 108020003175 receptors Proteins 0.000 description 368
- 239000002502 liposome Substances 0.000 description 184
- 239000002105 nanoparticle Substances 0.000 description 72
- 230000014509 gene expression Effects 0.000 description 60
- -1 small molecule compound Chemical class 0.000 description 54
- 102000001301 EGF receptor Human genes 0.000 description 44
- 108060006698 EGF receptor Proteins 0.000 description 43
- 239000000693 micelle Substances 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 30
- 206010028980 Neoplasm Diseases 0.000 description 26
- 229960000575 trastuzumab Drugs 0.000 description 26
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 24
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 24
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 23
- 101800003838 Epidermal growth factor Proteins 0.000 description 22
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 22
- 229940116977 epidermal growth factor Drugs 0.000 description 22
- 229960005395 cetuximab Drugs 0.000 description 21
- 150000003904 phospholipids Chemical class 0.000 description 21
- 230000035508 accumulation Effects 0.000 description 20
- 238000009825 accumulation Methods 0.000 description 20
- 238000012546 transfer Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 16
- 102000012803 ephrin Human genes 0.000 description 16
- 108060002566 ephrin Proteins 0.000 description 16
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 229960004641 rituximab Drugs 0.000 description 14
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 13
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 12
- 241000701806 Human papillomavirus Species 0.000 description 12
- 239000000562 conjugate Substances 0.000 description 12
- 230000021615 conjugation Effects 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 229960003301 nivolumab Drugs 0.000 description 12
- 229960001972 panitumumab Drugs 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 11
- 229960000455 brentuximab vedotin Drugs 0.000 description 11
- 238000004132 cross linking Methods 0.000 description 11
- 229960002450 ofatumumab Drugs 0.000 description 11
- 229960002621 pembrolizumab Drugs 0.000 description 11
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 10
- 229960000397 bevacizumab Drugs 0.000 description 10
- 229960001251 denosumab Drugs 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 229960003347 obinutuzumab Drugs 0.000 description 10
- 229960001592 paclitaxel Drugs 0.000 description 10
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 9
- 229930012538 Paclitaxel Natural products 0.000 description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 9
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 9
- 229960000548 alemtuzumab Drugs 0.000 description 9
- 229950002916 avelumab Drugs 0.000 description 9
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 229960002204 daratumumab Drugs 0.000 description 9
- 229950009791 durvalumab Drugs 0.000 description 9
- 210000001163 endosome Anatomy 0.000 description 9
- 229960005386 ipilimumab Drugs 0.000 description 9
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 9
- 229960000485 methotrexate Drugs 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 229960000513 necitumumab Drugs 0.000 description 9
- 229950008516 olaratumab Drugs 0.000 description 9
- 229960002087 pertuzumab Drugs 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 229960002633 ramucirumab Drugs 0.000 description 9
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 9
- 108010000817 Leuprolide Proteins 0.000 description 8
- 229960003852 atezolizumab Drugs 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 229960003008 blinatumomab Drugs 0.000 description 8
- 230000004700 cellular uptake Effects 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 229960004497 dinutuximab Drugs 0.000 description 8
- 229960004137 elotuzumab Drugs 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 229950005674 modotuximab Drugs 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 229960003323 siltuximab Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 229960003989 tocilizumab Drugs 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 102000000844 Cell Surface Receptors Human genes 0.000 description 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 7
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 7
- 229960000446 abciximab Drugs 0.000 description 7
- 229960002964 adalimumab Drugs 0.000 description 7
- 229960004669 basiliximab Drugs 0.000 description 7
- 229960003270 belimumab Drugs 0.000 description 7
- 229960001838 canakinumab Drugs 0.000 description 7
- 229960005243 carmustine Drugs 0.000 description 7
- 229960003115 certolizumab pegol Drugs 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229960004630 chlorambucil Drugs 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 229960002806 daclizumab Drugs 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 229960004679 doxorubicin Drugs 0.000 description 7
- 238000012377 drug delivery Methods 0.000 description 7
- 229960002224 eculizumab Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229960001743 golimumab Drugs 0.000 description 7
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 7
- 229960000598 infliximab Drugs 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 229960005027 natalizumab Drugs 0.000 description 7
- 229960000470 omalizumab Drugs 0.000 description 7
- 229960000402 palivizumab Drugs 0.000 description 7
- 229960003876 ranibizumab Drugs 0.000 description 7
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 6
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 6
- 108010008038 Synthetic Vaccines Proteins 0.000 description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
- 230000003042 antagnostic effect Effects 0.000 description 6
- 229950000321 benralizumab Drugs 0.000 description 6
- 229950008086 bezlotoxumab Drugs 0.000 description 6
- 229960003735 brodalumab Drugs 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 229950003468 dupilumab Drugs 0.000 description 6
- 229950006925 emicizumab Drugs 0.000 description 6
- 230000012202 endocytosis Effects 0.000 description 6
- 229960002027 evolocumab Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229960002308 idarucizumab Drugs 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 229960005435 ixekizumab Drugs 0.000 description 6
- 229960005108 mepolizumab Drugs 0.000 description 6
- 229960003419 obiltoxaximab Drugs 0.000 description 6
- 229950005751 ocrelizumab Drugs 0.000 description 6
- 229960004910 raxibacumab Drugs 0.000 description 6
- 229960003254 reslizumab Drugs 0.000 description 6
- 229950006348 sarilumab Drugs 0.000 description 6
- 229960004540 secukinumab Drugs 0.000 description 6
- 229960001612 trastuzumab emtansine Drugs 0.000 description 6
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 6
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 5
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 5
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 5
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 5
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 5
- 108010029961 Filgrastim Proteins 0.000 description 5
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108010025020 Nerve Growth Factor Proteins 0.000 description 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 5
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 5
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin-C1 Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 5
- 108700025316 aldesleukin Proteins 0.000 description 5
- HFCFMRYTXDINDK-WNQIDUERSA-N cabozantinib malate Chemical compound OC(=O)[C@@H](O)CC(O)=O.C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 HFCFMRYTXDINDK-WNQIDUERSA-N 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 5
- BIFMNMPSIYHKDN-FJXQXJEOSA-N dexrazoxane hydrochloride Chemical compound [H+].[Cl-].C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BIFMNMPSIYHKDN-FJXQXJEOSA-N 0.000 description 5
- 229940063519 doxorubicin hydrochloride liposome Drugs 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 5
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 5
- 229960004338 leuprorelin Drugs 0.000 description 5
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 5
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 5
- 229950010203 nimotuzumab Drugs 0.000 description 5
- 229960003359 palonosetron hydrochloride Drugs 0.000 description 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 5
- 150000003905 phosphatidylinositols Chemical class 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 description 5
- 238000004064 recycling Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 229960003824 ustekinumab Drugs 0.000 description 5
- 229960004914 vedolizumab Drugs 0.000 description 5
- 229950008250 zalutumumab Drugs 0.000 description 5
- WKJDWDLHIOUPPL-JSOSNVBQSA-N (2s)-2-amino-3-({[(2r)-2,3-bis(tetradecanoyloxy)propoxy](hydroxy)phosphoryl}oxy)propanoic acid Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCC WKJDWDLHIOUPPL-JSOSNVBQSA-N 0.000 description 4
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 4
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 4
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 4
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 description 4
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 4
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 4
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 4
- NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 4
- CJLHTKGWEUGORV-UHFFFAOYSA-N Artemin Chemical compound C1CC2(C)C(O)CCC(=C)C2(O)C2C1C(C)C(=O)O2 CJLHTKGWEUGORV-UHFFFAOYSA-N 0.000 description 4
- 241000193738 Bacillus anthracis Species 0.000 description 4
- KLFKZIQAIPDJCW-HTIIIDOHSA-N Dipalmitoylphosphatidylserine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-HTIIIDOHSA-N 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 4
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 4
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 4
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 description 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 4
- 108010056852 Myostatin Proteins 0.000 description 4
- RWKUXQNLWDTSLO-GWQJGLRPSA-N N-hexadecanoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC RWKUXQNLWDTSLO-GWQJGLRPSA-N 0.000 description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 description 4
- 102000014413 Neuregulin Human genes 0.000 description 4
- 108050003475 Neuregulin Proteins 0.000 description 4
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 description 4
- 108010067035 Pancrelipase Proteins 0.000 description 4
- 102100035194 Placenta growth factor Human genes 0.000 description 4
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 4
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 4
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 4
- GIOPVVHPRTWMHO-UHFFFAOYSA-N [2-aminoethoxy(octadecanoyloxy)phosphoryl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OP(=O)(OCCN)OC(=O)CCCCCCCCCCCCCCCCC GIOPVVHPRTWMHO-UHFFFAOYSA-N 0.000 description 4
- 229950009084 adecatumumab Drugs 0.000 description 4
- 229960005310 aldesleukin Drugs 0.000 description 4
- 229960004539 alirocumab Drugs 0.000 description 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 229950010876 aprutumab Drugs 0.000 description 4
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 4
- 229950009566 bemarituzumab Drugs 0.000 description 4
- 229950000025 brolucizumab Drugs 0.000 description 4
- 229950001178 capromab Drugs 0.000 description 4
- 229960000419 catumaxomab Drugs 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229950006647 cixutumumab Drugs 0.000 description 4
- 229960000928 clofarabine Drugs 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 229940094488 cytarabine liposome Drugs 0.000 description 4
- 229960002482 dalotuzumab Drugs 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229950002756 depatuxizumab Drugs 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 4
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 4
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 4
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 4
- 229940115080 doxil Drugs 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 229950006432 duligotuzumab Drugs 0.000 description 4
- 229960001776 edrecolomab Drugs 0.000 description 4
- 229950002519 elgemtumab Drugs 0.000 description 4
- 229950004255 emibetuzumab Drugs 0.000 description 4
- 229950008579 ertumaxomab Drugs 0.000 description 4
- 229940116862 faricimab Drugs 0.000 description 4
- 229940126612 fibatuzumab Drugs 0.000 description 4
- 229950008085 figitumumab Drugs 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 235000019152 folic acid Nutrition 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- 229950002140 futuximab Drugs 0.000 description 4
- 229950004896 ganitumab Drugs 0.000 description 4
- 229960000578 gemtuzumab Drugs 0.000 description 4
- 150000002327 glycerophospholipids Chemical class 0.000 description 4
- 229950010864 guselkumab Drugs 0.000 description 4
- 102000045108 human EGFR Human genes 0.000 description 4
- 229950006359 icrucumab Drugs 0.000 description 4
- 229950007275 ifabotuzumab Drugs 0.000 description 4
- 229960001101 ifosfamide Drugs 0.000 description 4
- 229950005646 imgatuzumab Drugs 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 4
- 229950009645 istiratumab Drugs 0.000 description 4
- 229950001813 laprituximab Drugs 0.000 description 4
- 230000007775 late Effects 0.000 description 4
- 229940059391 losatuxizumab Drugs 0.000 description 4
- 229950010079 lumretuzumab Drugs 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 102000049853 macrophage stimulating protein Human genes 0.000 description 4
- 108010053292 macrophage stimulating protein Proteins 0.000 description 4
- 229950003135 margetuximab Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229960004857 mitomycin Drugs 0.000 description 4
- DDBRXOJCLVGHLX-UHFFFAOYSA-N n,n-dimethylmethanamine;propane Chemical compound CCC.CN(C)C DDBRXOJCLVGHLX-UHFFFAOYSA-N 0.000 description 4
- OLDRWYVIKMSFFB-SSPJITILSA-N palonosetron hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 OLDRWYVIKMSFFB-SSPJITILSA-N 0.000 description 4
- 229950010966 patritumab Drugs 0.000 description 4
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229950005978 rinucumab Drugs 0.000 description 4
- 229950001808 robatumumab Drugs 0.000 description 4
- 229950008834 seribantumab Drugs 0.000 description 4
- 229950011267 solitomab Drugs 0.000 description 4
- 230000008866 synergistic binding Effects 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 229950009873 telisotuzumab Drugs 0.000 description 4
- 229960004964 temozolomide Drugs 0.000 description 4
- 229950010259 teprotumumab Drugs 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 229940060249 timigutuzumab Drugs 0.000 description 4
- 229940060960 tomuzotuximab Drugs 0.000 description 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 4
- 229940061162 varisacumab Drugs 0.000 description 4
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 4
- 229950008915 xentuzumab Drugs 0.000 description 4
- 229950007155 zenocutuzumab Drugs 0.000 description 4
- RWRDJVNMSZYMDV-SIUYXFDKSA-L (223)RaCl2 Chemical compound Cl[223Ra]Cl RWRDJVNMSZYMDV-SIUYXFDKSA-L 0.000 description 3
- IFGIYSGOEZJNBE-NQMNLMSRSA-N (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one;bromide Chemical compound [Br-].C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 IFGIYSGOEZJNBE-NQMNLMSRSA-N 0.000 description 3
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 3
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 3
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 3
- VXZCUHNJXSIJIM-MEBGWEOYSA-N (z)-but-2-enedioic acid;(e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound OC(=O)\C=C/C(O)=O.C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 VXZCUHNJXSIJIM-MEBGWEOYSA-N 0.000 description 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 3
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 3
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 3
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 3
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 description 3
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 3
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 3
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 3
- MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical compound Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 description 3
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 3
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 108010069236 Goserelin Proteins 0.000 description 3
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 3
- 101710154606 Hemagglutinin Proteins 0.000 description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 3
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 3
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 3
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 3
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 3
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 3
- 102100025390 Integrin beta-2 Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108050003558 Interleukin-17 Proteins 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 3
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 3
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 3
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 3
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 3
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 3
- 102100034256 Mucin-1 Human genes 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- 108090000772 Neuropilin-1 Proteins 0.000 description 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
- 101710176177 Protein A56 Proteins 0.000 description 3
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 3
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 3
- OUUYBRCCFUEMLH-YDALLXLXSA-N [(1s)-2-[4-[bis(2-chloroethyl)amino]phenyl]-1-carboxyethyl]azanium;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 OUUYBRCCFUEMLH-YDALLXLXSA-N 0.000 description 3
- 229950001573 abemaciclib Drugs 0.000 description 3
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 108010081667 aflibercept Proteins 0.000 description 3
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 3
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 3
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 3
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 description 3
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 3
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 3
- 229960002756 azacitidine Drugs 0.000 description 3
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229940031416 bivalent vaccine Drugs 0.000 description 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 3
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 3
- 229950004272 brigatinib Drugs 0.000 description 3
- 229960002092 busulfan Drugs 0.000 description 3
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 3
- 229960002865 cabozantinib s-malate Drugs 0.000 description 3
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960002436 cladribine Drugs 0.000 description 3
- 230000006395 clathrin-mediated endocytosis Effects 0.000 description 3
- 229960002271 cobimetinib Drugs 0.000 description 3
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 3
- STGQPVQAAFJJFX-UHFFFAOYSA-N copanlisib dihydrochloride Chemical compound Cl.Cl.C1=CC=2C3=NCCN3C(NC(=O)C=3C=NC(N)=NC=3)=NC=2C(OC)=C1OCCCN1CCOCC1 STGQPVQAAFJJFX-UHFFFAOYSA-N 0.000 description 3
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 3
- 229960000684 cytarabine Drugs 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 108010017271 denileukin diftitox Proteins 0.000 description 3
- 229960004102 dexrazoxane hydrochloride Drugs 0.000 description 3
- GFZPJHFJZGRWMQ-UHFFFAOYSA-M diOC18(3) dye Chemical compound [O-]Cl(=O)(=O)=O.O1C2=CC=CC=C2[N+](CCCCCCCCCCCCCCCCCC)=C1C=CC=C1N(CCCCCCCCCCCCCCCCCC)C2=CC=CC=C2O1 GFZPJHFJZGRWMQ-UHFFFAOYSA-M 0.000 description 3
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 3
- UFNVPOGXISZXJD-JBQZKEIOSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-JBQZKEIOSA-N 0.000 description 3
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 3
- 229960000752 etoposide phosphate Drugs 0.000 description 3
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 3
- 229960004177 filgrastim Drugs 0.000 description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 3
- 229960005304 fludarabine phosphate Drugs 0.000 description 3
- 238000005558 fluorometry Methods 0.000 description 3
- 229940014144 folate Drugs 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
- 108010049491 glucarpidase Proteins 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229960001507 ibrutinib Drugs 0.000 description 3
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 3
- IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 description 3
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 3
- FABUFPQFXZVHFB-PVYNADRNSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-PVYNADRNSA-N 0.000 description 3
- MBOMYENWWXQSNW-AWEZNQCLSA-N ixazomib citrate Chemical compound N([C@@H](CC(C)C)B1OC(CC(O)=O)(CC(O)=O)C(=O)O1)C(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MBOMYENWWXQSNW-AWEZNQCLSA-N 0.000 description 3
- 108010021336 lanreotide Proteins 0.000 description 3
- 150000002605 large molecules Chemical class 0.000 description 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 3
- HWLFIUUAYLEFCT-UHFFFAOYSA-N lenvatinib mesylate Chemical compound CS(O)(=O)=O.C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 HWLFIUUAYLEFCT-UHFFFAOYSA-N 0.000 description 3
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 3
- 229940087857 lupron Drugs 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 3
- 229960002514 melphalan hydrochloride Drugs 0.000 description 3
- 229960001428 mercaptopurine Drugs 0.000 description 3
- ORZHZQZYWXEDDL-UHFFFAOYSA-N methanesulfonic acid;2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol Chemical compound CS(O)(=O)=O.N=1C(C=2N=C(C=CC=2)C(F)(F)F)=NC(NCC(C)(O)C)=NC=1NC1=CC=NC(C(F)(F)F)=C1 ORZHZQZYWXEDDL-UHFFFAOYSA-N 0.000 description 3
- 229950010895 midostaurin Drugs 0.000 description 3
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 3
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 3
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 3
- 229950008835 neratinib Drugs 0.000 description 3
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 3
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 3
- 229950011068 niraparib Drugs 0.000 description 3
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 3
- 229940030960 nonavalent vaccine Drugs 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 description 3
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 3
- 229960003278 osimertinib Drugs 0.000 description 3
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 3
- 229960001756 oxaliplatin Drugs 0.000 description 3
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 3
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 3
- 229960005184 panobinostat Drugs 0.000 description 3
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 description 3
- MQHIQUBXFFAOMK-UHFFFAOYSA-N pazopanib hydrochloride Chemical compound Cl.C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 MQHIQUBXFFAOMK-UHFFFAOYSA-N 0.000 description 3
- 108010001564 pegaspargase Proteins 0.000 description 3
- 108010044644 pegfilgrastim Proteins 0.000 description 3
- 229960003931 peginterferon alfa-2b Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 3
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 3
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 3
- BWTNNZPNKQIADY-UHFFFAOYSA-N ponatinib hydrochloride Chemical compound Cl.C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 BWTNNZPNKQIADY-UHFFFAOYSA-N 0.000 description 3
- OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 description 3
- 229960002119 raloxifene hydrochloride Drugs 0.000 description 3
- 108010084837 rasburicase Proteins 0.000 description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 3
- 229950003687 ribociclib Drugs 0.000 description 3
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 3
- 108010091666 romidepsin Proteins 0.000 description 3
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 3
- 108010017584 romiplostim Proteins 0.000 description 3
- 229950004707 rucaparib Drugs 0.000 description 3
- INBJJAFXHQQSRW-STOWLHSFSA-N rucaparib camsylate Chemical compound CC1(C)[C@@H]2CC[C@@]1(CS(O)(=O)=O)C(=O)C2.CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23 INBJJAFXHQQSRW-STOWLHSFSA-N 0.000 description 3
- JFMWPOCYMYGEDM-XFULWGLBSA-N ruxolitinib phosphate Chemical compound OP(O)(O)=O.C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 JFMWPOCYMYGEDM-XFULWGLBSA-N 0.000 description 3
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 3
- VZZJRYRQSPEMTK-CALCHBBNSA-N sonidegib Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(N=C1)=CC=C1NC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=C1C VZZJRYRQSPEMTK-CALCHBBNSA-N 0.000 description 3
- IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 229940031351 tetravalent vaccine Drugs 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 108010078373 tisagenlecleucel Proteins 0.000 description 3
- 229960005267 tositumomab Drugs 0.000 description 3
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 3
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 3
- AUFUWRKPQLGTGF-FMKGYKFTSA-N uridine triacetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C(=O)NC(=O)C=C1 AUFUWRKPQLGTGF-FMKGYKFTSA-N 0.000 description 3
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 3
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 3
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 3
- 229960001183 venetoclax Drugs 0.000 description 3
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 3
- 229960004982 vinblastine sulfate Drugs 0.000 description 3
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 3
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 3
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 3
- QBADKJRRVGKRHP-JLXQGRKUSA-N (3as)-2-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3h-benzo[de]isoquinolin-1-one;2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethyl-n-[6-(4-methylpiperazin-1-yl)-4-[(3z)-penta-1,3-dien-3-yl]pyridin-3-yl]propanamide Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1.C\C=C(\C=C)C1=CC(N2CCN(C)CC2)=NC=C1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QBADKJRRVGKRHP-JLXQGRKUSA-N 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 2
- OVRJLLUJKRFEBG-UUWRZZSWSA-N 1-palmitoyl-2-lauroyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC OVRJLLUJKRFEBG-UUWRZZSWSA-N 0.000 description 2
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 2
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 2
- MXDPZUIOZWKRAA-UZOALHFESA-K 2-[4-[2-[[(2r)-1-[[(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-4-[[(1s,2r)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-y Chemical compound [Lu+3].C([C@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC1=O)C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1)C1=CC=CC=C1 MXDPZUIOZWKRAA-UZOALHFESA-K 0.000 description 2
- DJMJHIKGMVJYCW-UHFFFAOYSA-N 2-aminoethanol 3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid Chemical compound CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C.C(CO)N.C(CO)N DJMJHIKGMVJYCW-UHFFFAOYSA-N 0.000 description 2
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 2
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 102400001318 Adrenomedullin Human genes 0.000 description 2
- 101800004616 Adrenomedullin Proteins 0.000 description 2
- 102100038778 Amphiregulin Human genes 0.000 description 2
- 108010033760 Amphiregulin Proteins 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 108010009906 Angiopoietins Proteins 0.000 description 2
- 102000009840 Angiopoietins Human genes 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 102100026376 Artemin Human genes 0.000 description 2
- 101710205806 Artemin Proteins 0.000 description 2
- 101800001382 Betacellulin Proteins 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 2
- 102100038078 CD276 antigen Human genes 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 108010065524 CD52 Antigen Proteins 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 102100038518 Calcitonin Human genes 0.000 description 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- 108010016906 Epigen Proteins 0.000 description 2
- 102100030323 Epigen Human genes 0.000 description 2
- 101800000155 Epiregulin Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 102000010451 Folate receptor alpha Human genes 0.000 description 2
- 108050001931 Folate receptor alpha Proteins 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 2
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004858 Growth differentiation factor-9 Human genes 0.000 description 2
- 108090001086 Growth differentiation factor-9 Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 2
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 2
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 2
- 101001083798 Homo sapiens Hepatoma-derived growth factor Proteins 0.000 description 2
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 2
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
- 101000871708 Homo sapiens Proheparin-binding EGF-like growth factor Proteins 0.000 description 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 101900159346 Influenza A virus Hemagglutinin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102100025305 Integrin alpha-2 Human genes 0.000 description 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 2
- 108010041012 Integrin alpha4 Proteins 0.000 description 2
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 2
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 108010065637 Interleukin-23 Proteins 0.000 description 2
- 102100021596 Interleukin-31 Human genes 0.000 description 2
- 102100039881 Interleukin-5 receptor subunit alpha Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 2
- 102100027159 Membrane primary amine oxidase Human genes 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- 108090000556 Neuregulin-1 Proteins 0.000 description 2
- 102400000058 Neuregulin-1 Human genes 0.000 description 2
- 102100028762 Neuropilin-1 Human genes 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 102000004230 Neurotrophin 3 Human genes 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 108010015406 Neurturin Proteins 0.000 description 2
- 102100021584 Neurturin Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102100036660 Persephin Human genes 0.000 description 2
- 108010082093 Placenta Growth Factor Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 2
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 2
- 101710103506 Platelet-derived growth factor subunit A Proteins 0.000 description 2
- 102100029837 Probetacellulin Human genes 0.000 description 2
- 102100025498 Proepiregulin Human genes 0.000 description 2
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 2
- 101710194807 Protective antigen Proteins 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 101150030875 RAB7A gene Proteins 0.000 description 2
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 2
- 102100022873 Ras-related protein Rab-11A Human genes 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 102100029198 SLAM family member 7 Human genes 0.000 description 2
- 102100034201 Sclerostin Human genes 0.000 description 2
- 108010079723 Shiga Toxin Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 108010033576 Transferrin Receptors Proteins 0.000 description 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 description 2
- 229960004103 abiraterone acetate Drugs 0.000 description 2
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 2
- 229950009821 acalabrutinib Drugs 0.000 description 2
- RUGAHXUZHWYHNG-NLGNTGLNSA-N acetic acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 RUGAHXUZHWYHNG-NLGNTGLNSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 2
- USNRYVNRPYXCSP-JUGPPOIOSA-N afatinib dimaleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 USNRYVNRPYXCSP-JUGPPOIOSA-N 0.000 description 2
- 229960002736 afatinib dimaleate Drugs 0.000 description 2
- 229960001611 alectinib Drugs 0.000 description 2
- 229940098174 alkeran Drugs 0.000 description 2
- 229960001097 amifostine Drugs 0.000 description 2
- 229960002749 aminolevulinic acid Drugs 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229950007511 apalutamide Drugs 0.000 description 2
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 2
- 229960001372 aprepitant Drugs 0.000 description 2
- 229940102797 asparaginase erwinia chrysanthemi Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 229950009579 axicabtagene ciloleucel Drugs 0.000 description 2
- 229960003005 axitinib Drugs 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 229960003094 belinostat Drugs 0.000 description 2
- 229960001215 bendamustine hydrochloride Drugs 0.000 description 2
- MMIMIFULGMZVPO-UHFFFAOYSA-N benzyl 3-bromo-2,6-dinitro-5-phenylmethoxybenzoate Chemical compound [O-][N+](=O)C1=C(C(=O)OCC=2C=CC=CC=2)C([N+](=O)[O-])=C(Br)C=C1OCC1=CC=CC=C1 MMIMIFULGMZVPO-UHFFFAOYSA-N 0.000 description 2
- 229960002938 bexarotene Drugs 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 238000012575 bio-layer interferometry Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- 229960003736 bosutinib Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229960001573 cabazitaxel Drugs 0.000 description 2
- 235000008207 calcium folinate Nutrition 0.000 description 2
- 239000011687 calcium folinate Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229940112129 campath Drugs 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 238000001386 capillary affinity electrophoresis Methods 0.000 description 2
- 108010021331 carfilzomib Proteins 0.000 description 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 2
- 229960002438 carfilzomib Drugs 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229960001602 ceritinib Drugs 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 229960005061 crizotinib Drugs 0.000 description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 2
- 229960002465 dabrafenib Drugs 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 229940094732 darzalex Drugs 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- 229960003603 decitabine Drugs 0.000 description 2
- 229940076705 defibrotide sodium Drugs 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 229960002923 denileukin diftitox Drugs 0.000 description 2
- 229960000605 dexrazoxane Drugs 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 229960000284 efalizumab Drugs 0.000 description 2
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 2
- 229960001827 eltrombopag olamine Drugs 0.000 description 2
- 229950010133 enasidenib Drugs 0.000 description 2
- 229960004671 enzalutamide Drugs 0.000 description 2
- 229960003265 epirubicin hydrochloride Drugs 0.000 description 2
- 229940082789 erbitux Drugs 0.000 description 2
- 229960000439 eribulin mesylate Drugs 0.000 description 2
- 229960005073 erlotinib hydrochloride Drugs 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 229960000255 exemestane Drugs 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 102000006815 folate receptor Human genes 0.000 description 2
- 108020005243 folate receptor Proteins 0.000 description 2
- 229960002258 fulvestrant Drugs 0.000 description 2
- 101150082979 gdnf gene Proteins 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 2
- 229960004859 glucarpidase Drugs 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 229960003690 goserelin acetate Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 108010052188 hepatoma-derived growth factor Proteins 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 229960001176 idarubicin hydrochloride Drugs 0.000 description 2
- 229960003445 idelalisib Drugs 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 229960002751 imiquimod Drugs 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940068935 insulin-like growth factor 2 Drugs 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 229960003507 interferon alfa-2b Drugs 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 2
- 229940048117 irinotecan hydrochloride liposome Drugs 0.000 description 2
- 229960002014 ixabepilone Drugs 0.000 description 2
- 229960002951 ixazomib citrate Drugs 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 229960001739 lanreotide acetate Drugs 0.000 description 2
- 229960001320 lapatinib ditosylate Drugs 0.000 description 2
- 229960004942 lenalidomide Drugs 0.000 description 2
- 229960001429 lenvatinib mesylate Drugs 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- 229960002293 leucovorin calcium Drugs 0.000 description 2
- 229950001237 lilotomab Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 108700033205 lutetium Lu 177 dotatate Proteins 0.000 description 2
- 229940008393 lutetium lu 177 dotatate Drugs 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229950008001 matuzumab Drugs 0.000 description 2
- 229960002868 mechlorethamine hydrochloride Drugs 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960003151 mercaptamine Drugs 0.000 description 2
- 229960005558 mertansine Drugs 0.000 description 2
- 229960004635 mesna Drugs 0.000 description 2
- 229960002834 methylnaltrexone bromide Drugs 0.000 description 2
- AZBFJBJXUQUQLF-UHFFFAOYSA-N n-(1,5-dimethylpyrrolidin-3-yl)pyrrolidine-1-carboxamide Chemical compound C1N(C)C(C)CC1NC(=O)N1CCCC1 AZBFJBJXUQUQLF-UHFFFAOYSA-N 0.000 description 2
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 2
- 229960000801 nelarabine Drugs 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 229940097998 neurotrophin 4 Drugs 0.000 description 2
- 229960001346 nilotinib Drugs 0.000 description 2
- 229960002653 nilutamide Drugs 0.000 description 2
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 description 2
- 229960000572 olaparib Drugs 0.000 description 2
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 2
- 229960000770 ondansetron hydrochloride Drugs 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 229960004390 palbociclib Drugs 0.000 description 2
- 229960002404 palifermin Drugs 0.000 description 2
- 229960003978 pamidronic acid Drugs 0.000 description 2
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229960005492 pazopanib hydrochloride Drugs 0.000 description 2
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 2
- 229960001744 pegaspargase Drugs 0.000 description 2
- 229960001373 pegfilgrastim Drugs 0.000 description 2
- 229960003349 pemetrexed disodium Drugs 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 108010070453 persephin Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 229960002169 plerixafor Drugs 0.000 description 2
- 229960000688 pomalidomide Drugs 0.000 description 2
- 229960002183 ponatinib hydrochloride Drugs 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 229960000214 pralatrexate Drugs 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 229960001586 procarbazine hydrochloride Drugs 0.000 description 2
- 229940092597 prolia Drugs 0.000 description 2
- 229960004604 propranolol hydrochloride Drugs 0.000 description 2
- 229940092814 radium (223ra) dichloride Drugs 0.000 description 2
- 229960000424 rasburicase Drugs 0.000 description 2
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 2
- 229960004836 regorafenib Drugs 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229960001068 rolapitant Drugs 0.000 description 2
- FIVSJYGQAIEMOC-ZGNKEGEESA-N rolapitant Chemical compound C([C@@](NC1)(CO[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=2C=CC=CC=2)C[C@@]21CCC(=O)N2 FIVSJYGQAIEMOC-ZGNKEGEESA-N 0.000 description 2
- 229960003452 romidepsin Drugs 0.000 description 2
- 229960004262 romiplostim Drugs 0.000 description 2
- 239000010979 ruby Substances 0.000 description 2
- 229910001750 ruby Inorganic materials 0.000 description 2
- 229960002539 ruxolitinib phosphate Drugs 0.000 description 2
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 108091005475 signaling receptors Proteins 0.000 description 2
- 102000035025 signaling receptors Human genes 0.000 description 2
- 229960000714 sipuleucel-t Drugs 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 229960005325 sonidegib Drugs 0.000 description 2
- 229960000487 sorafenib tosylate Drugs 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 229960002812 sunitinib malate Drugs 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940121331 sutimlimab Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229950008461 talimogene laherparepvec Drugs 0.000 description 2
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 2
- 229960003454 tamoxifen citrate Drugs 0.000 description 2
- 229960000235 temsirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 2
- 229960001740 tipiracil hydrochloride Drugs 0.000 description 2
- KGHYQYACJRXCAT-UHFFFAOYSA-N tipiracil hydrochloride Chemical compound Cl.N1C(=O)NC(=O)C(Cl)=C1CN1C(=N)CCC1 KGHYQYACJRXCAT-UHFFFAOYSA-N 0.000 description 2
- 229950007137 tisagenlecleucel Drugs 0.000 description 2
- 229960002190 topotecan hydrochloride Drugs 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- 229960005026 toremifene Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 229960000977 trabectedin Drugs 0.000 description 2
- 229960004066 trametinib Drugs 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 229960003962 trifluridine Drugs 0.000 description 2
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 2
- 229960003498 uridine triacetate Drugs 0.000 description 2
- LFOHPKKMDYSRLY-UHFFFAOYSA-N uridine triacetate Natural products CC(=O)OCC1OC(CN2C=CC(=O)NC2=O)C(OC(=O)C)C1OC(=O)C LFOHPKKMDYSRLY-UHFFFAOYSA-N 0.000 description 2
- 229960000653 valrubicin Drugs 0.000 description 2
- 229960003862 vemurafenib Drugs 0.000 description 2
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 2
- 229960002110 vincristine sulfate Drugs 0.000 description 2
- 229940034332 vincristine sulfate liposome Drugs 0.000 description 2
- 229960002166 vinorelbine tartrate Drugs 0.000 description 2
- GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 229960004449 vismodegib Drugs 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- 229940014556 xgeva Drugs 0.000 description 2
- 229940055760 yervoy Drugs 0.000 description 2
- 229960002760 ziv-aflibercept Drugs 0.000 description 2
- 229960004276 zoledronic acid Drugs 0.000 description 2
- RCSZIBSPHRZNRQ-BTZXMIIFSA-N (2S)-2-amino-6-[6-[[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(2S)-3-(1H-indol-3-yl)-1-(oxazinan-2-yl)-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-methylamino]hexanoylamino]hexanoic acid Chemical compound OC(=O)[C@@H](N)CCCCNC(=O)CCCCCN(C)[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(=O)N1OCCCC1)CC1=CNC2=CC=CC=C12 RCSZIBSPHRZNRQ-BTZXMIIFSA-N 0.000 description 1
- OIXVKQDWLFHVGR-GQTDVWSESA-N (2r,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(1r,2r,3s,4r,6s)-4,6-diamino-2-[(2s,3r,4s,5r)-4-[(3r,4r,5s,6s)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)OC1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-GQTDVWSESA-N 0.000 description 1
- FFILOTSTFMXQJC-QCFYAKGBSA-N (2r,4r,5s,6s)-2-[3-[(2s,3s,4r,6s)-6-[(2s,3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(e)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hy Chemical compound O[C@@H]1[C@@H](O)[C@H](OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 FFILOTSTFMXQJC-QCFYAKGBSA-N 0.000 description 1
- ZZKNRXZVGOYGJT-VKHMYHEASA-N (2s)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 description 1
- ORFNVPGICPYLJV-YTVPMEHESA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropan Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C=CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 ORFNVPGICPYLJV-YTVPMEHESA-N 0.000 description 1
- ZMEWRPBAQVSBBB-GOTSBHOMSA-N (2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[[2-[2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetyl]amino]hexanoic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 ZMEWRPBAQVSBBB-GOTSBHOMSA-N 0.000 description 1
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- PJOHVEQSYPOERL-SHEAVXILSA-N (e)-n-[(4r,4as,7ar,12br)-3-(cyclopropylmethyl)-9-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a-yl]-3-(4-methylphenyl)prop-2-enamide Chemical compound C1=CC(C)=CC=C1\C=C\C(=O)N[C@]1(CCC(=O)[C@@H]2O3)[C@H]4CC5=CC=C(O)C3=C5[C@]12CCN4CC1CC1 PJOHVEQSYPOERL-SHEAVXILSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-O 2-(2,4-difluorophenyl)-1-(1h-1,2,4-triazol-2-ium-2-yl)-3-(1,2,4-triazol-1-yl)propan-2-ol Chemical compound C([C@](O)(C[N+]=1NC=NC=1)C=1C(=CC(F)=CC=1)F)N1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-O 0.000 description 1
- MXDPZUIOZWKRAA-PRDSJKGBSA-K 2-[4-[2-[[(2r)-1-[[(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-4-[[(1s,2r)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-y Chemical compound [177Lu+3].C([C@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC1=O)C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1)C1=CC=CC=C1 MXDPZUIOZWKRAA-PRDSJKGBSA-K 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- ZKEZEXYKYHYIMQ-UHFFFAOYSA-N 3-cyclohexyl-1-(2-morpholin-4-yl-2-oxoethyl)-2-phenyl-1h-indole-6-carboxylic acid Chemical compound C=1C=CC=CC=1C=1N(CC(=O)N2CCOCC2)C2=CC(C(=O)O)=CC=C2C=1C1CCCCC1 ZKEZEXYKYHYIMQ-UHFFFAOYSA-N 0.000 description 1
- JWEQLWMZHJSMEC-AFJTUFCWSA-N 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide (Z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12 JWEQLWMZHJSMEC-AFJTUFCWSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- PLIXOHWIPDGJEI-OJSHLMAWSA-N 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]-1h-pyrimidine-2,4-dione;1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione;hydrochloride Chemical compound Cl.N1C(=O)NC(=O)C(Cl)=C1CN1C(=N)CCC1.C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 PLIXOHWIPDGJEI-OJSHLMAWSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 102100027647 Activin receptor type-2B Human genes 0.000 description 1
- 102100032157 Adenylate cyclase type 10 Human genes 0.000 description 1
- ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 102100025665 Angiopoietin-related protein 1 Human genes 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 102100032412 Basigin Human genes 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 1
- 108700012439 CA9 Proteins 0.000 description 1
- 102100031168 CCN family member 2 Human genes 0.000 description 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- ZCZQNDCUMLBKAG-MPVKSFTFSA-N CN([C@@H](C(C)C)C(=O)N[C@H](C(=O)N(C)[C@H]([C@@H](CC(=O)N1[C@@H](CCC1)[C@H](OC)[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)OC)[C@@H](C)CC)C(C)C)CCCC(=O)NNC(=O)CCCCCN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O Chemical compound CN([C@@H](C(C)C)C(=O)N[C@H](C(=O)N(C)[C@H]([C@@H](CC(=O)N1[C@@H](CCC1)[C@H](OC)[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)OC)[C@@H](C)CC)C(C)C)CCCC(=O)NNC(=O)CCCCCN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O ZCZQNDCUMLBKAG-MPVKSFTFSA-N 0.000 description 1
- 108091011896 CSF1 Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
- 102000013602 Cardiac Myosins Human genes 0.000 description 1
- 108010051609 Cardiac Myosins Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 description 1
- 229940124957 Cervarix Drugs 0.000 description 1
- 108010082548 Chemokine CCL11 Proteins 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 102000005853 Clathrin Human genes 0.000 description 1
- 108010019874 Clathrin Proteins 0.000 description 1
- 102100040835 Claudin-18 Human genes 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 108700022831 Clostridium difficile toxB Proteins 0.000 description 1
- 101710198480 Clumping factor A Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102100031506 Complement C5 Human genes 0.000 description 1
- 108010028773 Complement C5 Proteins 0.000 description 1
- 108010078546 Complement C5a Proteins 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 102100035436 Complement factor D Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 102100036466 Delta-like protein 3 Human genes 0.000 description 1
- 102100033553 Delta-like protein 4 Human genes 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 101100189828 Drosophila melanogaster Ebp gene Proteins 0.000 description 1
- 101150016325 EPHA3 gene Proteins 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 102100038083 Endosialin Human genes 0.000 description 1
- XRHVZWWRFMCBAZ-UHFFFAOYSA-L Endothal-disodium Chemical compound [Na+].[Na+].C1CC2C(C([O-])=O)C(C(=O)[O-])C1O2 XRHVZWWRFMCBAZ-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000050554 Eph Family Receptors Human genes 0.000 description 1
- 108091008815 Eph receptors Proteins 0.000 description 1
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 1
- 102100032031 Epidermal growth factor-like protein 7 Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000005698 Frizzled receptors Human genes 0.000 description 1
- 108010045438 Frizzled receptors Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 229940124897 Gardasil Drugs 0.000 description 1
- 101710088083 Glomulin Proteins 0.000 description 1
- 102100040890 Glucagon receptor Human genes 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 102000010956 Glypican Human genes 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 108050007237 Glypican-3 Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 1
- 102100022662 Guanylyl cyclase C Human genes 0.000 description 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000937269 Homo sapiens Activin receptor type-2B Proteins 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000912622 Homo sapiens C-type lectin domain family 12 member A Proteins 0.000 description 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 description 1
- 101000749329 Homo sapiens Claudin-18 Proteins 0.000 description 1
- 101000737554 Homo sapiens Complement factor D Proteins 0.000 description 1
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 description 1
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000884275 Homo sapiens Endosialin Proteins 0.000 description 1
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
- 101000921195 Homo sapiens Epidermal growth factor-like protein 7 Proteins 0.000 description 1
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000899808 Homo sapiens Guanylyl cyclase C Proteins 0.000 description 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 1
- 101000913079 Homo sapiens IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 101001055308 Homo sapiens Immunoglobulin heavy constant epsilon Proteins 0.000 description 1
- 101001002508 Homo sapiens Immunoglobulin-binding protein 1 Proteins 0.000 description 1
- 101000606465 Homo sapiens Inactive tyrosine-protein kinase 7 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101000852980 Homo sapiens Interleukin-23 subunit alpha Proteins 0.000 description 1
- 101001043821 Homo sapiens Interleukin-31 Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101001039113 Homo sapiens Leucine-rich repeat-containing protein 15 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101001038507 Homo sapiens Ly6/PLAUR domain-containing protein 3 Proteins 0.000 description 1
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 1
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101000694615 Homo sapiens Membrane primary amine oxidase Proteins 0.000 description 1
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 description 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000756808 Homo sapiens Repulsive guidance molecule A Proteins 0.000 description 1
- 101000727472 Homo sapiens Reticulon-4 Proteins 0.000 description 1
- 101000835984 Homo sapiens SLIT and NTRK-like protein 6 Proteins 0.000 description 1
- 101000711796 Homo sapiens Sclerostin Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 1
- 101000934376 Homo sapiens T-cell differentiation antigen CD6 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 description 1
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 1
- 101000685848 Homo sapiens Zinc transporter ZIP6 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102100034980 ICOS ligand Human genes 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 102100026212 Immunoglobulin heavy constant epsilon Human genes 0.000 description 1
- 102100021042 Immunoglobulin-binding protein 1 Human genes 0.000 description 1
- 102100039813 Inactive tyrosine-protein kinase 7 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
- 102100033016 Integrin beta-7 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000001617 Interferon Receptors Human genes 0.000 description 1
- 108010054267 Interferon Receptors Proteins 0.000 description 1
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 1
- 102100035018 Interleukin-17 receptor A Human genes 0.000 description 1
- 101710186083 Interleukin-17 receptor A Proteins 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 102100036672 Interleukin-23 receptor Human genes 0.000 description 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 1
- 101710181613 Interleukin-31 Proteins 0.000 description 1
- 102100021594 Interleukin-31 receptor subunit alpha Human genes 0.000 description 1
- 101710131691 Interleukin-31 receptor subunit alpha Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 description 1
- 101710169536 Interleukin-4 receptor subunit alpha Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 101710098691 Interleukin-5 receptor subunit alpha Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 102100026244 Interleukin-9 receptor Human genes 0.000 description 1
- 101150069255 KLRC1 gene Proteins 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 102100040645 Leucine-rich repeat-containing protein 15 Human genes 0.000 description 1
- 108010014603 Leukocidins Proteins 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 101001089108 Lotus tetragonolobus Anti-H(O) lectin Proteins 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229940127049 Lutathera Drugs 0.000 description 1
- 229910052765 Lutetium Inorganic materials 0.000 description 1
- 102100040281 Ly6/PLAUR domain-containing protein 3 Human genes 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 1
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 1
- 102000034655 MIF Human genes 0.000 description 1
- 108060004872 MIF Proteins 0.000 description 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 1
- 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 description 1
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101710132836 Membrane primary amine oxidase Proteins 0.000 description 1
- 102100025096 Mesothelin Human genes 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100329495 Mus musculus C1sa gene Proteins 0.000 description 1
- 101100329496 Mus musculus C1sb gene Proteins 0.000 description 1
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 1
- 102100021831 Myelin-associated glycoprotein Human genes 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 description 1
- PLILLUUXAVKBPY-SBIAVEDLSA-N NCCO.NCCO.CC1=NN(C=2C=C(C)C(C)=CC=2)C(=O)\C1=N/NC(C=1O)=CC=CC=1C1=CC=CC(C(O)=O)=C1 Chemical compound NCCO.NCCO.CC1=NN(C=2C=C(C)C(C)=CC=2)C(=O)\C1=N/NC(C=1O)=CC=CC=1C1=CC=CC(C(O)=O)=C1 PLILLUUXAVKBPY-SBIAVEDLSA-N 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- 102100035486 Nectin-4 Human genes 0.000 description 1
- 101710043865 Nectin-4 Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 1
- 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 1
- 102000004207 Neuropilin-1 Human genes 0.000 description 1
- 108010070047 Notch Receptors Proteins 0.000 description 1
- 102000005650 Notch Receptors Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010022425 Platelet Glycoprotein GPIIb-IIIa Complex Proteins 0.000 description 1
- 101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 108010048233 Procalcitonin Proteins 0.000 description 1
- 241001415846 Procellariidae Species 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 101150060955 RAB11A gene Proteins 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 102000042022 Rab family Human genes 0.000 description 1
- 108091079902 Rab family Proteins 0.000 description 1
- 101710136851 Ras-related protein Rab-11A Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102100022813 Repulsive guidance molecule A Human genes 0.000 description 1
- 102100029831 Reticulon-4 Human genes 0.000 description 1
- 102100025504 SLIT and NTRK-like protein 6 Human genes 0.000 description 1
- 108050006698 Sclerostin Proteins 0.000 description 1
- 102100034136 Serine/threonine-protein kinase receptor R3 Human genes 0.000 description 1
- 101710082813 Serine/threonine-protein kinase receptor R3 Proteins 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 108010045517 Serum Amyloid P-Component Proteins 0.000 description 1
- 101710190759 Serum amyloid A protein Proteins 0.000 description 1
- 102100036202 Serum amyloid P-component Human genes 0.000 description 1
- 108010029389 Simplexvirus glycoprotein B Proteins 0.000 description 1
- 102000003673 Symporters Human genes 0.000 description 1
- 108090000088 Symporters Proteins 0.000 description 1
- 102100035721 Syndecan-1 Human genes 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100025131 T-cell differentiation antigen CD6 Human genes 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 108010014401 TWEAK Receptor Proteins 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100030859 Tissue factor Human genes 0.000 description 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102100033579 Trophoblast glycoprotein Human genes 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 102100028786 Tumor necrosis factor receptor superfamily member 12A Human genes 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 108010069584 Type III Secretion Systems Proteins 0.000 description 1
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 101150045640 VWF gene Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 241001115400 Zaire ebolavirus Species 0.000 description 1
- 102100023144 Zinc transporter ZIP6 Human genes 0.000 description 1
- ZSTCHQOKNUXHLZ-PIRIXANTSA-L [(1r,2r)-2-azanidylcyclohexyl]azanide;oxalate;pentyl n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate;platinum(4+) Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@@H]1CCCC[C@H]1[NH-].C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 ZSTCHQOKNUXHLZ-PIRIXANTSA-L 0.000 description 1
- OUOWRIRIGRPGBR-WUDDPNKVSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[1-[[(2S)-1-[[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]carbamate Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)C(C)(C)NC(=O)OCC=1C=CC(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(C=CC2=O)=O)C(C)C)=CC=1)C(C)C)OC)C=1SC=CN=1)C1=CC=CC=C1 OUOWRIRIGRPGBR-WUDDPNKVSA-N 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- HKGATZAPXCCEJR-OWRSNIELSA-N [4-[[(2s)-2-[[(2s)-2-[3-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]-3-methylbutanoyl]amino]propanoyl]amino]phenyl]methyl (6s,6as)-3-[5-[[(6as)-2-methoxy-8-methyl-1 Chemical compound N([C@H](C(=O)N[C@@H](C)C(=O)NC1=CC=C(C=C1)COC(=O)N1C=2C=C(C(=CC=2C(=O)N2C=C(C)C[C@H]2[C@@H]1O)OC)OCCCCCOC1=CC2=C(C(N3C=C(C)C[C@H]3C=N2)=O)C=C1OC)C(C)C)C(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCN1C(=O)C=CC1=O HKGATZAPXCCEJR-OWRSNIELSA-N 0.000 description 1
- 229950005186 abagovomab Drugs 0.000 description 1
- 229950005008 abituzumab Drugs 0.000 description 1
- 229940028652 abraxane Drugs 0.000 description 1
- 229940005624 abrezekimab Drugs 0.000 description 1
- 229950008347 abrilumab Drugs 0.000 description 1
- DEXPIBGCLCPUHE-UISHROKMSA-N acetic acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 DEXPIBGCLCPUHE-UISHROKMSA-N 0.000 description 1
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940119059 actemra Drugs 0.000 description 1
- 229940060199 actigall Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940062328 actos Drugs 0.000 description 1
- 229950004283 actoxumab Drugs 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229950008995 aducanumab Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229950008714 afasevikumab Drugs 0.000 description 1
- 229960003227 afelimomab Drugs 0.000 description 1
- 229940042992 afinitor Drugs 0.000 description 1
- 229940029184 akynzeo Drugs 0.000 description 1
- 229940060265 aldara Drugs 0.000 description 1
- 229940083773 alecensa Drugs 0.000 description 1
- 229940110282 alimta Drugs 0.000 description 1
- 229940014175 aloxi Drugs 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 229950009106 altumomab Drugs 0.000 description 1
- 229950001537 amatuximab Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229950004189 andecaliximab Drugs 0.000 description 1
- 108010069801 angiopoietin 4 Proteins 0.000 description 1
- 229950010117 anifrolumab Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229950005794 anrukinzumab Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229950003145 apolizumab Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229950005725 arcitumomab Drugs 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 229940087620 aromasin Drugs 0.000 description 1
- 229940014583 arranon Drugs 0.000 description 1
- 229950000847 ascrinvacumab Drugs 0.000 description 1
- 229950002882 aselizumab Drugs 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- 229950009583 atidortoxumab Drugs 0.000 description 1
- 229950005122 atinumab Drugs 0.000 description 1
- 229950000103 atorolimumab Drugs 0.000 description 1
- 229940062310 avandia Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229940075127 azintuxizumab Drugs 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229950001863 bapineuzumab Drugs 0.000 description 1
- 229950007843 bavituximab Drugs 0.000 description 1
- FUKOGSUFTZDYOI-BMANNDLBSA-O beacopp protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.CNNCC1=CC=C(C(=O)NC(C)C)C=C1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C FUKOGSUFTZDYOI-BMANNDLBSA-O 0.000 description 1
- 229950003269 bectumomab Drugs 0.000 description 1
- 229960004965 begelomab Drugs 0.000 description 1
- 229940018963 belantamab Drugs 0.000 description 1
- 229940077840 beleodaq Drugs 0.000 description 1
- 229940022836 benlysta Drugs 0.000 description 1
- 229950009572 berlimatoxumab Drugs 0.000 description 1
- 229940038699 bersanlimab Drugs 0.000 description 1
- 229950010015 bertilimumab Drugs 0.000 description 1
- 229950010559 besilesomab Drugs 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229950001303 biciromab Drugs 0.000 description 1
- 229940108502 bicnu Drugs 0.000 description 1
- 229950006326 bimagrumab Drugs 0.000 description 1
- 229950002853 bimekizumab Drugs 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940121416 birtamimab Drugs 0.000 description 1
- 229950002903 bivatuzumab Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229950000009 bleselumab Drugs 0.000 description 1
- 229940101815 blincyto Drugs 0.000 description 1
- 229950007686 blontuvetmab Drugs 0.000 description 1
- 229950005042 blosozumab Drugs 0.000 description 1
- 229950011350 bococizumab Drugs 0.000 description 1
- 229940083476 bosulif Drugs 0.000 description 1
- 229950009342 brazikumab Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960002874 briakinumab Drugs 0.000 description 1
- 229950001478 brontictuzumab Drugs 0.000 description 1
- 229950002817 burosumab Drugs 0.000 description 1
- 229940112133 busulfex Drugs 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 229950010831 cabiralizumab Drugs 0.000 description 1
- 229940036033 cabometyx Drugs 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229950009653 camidanlumab Drugs 0.000 description 1
- 229940088954 camptosar Drugs 0.000 description 1
- 229950007712 camrelizumab Drugs 0.000 description 1
- PGMBSCDPACPRSG-SCSDYSBLSA-N capiri Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PGMBSCDPACPRSG-SCSDYSBLSA-N 0.000 description 1
- 229950002176 caplacizumab Drugs 0.000 description 1
- 108010023376 caplacizumab Proteins 0.000 description 1
- 229940001981 carac Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229950000771 carlumab Drugs 0.000 description 1
- 229950005629 carotuximab Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940097647 casodex Drugs 0.000 description 1
- 229950006754 cedelizumab Drugs 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 229940067219 cetrelimab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940055196 cholbam Drugs 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229940070039 cibisatamab Drugs 0.000 description 1
- 229940090100 cimzia Drugs 0.000 description 1
- 229930193282 clathrin Natural products 0.000 description 1
- 230000006895 clathrin independent endocytosis Effects 0.000 description 1
- 210000002806 clathrin-coated vesicle Anatomy 0.000 description 1
- 229950001565 clazakizumab Drugs 0.000 description 1
- 229950002334 clenoliximab Drugs 0.000 description 1
- 229940103380 clolar Drugs 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229950007906 codrituzumab Drugs 0.000 description 1
- 229950009658 cofetuzumab Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229940034568 cometriq Drugs 0.000 description 1
- 229950007276 conatumumab Drugs 0.000 description 1
- 229950009735 concizumab Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000009146 cooperative binding Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229940053044 cosfroviximab Drugs 0.000 description 1
- 229940088547 cosmegen Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229950001954 crenezumab Drugs 0.000 description 1
- 229940092125 creon Drugs 0.000 description 1
- 229950004730 crizanlizumab Drugs 0.000 description 1
- 229950000938 crotedumab Drugs 0.000 description 1
- 229940085936 cusatuzumab Drugs 0.000 description 1
- IMBXRZKCLVBLBH-OGYJWPHRSA-N cvp protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 IMBXRZKCLVBLBH-OGYJWPHRSA-N 0.000 description 1
- 229940021393 cystadane Drugs 0.000 description 1
- 210000003674 cytoplasmic vesicle Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 1
- 229960003850 dabigatran Drugs 0.000 description 1
- 229950007409 dacetuzumab Drugs 0.000 description 1
- 229940059359 dacogen Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 229950008135 dectrekumab Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229940076711 defitelio Drugs 0.000 description 1
- 229960002272 degarelix Drugs 0.000 description 1
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229940127276 delta-like ligand 3 Drugs 0.000 description 1
- 229950007998 demcizumab Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 229940070968 depocyt Drugs 0.000 description 1
- 229950008962 detumomab Drugs 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229950006723 dezamizumab Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- FOCAHLGSDWHSAH-UHFFFAOYSA-N difluoromethanethione Chemical compound FC(F)=S FOCAHLGSDWHSAH-UHFFFAOYSA-N 0.000 description 1
- ZQSBJPAQPRVNHU-UHFFFAOYSA-M dilC18(5) dye Chemical compound [O-]Cl(=O)(=O)=O.CC1(C)C2=CC=CC=C2N(CCCCCCCCCCCCCCCCCC)C1=CC=CC=CC1=[N+](CCCCCCCCCCCCCCCCCC)C2=CC=CC=C2C1(C)C ZQSBJPAQPRVNHU-UHFFFAOYSA-M 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 229950011037 diridavumab Drugs 0.000 description 1
- 229950000274 domagrozumab Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 229950009964 drozitumab Drugs 0.000 description 1
- 229950011453 dusigitumab Drugs 0.000 description 1
- 229940057045 duvortuxizumab Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229950000006 ecromeximab Drugs 0.000 description 1
- 229950011109 edobacomab Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940099302 efudex Drugs 0.000 description 1
- 229950002209 efungumab Drugs 0.000 description 1
- 229950010217 eldelumab Drugs 0.000 description 1
- 229950005753 elezanumab Drugs 0.000 description 1
- 229940053603 elitek Drugs 0.000 description 1
- 229940087477 ellence Drugs 0.000 description 1
- 229940120655 eloxatin Drugs 0.000 description 1
- 229950002507 elsilimomab Drugs 0.000 description 1
- 229950004647 emactuzumab Drugs 0.000 description 1
- 229950004645 emapalumab Drugs 0.000 description 1
- 229940108890 emend Drugs 0.000 description 1
- 229940038483 empliciti Drugs 0.000 description 1
- 229940096918 enapotamab Drugs 0.000 description 1
- 229950003048 enavatuzumab Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950002798 enlimomab Drugs 0.000 description 1
- 229950004270 enoblituzumab Drugs 0.000 description 1
- 229950007313 enokizumab Drugs 0.000 description 1
- 229950001752 enoticumab Drugs 0.000 description 1
- 229950010640 ensituximab Drugs 0.000 description 1
- 229940104788 entyvio Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229950001757 epitumomab Drugs 0.000 description 1
- 229950009760 epratuzumab Drugs 0.000 description 1
- 229950006063 eptinezumab Drugs 0.000 description 1
- 229950001616 erenumab Drugs 0.000 description 1
- 229940014684 erivedge Drugs 0.000 description 1
- 229950004292 erlizumab Drugs 0.000 description 1
- 229940051398 erwinaze Drugs 0.000 description 1
- 229950009569 etaracizumab Drugs 0.000 description 1
- 229940098617 ethyol Drugs 0.000 description 1
- 229940115924 etigilimab Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229950004912 etrolizumab Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 229950004341 evinacumab Drugs 0.000 description 1
- 229940085363 evista Drugs 0.000 description 1
- 229940060343 evomela Drugs 0.000 description 1
- 229950005562 exbivirumab Drugs 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 229940093443 fanolesomab Drugs 0.000 description 1
- 229950001488 faralimomab Drugs 0.000 description 1
- 229940043168 fareston Drugs 0.000 description 1
- 229950009929 farletuzumab Drugs 0.000 description 1
- 229950000335 fasinumab Drugs 0.000 description 1
- 229940087861 faslodex Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229950001563 felvizumab Drugs 0.000 description 1
- 229940087476 femara Drugs 0.000 description 1
- 229950010512 fezakinumab Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229950002846 ficlatuzumab Drugs 0.000 description 1
- 229950004409 firivumab Drugs 0.000 description 1
- 229950010320 flanvotumab Drugs 0.000 description 1
- 229950010043 fletikumab Drugs 0.000 description 1
- 229940121282 flotetuzumab Drugs 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229940064300 fluoroplex Drugs 0.000 description 1
- 229940081995 fluorouracil injection Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 1
- PJZDLZXMGBOJRF-CXOZILEQSA-L folfirinox Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PJZDLZXMGBOJRF-CXOZILEQSA-L 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 229940039573 folotyn Drugs 0.000 description 1
- 229950004923 fontolizumab Drugs 0.000 description 1
- 229950004356 foralumab Drugs 0.000 description 1
- 229950011078 foravirumab Drugs 0.000 description 1
- 229950011509 fremanezumab Drugs 0.000 description 1
- 229950004003 fresolimumab Drugs 0.000 description 1
- 229940057864 frunevetmab Drugs 0.000 description 1
- 229950009370 fulranumab Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229950000118 galcanezumab Drugs 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 229940121448 gancotamab Drugs 0.000 description 1
- 229950002508 gantenerumab Drugs 0.000 description 1
- 229940102767 gardasil 9 Drugs 0.000 description 1
- 229940057296 gatipotuzumab Drugs 0.000 description 1
- 229950004792 gavilimomab Drugs 0.000 description 1
- 229940057053 gedivumab Drugs 0.000 description 1
- 229940020967 gemzar Drugs 0.000 description 1
- 229950003717 gevokizumab Drugs 0.000 description 1
- 229940087158 gilotrif Drugs 0.000 description 1
- 229940057047 gilvetmab Drugs 0.000 description 1
- 229950009614 gimsilumab Drugs 0.000 description 1
- 229950002026 girentuximab Drugs 0.000 description 1
- 229950000918 glembatumumab Drugs 0.000 description 1
- 229940084910 gliadel Drugs 0.000 description 1
- 229940126613 gomiliximab Drugs 0.000 description 1
- 229940121450 gosuranemab Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940118951 halaven Drugs 0.000 description 1
- 229940033776 hemangeol Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- 229940096120 hydrea Drugs 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229950009637 ianalumab Drugs 0.000 description 1
- 229950010245 ibalizumab Drugs 0.000 description 1
- 229940061301 ibrance Drugs 0.000 description 1
- 229940049235 iclusig Drugs 0.000 description 1
- 229940099279 idamycin Drugs 0.000 description 1
- 229940090411 ifex Drugs 0.000 description 1
- 229950002200 igovomab Drugs 0.000 description 1
- 229950009629 iladatuzumab Drugs 0.000 description 1
- 229940071829 ilaris Drugs 0.000 description 1
- 229950003680 imalumab Drugs 0.000 description 1
- 229940121287 imaprelimab Drugs 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 229950007354 imciromab Drugs 0.000 description 1
- 229940091204 imlygic Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229950009230 inclacumab Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229950006289 indusatumab Drugs 0.000 description 1
- 229950005015 inebilizumab Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940005319 inlyta Drugs 0.000 description 1
- 229950007937 inolimomab Drugs 0.000 description 1
- 108010043603 integrin alpha4beta7 Proteins 0.000 description 1
- 108010021315 integrin beta7 Proteins 0.000 description 1
- 108090000681 interleukin 20 Proteins 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 108040003610 interleukin-12 receptor activity proteins Proteins 0.000 description 1
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 description 1
- 108040001304 interleukin-17 receptor activity proteins Proteins 0.000 description 1
- 102000053460 interleukin-17 receptor activity proteins Human genes 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 108040001834 interleukin-20 receptor activity proteins Proteins 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 108010027445 interleukin-22 receptor Proteins 0.000 description 1
- 102000009548 interleukin-22 receptor activity proteins Human genes 0.000 description 1
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 108040006862 interleukin-9 receptor activity proteins Proteins 0.000 description 1
- 229950001014 intetumumab Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 229950010939 iratumumab Drugs 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- KLEAIHJJLUAXIQ-JDRGBKBRSA-N irinotecan hydrochloride hydrate Chemical compound O.O.O.Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 KLEAIHJJLUAXIQ-JDRGBKBRSA-N 0.000 description 1
- 229950007752 isatuximab Drugs 0.000 description 1
- 229940121288 iscalimab Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940011083 istodax Drugs 0.000 description 1
- 229950003818 itolizumab Drugs 0.000 description 1
- 229940111707 ixempra Drugs 0.000 description 1
- 229940045773 jakafi Drugs 0.000 description 1
- 229940025735 jevtana Drugs 0.000 description 1
- 229950010828 keliximab Drugs 0.000 description 1
- 229940065223 kepivance Drugs 0.000 description 1
- 229940045426 kymriah Drugs 0.000 description 1
- 229940000764 kyprolis Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229950000518 labetuzumab Drugs 0.000 description 1
- 229940057958 lacnotuzumab Drugs 0.000 description 1
- 229950009646 ladiratuzumab Drugs 0.000 description 1
- 229950000482 lampalizumab Drugs 0.000 description 1
- 108010032674 lampalizumab Proteins 0.000 description 1
- 229950005287 lanadelumab Drugs 0.000 description 1
- 229950006481 landogrozumab Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 229940058688 larcaviximab Drugs 0.000 description 1
- 229950002183 lebrikizumab Drugs 0.000 description 1
- 229950001275 lemalesomab Drugs 0.000 description 1
- 229940126615 lendalizumab Drugs 0.000 description 1
- 229940121291 lenvervimab Drugs 0.000 description 1
- 229940064847 lenvima Drugs 0.000 description 1
- 229950007439 lenzilumab Drugs 0.000 description 1
- 229950010470 lerdelimumab Drugs 0.000 description 1
- 229940121292 leronlimab Drugs 0.000 description 1
- 229940058355 lesofavumab Drugs 0.000 description 1
- 229940058170 letolizumab Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940063725 leukeran Drugs 0.000 description 1
- 229940118199 levulan Drugs 0.000 description 1
- 229950002884 lexatumumab Drugs 0.000 description 1
- 229950005173 libivirumab Drugs 0.000 description 1
- 229950009923 ligelizumab Drugs 0.000 description 1
- 229950002950 lintuzumab Drugs 0.000 description 1
- 230000004576 lipid-binding Effects 0.000 description 1
- 229940103064 lipodox Drugs 0.000 description 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
- 229950011263 lirilumab Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229950006208 lodelcizumab Drugs 0.000 description 1
- 229950000359 lokivetmab Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229950009756 loncastuximab Drugs 0.000 description 1
- 229940024740 lonsurf Drugs 0.000 description 1
- 229950004563 lucatumumab Drugs 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 229950000128 lumiliximab Drugs 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229950003828 lupartumab Drugs 0.000 description 1
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 1
- 229950007141 lutikizumab Drugs 0.000 description 1
- 108091004583 lutikizumab Proteins 0.000 description 1
- 229940100352 lynparza Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229950001869 mapatumumab Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229940034322 marqibo Drugs 0.000 description 1
- 229940121460 marstacimab Drugs 0.000 description 1
- 229950008083 maslimomab Drugs 0.000 description 1
- 229940087732 matulane Drugs 0.000 description 1
- 229950007254 mavrilimumab Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- 229940083118 mekinist Drugs 0.000 description 1
- 230000028018 membrane docking Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 1
- 229940101533 mesnex Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229950005555 metelimumab Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 229950003734 milatuzumab Drugs 0.000 description 1
- 229950002142 minretumomab Drugs 0.000 description 1
- 229950009792 mirikizumab Drugs 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004169 mitoxantrone hydrochloride Drugs 0.000 description 1
- 229950003063 mitumomab Drugs 0.000 description 1
- 229950007699 mogamulizumab Drugs 0.000 description 1
- 229950001907 monalizumab Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229950008897 morolimumab Drugs 0.000 description 1
- 229950009794 mosunetuzumab Drugs 0.000 description 1
- 229960001521 motavizumab Drugs 0.000 description 1
- 229940074923 mozobil Drugs 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 229940087004 mustargen Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940090009 myleran Drugs 0.000 description 1
- TWQIMWSQDICMSE-DGCIIGOYSA-N n-[(2s)-1-[[(2s)-1-[4-[(6as)-3-[3-[[(6as)-2-methoxy-8-(4-methoxyphenyl)-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]propoxy]-2-methoxy-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-8-yl]anilino]-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C1=CC(OC)=CC=C1C1=CN2C(=O)C3=CC(OC)=C(OCCCOC=4C(=CC=5C(=O)N6C=C(C[C@H]6C=NC=5C=4)C=4C=CC(NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CCCCCN5C(C=CC5=O)=O)C(C)C)=CC=4)OC)C=C3N=C[C@@H]2C1 TWQIMWSQDICMSE-DGCIIGOYSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- 229950007708 namilumab Drugs 0.000 description 1
- 229950002138 naratuximab Drugs 0.000 description 1
- 229950008353 narnatumab Drugs 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 229950005790 navicixizumab Drugs 0.000 description 1
- 229950010591 navivumab Drugs 0.000 description 1
- 229940121585 naxitamab Drugs 0.000 description 1
- 229960002915 nebacumab Drugs 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 229950010012 nemolizumab Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229950009675 nerelimomab Drugs 0.000 description 1
- 229950002697 nesvacumab Drugs 0.000 description 1
- 229940121307 netakimab Drugs 0.000 description 1
- WAXQNWCZJDTGBU-UHFFFAOYSA-N netupitant Chemical compound C=1N=C(N2CCN(C)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WAXQNWCZJDTGBU-UHFFFAOYSA-N 0.000 description 1
- 229960005163 netupitant Drugs 0.000 description 1
- 229940071846 neulasta Drugs 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- 229940099637 nilandron Drugs 0.000 description 1
- 229940030115 ninlaro Drugs 0.000 description 1
- 229940121468 nirsevimab Drugs 0.000 description 1
- 229940085033 nolvadex Drugs 0.000 description 1
- 235000021231 nutrient uptake Nutrition 0.000 description 1
- 229960001601 obeticholic acid Drugs 0.000 description 1
- 229940055679 ocaliva Drugs 0.000 description 1
- 229950009090 ocaratuzumab Drugs 0.000 description 1
- 229940024847 odomzo Drugs 0.000 description 1
- 229950010465 odulimomab Drugs 0.000 description 1
- 229940059392 oleclumab Drugs 0.000 description 1
- 229940059427 olendalizumab Drugs 0.000 description 1
- 229950010006 olokizumab Drugs 0.000 description 1
- 229950000846 onartuzumab Drugs 0.000 description 1
- 229940099216 oncaspar Drugs 0.000 description 1
- 229940048191 onivyde Drugs 0.000 description 1
- 229940100027 ontak Drugs 0.000 description 1
- 229950002104 ontuxizumab Drugs 0.000 description 1
- 229940121310 onvatilimab Drugs 0.000 description 1
- 229950010704 opicinumab Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229950009007 orticumab Drugs 0.000 description 1
- 229950002610 otelixizumab Drugs 0.000 description 1
- 229940121480 otilimab Drugs 0.000 description 1
- 229950000121 otlertuzumab Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229950003709 oxelumab Drugs 0.000 description 1
- 229950009723 ozanezumab Drugs 0.000 description 1
- 229950007318 ozogamicin Drugs 0.000 description 1
- 229950004327 ozoralizumab Drugs 0.000 description 1
- 229950010626 pagibaximab Drugs 0.000 description 1
- 229950003481 pamrevlumab Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940103518 pancreaze Drugs 0.000 description 1
- 229940045258 pancrelipase Drugs 0.000 description 1
- 229940126618 pankomab Drugs 0.000 description 1
- 229950003570 panobacumab Drugs 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- 229950004260 parsatuzumab Drugs 0.000 description 1
- 229950011485 pascolizumab Drugs 0.000 description 1
- 229950000037 pasotuxizumab Drugs 0.000 description 1
- 229950003522 pateclizumab Drugs 0.000 description 1
- 229940106366 pegintron Drugs 0.000 description 1
- NYDXNILOWQXUOF-GXKRWWSZSA-L pemetrexed disodium Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-GXKRWWSZSA-L 0.000 description 1
- 229960005570 pemtumomab Drugs 0.000 description 1
- 229950011098 pendetide Drugs 0.000 description 1
- 229940067082 pentetate Drugs 0.000 description 1
- 229950005079 perakizumab Drugs 0.000 description 1
- 229940098844 pertzye Drugs 0.000 description 1
- 229950003203 pexelizumab Drugs 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 229940126620 pintumomab Drugs 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229950008092 placulumab Drugs 0.000 description 1
- 229940063179 platinol Drugs 0.000 description 1
- 229950004423 plozalizumab Drugs 0.000 description 1
- 229940126621 pogalizumab Drugs 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229940008606 pomalyst Drugs 0.000 description 1
- 229950003486 ponezumab Drugs 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 229940059500 porgaviximab Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229950007082 prasinezumab Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940126623 prezalizumab Drugs 0.000 description 1
- 229950003700 priliximab Drugs 0.000 description 1
- 229950011407 pritoxaximab Drugs 0.000 description 1
- 229950009904 pritumumab Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940021945 promacta Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 229940034080 provenge Drugs 0.000 description 1
- 229940117820 purinethol Drugs 0.000 description 1
- 229940069591 purixan Drugs 0.000 description 1
- 229950003033 quilizumab Drugs 0.000 description 1
- 229950011613 racotumomab Drugs 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 229950011639 radretumab Drugs 0.000 description 1
- 229950002786 rafivirumab Drugs 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- 229950009885 ralpancizumab Drugs 0.000 description 1
- 229950010862 ranevetmab Drugs 0.000 description 1
- 229940121319 ravagalimab Drugs 0.000 description 1
- 229950007085 ravulizumab Drugs 0.000 description 1
- 229950000987 refanezumab Drugs 0.000 description 1
- 229950005854 regavirumab Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940105899 relistor Drugs 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 229950006192 remtolumab Drugs 0.000 description 1
- 229940107685 reopro Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940120975 revlimid Drugs 0.000 description 1
- 229940061969 rheumatrex Drugs 0.000 description 1
- 229950003238 rilotumumab Drugs 0.000 description 1
- 229950007943 risankizumab Drugs 0.000 description 1
- 229950002198 rivabazumab Drugs 0.000 description 1
- GZQWMYVDLCUBQX-WVZIYJGPSA-N rolapitant hydrochloride hydrate Chemical compound O.Cl.C([C@@](NC1)(CO[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=2C=CC=CC=2)C[C@@]21CCC(=O)N2 GZQWMYVDLCUBQX-WVZIYJGPSA-N 0.000 description 1
- 229950010699 roledumab Drugs 0.000 description 1
- 229940121324 romilkimab Drugs 0.000 description 1
- 229950010968 romosozumab Drugs 0.000 description 1
- 229950010316 rontalizumab Drugs 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 1
- 229950005380 rosmantuzumab Drugs 0.000 description 1
- 229950007463 rovalpituzumab Drugs 0.000 description 1
- 229950009092 rovelizumab Drugs 0.000 description 1
- 229950005039 rozanolixizumab Drugs 0.000 description 1
- 229950005374 ruplizumab Drugs 0.000 description 1
- HNMATTJJEPZZMM-BPKVFSPJSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2s,5z,9r,13e)-13-[2-[[4-[(2e)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
- 229950000106 samalizumab Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229940121325 samrotamab Drugs 0.000 description 1
- 229940060041 satralizumab Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 229940053186 sclerosol Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940060040 selicrelumab Drugs 0.000 description 1
- 229950003850 setoxaximab Drugs 0.000 description 1
- 229950007181 setrusumab Drugs 0.000 description 1
- 229950004951 sevirumab Drugs 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 229950008684 sibrotuzumab Drugs 0.000 description 1
- 229950010077 sifalimumab Drugs 0.000 description 1
- 229940068638 simponi Drugs 0.000 description 1
- 229950009513 simtuzumab Drugs 0.000 description 1
- 229940115586 simulect Drugs 0.000 description 1
- 229950003804 siplizumab Drugs 0.000 description 1
- 229950007210 sirtratumab Drugs 0.000 description 1
- 229950006094 sirukumab Drugs 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229950007874 solanezumab Drugs 0.000 description 1
- 229940055944 soliris Drugs 0.000 description 1
- 229940078986 somatuline Drugs 0.000 description 1
- 229950006551 sontuzumab Drugs 0.000 description 1
- XNZLMZRIGGHITK-VKXBZTRUSA-N soravtansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCC[C@@H](C(O)=O)S(O)(=O)=O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2.CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCC[C@H](C(O)=O)S(O)(=O)=O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 XNZLMZRIGGHITK-VKXBZTRUSA-N 0.000 description 1
- 229950007213 spartalizumab Drugs 0.000 description 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229950002549 stamulumab Drugs 0.000 description 1
- 108010092231 staphylococcal alpha-toxin Proteins 0.000 description 1
- 229940071598 stelara Drugs 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229940090374 stivarga Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 229950010708 sulesomab Drugs 0.000 description 1
- 229950010758 suptavumab Drugs 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 229950001915 suvizumab Drugs 0.000 description 1
- 229940060034 suvratoxumab Drugs 0.000 description 1
- 229940110546 sylatron Drugs 0.000 description 1
- 229940053017 sylvant Drugs 0.000 description 1
- 229940036185 synagis Drugs 0.000 description 1
- 229940022873 synribo Drugs 0.000 description 1
- 229950010265 tabalumab Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095374 tabloid Drugs 0.000 description 1
- 229950001072 tadocizumab Drugs 0.000 description 1
- 229940121503 tafasitamab Drugs 0.000 description 1
- 229940081616 tafinlar Drugs 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 229950007205 talacotuzumab Drugs 0.000 description 1
- 229950004218 talizumab Drugs 0.000 description 1
- 229950009696 tamtuvetmab Drugs 0.000 description 1
- 229950008160 tanezumab Drugs 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 229950007435 tarextumab Drugs 0.000 description 1
- 229940099419 targretin Drugs 0.000 description 1
- 229940069905 tasigna Drugs 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 229940126625 tavolimab Drugs 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 229950001788 tefibazumab Drugs 0.000 description 1
- 229940061353 temodar Drugs 0.000 description 1
- CBPNZQVSJQDFBE-HGVVHKDOSA-N temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HGVVHKDOSA-N 0.000 description 1
- 229950001289 tenatumomab Drugs 0.000 description 1
- 229950000301 teneliximab Drugs 0.000 description 1
- 229950010127 teplizumab Drugs 0.000 description 1
- 229940121339 tepoditamab Drugs 0.000 description 1
- 229950009054 tesidolumab Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229950008998 tezepelumab Drugs 0.000 description 1
- 229940034915 thalomid Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229950007199 tibulizumab Drugs 0.000 description 1
- 229950004742 tigatuzumab Drugs 0.000 description 1
- 229950005515 tildrakizumab Drugs 0.000 description 1
- 229950006757 timolumab Drugs 0.000 description 1
- 229950007123 tislelizumab Drugs 0.000 description 1
- 229950000154 tisotumab Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940083100 tolak Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229950001802 toralizumab Drugs 0.000 description 1
- 229940100411 torisel Drugs 0.000 description 1
- 229950008836 tosatoxumab Drugs 0.000 description 1
- 229950005808 tovetumab Drugs 0.000 description 1
- 229950000835 tralokinumab Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 229940066958 treanda Drugs 0.000 description 1
- 229950010086 tregalizumab Drugs 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 229950006444 trevogrumab Drugs 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 229940086984 trisenox Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000036326 tumor accumulation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 1
- 229950005082 tuvirumab Drugs 0.000 description 1
- 229940094060 tykerb Drugs 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 229950004593 ublituximab Drugs 0.000 description 1
- 229950010095 ulocuplumab Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 229940034796 ultresa Drugs 0.000 description 1
- 229940022919 unituxin Drugs 0.000 description 1
- 229950005972 urelumab Drugs 0.000 description 1
- 229940054870 urso Drugs 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 229950004362 urtoxazumab Drugs 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 229950003520 utomilumab Drugs 0.000 description 1
- 229950000302 vadastuximab Drugs 0.000 description 1
- 229940054937 valstar Drugs 0.000 description 1
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 description 1
- 229940121349 vanalimab Drugs 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 229950008718 vantictumab Drugs 0.000 description 1
- 229950000449 vanucizumab Drugs 0.000 description 1
- 229950000386 vapaliximab Drugs 0.000 description 1
- 229950001067 varlilumab Drugs 0.000 description 1
- 229940074791 varubi Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 229950002148 vatelizumab Drugs 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 229950000815 veltuzumab Drugs 0.000 description 1
- 229950005208 vepalimomab Drugs 0.000 description 1
- 229950010789 vesencumab Drugs 0.000 description 1
- 229940061389 viadur Drugs 0.000 description 1
- 229940065658 vidaza Drugs 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- 229940028393 vincasar Drugs 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 229940034841 viokace Drugs 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
- 229940054221 vistogard Drugs 0.000 description 1
- 229950007269 vobarilizumab Drugs 0.000 description 1
- 229950001212 volociximab Drugs 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229940061144 vonlerolizumab Drugs 0.000 description 1
- 229940121351 vopratelimab Drugs 0.000 description 1
- 229940110059 voraxaze Drugs 0.000 description 1
- 229950006959 vorsetuzumab Drugs 0.000 description 1
- 229940069559 votrient Drugs 0.000 description 1
- 229950003511 votumumab Drugs 0.000 description 1
- 229950000124 vunakizumab Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- JFCFGYGEYRIEBE-YVLHJLIDSA-N wob38vs2ni Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)S)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 JFCFGYGEYRIEBE-YVLHJLIDSA-N 0.000 description 1
- 229940049068 xalkori Drugs 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
- 229940066799 xofigo Drugs 0.000 description 1
- 229940099073 xolair Drugs 0.000 description 1
- 229940085728 xtandi Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229940045208 yescarta Drugs 0.000 description 1
- 229940004212 yondelis Drugs 0.000 description 1
- 229940036061 zaltrap Drugs 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
- 229940007162 zarxio Drugs 0.000 description 1
- 229940034727 zelboraf Drugs 0.000 description 1
- 229940106454 zenpep Drugs 0.000 description 1
- 229950009083 ziralimumab Drugs 0.000 description 1
- 229940072018 zofran Drugs 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
- 229950007157 zolbetuximab Drugs 0.000 description 1
- 229940061261 zolinza Drugs 0.000 description 1
- 229940002005 zometa Drugs 0.000 description 1
- 229940095188 zydelig Drugs 0.000 description 1
- 229940052129 zykadia Drugs 0.000 description 1
- 229940051084 zytiga Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
Definitions
- This disclosure relates to novel ligand-drug particles comprising at least one ligand specific for one or more cell surface receptor molecules for targeting the particles to a target cell.
- This disclosure also relates to pharmaceutical compositions comprising the particles herein and systems and methods for determining the ligand valency of the particles.
- ligand-drug particles have been predominately optimized by trial and error experimentation.
- researchers may traditionally assess the impact of an array of variables on cellular uptake, such as ligand types, ligand surface valency, particle concentration, incubation time, and temperature.
- the present disclosure provides ligand-drug particles whose design is based on the use of particular crosslink multivalent binding model, which considers ligand valence, ligand-target equilibrium dissociation constant, and total receptor expression level on the target cell (i.e., average number of receptors per cell).
- This model has predicted the observed cellular uptake behavior of particular ligand-drugs that target cells expressing HER2, for example, and may be used to design ligand-drug particles with an optimized uptake efficiency of drugs and to reduce the experimentation necessary for determining optimal uptake efficiency for a novel ligand-drug particle.
- the present disclosure contemplates ligand-drug particles comprising a lipid surface layer and an optional coating layer, at least one ligand molecule exposed on the particle surface or on the lipid surface layer, and at least one drug in the interior of the particle or embedded in the lipid surface layer.
- the ligand has a particular valency or range of valency (number of ligands per particle) depending on the affinity of the ligand for its receptor on the cell surface of the target cell and depending on the expression level of the receptor in the target cell (expressed herein as the average number of receptors per cell).
- the ligand-drug particle comprises a lipid surface layer, at least one drug in the interior of the particle or embedded in the lipid surface layer, and a ligand specific for a cell surface receptor on a target cell, wherein: (a) the ligand is exposed on the lipid surface layer; (b) the ligand binds to its receptor with an in vitro binding affinity of 0.001 to 1000 nM; (c) the target cell that the particle targets comprises an average on the order of 103 to 10′ receptors; and (d) the particle has a ligand valency as described in Table 1 or 2, the ligand valency depending upon the ligand-receptor in vitro binding affinity and the average number of receptors per target cell.
- the particle has a ligand valency as follows: (a) a valency of 6-12 where the target cell has an average on the order of 3 ⁇ 10 6 receptors per cell; (b) a valency of 10-19 where the target cell has an average on the order of 1 ⁇ 10 6 receptors per cell; (c) a valency of 10-20 where the target cell has an average on the order of 9 ⁇ 10 5 receptors per cell; (d) a valency of 11-21 where the target cell has an average on the order of 8 ⁇ 10 5 receptors per cell; (e) a valency of 12-23 where the target cell has an average on the order of 7 ⁇ 10 5 receptors per cell; (f) a valency of 13-25 where the target cell has an average on the order of 6 ⁇ 10 5 receptors per cell; (g) a valency of 15-29 where the target cell has an average on the order of 5 ⁇ 10 5 receptors per cell; or (h) a valency of 18-36 where the target cell has
- the ligand-receptor in vitro binding affinity is 0.1 to 10 nM and the particle has a ligand valency as follows: (a) a valency of 8-10 where the target cell has an average on the order of 3 ⁇ 10 6 receptors per cell; (b) a valency of 13-16 where the target cell has an average on the order of 9 ⁇ 10 5 to 1 ⁇ 10 6 receptors per cell; (c) a valency of 14-18 where the target cell has an average on the order of 8 ⁇ 10 5 receptors per cell; (d) a valency of 15-19 where the target cell has an average on the order of 7 ⁇ 10 5 receptors per cell; (e) a valency of 17-21 where the target cell has an average on the order of 6 ⁇ 10 5 receptors per cell; (f) a valency of 19-24 where the target cell has an average on the order of 5 ⁇ 10 5 receptors per cell; or (g) a valency of 24-30 where the target cell has an average on the order
- the ligand-drug particle has a ligand-receptor in vitro binding affinity is 0.001 to 0.1 nM and the particle has a ligand valency as follows, depending on the number of receptors per cell: (a) a valency of 15-24 where the target cell has an average on the order of 4 ⁇ 10 5 to 5 ⁇ 10 5 receptors per cell; (b) a valency of 13-19 where the target cell has an average on the order of 5 ⁇ 10 5 to 6 ⁇ 10 5 receptors per cell; (c) a valency of 12-17 where the target cell has an average on the order of 6 ⁇ 10 5 to 7 ⁇ 10 5 receptors per cell; (d) a valency of 11-15 where the target cell has an average on the order of 7 ⁇ 10 5 to 8 ⁇ 10 5 receptors per cell; (e) a valency of 10-14 where the target cell has an average on the order of 8 ⁇ 10 5 to 9 ⁇ 10 5 receptors per cell; (f) a valency of 10-13 where
- the ligand-receptor in vitro binding affinity is 0.1 to 10 nM and the particle has a ligand valency as follows: (a) a valency of 19-30 where the target cell has an average on the order of 4 ⁇ 10 5 to 5 ⁇ 10 5 receptors per cell; (b) valency of 17-24 where the target cell has an average on the order of 5 ⁇ 10 5 to 6 ⁇ 10 5 receptors per cell; (c) a valency of 15-21 where the target cell has an average on the order of 6 ⁇ 10 5 to 7 ⁇ 10 5 receptors per cell; (d) a valency of 14-19 where the target cell has an average on the order of 7 ⁇ 10 5 to 8 ⁇ 10 5 receptors per cell; (d a valency of 13-18 where the target cell has an average on the order of 8 ⁇ 10 5 to 9 ⁇ 10 5 receptors per cell; (f) a valency of 13-16 where the target cell has an average on the order of 9 ⁇ 10 5 to 1 ⁇ 10 6 receptors per cell; or
- the ligand-receptor in vitro binding affinity is 10 to 1000 nM and the particle has a ligand valency as follows: (a) valency of 24-36 where the target cell has an average on the order of 4 ⁇ 10 5 to 5 ⁇ 10 5 receptors per cell; (b) a valency of 21-29 where the target cell has an average on the order of 5 ⁇ 10 5 to 6 ⁇ 10 5 receptors per cell; (c) a valency of 19-25 where the target cell has an average on the order of 6 ⁇ 10 5 to 7 ⁇ 10 5 receptors per cell; (d) a valency of 18-23 where the target cell has an average on the order of 7 ⁇ 10 5 to 8 ⁇ 10 5 receptors per cell; (e) a valency of 16-21 where the target cell has an average on the order of 8 ⁇ 10 5 to 9 ⁇ 10 5 receptors per cell; (f) a valency of 16-20 where the target cell has an average on the order of 9 ⁇ 10 5 to 1 ⁇ 10 6 receptors per cell;
- the ligand is an antibody, such as an antigen binding fragment of an antibody, such as an Fv, scFv, Fab′, or F(ab′) 2 fragment.
- the lipid surface layer comprises one or more of: phosphatidylcholine, soybean phosphatidylcholine, hydrogenated soybean phosphatidylcholine, egg phosphatidylcholine, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dioleoyl phosphatidylcholine, distearoyl phosphatidylcholine, palmitoyl oleoyl phosphatidylcholine, phosphatidylethanolamine, distearoyl phosphoethanolamine, dimyristoyl phosphatidylethanolamine, dipalmitoyl phosphatidyl phosphatidylethanolamine, dioleoyl phosphatidylethanolamine,
- the lipid surface layer is a lipid bilayer, while in other embodiments, it is a lipid monolayer.
- the at least one drug may comprise a polar, small molecule compound located in an aqueous space at the interior of the particle.
- the at least one drug comprises a hydrophobic, small molecule compound embedded in the lipid surface layer.
- the particle may contain one drug compound, two drug compounds, or more depending on its utility. In some embodiments, the particle also contains further excipients for solubilizing or protecting the drug compound or for maintaining pH, for example.
- the ligand is an antibody and the antibody ligand is selected from: abciximab, adalimumab, adecatumumab, alacizumab, alemtuzumab, alirocumab, aprutumab, atezolizumab, avelumab, basiliximab, batuzumab, belimumab, bemarituzumab, benralizumab, bevacizumab, bezlotoxumab, blinatumomab, brentuximab, brodalumab, brolucizumab, canakinumab, capromab, catumaxomab, certolizumab, cetuximab, citatuzumab, cixutumumab, daclizumab, dalotuzumab, daratumumab, denosumab, depatuxizumab, dinutuxim
- the target cell is a tumor cell, an infectious cell, or an immune cell.
- the particle further comprises a coating comprising polyethylene glycol (PEG).
- ligand-drug particles that comprise two different ligands, specific for two different receptors on a target cell.
- Such ligand-drug particles may comprise a lipid surface layer, at least one drug in the interior of the particle or embedded in the lipid surface layer, and two ligands specific for two different cell surface receptors on a target cell, wherein the ligands are exposed on the lipid surface layer; the ligands bind to their receptors with in vitro binding affinity of 0.1 to 100 nM; the target cell that the particle targets comprises an average on the order of 103 to 10′ of each receptor; and the particle has a ligand valency for each of the two ligands as described in Table 3, the ligand valency depending upon the ligand-receptor in vitro binding affinity or each receptor-ligand pair, the average number of each receptor per target cell, and whether ligand-receptor binding is additive or synergistic.
- the particle has a ligand valency for each of the ligands as follows: (a) a valency of 13-17 where each receptor is highly expressed by the target cell and where binding of the two receptors by the two ligands is additive; (b) valency of 9-13 where each receptor is highly expressed by the target cell and where binding of the two receptors by the two ligands is synergistic; (c) a valency of 13-17 where one receptor is highly expressed by the target cell and the other receptor is moderately expressed, and where binding of the two receptors by the two ligands is additive; (d) a valency of 7-10 where one receptor is highly expressed by the target cell and the other receptor is moderately expressed, and where binding of the two receptors by the two ligands is synergistic; (e) a valency of 15-21 where each receptor is moderately expressed by the target cell and where binding of the two receptors by the two ligands is additive; or (f) a valency of
- the dual-ligand particle has a ligand valency for each ligand as follows: (a) a valency of 17-21 where the in vitro binding affinity for each ligand-receptor pair is on the order of 100 nM and binding is additive; (b) a valency of 16-20 where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 10 nM and binding is additive; (c) a valency of 16-19 where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 1 nM and binding is additive; (d) a valency of 15-19 where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is
- At least one ligand in a dual-ligand particle, is an antibody, or both ligands are antibodies. In some embodiments, at least one ligand is an antigen binding fragment of an antibody, or both ligands are antigen binding fragments of antibodies, such as an Fv, scFv, Fab′, or F(ab′) 2 fragment.
- the lipid surface layer comprises one or more of phosphatidylcholine, soybean phosphatidylcholine, hydrogenated soybean phosphatidylcholine, egg phosphatidylcholine, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dioleoyl phosphatidylcholine, distearoyl phosphatidylcholine, palmitoyl oleoyl phosphatidylcholine, phosphatidylethanolamine, distearoyl phosphoethanolamine, dimyristoyl phosphatidylethanolamine, dipalmitoyl phosphatidylethanolamine, dioleoyl phosphatidylethanolamine, phosphatidylserine, dimyristoyl phosphatidylserine, dipalmitoyl phosphatidylserine, dioleoyl phosphatidylserine, dioleoy
- the lipid surface layer is a lipid bilayer; in others it is a lipid monolayer.
- the at least one drug may comprise a polar, small molecule compound located in an aqueous space at the interior of the particle.
- the at least one drug comprises a hydrophobic, small molecule compound embedded in the lipid surface layer.
- the particle may contain one drug compound, two drug compounds, or more depending on its utility. In some embodiments, the particle also contains further excipients for solubilizing or protecting the drug compound or for maintaining pH, for example.
- an antibody ligand is selected from: abciximab, adalimumab, adecatumumab, alacizumab, alemtuzumab, alirocumab, aprutumab, atezolizumab, avelumab, basiliximab, batuzumab, belimumab, bemarituzumab, benralizumab, bevacizumab, bezlotoxumab, blinatumomab, brentuximab, brodalumab, brolucizumab, canakinumab, capromab, catumaxomab, certolizumab, cetuximab, citatuzumab, cixutumumab, daclizumab, dalotuzumab, daratumumab, denosumab, depatuxizumab, dinutuximab, duligotu
- the target cell is a tumor cell, an infectious cell, or an immune cell.
- the particle further comprises a coating comprising PEG.
- any of the particles contemplated herein may be 10-500 nm, 50-150 nm, 70-120 nm, 80-110 nm, 90-110 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, or 120 nm in diameter.
- This disclosure also contemplates a system for determining ligand valency for a ligand-drug particle, wherein the particle comprises a lipid surface layer, at least one drug in the interior of the particle or embedded in the lipid surface layer, and a ligand specific for a receptor on a target cell, the ligand exposed on the lipid surface layer, the system comprising software capable of determining ligand valency from in vitro ligand-receptor dissociation constant and average number of receptors per target cell according to a crosslink multivalent binding model.
- the disclosure further contemplates a system for determining ligand valency for a ligand-drug particle, wherein the particle comprises a lipid surface layer, at least one drug in the interior of the particle or embedded in the lipid surface layer, and two ligands each specific for a receptor on a target cell, the ligands exposed on the lipid surface layer, the system comprising software capable of determining ligand valency from in vitro ligand-receptor dissociation constants for each ligand-receptor pair and average number of each receptor per target cell and either additive or synergistic binding according to a crosslink multivalent binding model.
- FIG. 1 provides a schematic of monovalent receptor-ligand binding.
- Ligand (L g ) binds to receptor (R) to form a ligand/receptor complex (C Lg ).
- FIGS. 2 A and 2 B show a schematic of the crosslink multivalent binding model of multivalent nanoparticles to monovalent receptors.
- a free nanoparticle binds to a single receptor on the cell surface.
- the nanoparticle binds to a second receptor, and then to a third, as shown in FIG. 2 B at right.
- FIG. 3 provides a cell association of F5 scFv-conjugated immunoliposomes (ILS) with increasing valence in MCF-7/HER2 cells.
- ILS liposomes
- DiD 75 uM PL
- flow cytometry mean fluorescent intensity [MFI] with a tight spread of 5*10 3 cells.
- FIGS. 5 A and 5 B provide crosslink multivalent binding model predictions for all plausible valence and effective valence (f ⁇ v) in high receptor expressing cells.
- FIGS. 6 A and 6 B provide crosslink multivalent binding model predictions in moderate ( FIG. 6 A ) and low ( FIG. 6 B ) receptor expressing cells. Plots of nanoparticle cell association (C Beq ) and free receptors (R eq ) as a function of valence (v) in moderate receptor expressing cells (10 5 #/cell) ( FIG. 6 a ) and low receptor expressing cells (10 4 #/cell) ( FIG. 6 B ) with an effective valence (f) of 10 or v ligands per nanoparticle.
- C Beq nanoparticle cell association
- R eq free receptors
- FIG. 7 provides a crosslink multivalent binding model prediction for increased affinity.
- FIG. 8 provides a plot of optimal calculated valence for a single ligand (#ligands/particle) against equilibrium dissociation constant for ligand-receptor binding under both high receptor expression (on the order of 10 6 ) or moderate receptor expression (on the order of 10 5 ) models. Additional data based on this curve may be found in Table 1 below.
- FIG. 9 A provides a plot of optimal calculated valence for a single ligand (# ligands/particle) against equilibrium dissociation constant for ligand-receptor binding under several different receptor expression levels.
- FIG. 9 B provides the relationship of optimal valence against receptor expression level (# receptors/cell) at different ligand-receptor equilibrium dissociation constants. Additional data based on FIGS. 9 A and 9 B may be found in Table 2 below.
- FIGS. 10 A, 10 B, 10 C and 10 D show a schematic of steps in a synthesis of a Fab′-PEG-DSPE linkage, for example, as means of attaching a Fab′ ligand to a lipid surface layer of a ligand-drug particle.
- FIGS. 11 A and 11 B show a schematic of steps in a synthesis of a peptide or protein ligand (such as EGF or TGF ⁇ ) to PEG-DSPE as a means of attaching the ligand to a lipid surface layer of a ligand-drug particle.
- a peptide or protein ligand such as EGF or TGF ⁇
- FIGS. 12 A and 12 B provide schematics showing how a ligand-PEG-DSPE compound can be incorporated into a lipid surface layer of a liposome particle, by a micelle transfer method ( FIG. 12 A ) or by a sequential micelle transfer-conjugation method ( FIG. 12 B ).
- a micelle transfer method FIG. 12 A
- a sequential micelle transfer-conjugation method FIG. 12 B
- Liposome+Ligand-PEG-DSPE produce a Ligand-Liposome.
- FIG. 12 B Liposome+Mal-PEG-DSPE first yield Mal-Liposome, which is then subject to a further reaction to yield Ligand-Liposome (where Mal stands for maleimide).
- FIGS. 13 A and 13 B provide schematics of constructing two antibody ligand dual-targeted ligand-drug liposome particles via a micelle transfer-conjugation method.
- Liposome+Mal-PEG-DSPE first yields Mal-Liposome, and then Mal is replaced by a Fab′ ligand (cetuximab Fab′) to yield Fab′-Liposome.
- Fab′ ligand cetuximab Fab′
- FIG. 13 B a second scFv ligand (F5 scFv) is added to the liposome.
- FIGS. 14 A- 14 F show concentration profile examples of the cell associated particle concentration at equilibrium (C Beq ) as a function of C Beq (v,fx,R T ,K D ,K X ) under different conditions. Plots of cell associated particle concentration at equilibrium (C Beq ) against valency (ligands/particle) are provided. For optimal cell association, of design interest, for example, are the peak C Beq and its corresponding valences.
- FIGS. 15 A- 15 D show plots of cell associated particle concentration at equilibrium (C Beq ) against valency (ligands/particle) for a multi-targeted multi-valent crosslink binding model under different conditions. These examples depict dual-targeted multi-valent nanoparticles to dual receptors where each ligand/receptor may have unique R T , K D , and/or K X . Additive and synergetic binding benefits were explored. For optimal cell association, of design interest are, for example, the peak C Beq and its corresponding valences.
- FIG. 15 A shows a model where the K DS of the receptor-ligand interactions are both 0.1 nM under additive binding.
- FIG. 15 B shows a model where the K DS of the receptor-ligand interactions are both 0.1 nM under synergistic binding.
- FIG. 15 C shows a model where the K DS of the receptor-ligand interactions are both 1 nM under additive binding.
- FIG. 15 D shows a model where the K DS of the receptor-ligand interactions are both 01 nM under synergistic binding.
- C BeqHH indicates that the cell highly expresses both receptors while C BeqMM indicates that the cell moderately expresses both receptors and C BeqHM indicates that the cell highly expresses one receptor and moderately expresses the other.
- the C BeqH and C BeqM curves show cell association for a corresponding highly expressed and moderately expressed single ligand.
- any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated.
- a “conjugate particle” or “ligand-drug particle” or “particle” herein refers to a composition, generally in the form of an organized particle, comprising one or more lipids, at least one ligand, and at least one drug.
- a “ligand drug particle” is a liposomal particle comprising at least one lipid surface layer into which at least one ligand may be incorporated or to which a ligand may be attached.
- the at least one drug may be incorporated in the interior of a particle, or embedded in a lipid surface layer, or otherwise coated with lipid particles, or may otherwise be attached to the surface of a particle.
- a ligand may be attached to the surface of a particle or interspersed between lipids of a lipid bilayer so that it is sufficiently exposed on the surface of the particle to interact with its intended receptor on a target cell.
- a “particle” may have any shape, but in the case of a lipid-coated particle, is often roughly spherical.
- a particle may be a “liposome” particle.
- a liposome comprises a particle with an aqueous interior that is surrounded by a lipid surface layer.
- the lipid surface layer may be a lipid bilayer or lipid monolayer depending upon which types of lipids are present.
- a “ligand” herein refers to a molecule located in a ligand-drug particle that binds to a receptor molecule on the surface of a target cell.
- a ligand herein is generally a protein, such as an antibody.
- a ligand is an antibody, such as an antigen binding fragment of an antibody.
- a “ligand” herein may merely function to target a ligand-drug particle to a target cell, but in some embodiments, may also itself have biological or therapeutic activity.
- a “drug” as used in the context of a ligand drug particle herein includes any chemical compound that has a therapeutic effect on a disease or condition or that can be used as a diagnostic compound, for example inside an animal cell.
- Drugs include small organic molecules as well as macromolecular therapeutics such as nucleic acid and protein therapeutics. Some drugs are hydrophilic, and thus may be located in an aqueous compartment in a particle such as in the interior, while some drugs are hydrophobic and may be found surrounded by lipids or other hydrophobic molecules, for example, in a lipid surface layer.
- a “target cell” herein refers to a cell to which a ligand-drug particle is intended to bind, such as a tumor cell or an infectious cell or an inflammatory cell.
- a ligand on a ligand-drug particle may bind to a component of a target cell such as a receptor protein, allowing the contents of the particle to enter the cell through endocytosis.
- valence refers to the number of ligands per particle.
- the “effective valence” refers to the number of ligands per particle that are assumed to be able to bind to a target cell. An effective valence might differ from the valence, for instance, due to steric hindrance or other limitations of a particular ligand's ability to bind to its target.
- the term “on the order of” followed by a number means that the actual reported or measured quantity rounds up or down to the numerical quantity provided.
- 8 ⁇ 10 5 and 2 ⁇ 10 6 are each on the order of 10 6 or 1 ⁇ 10 6
- 20 nM and 8 nM are each on the order of 10 nM.
- binding affinity or “equilibrium dissociation constant” or “dissociation constant” or “K D ” are used interchangeably.
- the binding is generally measured in vitro such as in aqueous solution or in cell culture unless specified otherwise.
- the dissociation constant of a binding pair can be assessed using various scientific and surface-based methods including surface plasmon resonance (SPR), biolayer interferometry (BLI), enzyme linked immunosorbent assays (ELISA), affinity capillary electrophoresis (ACE), electrophoretic mobility shift assay (EMSA), and microarray-based platform.
- polypeptide and “protein” are used interchangeably to refer to a polymer of amino acid residues, and are not limited to a minimum length. Such polymers of amino acid residues may contain natural or non-natural amino acid residues, and include, but are not limited to, peptides, oligopeptides, dimers, trimers, and multimers of amino acid residues. Both full-length proteins and fragments thereof are encompassed by the definition.
- the terms also include post-expression modifications of the polypeptide, for example, glycosylation, sialylation, acetylation, phosphorylation, and the like.
- a “polypeptide” refers to a protein which includes modifications, such as deletions, additions, and substitutions (generally conservative in nature), to the native sequence, as long as the protein maintains the desired activity. These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts which produce the proteins or errors due to PCR amplification.
- antibody refers to a molecule comprising at least complementarity-determining region (CDR) 1, CDR2, and CDR3 of a heavy chain and at least CDR1, CDR2, and CDR3 of a light chain, wherein the molecule is capable of binding to antigen.
- CDR complementarity-determining region
- the term “antibody” includes, but is not limited to, fragments that are capable of binding antigen (i.e., “antigen binding fragments”), such as Fv, single-chain Fv (scFv), Fab, Fab′, and (Fab′) 2 .
- the antibody is an Fab′ fragment.
- an antibody comprises a heavy chain variable region and a light chain variable region.
- an antibody comprises at least one heavy chain comprising a heavy chain variable region and at least a portion of a heavy chain constant region, and at least one light chain comprising a light chain variable region and at least a portion of a light chain constant region.
- the antibody comprises a full length light chain (i.e. a complete variable region and a complete constant region).
- the antibody comprises a full length heavy chain.
- the antibody comprises both a full length light chain and a full length heavy chain.
- a single-chain Fv or any other antibody that comprises, for example, a single polypeptide chain comprising all six CDRs (three heavy chain CDRs and three light chain CDRs) is considered to have a heavy chain and a light chain.
- the heavy chain is the region of the antibody that comprises the three heavy chain CDRs and the light chain in the region of the antibody that comprises the three light chain CDRs.
- Ligand-drug particles herein may, for example, comprise liposomal particles.
- Liposomal particles are artificial particles that typically comprise an aqueous interior surrounded by a lipid surface layer such as a lipid bilayer or lipid monolayer. The aqueous interior is favorable to entrap water-soluble drug agents while lipid-soluble hydrophobic drug agents can be partitioned into the lipid bilayer.
- Liposomes may also comprise polyethylene glycol (PEG), for example, to provide a protective layer.
- Ligands may be incorporated into the lipid surface layer, for example, if they are hydrophobic. Excipients may also be included in the particles, for example, to help stabilize or solubilize a drug in the particle or to help maintain a particular pH.
- Liposomes as a drug delivery system may alter the pharmacokinetic profile of the drug encapsulated to the profile of liposomal carrier.
- Some chemotherapeutic drugs that may be encapsulated in the aqueous core or incorporated in the lipid surface layer of a liposome include daunomycin, doxorubicin (e.g., Doxil®), cisplatin, vinorelbine, topotecan, AraC, vinblastine, vincristine, PALA, methotrexate, paclitaxel, and irinotecan.
- Doxil® (Janssen Products, Johnson & Johnson) is a sterically stabilized liposome-encapsulated form of doxorubicin used for the treatment of ovarian cancer, multiple myeloma, and Kaposi's sarcoma, for example.
- the surface of the Doxil® particle, for example, is pegylated.
- Ligand-drug particles herein may be taken up by target cells either passively or actively.
- solid tumors are supported by a discontinuous microvasculature and may have pore sizes varying between 100-780 nm, which allows the passage of large molecules and nanoparticles such as liposomes.
- EPR is limited to pathological sites with affected and leaky vasculature such as solid tumors, sites of inflammations, and infarcted areas.
- Liposomes in the interstitium space are not usually found within tumor cells but are found inside tumor macrophages. Ideally once in the interstitium space, drug leaks at sufficient rate to become bioavailable at the tumor.
- Drug may leak due to instabilities from conditions in the interstitium, plasma protein, enzymes, or liposomal degradation by macrophages. Released drug can act on neighboring cells via a bystander effect. Passive targeting is limited to pathological sites susceptible to the EPR. In addition, it relies on the diffusion of drugs from the liposomes into the cells of interest. As a result, the delivery of drugs that are prone to degradation from the plasma environment may not be ideal for delivery.
- Ligands that induce receptor-mediated endocytosis upon binding can be engineered onto liposomes for the delivery of drugs intracellularly to tumors. Liposomes delivered for solid tumors, for example, may first benefit from passive targeting, accumulating in the tumor interstitium due to the EPR. But ligand targeting also allows for uptake via endocytosis into target cells. Ligand targeting also allows for delivery to other types of target cells such as endothelial cells, infectious cells, and the like.
- All eukaryotic cells exhibit some form of endocytosis to maintain homeostasis, at the cellular level by recovering protein and lipid components and at the organismal level by controlling activities including transmission of neuronal, metabolic, and proliferative signals, nutrient uptake, and defense preparation.
- Multiple types of endocytosis exist including phagocytosis, clathrin-independent endocytosis, and clathrin-dependent endocytosis.
- the endocytosis of many signaling receptors is stimulated by ligand-induced activation, with virtually every signaling receptor family undergoing clathrin-dependent endocytosis.
- attached high affinity ligands may internalize to induce receptor-mediated clathrin-dependent endocytosis upon binding.
- Endocytosis is typically initiated by the binding of transmembrane receptors and their extracellular ligands into cytoplasmic vesicles that are pinched off from the plasma membrane.
- Receptor-ligand complexes are recruited to clathrin-coated pits and invaginate inwards to form clathrin-coated vesicles.
- Endocytosed vesicles fuse with early endosomes, and subsequently receptor-ligand complexes can dissociate and traffic to the recycling compartment containing Rab 11 or to the late endosomal compartment containing Rab7.
- Many receptor-ligand complexes dissociate in the early endosomes due to the slightly acidic pH (pH ⁇ 6.0-6.8). While receptors and ligands in recycling endosomes are returned to the plasma membrane, fusion of late endosomes with lysosomes (pH ⁇ 4.0-5.5) carrying proteolytic enzymes results in cargo degradation.
- Rab proteins small guanosine triphosphate-binding proteins.
- the Rab family is the largest branch of the Ras superfamily with more than 60 members found in mammalian cells. Rab proteins reside in particular types of endosomes and function by recruiting specific effector proteins. Rab proteins distinguish certain intracellular compartments and are involved in vesicle budding, vesicular movement, membrane tethering, membrane docking, and membrane fusion.
- Rab7 is primarily localized on the late endosomes and has been shown to be essential for lysosomes biogenesis.
- Rab11 is primarily localized on the recycling endosomes and has been extensively studied for its involvement in transferrin receptor recycling. Tagged Rab proteins as markers are useful for the isolation and localization of nanoparticles within the late endosomes and the recycling endosomes.
- the ligand-drug particle is a liposome.
- liposomes may be, for example, 10 nm to 500 nm in diameter, such as 50-150 nm in diameter, such as 70-120 nm, 80-110 nm, or 90-110 nm, or 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, or 120 nm.
- liposomes are charge-neutral.
- liposomes comprise a lipid monolayer while in others they comprise a lipid bilayer as a lipid surface layer.
- liposomes comprise a lipid surface layer comprising both one or more phospholipids as well as PEG and/or cholesterol.
- the liposome comprises a PEG coating.
- phospholipids may be neutral or charged, and may be selected from phosphatidylcholine, soybean phosphatidylcholine, hydrogenated soybean phosphatidylcholine, egg phosphatidylcholine, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dioleoyl phosphatidylcholine, distearoyl phosphatidylcholine, palmitoyl oleoyl phosphatidylcholine, phosphatidylethanolamine, distearoyl phosphoethanolamine, dimyristoyl phosphatidylethanolamine, dipalmitoyl phosphatidyl phosphatiidyl phosphati
- they may be selected from phosphatidyl choline, phosphatidylserine, phosphatidylinositol, phosphatidylethanolamine, sphingomyelin, HSPC (hydrogenated soybean phosphatidylcholine), DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), and PLPC (1-palmitoyl-2-lauroyl-sn-glycero-3-phosphocholine).
- HSPC hydrogenated soybean phosphatidylcholine
- DSPC 1,2-distearoyl-sn-glycero-3-phosphocholine
- DSPE 1,2-distearoyl-sn-glycero-3-phosphoethanolamine
- DPPC
- the lipid surface layer may comprise one or more lipids or carriers such as phosphatidylcholine, soybean phosphatidylcholine, hydrogenated soybean phosphatidylcholine, egg phosphatidylcholine, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dioleoyl phosphatidylcholine, distearoyl phosphatidylcholine, palmitoyl oleoyl phosphatidylcholine, phosphatidylethanolamine, distearoyl phosphoethanolamine, dimyristoyl phosphatidylethanolamine, dipalmitoyl phosphatidylethanolamine, dioleoyl phosphatidylethanolamine, phosphatidylserine, dimyristoyl phosphatidylserine, dipalmitoyl phosphatidylserine, dioleoyl phosphatidyl phosphat
- drugs that may be incorporated into the aqueous interior or lipid surface layer of a liposomal particle include, for example, small molecule chemotherapy agents, kinase inhibitors, nucleic acid-based therapeutics, peptide therapeutics and the like. Drugs may also include diagnostic agents, for example, fluorescent or radio-labeled molecules.
- liposomal particles may encapsulate, for example 1-5 ⁇ 10 4 drug molecules per liposome, such as 1.5-4 ⁇ 10 4 drug molecules, or 2-3 ⁇ 10 4 drug molecules.
- a drug is enclosed in the interior space or is embedded in the lipid surface layer of a ligand-drug particle comprising a ligand, and is not covalently attached to a ligand or otherwise covalently attached to the surface of the particle or exposed on the surface of the particle.
- ligands exposed on the lipid surface layer of the particle may be covalently attached to another surface molecule or may be otherwise associated on the surface of the particle, for example, through attachment to a trans-membrane peptide domain that spans a lipid bilayer.
- the ligand is an antibody.
- the ligand is an antigen binding fragment of an antibody.
- the antigen binding fragment is an Fv, scFv, Fab, Fab′, or (Fab′) 2 fragment. In some embodiments, it is an scFv or Fab′ fragment.
- the antibody may be selected from abciximab, adalimumab, adecatumumab, alacizumab, alemtuzumab, alirocumab, aprutumab, atezolizumab, avelumab, basiliximab, batuzumab, belimumab, bemarituzumab, benralizumab, bevacizumab, bezlotoxumab, blinatumomab, brentuximab, brodalumab, brolucizumab, canakinumab, capromab, catumaxomab, certolizumab, cetuximab, citatuzumab, cixutumumab, daclizumab, dalotuzumab, daratumumab, denosumab, depatuxizumab, dinutuximab, duligotuzumab
- a ligand may be selected from: Orthoclone® OKT3 (muromonab-CD3), ReoPro® (abciximab), Zenapax® (daclizumab), Rituxan/Mabthera® (rituximab), Simulect® (basiliximab), Remicade® (infliximab), Synagis® (palivizumab), Herceptin® (trastuzumab), Campath® (alemtuzumab), Humira® (adalimumab), Raptiva® (efalizumab), Zevalin® (ibritumomab tiuxetan), Bexxar® (tositumomab), Avastin® (bevacizumab), Erbitux® (cetuximab), Xolair® (omalizumab), Tysabri® (natalizumab), Vectibix® (panitum
- the ligand may be derived from the antibody component of Mylotarg® (gemtuzumab ozogamicin), Adcetris® (brentuximab vedotin), or Kadcyla® (trastuzumab emtansine).
- the ligand may be selected from: 3f8, 8h9, abagovomab, abciximab, abituzumab, abrezekimab, abrilumab, actoxumab, adalimumab, adecatumumab, adrenomedullin, aducanumab, afasevikumab, afelimomab, afutuzumab, alacizumab, alemtuzumab, alirocumab, altumomab, amatuximab, amphiregulin, anatumomab, andecaliximab, anetumab, angiopoietin, anifrolumab, anrukinzumab, anti-apoptotic survival factor, apolizumab, aprutumab, arcitumomab, artemin, ascrinvac
- a ligand may be attached to a lipid molecule in a particle through a polymer linkage.
- amphiphilic particles of targeting ligands comprising a hydrophilic polymer spacer between a lipid anchor and a ligand group can be attached to the surface of liposomes to offer receptor-specific targeting.
- the particle can be synthesized with three main conjugation methods: reaction between activated carboxyl groups and amino groups yielding an amide bond, reaction between pyridyldithiols and thiols yielding disulfide bonds, and reaction between maleimide derivatives and thiols yielding thioether bonds.
- ligands such as antibody fragments with maleimide chemistry using naturally occurring cysteine residue, engineered C-terminal cysteine, or thiolated with Traut's reagent may provide strong stable bonds. Reactions with the cysteine on antibody fragments can offer ideal orientation, distant from antibody binding site, minimizing interference with binding.
- a polymer linker like PEG also helps with the orientation, extending the ligand far enough from the PEG shielding so the ligand is accessible to receptors on cells.
- a micelle transfer method may be used to construct particles herein.
- micellar conjugates of the ligand and an amphiphilic lipid co-incubated with preformed liposomes spontaneously insert themselves into liposome bilayers without the loss of the liposome integrity, providing a rapid and simple method for transforming non-targeted liposomes into antibody-targeted liposomes. Insertion is performed at 55-60° C., so the denaturation of protein ligands is a concern, but longer overnight incubation at 37° C. is also possible. Liposomes may remain mostly unaltered through conjugations.
- the ligand targets a specific cell surface receptor on a target cell, for example, a receptor that is overexpressed on a particular target cell such as a tumor cell.
- the receptor may comprise one or more of: CD44, GD2, folate receptor, transferrin receptor, CD3, glycoprotein IIb/IIIa, IL-2R ⁇ receptor (CD25), CD20, IL-2R ⁇ receptor (CD25), TNF ⁇ , RSV F protein, ErbB2/HER2, CD52, CD11a, VEGF, VEGFR, EGFR, immunoglobulin E (IgE), alpha-4 ( ⁇ 4) integrin, complement system protein C5, IL-1 ⁇ , IL-6R, BAFF, CD30, CTLA-4, IL-12, IL-23, PD-1, ⁇ 4 ⁇ 7, CD38, or a receptor tyrosine kinase.
- the ligand targets one or more members of the ErbB family of receptor tyrosine kinases.
- the ErbB family consists of four structurally related transmembrane receptor tyrosine kinases EGFR/HER1 (epidermal growth factor receptor/human EGFR 1), HER2 (human EGFR 2), HER3 (human EGFR 3), and HER4 (human EGFR 4).
- EGFR/HER1 epidermal growth factor receptor/human EGFR 1
- HER2 human EGFR 2
- HER3 human EGFR 3
- HER4 human EGFR 4
- HER2 overexpression is also known to occur in ovarian, stomach, prostrate, lung, uterine, pancreas, and thyroid carcinomas.
- EGFR overexpression occurs in many human cancers including breast, lung, colorectal and brain cancers and can result in poor prognosis.
- the ligand may be derived from one or more of cetuximab, panitumumab, zalutumumab, nimotuzumab, and matuzumab. In some embodiments, the ligand does not target HER2 or EGFR, but may target one of the other above receptor proteins.
- the ligand targets a molecule such as one or more of the following: 1-40- ⁇ -amyloid, 4-1BB, SAC, 5′-nucleotidase, 5T4, activated F9, F10, activin receptor-like kinase 1, ACVR2B, adenocarcinoma antigen, adrenomedullin, alpha-4 integrin, alpha-fetoprotein, amphiregulin, amyloid, angiopoietin, angiopoietin 2, angiopoietin 3, anthrax toxin, anti-apoptotic survival factor, AOC3, artemin, autocrine motility factor, AXL, B7-H3, Bacillus anthracis anthrax, BAFF, BAFF-R, BCMA, beta amyloid, betacellulin, B-lymphoma cell, BLyS, bone morphogenetic proteins, C1s, C242 antigen, C5, CA-
- coli shiga toxin type-1 E. coli shiga toxin type-2, ebolavirus glycoprotein, EGFL7, EGFR, EGFR 1-4, EGFR extracellular domain III, endoglin, endotoxin, eotaxin-1, EpCAM, EPHA3, ephrin a2, ephrin a3, ephrin a4, ephrin a5, ephrin b1, ephrin b2, ephrin b3, ephrin receptor A3, ephrins, epidermal growth factor, epigen, epiregulin, episialin, erythropoietin, Escherichia coli , F protein of respiratory syncytial virus, F protein of RSV, Factor Ixa, Factor X, FAP, FCGRT, FGF 23, FGFR2, fibrin II beta chain, fibroblast growth factor 1-23, fibroblast
- the target cell is a tumor cell, such as a solid tumor cell or a lymphoma or leukemia cell.
- the target tumor or tumor-associated cell is selected from a solid tumor cell, a tumor stem cell, or a tumor-associated macrophage.
- the target cell is an infectious cell, such as a bacterial cell, fungal cell such as a yeast cell, or a eukaryotic infectious cell.
- the target cell is an epithelial cell.
- the target cell is an inflammatory cell such as a monocyte or macrophage cell.
- Drugs that can be incorporated into particles herein may comprise any drug molecule capable of inhabiting the interior of a liposome particle or associating with the lipid surface layer of a particle.
- Drugs may include small molecule chemicals as well as peptide or protein drugs and nucleic acid drugs, for example.
- the drug or drugs included in a particle may be anti-cancer drugs, anti-inflammatory agents, chemotherapy drugs, or kinase inhibitors.
- drugs may comprise compounds intended for diagnostic purposes, including dyes or fluorescent or radio-labeled molecules.
- Therapeutic agents compatible with embodiments of ligand-drug particles herein may include agents such as 5-FU (Fluorouracil), Abemaciclib, Abiraterone Acetate, Abitrexate® (Methotrexate), Abraxane® (Paclitaxel Albumin-stabilized Nanoparticle Formulation), ABVD, ABVE, ABVE-PC, AC, Acalabrutinib, AC-T, Actigall®, Actos®, Adcetris® (Brentuximab Vedotin), ADE, Ado-Trastuzumab Emtansine, Adriamycin (Doxorubicin Hydrochloride), Afatinib Dimaleate, Afinitor® (Everolimus), Akynzeo
- ligands should have high affinity binding to the targeted receptors.
- the rapid screening and identifying of tumor-specific high affinity internalizing human antibodies and antibody fragments from phage and yeast display of non-immune phage antibody libraries may be used for ligand selection.
- Access of the ligand to the receptor may also be important.
- a polymer linker such as PEG, for example, may be helpful to distance low molecular weight ligands such as folate from the liposomal surface and to allow receptor binding.
- Coupling of ligands to polymer linkers of various lengths to the distal terminals of antibody fragments and other ligands may improve binding, internalizing, and overall bioactivity in the delivery of drugs.
- the affinity of soluble ligands for their receptors in vitro may not differ drastically from the affinity of ligands conjugated to liposomes for their receptors.
- HER2-overexpressing human breast cancer cells it has been documented that the cell binding and internalization of anti-HER2 immunoliposomes increased at higher surface valency of conjugated ligands, reaching a plateau, depending on ligand, at ⁇ 40 trastuzumab-Fab′/liposome and a plateau at ⁇ 30 F5 scFv/liposome.
- a plateau was reached, depending on ligand, at ⁇ 30-40 cetuximab-Fab′/liposome.
- the limit on the binding and uptake of ligand-conjugated liposomes may be dependent on ligand valency per liposome and receptor expression level rather than on the cells than to ligand affinity.
- a particle comprises more than one targeting ligand.
- a particle may comprise anti-HER2 and anti-EGFR dual-targeted ligands. Dual-targeted particles may allow for the examination of the antagonistic effects of a non-specific ligand possibly from steric hindrance on cells expressing only one of the receptors. Dual-targeting liposomes against HER2 and EGFR may improve the delivery of immunoliposomes to cell lines expressing both receptors by increasing the receptor density, but can also serve to simplify the formulation of ligand-targeted lipid particles that can target a larger array of cells, similar to a cocktail-targeting approach.
- the efficiency of uptake of a ligand-drug particle into a cell increases with the number of ligands found on the particle up to an optimum valency, and then plateaus or decreases as more ligands are added to the particle.
- the present disclosure provides results of mathematical modeling experiments conducted to predict the optimal valency for ligand-drug particles based on the dissociation constant for the ligand and its receptor on the target cell and on the expression level of the receptor by the target cell. For example, as described in the Examples below, an optimal valency for a ligand-drug particle may be determined where the target cell expresses on the order of from 10 3 to 10 7 receptors per cell.
- a value is provided for the number of receptors expressed in a target cell, it is understood that the value is an average number for cells of that type as determined experimentally. Generally such values are rounded to one significant figure.
- a value that is “on the order of,” for instance, 10 5 or 10 6 means a value that would round closest to 1 ⁇ 10 5 or 1 ⁇ 10 6 (for example 9 ⁇ 10 5 would round closest to 1 ⁇ 10 6 while 3 ⁇ 10 5 would round closest to 1 ⁇ 10 5 ).
- a cell providing “high expression” or cell “highly expressing” a particular receptor means a cell that expresses on the order of 10 6 receptor molecules per cell.
- a “moderate expression” cell expresses on the order of 10 5 receptor molecules per cell, while a “low expression” cell expresses on the order of 10 4 receptor molecules per cell.
- Table 1 below (also in the Examples below) provides calculated optimal valence for particles with a single ligand species specific for a receptor with high expression or moderate expression in the target cell, the valence also depending on the in vitro equilibrium dissociation constant of the ligand and receptor.
- ligand-drug particles comprising one ligand may have specific ligand valencies or ranges of ligand valencies depending upon the K D of the ligand-receptor interaction measured in vitro and on the average receptor expression level for the target cells, for example, measured in tissue culture.
- Actual chosen valencies where the R T and K D are on the order of the numbers shown in the two above tables may vary by plus or minus one. For example, for a K D on the order of 10 nM and an R T on the order of 5 ⁇ 10 5 , the valency may be 24+/ ⁇ 1 or 23-25.
- the ligand-drug particle may have a valency of 10-19 ligands per particle, based on Table 1 above. If the target cell moderately expresses the receptor, then the ligand-drug particle may have a valency of 12-23 ligands per particle, based on Table 1 above.
- the specific valency or valency range may depend further on the K D of the ligand for its receptor.
- the particle may have a valency of 15-17, or may have a valency of 15, 16, or 17, or of 16.
- the ligand-receptor K D is on the order of 10 nM (i.e., a value rounding closest to 10 nM), and the receptor is highly expressed as defined above, then the particle may have a valency of 15-17, or may have a valency of 15, 16, or 17, or of 16.
- the ligand-receptor K D is on the order of 1 nM (i.e., a value rounding closest to 1 nM), and the receptor is moderately expressed as defined above, then the particle may have a valency of 16-18, or may have a valency of 16, 17 or 18, or of 17.
- the particle may have a valency of 14-16, or may have a valency of 14, 15, or 16, or of 15. Similar valencies may be determined for a ligand-drug particle embodiment herein for all of the other combinations of R T and K D shown in Tables 1 and 2.
- the particle has a ligand valency as follows: (a) a valency of 6-12 where the target cell has an average on the order of 3 ⁇ 10 6 receptors per cell; (b) a valency of 10-19 where the target cell has an average on the order of 1 ⁇ 10 6 receptors per cell; (c) a valency of 10-20 where the target cell has an average on the order of 9 ⁇ 10 5 receptors per cell; (d) a valency of 11-21 where the target cell has an average on the order of 8 ⁇ 10 5 receptors per cell; (e) a valency of 12-23 where the target cell has an average on the order of 7 ⁇ 10 5 receptors per cell; (f) a valency of 13-25 where the target cell has an average on the order of 6 ⁇ 10 5 receptors per cell; (g) a valency of 15-29 where the target cell has an average on the
- the ligand-receptor equilibrium dissociation constant, measured in vitro, is 0.1 to 10 nM and the particle has a ligand valency as follows: (a) a valency of 8-10 where the target cell has an on the order of 3 ⁇ 10 6 receptors per cell; (b) a valency of 13-16 where the target cell has an average on the order of 9 ⁇ 10 5 to 1 ⁇ 10 6 receptors per cell; (c) a valency of 14-18 where the target cell has an average on the order of 8 ⁇ 10 5 receptors per cell; (d) a valency of 15-19 where the target cell has an average on the order of 7 ⁇ 10 5 receptors per cell; (e) a valency of 17-21 where the target cell has an average on the order of 6 ⁇ 10 5 receptors per cell; (f) a valency of 19-24 where the target cell has an average on the order of 5 ⁇ 10 5 receptors per cell; or (g) a valency of 24-30 where the target cell has
- the ligand-receptor equilibrium dissociation constant, measured in vitro, is 0.01 to 0.1 nM and the particle has a ligand valency as follows: (a) a valency of 7-8 where the target cell has an on the order of 3 ⁇ 10 6 receptors per cell; (b) a valency of 11-13 where the target cell has an average on the order of 9 ⁇ 10 5 receptors per cell; (c) a valency of 12-13 where the target cell has an average on the order of 1 ⁇ 10 6 receptors per cell; (d) a valency of 12-14 where the target cell has an average on the order of 8 ⁇ 10 5 receptors per cell; (e) a valency of 13-15 where the target cell has an average on the order of 7 ⁇ 10 5 receptors per cell; (f) a valency of 15-17 where the target cell has an average on the order of 6 ⁇ 10 5 receptors per cell; (g) a valency of 17-19 where the target cell has an average on the order
- the ligand-receptor equilibrium dissociation constant, measured in vitro, is 0.1 to 1 nM and the particle has a ligand valency as follows: (a) a valency of 8-9 where the target cell has an on the order of 3 ⁇ 10 6 receptors per cell; (b) a valency of 13-14 where the target cell has an average on the order of 9 ⁇ 10 5 receptors per cell; (c) a valency of 13-15 where the target cell has an average on the order of 1 ⁇ 10 6 receptors per cell; (d) a valency of 14-16 where the target cell has an average on the order of 8 ⁇ 10 5 receptors per cell; (e) a valency of 15-17 where the target cell has an average on the order of 7 ⁇ 10 5 receptors per cell; (f) a valency of 17-19 where the target cell has an average on the order of 6 ⁇ 10 5 receptors per cell; (g) a valency of 19-22 where the target cell has an average on the order of 5
- the ligand-receptor equilibrium dissociation constant, measured in vitro, is 1 to 10 nM and the particle has a ligand valency as follows: (a) a valency of 9-10 where the target cell has an on the order of 3 ⁇ 10 6 receptors per cell; (b) a valency of 14-16 where the target cell has an average on the order of 9 ⁇ 10 5 receptors per cell; (c) a valency of 15-16 where the target cell has an average on the order of 1 ⁇ 10 6 receptors per cell; (d) a valency of 16-18 where the target cell has an average on the order of 8 ⁇ 10 5 receptors per cell; (e) a valency of 17-19 where the target cell has an average on the order of 7 ⁇ 10 5 receptors per cell; (f) a valency of 19-21 where the target cell has an average on the order of 6 ⁇ 10 5 receptors per cell; (g) a valency of 22-24 where the target cell has an average on the order of 5 ⁇
- the ligand-receptor equilibrium dissociation constant, measured in vitro, is 10 to 100 nM and the particle has a ligand valency as follows: (a) a valency of 10-11 where the target cell has an on the order of 3 ⁇ 10 6 receptors per cell; (b) a valency of 16-17 where the target cell has an average on the order of 9 ⁇ 10 5 receptors per cell; (c) a valency of 16-18 where the target cell has an average on the order of 1 ⁇ 10 6 receptors per cell; (d) a valency of 18-19 where the target cell has an average on the order of 8 ⁇ 10 5 receptors per cell; (e) a valency of 19-21 where the target cell has an average on the order of 7 ⁇ 10 5 receptors per cell; (f) a valency of 21-23 where the target cell has an average on the order of 6 ⁇ 10 5 receptors per cell; (g) a valency of 24-27 where the target cell has an average on the order of 5
- the ligand-drug particle has a ligand-receptor in vitro binding affinity is 0.001 to 0.1 nM and the particle has a ligand valency as follows, depending on the number of receptors per cell: (a) a valency of 15-24 where the target cell has an average on the order of 4 ⁇ 10 5 to 5 ⁇ 10 5 receptors per cell; (b) a valency of 13-19 where the target cell has an average on the order of 5 ⁇ 10 5 to 6 ⁇ 10 5 receptors per cell; (c) a valency of 12-17 where the target cell has an average on the order of 6 ⁇ 10 5 to 7 ⁇ 10 5 receptors per cell; (d) a valency of 11-15 where the target cell has an average on the order of 7 ⁇ 10 5 to 8 ⁇ 10 5 receptors per cell; (e) a valency of 10-14 where the target cell has an average on the order of 8 ⁇ 10 5 to 9 ⁇ 10 5 receptors per cell; (f) a valency of 10-13 where
- the ligand-receptor in vitro binding affinity is 0.1 to 10 nM and the particle has a ligand valency as follows: (a) a valency of 19-30 where the target cell has an average on the order of 4 ⁇ 10 5 to 5 ⁇ 10 5 receptors per cell; (b) valency of 17-24 where the target cell has an average on the order of 5 ⁇ 10 5 to 6 ⁇ 10 5 receptors per cell; (c) a valency of 15-21 where the target cell has an average on the order of 6 ⁇ 10 5 to 7 ⁇ 10 5 receptors per cell; (d) a valency of 14-19 where the target cell has an average on the order of 7 ⁇ 10 5 to 8 ⁇ 10 5 receptors per cell; (d a valency of 13-18 where the target cell has an average on the order of 8 ⁇ 10 5 to 9 ⁇ 10 5 receptors per cell; (f) a valency of 13-16 where the target cell has an average on the order of 9 ⁇ 10 5 to 1 ⁇ 10 6 receptors per cell; or
- the ligand-receptor in vitro binding affinity is 10 to 1000 nM and the particle has a ligand valency as follows: (a) valency of 24-36 where the target cell has an average on the order of 4 ⁇ 10 5 to 5 ⁇ 10 5 receptors per cell; (b) a valency of 21-29 where the target cell has an average on the order of 5 ⁇ 10 5 to 6 ⁇ 10 5 receptors per cell; (c) a valency of 19-25 where the target cell has an average on the order of 6 ⁇ 10 5 to 7 ⁇ 10 5 receptors per cell; (d) a valency of 18-23 where the target cell has an average on the order of 7 ⁇ 10 5 to 8 ⁇ 10 5 receptors per cell; (e) a valency of 16-21 where the target cell has an average on the order of 8 ⁇ 10 5 to 9 ⁇ 10 5 receptors per cell; (f) a valency of 16-20 where the target cell has an average on the order of 9 ⁇ 10 5 to 1 ⁇ 10 6 receptors per cell;
- the ligand valency may be (a) 35-37; or 35, 36, or 37; or 36 if the ligand-receptor K D is on the order of 1000 nM; (b) 32-34; or 32, 33, or 34; or 33 if the ligand-receptor K D is on the order of 100 nM; (c) 29-31; or 29, 30, or 31; or 30 if the ligand-receptor K D is on the order of 10 nM; (d) 26-28; or 26, 27, or 28; or 27 if the ligand-receptor K D is on the order of 1 nM; (e) 23-25; or 23, 24, or 25; or 24 if the ligand-receptor K D is on the order of 0.1 nM; (f) 20-22; or 20, 21, or 22; or 21 if the ligand-receptor K D is on the order of 1000 nM; (b) 32-34; or 32, 33, or 34; or 33 if the
- the ligand valency may be (a) 28-30; or 28, 29, or 30; or 29 if the ligand-receptor K D is on the order of 1000 nM; (b) 26-28; or 26, 27, or 28; or 27 if the ligand-receptor K D is on the order of 100 nM; (c) 23-25; or 23, 24, or 25; or 24 if the ligand-receptor K D is on the order of 10 nM; (d) 21-23; or 21, 22, or 23; or 22 if the ligand-receptor K D is on the order of 1 nM; (e) 18-20; or 18, 19, or 20; or 19 if the ligand-receptor K D is on the order of 0.1 nM; (f) 16-18; or 16, 17, or 18; or 17 if the ligand-receptor K
- the ligand valency may be (a) 24-26; or 24, 25, or 26; or 25 if the ligand-receptor K D is on the order of 1000 nM; (b) 22-24; or 22, 23, or 24; or 23 if the ligand-receptor K D is on the order of 100 nM; (c) 20-22; or 20, 21, or 22; or 21 if the ligand-receptor K D is on the order of 10 nM; (d) 18-20; or 18, 19, or 20; or 19 if the ligand-receptor K D is on the order of 1 nM; (e) 16-18; or 16, 17, or 18; or 17 if the ligand-receptor K D is on the order of 0.1 nM; (f) 14-16; or 14, 15, or 16; or 15 if the ligand-receptor K D is
- the ligand valency may be (a) 22-24; or 22, 23, or 24; or 23 if the ligand-receptor K D is on the order of 1000 nM; (b) 20-22; or 20, 21, or 22; or 21 if the ligand-receptor K D is on the order of 100 nM; (c) 18-20; or 18, 19, or 20; or 19 if the ligand-receptor K D is on the order of 10 nM; (d) 16-18; or 16, 17, or 18; or 17 if the ligand-receptor K D is on the order of 1 nM; (e) 14-16; or 14, 15, or 16; or 15 if the ligand-receptor K D is on the order of 0.1 nM; (f) 12-14; or 12, 13, or 14; or 13 if the ligand-receptor K D is
- the ligand valency may be (a) 20-22; or 20, 21, or 22; or 21 if the ligand-receptor K D is on the order of 1000 nM; (b) 18-20; or 18, 19, or 20; or 19 if the ligand-receptor K D is on the order of 100 nM; (c) 17-19; or 17, 18, or 19; or 18 if the ligand-receptor K D is on the order of 10 nM; (d) 15-17; or 15, 16, or 17; or 16 if the ligand-receptor K D is on the order of 1 nM; (e) 13-15; or 13, 14, or 15; or 14 if the ligand-receptor K D is on the order of 0.1 nM; (f) 11-13; or 11, 12, or 13; or 12 if the ligand-receptor K D is
- the ligand valency may be (a) 19-21; or 19, 20, or 21; or 20 if the ligand-receptor K D is on the order of 1000 nM; (b) 17-19; or 17, 18, or 19; or 18 if the ligand-receptor K D is on the order of 100 nM; (c) 15-17; or 15, 16, or 17; or 16 if the ligand-receptor K D is on the order of 10 nM; (d) 14-16; or 14, 15, or 16; or 15 if the ligand-receptor K D is on the order of 1 nM; (e) 12-14; or 12, 13, or 14; or 13 if the ligand-receptor K D is on the order of 0.1 nM; (f) 11-13; or 11, 12, or 13; or 12 if the ligand-receptor K D is
- the ligand valency may be (a) 18-20; or 18, 19, or 20; or 19 if the ligand-receptor K D is on the order of 1000 nM; (b) 16-18; or 16, 17, or 18; or 17 if the ligand-receptor K D is on the order of 100 nM; (c) 15-17; or 15, 16, or 17; or 16 if the ligand-receptor K D is on the order of 10 nM; (d) 13-15; or 13, 14, or 15; or 14 if the ligand-receptor K D is on the order of 1 nM; (e) 12-14; or 12, 13, or 14; or 13 if the ligand-receptor K D is on the order of 0.1 nM; (f) 10-12; or 10, 11, or 12; or 11 if the ligand-receptor K D is
- the ligand valency may be (a) 11-13; or 11, 12, or 13; or 12 if the ligand-receptor K D is on the order of 1000 nM; (b) 10-12; or 10, 11, or 12; or 11 if the ligand-receptor K D is on the order of 100 nM; (c) 9-11; or 9, 10, or 11; or 10 if the ligand-receptor K D is on the order of 10 nM; (d) 8-10; or 8, 9, or 10; or 9 if the ligand-receptor K D is on the order of 1 nM; (e) 7-9; or 7, 8, or 9; or 8 if the ligand-receptor K D is on the order of 0.1 nM; (f) 6-8; or 6, 7, or 8; or 7 if the ligand-receptor K D is
- ligand-drug particles that comprise two different ligands, specific for two different receptors on a target cell.
- Such ligand-drug particles may comprise a lipid surface layer, at least one drug in the interior of the particle or embedded in the lipid surface layer, and two ligands specific for two different cell surface receptors on a target cell, wherein the ligands are exposed on the lipid surface layer; the ligands bind to their receptors with in vitro binding affinity of 0.1 to 100 nM; the target cell that the particle targets comprises an average on the order of 103 to 10′ of each receptor; and the particle has a ligand valency that depends upon the ligand-receptor in vitro binding affinity or each receptor-ligand pair, the average number of each receptor per target cell, and whether ligand-receptor binding is additive or synergistic.
- At least one ligand in a dual-ligand particle, is an antibody, or both ligands are antibodies. In some embodiments, at least one ligand is an antigen binding fragment of an antibody, or both ligands are antigen binding fragments of antibodies, such as an Fv, scFv, Fab′, or F(ab′) 2 fragment.
- Table 3 below (also in the Examples below) provides calculated optimal valence of each ligand for particles with two different ligand species specific for two different receptors with high expression or moderate expression in the target cell, the valence also depending on the in vitro equilibrium dissociation constant of the ligand and receptor, and on whether the interaction between the ligands and receptors on the target cell is observed to be additive or synergistic.
- the valence in Table 3 below refers to the valence of each ligand per particle. Thus, for example, if the table indicates an optimal valency of, say, 16, the valency would be 16 for each of the two ligands for a total ligand valency of 32.
- Table 3 which is also provided in the Examples below, provides optimal valence for each ligand calculated based on particular sets of ligand equilibrium dissociation constants and the expression levels of each receptor (high (H) on the order of 1 ⁇ 10 6 or moderate (M) on the order of 1 ⁇ 10 5 ) and whether the binding is additive (a) or synergistic (s).
- the particle has a ligand valency as follows: (a) a valency of 13-17 where each receptor is highly expressed by the target cell and where binding of the two receptors by the two ligands is additive (HHa in Table 3); (b) valency of 9-13 where each receptor is highly expressed by the target cell and where binding of the two receptors by the two ligands is synergistic (HHs); (c) a valency of 13-17 where one receptor is highly expressed by the target cell and the other receptor is moderately expressed, and where binding of the two receptors by the two ligands is additive (HMa); (d) a valency of 7-10 where one receptor is highly expressed by the target cell and the other receptor is moderately expressed, and where binding of the two receptors by the two ligands is synergistic (HMs); (e) a valency of 15-21 where each receptor is moderately expressed by the target cell and where binding of the two receptors by the two ligands is additive (HHa in Table 3); (
- the dual-ligand particle has a ligand valency as follows: (a) a valency of 17-21 where the in vitro binding affinity for each ligand-receptor pair is on the order of 100 nM and binding is additive; (b) a valency of 16-20 where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 10 nM and binding is additive; (c) a valency of 16-19 where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 1 nM and binding is additive; (d) a valency of 15-19 where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is additive; (e)
- the dual-ligand particle has a ligand valency as follows, where the target cell highly expresses both receptors: (a) a valency of 16-18; or 16, 17, or 18; or 17, where the in vitro binding affinity for each ligand-receptor pair is on the order of 100 nM and binding is additive; (b) a valency of 15-17; or 15, 16, or 17; or 16, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 10 nM and binding is additive; (c) a valency of 15-17; or 15, 16, or 17; or 16, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 1 nM and binding is additive; (d) a valency of 14-16; or 14, 15, or 16; or 15, where the in vitro binding affinity
- the dual-ligand particle has a ligand valency as follows, where the target cell moderately expresses both receptors: (a) a valency of 20-22; or 20, 21, or 22; or 21, where the in vitro binding affinity for each ligand-receptor pair is on the order of 100 nM and binding is additive; (b) a valency of 19-21; or 19, 20, or 21; or 20, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 10 nM and binding is additive; (c) a valency of 18-20; or 18, 19, or 20; or 19, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 1 nM and binding is additive; (d) a valency of 18-20; or 18, 19, or 20; or 19, where the in vitro binding
- the dual-ligand particle has a ligand valency as follows, where the target cell highly expresses one receptor and moderately expresses the other: (a) a valency of 16-18; or 16, 17, or 18; or 17, where the in vitro binding affinity for each ligand-receptor pair is on the order of 100 nM and binding is additive; (b) a valency of 16-18; or 16, 17, or 18; or 17, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 10 nM and binding is additive; (c) a valency of 16-18; or 16, 17, or 18; or 17, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 1 nM and binding is additive; (d) a valency of 16-18; or 16, 17, or 18; or 17,
- the equilibrium dissociation constant for a particular ligand will have been previously measured in vitro, and this information may be used to obtain an optimal ligand valence for a particle comprising that ligand.
- some reported equilibrium dissociation constants for potential ligand molecules include: abciximab 5 nM, adalimumab 0.05-0.1 nM, alemtuzumab 3-10 nM, atezolizumab 0.4 nM, avelumab 0.7 nM, basiliximab 0.1 nM, belimumab 0.1-0.3 nM, benralizumab 0.016 nM, bevacizumab 0.5-20 nM, bezlotoxumab 0.02-0.04 nM, blinatumomab 1.5 nM, brentuximab 0.2 nM, brodalumab 0.24 nM, canakinumab 0.02-1.3 nM,
- cell lines from disease models may be used to estimate the expression level of target cells in a human patient, for example.
- ligand-drug particles with one or more ligands specific for the epidermal growth factor receptor (EGFR) one can obtain cancer cell lines such as MDA-MB-468, MB-MB-231, and MCF-7 with published 1-1.3*10 ⁇ circumflex over ( ) ⁇ 6 EGFR/cell, 1-1.3*10 ⁇ circumflex over ( ) ⁇ 5 EGFR/cell, and 1-1.5*10 ⁇ circumflex over ( ) ⁇ 4 EGFR/cell respectively.
- HER2-overexpressing cancer cell lines such as BT474 (10 ⁇ circumflex over ( ) ⁇ 6 HER2/cell), SK-BR-3 (3*10 ⁇ circumflex over ( ) ⁇ 6 HER2/cell), etc.
- BT474 10 ⁇ circumflex over ( ) ⁇ 6 HER2/cell
- SK-BR-3 3*10 ⁇ circumflex over ( ) ⁇ 6 HER2/cell
- Valency (number of ligands per particle) may be measured experimentally, for example, from the ratio of protein to phospholipid (see references 35, 36, 38, 42, 44 below).
- phospholipid concentration of a ligand-drug particle can be measured by a phosphate assay (ref. 118) or high performance liquid chromatography (HPLC).
- Ligand concentration of a ligand-drug particle can be determined by ImageJ® (National Institutes of Health) from SDS-PAGE stained with SYPRO® Ruby.
- Protein quantification methods are possible such as BCA Protein Assay Kit (Thermo Scientific), Quant-iT® Protein Assay Kit (Life Technologies), SDS-PAGE (Bio-Rad), UV spectrometry, and HPLC. All measurements are against a phosphate or protein standard. For example, for a liposome size of 100 nm in diameter and an average area per phospholipid molecule of 75 ⁇ circumflex over ( ) ⁇ 2, this gives an average of 80,000 phospholipid molecules per liposome.
- Antibodies have an average molecular weight of 150-160 kDa, Fab′ of ⁇ 50 kDa, and scFv of ⁇ 25 kDa.
- Protein concentration to phospholipid concentration provides the protein to phospholipid ratio, which with the phospholipid per particle and protein per ligand correction factors, determine the valency.
- Other techniques are also possible such as dual measurements of protein and lipid through HPLC, labeling the ligands and/or lipids with a fluorescent marker for quantification, or secondary component measurements such as quantification of encapsulated drug or embedded cholesterol or PEG.
- This disclosure also contemplates systems for determining ligand valency for a ligand-drug particle, wherein the particle comprises a lipid surface layer, at least one drug in the interior of the particle or embedded in the lipid surface layer, and a ligand specific for a receptor on a target cell, the ligand exposed on the lipid surface layer, the system comprising software capable of determining ligand valency from in vitro ligand-receptor dissociation constant and average number of receptors per target cell according to a crosslink multivalent binding model.
- the disclosure also contemplates systems for determining ligand valency for a ligand-drug particle, wherein the particle comprises a lipid surface layer, at least one drug in the interior of the particle or embedded in the lipid surface layer, and two ligands each specific for a receptor on a target cell, the ligands exposed on the lipid surface layer, the system comprising software capable of determining ligand valency from in vitro ligand-receptor dissociation constants for each ligand-receptor pair and average number of each receptor per target cell and either additive or synergistic binding according to a crosslink multivalent binding model.
- software may be used, for example, to determine an optimal valency based on methods described in Example 1 below.
- a ligand-receptor K D and a receptor expression level e.g., number of receptors per target cell; R T
- C Beq the number of cell-associated particles per cell at equilibrium
- valences ratios of 1:1 for each ligand duals were accessed; other combinations can also be examined.
- a working range of K D and R T were examined and disclosed as examples.
- These calculations also display the cellular uptake levels of ligand-drug particles.
- Other mathematical software are possible to assist in the calculations such as Mathcad®, Matlab®, Maple®, Mathematica®, Python®, R, etc.
- R eq is the number of free receptors per cell at equilibrium
- C Beq is the number of cell-associated particles per cell at equilibrium
- R T is the total number of receptors per cell
- L o which is the free particle concentration in solution
- K D is the equilibrium dissociation constant of the ligand for its receptor on the cell
- v valence
- f is the effective valence, which is essentially the effective number of ligands per particle that can bind to a cell out of the total valence (v)
- K X k x /k ⁇ x is the crosslinking equilibrium constant
- Nanoparticles such as ligand-drug particles are multivalent. Nanoparticles are nanometers in size, for example 10-500 nm in length or diameter. The first bond of a single ligand on a nanoparticle to a single receptor on the cell surface can still be applied with the base model, but subsequent interactions should be considered and adjusted to more accurately model the avidity.
- the receptor can interact with other receptors and proteins, forming ternary complexes.
- the ErbB family of receptor tyrosine kinases such as EGFR and HER2 are known to form dimers, for example.
- the affinity of ligands to single receptors compared to dimers, whether with one or more binding sites occupied, can greatly change the binding and internalizing kinetics, with the later, dimerization with higher binding site occupancy usually associated with higher affinity(133, 138, 141).
- the separation distance between the sites of a bivalent antibody is between 9 and 20 nm(135, 142, 143).
- the separation between ligands is approximately 40 nm assuming equal distribution. This distance can be slightly greater through a polymer linker attached to the ligand. Due to the spacing of the targeting groups on a nanoparticle such as a ligand-drug liposome particle, it is unlikely for a single nanoparticle to occupy both sites of a bivalent receptor or even occupy both dimerized receptors. Hence, it is assumed that nanoparticles with functional monovalent ligands can only occupy one site per single receptor or set of dimerized receptors. This simplifies the model, treating the receptors as monovalent.
- nanoparticles are large, increasing interaction with multiple components on a cell such as additional receptors, proteins, lipids, and macromolecules that may induce binding.
- Non-specific binding can skew a binding model.
- Immunoliposomes are coated with a layer of polyethylene glycol, providing sterical stabilization that limits the non-specific binding and interaction with cells. Therefore, it is assumed that non-specific binding is minimal, as also evident by low cell association for non-targeted liposomes.
- the experimental studies mainly focused on targeting cancer cells that overexpressed receptors, specifically EGFR and HER2, and likewise, these may be used as targets of the model.
- the receptor to ligand per surface area ratio is 5, meaning that for every ligand there are 5 receptors available to bind.
- Crosslink multivalent binding of liposomes to multiple receptors is a possible and plausible outcome.
- the crosslink multivalent binding model for multivalent ligands to monovalent receptors was applied to model the cell association of nanoparticles ( FIG. 2 A- 2 B ).
- R T R eq ⁇ [ 1 + v ⁇ ( L o K D ) ⁇ ( 1 + K X ⁇ R eq ) f - 1 ] ( 5 - 3 ⁇ b )
- C ieq [ f ! i ! ⁇ ( f - i ) !
- the free nanoparticle concentration in solution (L o ) is 10 6 nanoparticles per cell ( ⁇ 70-100 ⁇ M PL), which is approximately the saturating concentration observed at the optimal cell association.
- K X of 1/(10K #/cell) and 1/(3K #/cell) were estimated, respectively.
- R eq The number of free receptors per cell at equilibrium
- C Beq the number of cell associated nanoparticles per cell at equilibrium
- Moderate and low receptor expression models were also considered ( FIG. 6 A- 6 B ).
- the crosslink multivalent binding model allows researchers to estimate the optimum valence and cell association by knowing the dissociation constants of the ligand and the receptor expression level of a cell.
- the current systems may have already been optimized purely from experimental data. Varying monovalent ligand valency beyond the 10+v range will not significantly alter the binding and uptake of nanoparticles.
- the model also predicted the limitations of ligand affinity as experimentally observed by Zhou and associates, where ultrahigh affinity anti-EGFR scFv is unnecessary for optimal nanoparticle targeting(93).
- Zhou empirically detected an increase of 24% in targeted liposomal cell association when comparing surface attached C10 scFv (264 nM K D ) to 224 scFv (0.94 nM K D ).
- the affinity must be improved by an order of 5 magnitudes to merely increase cell association by 2-fold ( FIG. 7 ).
- the model has been expanded to design and optimize the uptake efficiency of ligand-based drugs and nanomedicines relative to ligand surface valency, receptor expression level, mono-targeting as well as dual-targeting to multiple receptors, multi-targeted and multi-valent, and ultimately the consequential biological activity in the delivery of drugs for any ligand and to any antigen target.
- ranges of equilibrium dissociation constants in the literature are abciximab 5 nM, adalimumab 0.05-0.1 nM, alemtuzumab 3-10 nM, atezolizumab 0.4 nM, avelumab 0.7 nM, basiliximab 0.1 nM, belimumab 0.1-0.3 nM, benralizumab 0.016 nM, bevacizumab 0.5-20 nM, bezlotoxumab 0.02-0.04 nM, blinatumomab 1.5 nM, brentuximab 0.2 nM, brodalumab 0.24 nM, canakinumab 0.02-1.3 nM, certolizumab 0.09 nM, cetuximab 0.1-0.4 nM, daclizumab 0.3-0.5 nM, daratumumab 4.4 nM, denosumab 0.003
- For optimal cell association, of design interest are the peak C Beq and its corresponding valences. Table 3 below shows the optimal valencies from application of the model to particles with two ligands binding to two different receptors on a target cell.
- Optimal Multi-Targeted Multi-Valent Binding For Any Ligand and to Any Antigen Target Optimal Multi-Valent Binding: Dual-Targeted K D (nM) Valence (Ligands/Particle) Ligand 1 Ligand 2 HHa HMa MMa HHs HMs MMs 100 100 17 17 21 13 10 15 100 10 16 17 20 13 10 15 100 1 16 17 19 13 10 15 100 0.1 15 17 19 13 10 15 10 10 16 16 19 12 9 13 10 1 15 16 18 12 9 13 10 0.1 14 16 17 12 9 13 1 1 14 14 17 10 8 12 1 0.1 13 14 16 10 8 12 0.1 0.1 13 13 15 9 7 11
- HER2-targeting liposomes were functionalized with an antigen-binding fragment (Fab′) derived from trastuzumab or F5 single-chain variable fragment (scFv).
- Fab′ antigen-binding fragment
- scFv F5 single-chain variable fragment
- EGFR-targeting liposomes were functionalized with a Fab′ derived from cetuximab, or with epidermal growth factor (EGF), or transforming growth factor alpha (TGF ⁇ ).
- the surface attachment of ligand conjugates onto liposomes was achieved by the micelle transfer method or a novel sequential micelle transfer-conjugation method.
- dual-targeted immunoliposomes of various ligand ratios of anti-HER2 F5 scFv and anti-EGFR cetuximab-Fab′ were constructed.
- EGF and TGF ⁇ were investigated as potential targeting groups for liposomal delivery to EGFR-expressing cell lines. Cell association, uptake, and cytotoxicity studies were performed on a panel of human breast cancer cell lines that express either or both HER2 and EGFR at different expression levels.
- HER2-overexpessing and EGFR-overexpressing cell lines the receptor-mediated uptake studies confirmed the observation that increasing ligand valency per liposome increases targeted uptake until saturation (trastuzumab, F5 scFv, and cetuximab).
- ligand surface valencies at optimum binding and higher, as well as high liposomal concentration in incubation there is roughly a 1:1 ratio of ligands to expressed receptors for MCF-7/HER2, BT-474, SK-BR-3, and MDA-468 cells.
- liposomes and ligands for anti-HER2 and anti-EGFR dual-targeted immunoliposomes were roughly additive of their mono-targeted counterparts in BT-474 and MKN-7 cells.
- No antagonistic effects were observed from the additional of a non-targeted ligand in all cell lines except for SK-BR-3 cells unless beyond 10 anti-EGFR ligand per liposome, where anti-EGFR ligands decreased overall uptake.
- dual-targeted liposomal delivery of doxorubicin to cell lines expressing HER2 and EGFR was only slightly better in the inhibition of cell proliferation.
- an array of anti-HER2, anti-EGFR, and dual-targeted lipid nanoparticles at varying ligand valencies were formulated.
- the various engineered liposomal formulations served as probes to help understand the uptake efficiency of liposomes relative to ligand surface valency and receptor expression level, mono-targeting as well as dual-targeting to multiple receptors, intracellular trafficking, and ultimately the consequential biological activity in the delivery of drugs.
- Liposomes were approximately 80-120 nm in diameter, composed of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), and a fluorescent lipophilic tracer 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine perchlorate (DiD), or 3,3′-dioctadecyloxacarbocyanine perchlorate (DiO).
- doxorubicin or paclitaxel were also encapsulated.
- Amphiphilic targeting ligand conjugates synthesized by maleimide chemistry consisting of a hydrophilic polymer spacer PEG between a lipid anchor DSPE and a ligand group were attached to the surface of liposomes to offer receptor-specific targeting.
- the conjugation of ligands such as antibody fragments by reactions between maleimide derivatives and thiols using naturally occurring cysteine residue, engineered C-terminal cysteine, or thiolated with Traut's reagent provide strong stable thioether bonds. Reactions with the cysteine on antibody fragments can offer ideal orientation, distant from antibody binding site, minimizing interference with binding.
- a polymer linker like PEG also helps with the orientation, extending the ligand far enough from the PEG shielding so the ligand are accessible to receptors on cells.
- Fab′ conjugates of cetuximab and trastuzumab with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000]) (Mal-PEG-DSPE) were synthesized as previously described(35, 36), taking advantage of the naturally occurring cysteine residue of Fab′. Briefly, cetuximab and trastuzumab IgG were cleaved with pepsin to two antigen-binding fragments connected by disulfide bonds (Fab 2 ), reduced with cysteamine to Fab′, and conjugated to Mal-PEG-DSPE ( FIG. 10 A- 10 D ).
- Fab′-PEG-DSPE The yielded efficiency of Fab′-PEG-DSPE confirmed by size-exclusion chromatography and SDS-PAGE was a reasonable 25-50%. Unfortunately, Fab′ conjugates derived from Mal-PEG-DSPE manufactured by Avanti Polar Lipids poorly incorporated to the surface of liposomes by the micelle transfer method.
- micellar conjugates of the ligand and an amphiphilic lipid co-incubated with preformed liposomes spontaneously insert themselves into liposome bilayers without the loss of the liposome integrity(47), providing a rapid and simple method for transforming non-targeted liposomes into antibody-targeted liposomes(48, 49) ( FIG. 12 A- 12 B ). Insertion is performed at 50-60° C., so the denaturation of protein ligands is a concern, but longer overnight incubation at 37° C. is also possible(34, 48). Liposomes remain mostly unaltered through conjugations, and the techniques have shown to be simple and reproducible.
- insertion efficiency for ligand conjugates of F5 scFv-PEG-DSPE, EGF-PEG-DSPE and TGF ⁇ -PEG-DSPE onto liposomes via the micelle transfer method(35, 44) was highly efficient (90-100%).
- the insertion efficiency of Fab′-PEG-DSPE from trastuzumab and cetuximab onto liposomes was low (5-10%). No more than 10 Fab′ per liposome was possible despite an excessive concentration of Fab′-PEG-DSPE incubation, and receptor-specific cell association was low.
- Mal-PEG-DSPE available from Avanti Polar Lipids conjugated to small ligands (F5 scFv, EGF, and TGF ⁇ ) is effective for liposomal insertion by the micelle transfer method, but is also effective for Fab′ if Mal-PEG-DSPE is sequential micelle transfer-onto liposomes prior to Fab′ conjugation.
- Another benefit of the sequential micelle transfer-conjugation method is the reduced exposure of the ligands to high temperature incubations required of micelle transfer. This may help with protein stability. Compared to constructing liposomes pre-consisting of Mal-PEG-DSPE, this method allows for a more controlled means to functionalized pre-existing liposomes. Finally, the method also allows for the serial addition of a second targeting group in the case of anti-HER2 and anti-EGFR dual-targeted.
- liposomes of varying ligand valencies of anti-HER2 F5 scFv (0-40 ligands/liposomes), anti-EGFR cetuximab-Fab′ (0-60 ligands/liposomes), and combinations of both for dual-targeting were constructed.
- Conjugate incorporation efficiency was measured and determined by ImageJ (National Institutes of Health) from SDS-PAGE (Bio-Rad) stained with SYPRO Ruby. Because the conjugation efficiency of cetuximab-Fab′ to Mal-PEG-DSPE sequential micelle transfer-conjugated liposomes was variable at 25-50%, lower than the ⁇ 100% insertion efficiency of F5 scFv-PEG-DSPE, a range of cetuximab-Fab′ conjugated immunoliposomes were first constructed and quantified for ligand valency. From these, cetuximab-Fab′ conjugated liposomes of desired ligand valencies were selected for F5 scFv-PEG-DSPE micelle transfer. Cell association studies showed ligand valency dependent binding of liposomes with cells overexpressing HER2 and/or EGFR, and were further investigated for dose-uptake and cytotoxicity studies.
- EGF and TGF ⁇ were thiolated with Traut's reagent, conjugated to Mal-PEG-DSPE, and micelle transferred onto liposomes.
- EGF and TGF ⁇ are well characterized, little has been documented for their EGFR-targeting capabilities as functional groups on liposomes in EGFR-overexpressing cells.
- Cell association studies of EGF-conjugated and TGF ⁇ -conjugated liposomes in EGFR-overexpressing MDA-468 cells were conducted to determine optimum ligand valencies, incubation times, and phospholipid concentrations.
- MDA-468 cells were incubated with EGFR-targeted liposomes labeled with DiD of varying ligand valencies of EGF (0-50 ligands/liposomes) and TGF ⁇ (0-50 ligands/liposomes) at 37° C. for 1-24 hr, 0-750 ⁇ M PL, and analyzed by flow cytometry and fluorometry.
- EGF and TGF ⁇ ligands per liposomes correlated to amplified targeted binding in MDA-468 cells until a plateau. Similar to the binding results of other anti-HER2 and anti-EGFR targeted immunoliposomes, maximum binding was achieved at ⁇ 20 ligand per liposome for both EGF-conjugated and TGF ⁇ -conjugated liposomes. Although the ligand valency ratio dependent uptake was similar for 0-50 ligands per liposomes, the binding of EGF-conjugated liposomes was 10-fold higher than that of TGF ⁇ -conjugated liposomes. By increasing the incubation times from 1-11 hr, binding also increased but saturation was not reached.
- EGF-conjugated and TGF ⁇ -conjugated liposomes also exhibited 1-2 magnitude lower cell association than cetuximab-conjugated immunoliposomes as expected since the equilibrium dissociation constant for cetuximab (0.1-0.4 nM)(116) is one magnitude lower than that of the growth factors.
- the plateau is harder to reach despite higher concentrations and incubation times.
- EGFR is not depleted, insuring a constant stream of binding and uptake.
- EGF-conjugated and TGF ⁇ -conjugated liposomes proved effective in cell association with MDA-468 cells.
- the modeling of crosslink multivalent binding of lipid nanoparticles to monovalent receptors can offer some insights on the relationship of equilibrium dissociation constant and cell association.
- HER2 and EGFR moderately expressing MKN-7 cells
- binding was low but significant for HER2-targeted and EGFR-targeted immunoliposomes in comparison to non-targeted liposomes ( ⁇ 300 fold>NT).
- maximum binding was observed at ⁇ 20 cetuximab-Fab′ per liposome for EGFR-targeted immunoliposomes and ⁇ 15-20 F5 scFv per liposome for HER2-targeted immunoliposomes in MKN-7 cells.
- Dual-targeted immunoliposomes resulted in higher binding than their mono-targeted counterparts ( ⁇ 500 fold>NT), indicating possible synergistic or additive effects.
- the cell association studies were quick preliminary tests for targeted functionality and were further investigated in the dose-uptake studies.
- Dual-targeted immunoliposomes resulted in similar cell association as EGFR-targeted immunoliposomes, confirming negligible HER2 binding as well as a lack of antagonistic effects from additional non-targeted functional groups or sterical hindrance.
- BT-474 cells overexpress HER2, they also moderately express EGFR, corroborating with the results for high HER2-targeted and low EGFR-targeted cell association.
- potential additive effects were observed with dual-targeted liposomes only with low F5 scFv valencies. Again, no antagonistic binding effects were observed for dual-targeted immunoliposomes.
- MKN-7 cells express moderate levels of both HER2 and EGFR, and accordingly moderate cell association with immunoliposomes targeting either receptor was observed. Dual-targeted immunoliposomes resulted in higher cell association than all mono-targeted counterparts.
- immunoliposomes with dual-targeting to HER2 and EGFR may increase cell association with targeted cells when conditions are not optimum, in the case of low F5 scFv valencies in BT-474 cells and moderately HER2-expressing and EGFR-expressing MKN-7 cells. Based on these results, ligand valencies were chosen for uptake studies for further investigation.
- trastuzumab is higher when attached to immunoliposomes or as a free antibody in HER2-overexpressing cell lines.
- an uptake study was conducted and evaluated by fluorometry.
- MCF-7/HER2 and BT-474 cells were oversaturated with trastuzumab labeled with Alexa Fluor 488 (40 nM) or immunoliposomes labeled with DiD (23 trastuzumab-Fab′ per liposome, 375 ⁇ M PL).
- trastuzumab as an IgG and trastuzumab-Fab′ from the immunoliposomes were comparable in MCF-7/HER2 cells, 5-7*10 5 ligands per cell (P ⁇ 0.1). Although the accumulation was significantly different in BT-474 cells, 0.8-1.2*10 6 trastuzumab ligands per cell (P ⁇ 0.002), they were in the same range.
- HER2 is overexpressed in the human breast cancer cell lines BT-474 (10 6 HER2/cell)(44, 124) and MCF-7/HER2 (10 6 HER2/cell)(44, 125). Regardless as a free antibody or conjugated as an antibody fragment onto liposomes, the total accumulation of the trastuzumab ligands is close to a 1:1 ratio of ligands to HER2 expressed on BT-474 and MCF-7/HER2 cells. This raises an interesting question in the targeted delivering of drugs, whether it is more efficient as an antibody-ligand-drug such as trastuzumab emtansine (Roche) or drug-encapsulated liposomal formulations?
- an antibody-ligand-drug such as trastuzumab emtansine (Roche) or drug-encapsulated liposomal formulations?
- Typical immunoliposomes (100 nm) can encapsulate 15-40*10 3 drug molecules per liposome, but may require 15-40 ligands per liposome for optimum delivery(4).
- the total maximum accumulation of liposomal particles compared to antibody-drug particles can be 1-2 magnitudes less due to the rate limiting 1:1 ratio of ligands to HER2 expressed.
- immunoliposomes still offer roughly a 3 magnitude advantage in drug delivery over antibody-ligand-drugs (assuming 1:1 ratio) due to the high drug-loading efficiency and large payload of liposomal delivery.
- the advantage may be even higher in vivo due to other benefits from liposomal delivery compared to antibody-bound delivery, such as increased drug stability, prolonged circulation, and enhanced permeability and retention effect.
- Immunoliposomes consisted of varying ligand valencies of anti-HER2 F5 scFv (0-15 ligands/liposomes), anti-EGFR cetuximab-Fab′ (0-20 ligands/liposomes), and combinations of both for dual-targeting. Similar studies using immunoliposomes labeled with DiD, loaded with doxorubicin, and slightly different ligand combinations were also evaluated and yielded comparable results (data not shown).
- Immunoliposomes with varying cetuximab-Fab′ valencies had no significant uptake compared to non-targeted liposomes. There is higher uptake of anti-HER2 targeted immunoliposomes in SK-BR3 cells than in BT-474 cells.
- the MDA-468 human breast cancer cell line overexpresses roughly 10 6 EGFR per cell(126, 127) but negligible HER2, and the SK-BR-3 human breast cancer cell line overexpresses 2-3*10 6 HER2 per cell(128, 129) but negligible EGFR.
- the plateau there is roughly a 1:1 ratio of ligands to receptors for both cell lines with their respective overexpressed receptors.
- non-specific anti-HER2 ligands did not interfere with targeted uptake.
- non-specific anti-EGFR ligands can interfere with targeted uptake in an antagonistic manner beyond 10 anti-EGFR ligands per liposome.
- 10 anti-EGFR ligands per liposome there is no significant effect.
- mono-targeted cetuximab-immunoliposomes had no significant uptake compared to non-targeted liposomes, in the case of anti-HER2 and anti-EGFR dual-targeted immunoliposomes with 20 cetuximab-Fab′ per liposome, uptake was lower for all combinations with F5 scFv compared to mono-targeted counterparts.
- F5 scFv-ILS reached a plateau at ⁇ 100-200 ⁇ M PL, resulting in ⁇ 7*10 4 liposomes and ⁇ 1*10 6 F5 scFv per cell.
- F5 scFv there is again roughly a 1:1 ratio of ligands to receptors, similar ratios seen from trastuzumab as an IgG and trastuzumab-Fab′ from the immunoliposomes.
- Immunoliposomes with varying cetuximab-Fab′ valencies exhibited low uptake ( ⁇ 2*10 4 liposomes/cell), but significantly higher compared to non-targeted liposomes.
- uptake was significantly higher compared to anti-HER2 immunoliposomes of similar F5 scFv valencies (P ⁇ 4*10 ⁇ 3 for ExH15; P ⁇ 8*10 ⁇ 5 for ExH10; P ⁇ 9*10 ⁇ 5 for ExH5).
- dual-targeted immunoliposomes resulted in 1.2*10 6 F5 scFv per cell, which is also the additive accumulation of mono-targeted F5 scFv (1*10 6 F5 scFv/cell) and cetuximab-ILS (2*10 5 F5 scFv/cell, extrapolated from 3*10 5 cetuximab-Fab′ assuming 15:20 ratio).
- the additive accumulation of liposomes and ligands for dual-targeted immunoliposomes from their mono-targeted counterparts were close for all ratios, 0-15 F5 scFv and 0-20 cetuximab-Fab′ per liposome.
- Immunoliposomes exhibited low uptake ( ⁇ 2*10 4 liposomes/cell), but significantly higher compared to non-targeted liposomes, except for 10 cetuximab-Fab′ per liposome.
- Dual-targeted immunoliposomes with 15 F5 scFv and 20 cetuximab-Fab′ resulted in ⁇ 9*10 3 liposomes per cell, which is the additive accumulation of mono-targeted 15 F5 scFv-ILS (4*10 3 liposomes/cell) and 20 cetuximab-ILS (4*10 3 liposomes/cell).
- dual-targeted immunoliposomes resulted in ⁇ 1.3*10 5 F5 scFv per cell, which is the additive accumulation of mono-targeted F5 scFv (6.1*10 5 F5 scFv/cell) and cetuximab-ILS (5.4*10 5 F5 scFv/cell, extrapolated from 7.2*10 5 cetuximab-Fab′ assuming 15:20 ratio).
- the additive accumulation of liposomes and ligands for dual-targeted immunoliposomes from their mono-targeted counterparts were close for all ratios, 0-15 F5 scFv and 0-20 cetuximab-Fab′ per liposome.
- Table 4 above shows the accumulation of liposomes (LS) and ligands (L g ) from HER2-targeted, EGFR-targeted, and dual-targeted immunoliposomes (ILS) in BT-474, MKN-7, and MDA-468 cells from dose-uptake studies.
- Max is the maximum measured accumulation;
- Sum is the total calculated accumulation from mono-targeted immunoliposomes counterparts.
- x and y specify the number of ligands per liposome against EGFR (cetuximab-Fab′) and HER2 (F5 scFv), respectively, while NT stands for non-targeted (i.e., no ligands).
- HER2-overexpressing and EGFR-overexpressing human breast cancer cell lines increasing the valency of ligands per liposomes increased targeted uptake until saturation. After which point, increased ligand valency may decrease uptake, maintaining a 1:1 ratio of ligands to receptors.
- the equal ligands to receptors ratio may be explained by multivalent binding and receptor crosslinking. In such ideal situations with both high receptor expression on the cells and high affinity constants for ligands to receptors, it may be possible that multiple ligands are binding to multiple receptors during the process of receptor-mediated endocytosis. In essence, a liposome is behaving as a multivalent ligand that can multivalent bind and crosslink monovalent receptors expressed on the cells.
- HER2 have been shown to form clusters in cell membranes which may even increase the chances of crosslink binding(130, 131).
- per surface area there are more receptors available per ligand. Assuming an average cell diameter of 10 ⁇ m with 10 6 receptors and an average liposome diameter of 100 nm with 20 ligands, the receptor to ligand per surface area ratio is 5, meaning that for every ligand there are 5 receptors available to bind.
- Crosslink multivalent binding of liposomes to clustered receptors is a possible and plausible outcome.
- anti-HER2 and anti-EGFR dual-targeted immunoliposomes can increase the overall accumulation of liposomes and ligands beyond the saturation point of mono-targeted immunoliposomes.
- the uptake is roughly additive of their mono-targeted counterparts. Because the uptake of dual-targeted immunoliposomes appears to be additive instead of synergistic, the overall accumulation is only marginally higher (folds, not magnitudes), and hence may result only in marginally increased benefits from increased accumulation.
- the main advantage may be more of a simplified multi-targeting formulation, where the immunoliposomes can target multiple receptors, and hence effective with more cell lines and accordingly heterogeneous receptor expressing tumors. Only in the SK-BR-3 cell line that the addition of a non-targeting functional group may be antagonistic to uptake at high anti-EGFR ligand valence. Despite that, uptake was only marginally lower.
- cytotoxicity studies with doxorubicin-encapsulated HER2-targeted, EGFR-targeted, and dual-targeted immunoliposomes were also examined for any correlations between increased targeted uptake and toxicity benefits of dual-targeted drug delivery.
- immunoliposomes with higher cetuximab-Fab′ per liposome ligand valencies (0-60 ligands/liposome) correlated with higher cell death.
- Immunoliposomes with varying F5 scFv valencies (0-15 ligands/liposome) had no significant cytotoxicity compared to non-targeted liposomes.
- immunoliposomes with varying F5 scFv per liposome valencies yielded significant cytotoxicity compared to non-targeted liposomes, but no significant difference among each other.
- Immunoliposomes with varying cetuximab-Fab′ valencies resulted in no significant cell viability.
- immunoliposomes with varying cetuximab-Fab′ per liposome ligand valencies (10 ⁇ 60 ligands/liposome) yielded higher cytotoxicity compared to non-targeted liposomes (P ⁇ 10 ⁇ 4 ), but no significant difference among each other (Error! Reference source not found).
- Immunoliposomes with varying F5 scFv valencies (0-15 ligands/liposome) resulted in no significant cell growth inhibition (P ⁇ 1).
- cell viability was not significant compared to any mono-targeted immunoliposomes (0.01 ⁇ P ⁇ 1).
- the targeted uptake studies with anti-HER2 and anti-EGFR immunoliposomes resulted in higher resolution, showing differences between ligand valencies and the additive effects of using dual-targeted immunoliposomes.
- the additive and possible synergistic effects of using dual-targeting ligands only significantly enhanced the cell growth inhibition with doxorubicin for a few formulations where both anti-EGFR and anti-HER2 ligands were of high valency in the BT-474 and OVA-420 cell lines.
- Anti-HER2, anti-EGFR, and dual-targeted lipid nanoparticles at varying ligand valencies were formulated with receptor-specific targeting against cells lines expressing HER2 and/or EGFR.
- liposomes were functionalized with Fab′ reduced from trastuzumab or F5 scFv.
- Fab′ reduced from trastuzumab, EGF, or TGF ⁇ were functionalized with Fab′ reduced from cetuximab, EGF, or TGF ⁇ .
- liposomes and ligands for anti-HER2 and anti-EGFR dual-targeted immunoliposomes were roughly additive of their mono-targeted counterparts in BT-474 and MKN-7 cells.
- No antagonistic effects were observed from the additional of a non-targeted ligand in all cell lines except for SK-BR-3 at high anti-EGFR ligand valence, where anti-EGFR ligands decreased overall uptake.
- dual-targeted liposomal delivery of doxorubicin to cell lines expressing HER2 and EGFR only significantly enhanced the cell growth inhibition compared to mono-targeted liposomal delivery for a few liposomal formulations where both anti-EGFR and anti-HER2 ligands were of high valency. Although significant, the improvement was minimal and hence not valuable on a purely increased of cellular drug accumulation standpoint. Dual-targeting lipid nanoparticles can still be beneficial as a system to target heterogeneous cancers.
- DSPC 1,2-distearoyl-sn-glycero-3-phosphocholine
- PEG-DSPE 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]
- Mal-PEG-DSPE 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000]
- F5 single-chain variable fragment (scFv) conjugated to Mal-PEG-DSPE was manufactured by the National Cancer Institute as previously described(38, 42).
- EGF and TGF ⁇ were purchased from Millipore (Billerica, MA) and Peprotech (Rocky Hill, NJ).
- Doxorubicin Dox; Bedford Laboratories
- Pepsin, cysteamine, 2-iminothiolane, glycine, and thiazolyl blue tetrazolium bromide were purchased from Sigma-Aldrich (St. Louis, MO).
- Cell culture media, fetal calf serum, penicillin-streptomycin, trypsin, and phosphate buffered saline (PBS) were purchased from the UCSF Cell Culture Facility (San Francisco, CA).
- MDA-468 and BT-474 human breast cancer cell lines were obtained from the American Type Culture Collection (Rockville, MD), MKN-7 and SK-BR-3 human breast cancer cell lines from the UCSF Cell Culture Facility (San Francisco, CA), and MCF-7/HER2(125) human breast cancer cell line from the UCSF Preclinical Therapeutics Core (San Francisco, CA).
- MDA-468 cells were maintained in Leibovitz's L-15 medium without NaHCO 3
- BT-474 and MKN-7 cells in RPMI-1640 medium
- SK-BR-3 in McCoy's 5A medium
- MCF-7/HER2 in DEM H-21 medium with gentamycin (200 ⁇ g/ml). All media were supplemented with 10% fetal calf serum and 1% penicillin-streptomycin. All cells were cultured as monolayer at 37° C. in 5% CO 2 except in the absence of CO 2 for MDA-468 cells.
- Liposomes were prepared by the lipid film hydration-extrusion method(117). Lipid solution of DSPC, cholesterol, PEG-DSPE (3:2:0.3), and a fluorescent lipophilic tracer (DiD or DiO, 0.5%) were dissolved in chloroform with a few drops of methanol, and dried under reduced pressure at 60° C. using rotary evaporation. Lipid films were hydrated in HEPES buffered saline (HBS 6.5; 5 mM HEPES, 135 mM NaCl, pH 6.5), and liposomes were prepared according to the repeated freeze-thawing method (6 cycles).
- HBS 6.5 HEPES buffered saline
- Liposomes were subsequently extruded 10 times through 100 nm polycarbonate membrane filters using an extruder, resulting in liposomes of 80-120 nm diameter as determined by dynamic light scattering. Liposome concentration was measured using a standard phosphate assay(118).
- doxorubicin For encapsulation of doxorubicin, the remote-loading method using ammonium sulfate was performed(119, 120). Lipid films were hydrated in ammonium sulfate (250 mM, pH 6), followed by the freeze-thawing method and extrusion as described. Free ammonium sulfate was removed by size-exclusion chromatography using a Sephadex G75 column eluted with HEPES buffered saline (20 mM HEPES, 135 mM NaCl, pH 5.5). Liposomes were then incubated with doxorubicin (150 ⁇ g Dox/ ⁇ mol PL) at 60° C. for 1 hr.
- doxorubicin 150 ⁇ g Dox/ ⁇ mol PL
- Unencapsulated drugs were removed by size-exclusion chromatography using a Sephadex G75 column eluted with HBS 6.5. Loading efficiencies were typically in the range of 95-100% as determined by fluorometry (485/20:590/35 nm). Final liposomal formulations were all filtered through a 0.2 ⁇ m Nalgene® polyethersulfone membrane (Thermo Scientific) before cellular experiments.
- IgG (trastuzumab or cetuximab) was cleaved and reduced to Fab′(35, 36), but incorporated onto liposomes via a modified version of the micelle transfer method(35, 44).
- IgG was cleaved with pepsin (weight ratio 1:20) in sodium acetate (0.1 M, pH 3.7) at 37° C. for 2 h under argon, followed by dialysis against MES buffered saline (5 mM MES, 135 mM NaCl, pH 6.0).
- the Fab 2 was reduced with cysteamine (16 mM) at 37° C.
- EGF and TGF ⁇ were thiolated with Traut's reagent(121), conjugated to Mal-PEG-DSPE, and incorporated onto liposomes via the micelle transfer method(35, 44).
- EGF or TGF ⁇ at 0.2-0.5 g/l in Traut's buffer 50 mM triethanolamine, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, pH 8) was modified with a 7:1 excess of 2-iminothiolane at room temperature for 1 hr under argon.
- Excess reagent was removed by size-exclusion chromatography on a Sephadex G25 column eluted with sodium phosphate buffer (0.1 M sodium phosphate, 0.1 M NaCl, pH 7.5) in 200 ul fractions.
- the thiolated EGF or TGF ⁇ was conjugated with a 5:1 excess of Mal-PEG-DSPE at room temperature for 2 hr under argon.
- the mixture was quenched with 1 mM 2-mercaptoethnaol (200 mM stock in 5 mM MES, 135 mM NaCl, pH 6.0) at room temperature for 15 min under argon.
- Unbound growth factor was removed by size-exclusion chromatography on a Sephadex G75 column eluted with HBS (20 mM Hepes, 150 mM NaCl, pH 7.4) in 200 ul fractions.
- the fraction of growth factor conjugated to micellar lipids was measured and determined by BCA Protein Assay Kit (Thermo Scientific), Quant-iT Protein Assay Kit (Life Technologies), and SDS-PAGE (Bio-Rad).
- Ligands were incorporated onto liposomes either by the micelle transfer method(35, 44) or the sequential micelle transfer-conjugation method.
- the micelle transfer method conjugates of F5 scFv-PEG-DSPE, EGF-PEG-DSPE or TGF ⁇ -PEG-DSPE were incubated with liposomes at 50° C. for 40 min under argon (0-100 ligands per liposome, assuming 8*10 4 PL per liposome)(35, 122). Unincorporated conjugates were removed by size-exclusion chromatography on a Sepharose 4B column eluted with HBS 6.5.
- Dual-targeted immunoliposomes of various ligand ratios were achieved by a combination of both the sequential micelle transfer-conjugation and the micelle transfer methods.
- Mal-PEG-DSPE (0-1%) was first incubated with liposomes at 50° C. for 40 min under argon, followed by incubation with cetuximab-Fab′ at room temperature for 2 hr under argon (1:1 Fab′:Mal-PEG-DSPE). Unbound Fab′ was removed by size-exclusion chromatography on a Sepharose® 4B eluted with HBS 6.5.
- F5 scFv-PEG-DSPE (0-1%) was incubated with cetuximab-ILS at 50° C. for 40 min under argon. Unincorporated conjugates were again removed by size-exclusion chromatography on a Sepharose® 4B column eluted with HBS 6.5.
- F5 scFv-PEG-DSPE (0-1%) and Mal-PEG-DSPE (0-1%) can simultaneously be incubated with liposomes at 50° C. for 40 min under argon, followed by incubation with cetuximab-Fab′ at room temperature for 2 hr under argon. Conjugate incorporation efficiency was measured and determined by ImageJ (National Institutes of Health) from SDS-PAGE (Bio-Rad) stained with SYPRO Ruby following each conjugation step. F5 scFv conjugation was assumed to be 100% as previously determined.
- ligands were fluorescently labeled with Alexa Fluor 488 or 546.
- Trastuzumab, F5 scFv, cetuximab, EGF, and TGF ⁇ were conjugated with Alexa Fluor 488 carboxylic acid succinimidyl ester (Life Technologies) as described by vendor, yielding 1-2 fluorophores per ligand.
- Alexa Fluor 546 carboxylic acid succinimidyl ester (Life Technologies) yielded 3-4 fluorophores per ligand.
- the relative efficiency of labeling was determined by measurements on the NanoDrop 1000 spectrophotometer and Quant-iT Protein Assay Kit (Life Technologies).
- Cell count was estimated based on a hemacytometer and MTT assay ((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), showing negligible cell detachment or toxicity under these conditions between groups.
- cells cultured overnight in 96-well plates were incubated with liposomes labeled with DiD (75 or 375 ⁇ M PL) or ligands labeled with Alexa Fluor 488 (40 nM) at 37° C. for 4 hr, stripped with an acid wash (50 mM glycine, 150 mM NaCl, pH 3) at 4° C. for 5 min, washed with PBS 2 ⁇ , freeze-thawed 3 ⁇ , and lysed with 80% isopropyl alcohol (IPA) and 1% Triton X-100.
- IPA isopropyl alcohol
Abstract
This disclosure relates to novel ligand-drug particles comprising at least one ligand specific for one or more cell surface receptor molecules for targeting the ligand-drug particles to a target cell. This disclosure also relates to pharmaceutical compositions comprising the particles herein and systems and methods for determining the ligand valency of the particles.
Description
- This application claims priority to U.S. Provisional Patent Application No. 62/492,085, filed Apr. 28, 2017, which is incorporated by reference herein in its entirety.
- This disclosure relates to novel ligand-drug particles comprising at least one ligand specific for one or more cell surface receptor molecules for targeting the particles to a target cell. This disclosure also relates to pharmaceutical compositions comprising the particles herein and systems and methods for determining the ligand valency of the particles.
- In the field of targeted drug delivery systems such as liposome-based ligand-drug particles, efficiency has mainly focused on cell-specificity, internalization, and subsequent effects on bioactivity such as cell growth inhibition. To improve the delivery of drugs to targeted cells from these particles, functional groups such as ligands for receptors on the surface of target cells may be incorporated, for example, such as antibody binding fragments. The ideal valence (i.e., number of ligands per particle) of such ligands on the particles, however, has been difficult to determine. Increasing valence does not always improve cell association. In fact, an overly high ligand valency can actually decrease binding and uptake of drugs by target cells.
- The cell association and trafficking of ligand-drug particles have been predominately optimized by trial and error experimentation. In designing a particle with an incorporated targeting ligand, for example, researchers may traditionally assess the impact of an array of variables on cellular uptake, such as ligand types, ligand surface valency, particle concentration, incubation time, and temperature. The present disclosure, in contrast, provides ligand-drug particles whose design is based on the use of particular crosslink multivalent binding model, which considers ligand valence, ligand-target equilibrium dissociation constant, and total receptor expression level on the target cell (i.e., average number of receptors per cell). This model has predicted the observed cellular uptake behavior of particular ligand-drugs that target cells expressing HER2, for example, and may be used to design ligand-drug particles with an optimized uptake efficiency of drugs and to reduce the experimentation necessary for determining optimal uptake efficiency for a novel ligand-drug particle.
- In some embodiments, the present disclosure contemplates ligand-drug particles comprising a lipid surface layer and an optional coating layer, at least one ligand molecule exposed on the particle surface or on the lipid surface layer, and at least one drug in the interior of the particle or embedded in the lipid surface layer. The ligand has a particular valency or range of valency (number of ligands per particle) depending on the affinity of the ligand for its receptor on the cell surface of the target cell and depending on the expression level of the receptor in the target cell (expressed herein as the average number of receptors per cell).
- In some embodiments, the ligand-drug particle comprises a lipid surface layer, at least one drug in the interior of the particle or embedded in the lipid surface layer, and a ligand specific for a cell surface receptor on a target cell, wherein: (a) the ligand is exposed on the lipid surface layer; (b) the ligand binds to its receptor with an in vitro binding affinity of 0.001 to 1000 nM; (c) the target cell that the particle targets comprises an average on the order of 103 to 10′ receptors; and (d) the particle has a ligand valency as described in Table 1 or 2, the ligand valency depending upon the ligand-receptor in vitro binding affinity and the average number of receptors per target cell. In some embodiments, the particle has a ligand valency as follows: (a) a valency of 6-12 where the target cell has an average on the order of 3×106 receptors per cell; (b) a valency of 10-19 where the target cell has an average on the order of 1×106 receptors per cell; (c) a valency of 10-20 where the target cell has an average on the order of 9×105 receptors per cell; (d) a valency of 11-21 where the target cell has an average on the order of 8×105 receptors per cell; (e) a valency of 12-23 where the target cell has an average on the order of 7×105 receptors per cell; (f) a valency of 13-25 where the target cell has an average on the order of 6×105 receptors per cell; (g) a valency of 15-29 where the target cell has an average on the order of 5×105 receptors per cell; or (h) a valency of 18-36 where the target cell has an average on the order of 4×105 receptors per cell. In some such embodiments, the ligand-receptor in vitro binding affinity is 0.1 to 10 nM and the particle has a ligand valency as follows: (a) a valency of 8-10 where the target cell has an average on the order of 3×106 receptors per cell; (b) a valency of 13-16 where the target cell has an average on the order of 9×105 to 1×106 receptors per cell; (c) a valency of 14-18 where the target cell has an average on the order of 8×105 receptors per cell; (d) a valency of 15-19 where the target cell has an average on the order of 7×105 receptors per cell; (e) a valency of 17-21 where the target cell has an average on the order of 6×105 receptors per cell; (f) a valency of 19-24 where the target cell has an average on the order of 5×105 receptors per cell; or (g) a valency of 24-30 where the target cell has an average on the order of 4×105 receptors per cell.
- In further embodiments, the ligand-drug particle has a ligand-receptor in vitro binding affinity is 0.001 to 0.1 nM and the particle has a ligand valency as follows, depending on the number of receptors per cell: (a) a valency of 15-24 where the target cell has an average on the order of 4×105 to 5×105 receptors per cell; (b) a valency of 13-19 where the target cell has an average on the order of 5×105 to 6×105 receptors per cell; (c) a valency of 12-17 where the target cell has an average on the order of 6×105 to 7×105 receptors per cell; (d) a valency of 11-15 where the target cell has an average on the order of 7×105 to 8×105 receptors per cell; (e) a valency of 10-14 where the target cell has an average on the order of 8×105 to 9×105 receptors per cell; (f) a valency of 10-13 where the target cell has an average on the order of 9×105 to 1×106 receptors per cell; or (g) a valency of 6-13 where the target cell has an average on the order of 1×106 to 3×106 receptors per cell. In additional embodiments, the ligand-receptor in vitro binding affinity is 0.1 to 10 nM and the particle has a ligand valency as follows: (a) a valency of 19-30 where the target cell has an average on the order of 4×105 to 5×105 receptors per cell; (b) valency of 17-24 where the target cell has an average on the order of 5×105 to 6×105 receptors per cell; (c) a valency of 15-21 where the target cell has an average on the order of 6×105 to 7×105 receptors per cell; (d) a valency of 14-19 where the target cell has an average on the order of 7×105 to 8×105 receptors per cell; (d a valency of 13-18 where the target cell has an average on the order of 8×105 to 9×105 receptors per cell; (f) a valency of 13-16 where the target cell has an average on the order of 9×105 to 1×106 receptors per cell; or (g) a valency of 8-16 where the target cell has an average on the order of 1×106 to 3×106 receptors per cell. In yet other embodiments, the ligand-receptor in vitro binding affinity is 10 to 1000 nM and the particle has a ligand valency as follows: (a) valency of 24-36 where the target cell has an average on the order of 4×105 to 5×105 receptors per cell; (b) a valency of 21-29 where the target cell has an average on the order of 5×105 to 6×105 receptors per cell; (c) a valency of 19-25 where the target cell has an average on the order of 6×105 to 7×105 receptors per cell; (d) a valency of 18-23 where the target cell has an average on the order of 7×105 to 8×105 receptors per cell; (e) a valency of 16-21 where the target cell has an average on the order of 8×105 to 9×105 receptors per cell; (f) a valency of 16-20 where the target cell has an average on the order of 9×105 to 1×106 receptors per cell; or (g) a valency of 10-19 where the target cell has an average on the order of 1×106 to 3×106 receptors per cell.
- In some of the above embodiments, the ligand is an antibody, such as an antigen binding fragment of an antibody, such as an Fv, scFv, Fab′, or F(ab′)2 fragment. In some of the above embodiments, the lipid surface layer comprises one or more of: phosphatidylcholine, soybean phosphatidylcholine, hydrogenated soybean phosphatidylcholine, egg phosphatidylcholine, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dioleoyl phosphatidylcholine, distearoyl phosphatidylcholine, palmitoyl oleoyl phosphatidylcholine, phosphatidylethanolamine, distearoyl phosphoethanolamine, dimyristoyl phosphatidylethanolamine, dipalmitoyl phosphatidylethanolamine, dioleoyl phosphatidylethanolamine, phosphatidylserine, dimyristoyl phosphatidylserine, dipalmitoyl phosphatidylserine, dioleoyl phosphatidylserine, phosphatidic acid, phosphatidylinositol, phosphatidylglycerol, dimyristoyl phosphatidylglycerol, dipalmitoyl phosphatidylglycerol, dioleoyl phosphatidylglycerol, distearoyl phosphatidylglycerol, egg sphingomyelin, cholesterol, glycerophospholipids, sphingomyelins, and dioleoyl trimethylammonium propane. In some of the above embodiments, the lipid surface layer is a lipid bilayer, while in other embodiments, it is a lipid monolayer. In any of the above embodiments, the at least one drug may comprise a polar, small molecule compound located in an aqueous space at the interior of the particle. In some embodiments, the at least one drug comprises a hydrophobic, small molecule compound embedded in the lipid surface layer. And the particle may contain one drug compound, two drug compounds, or more depending on its utility. In some embodiments, the particle also contains further excipients for solubilizing or protecting the drug compound or for maintaining pH, for example.
- In some embodiments, the ligand is an antibody and the antibody ligand is selected from: abciximab, adalimumab, adecatumumab, alacizumab, alemtuzumab, alirocumab, aprutumab, atezolizumab, avelumab, basiliximab, batuzumab, belimumab, bemarituzumab, benralizumab, bevacizumab, bezlotoxumab, blinatumomab, brentuximab, brodalumab, brolucizumab, canakinumab, capromab, catumaxomab, certolizumab, cetuximab, citatuzumab, cixutumumab, daclizumab, dalotuzumab, daratumumab, denosumab, depatuxizumab, dinutuximab, duligotuzumab, dupilumab, durvalumab, eculizumab, edrecolomab, elgemtumab, elotuzumab, emibetuzumab, emicizumab, ertumaxomab, evolocumab, faricimab, fibatuzumab, figitumumab, futuximab, ganitumab, gemtuzumab, golimumab, guselkumab, ibritumomab, icrucumab, idarucizumab, ifabotuzumab, imgatuzumab, infliximab, inotuzumab, ipilimumab, istiratumab, ixekizumab, laprituximab, losatuxizumab, lumretuzumab, margetuximab, mepolizumab, modotuximab, natalizumab, necitumumab, nimotuzumab, nivolumab, obiltoxaximab, obinutuzumab, ocrelizumab, ofatumumab, olaratumab, omalizumab, oportuzumab, palivizumab, panitumumab, patritumab, pembrolizumab, pertuzumab, ramucirumab, ranibizumab, raxibacumab, reslizumab, rinucumab, rituximab, robatumumab, sarilumab, secukinumab, seribantumab, siltuximab, solitomab, tanibirumab, telisotuzumab, teprotumumab, timigutuzumab, tocilizumab, tomuzotuximab, trastuzumab, tucotuzumab, ustekinumab, varisacumab, vedolizumab, xentuzumab, zalutumumab, zatuximab, and zenocutuzumab, and antigen binding fragments thereof, such as Fv, scFv, Fab′, or F(ab′)2 fragments of the above-listed antibodies.
- In some embodiments, the target cell is a tumor cell, an infectious cell, or an immune cell. In some embodiments, the particle further comprises a coating comprising polyethylene glycol (PEG).
- Also contemplated herein are ligand-drug particles that comprise two different ligands, specific for two different receptors on a target cell. Such ligand-drug particles may comprise a lipid surface layer, at least one drug in the interior of the particle or embedded in the lipid surface layer, and two ligands specific for two different cell surface receptors on a target cell, wherein the ligands are exposed on the lipid surface layer; the ligands bind to their receptors with in vitro binding affinity of 0.1 to 100 nM; the target cell that the particle targets comprises an average on the order of 103 to 10′ of each receptor; and the particle has a ligand valency for each of the two ligands as described in Table 3, the ligand valency depending upon the ligand-receptor in vitro binding affinity or each receptor-ligand pair, the average number of each receptor per target cell, and whether ligand-receptor binding is additive or synergistic. In some embodiments, the particle has a ligand valency for each of the ligands as follows: (a) a valency of 13-17 where each receptor is highly expressed by the target cell and where binding of the two receptors by the two ligands is additive; (b) valency of 9-13 where each receptor is highly expressed by the target cell and where binding of the two receptors by the two ligands is synergistic; (c) a valency of 13-17 where one receptor is highly expressed by the target cell and the other receptor is moderately expressed, and where binding of the two receptors by the two ligands is additive; (d) a valency of 7-10 where one receptor is highly expressed by the target cell and the other receptor is moderately expressed, and where binding of the two receptors by the two ligands is synergistic; (e) a valency of 15-21 where each receptor is moderately expressed by the target cell and where binding of the two receptors by the two ligands is additive; or (f) a valency of 11-15 where each receptor is moderately expressed by the target cell and where binding of the two receptors by the two ligands is synergistic.
- In some embodiments, the dual-ligand particle has a ligand valency for each ligand as follows: (a) a valency of 17-21 where the in vitro binding affinity for each ligand-receptor pair is on the order of 100 nM and binding is additive; (b) a valency of 16-20 where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 10 nM and binding is additive; (c) a valency of 16-19 where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 1 nM and binding is additive; (d) a valency of 15-19 where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is additive; (e) a valency of 16-19 where the in vitro binding affinity for each ligand-receptor pair is on the order of 10 nM and binding is additive; (f) a valency of 15-18 where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 1 nM and binding is additive; (g) a valency of 14-17 where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is additive; (h) a valency of 14-17 where the in vitro binding affinity for each ligand-receptor pair is on the order of 1 nM and binding is additive; (i) a valency of 13-16 where the in vitro binding affinity for one ligand-receptor pair is on the order of 1 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is additive; (j) a valency of 13-15 where the in vitro binding affinity for each ligand-receptor pair is on the order of 0.1 nM and binding is additive; (k) a valency of 10-15 where the in vitro binding affinity for each ligand-receptor pair is on the order of 100 nM and binding is synergistic; (l) a valency of 10-15 where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 10 nM and binding is synergistic; (m) a valency of 10-15 where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 1 nM and binding is synergistic; (n) a valency of 10-15 where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is synergistic; (o) a valency of 9-13 where the in vitro binding affinity for each ligand-receptor pair is on the order of 10 nM and binding is synergistic; (p) a valency of 9-13 where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 1 nM and binding is synergistic; (q) a valency of 9-13 where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is synergistic; (r) a valency of 8-12 where the in vitro binding affinity for each ligand-receptor pair is on the order of 1 nM and binding is synergistic; (s) a valency of 8-12 where the in vitro binding affinity for one ligand-receptor pair is on the order of 1 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is synergistic; or (t) a valency of 7-11 where the in vitro binding affinity for each ligand-receptor pair is on the order of 0.1 nM and binding is synergistic.
- In some embodiments, in a dual-ligand particle, at least one ligand is an antibody, or both ligands are antibodies. In some embodiments, at least one ligand is an antigen binding fragment of an antibody, or both ligands are antigen binding fragments of antibodies, such as an Fv, scFv, Fab′, or F(ab′)2 fragment.
- In some of the above embodiments, the lipid surface layer comprises one or more of phosphatidylcholine, soybean phosphatidylcholine, hydrogenated soybean phosphatidylcholine, egg phosphatidylcholine, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dioleoyl phosphatidylcholine, distearoyl phosphatidylcholine, palmitoyl oleoyl phosphatidylcholine, phosphatidylethanolamine, distearoyl phosphoethanolamine, dimyristoyl phosphatidylethanolamine, dipalmitoyl phosphatidylethanolamine, dioleoyl phosphatidylethanolamine, phosphatidylserine, dimyristoyl phosphatidylserine, dipalmitoyl phosphatidylserine, dioleoyl phosphatidylserine, phosphatidic acid, phosphatidylinositol, phosphatidylglycerol, dimyristoyl phosphatidylglycerol, dipalmitoyl phosphatidylglycerol, dioleoyl phosphatidylglycerol, distearoyl phosphatidylglycerol, egg sphingomyelin, cholesterol, glycerophospholipids, sphingomyelins, and dioleoyl trimethylammonium propane. In some of the above embodiments, the lipid surface layer is a lipid bilayer; in others it is a lipid monolayer. In any of the above embodiments, the at least one drug may comprise a polar, small molecule compound located in an aqueous space at the interior of the particle. In some embodiments, the at least one drug comprises a hydrophobic, small molecule compound embedded in the lipid surface layer. And the particle may contain one drug compound, two drug compounds, or more depending on its utility. In some embodiments, the particle also contains further excipients for solubilizing or protecting the drug compound or for maintaining pH, for example.
- In some embodiments, an antibody ligand is selected from: abciximab, adalimumab, adecatumumab, alacizumab, alemtuzumab, alirocumab, aprutumab, atezolizumab, avelumab, basiliximab, batuzumab, belimumab, bemarituzumab, benralizumab, bevacizumab, bezlotoxumab, blinatumomab, brentuximab, brodalumab, brolucizumab, canakinumab, capromab, catumaxomab, certolizumab, cetuximab, citatuzumab, cixutumumab, daclizumab, dalotuzumab, daratumumab, denosumab, depatuxizumab, dinutuximab, duligotuzumab, dupilumab, durvalumab, eculizumab, edrecolomab, elgemtumab, elotuzumab, emibetuzumab, emicizumab, ertumaxomab, evolocumab, faricimab, fibatuzumab, figitumumab, futuximab, ganitumab, gemtuzumab, golimumab, guselkumab, ibritumomab, icrucumab, idarucizumab, ifabotuzumab, imgatuzumab, infliximab, inotuzumab, ipilimumab, istiratumab, ixekizumab, laprituximab, losatuxizumab, lumretuzumab, margetuximab, mepolizumab, modotuximab, natalizumab, necitumumab, nimotuzumab, nivolumab, obiltoxaximab, obinutuzumab, ocrelizumab, ofatumumab, olaratumab, omalizumab, oportuzumab, palivizumab, panitumumab, patritumab, pembrolizumab, pertuzumab, ramucirumab, ranibizumab, raxibacumab, reslizumab, rinucumab, rituximab, robatumumab, sarilumab, secukinumab, seribantumab, siltuximab, solitomab, tanibirumab, telisotuzumab, teprotumumab, timigutuzumab, tocilizumab, tomuzotuximab, trastuzumab, tucotuzumab, ustekinumab, varisacumab, vedolizumab, xentuzumab, zalutumumab, zatuximab, and zenocutuzumab, and binding fragments thereof, such as Fv, scFv, Fab′, or F(ab′)2 fragments of the above-listed antibodies.
- In some embodiments, the target cell is a tumor cell, an infectious cell, or an immune cell. In some embodiments, the particle further comprises a coating comprising PEG.
- Any of the particles contemplated herein may be 10-500 nm, 50-150 nm, 70-120 nm, 80-110 nm, 90-110 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, or 120 nm in diameter.
- This disclosure also contemplates a system for determining ligand valency for a ligand-drug particle, wherein the particle comprises a lipid surface layer, at least one drug in the interior of the particle or embedded in the lipid surface layer, and a ligand specific for a receptor on a target cell, the ligand exposed on the lipid surface layer, the system comprising software capable of determining ligand valency from in vitro ligand-receptor dissociation constant and average number of receptors per target cell according to a crosslink multivalent binding model. The disclosure further contemplates a system for determining ligand valency for a ligand-drug particle, wherein the particle comprises a lipid surface layer, at least one drug in the interior of the particle or embedded in the lipid surface layer, and two ligands each specific for a receptor on a target cell, the ligands exposed on the lipid surface layer, the system comprising software capable of determining ligand valency from in vitro ligand-receptor dissociation constants for each ligand-receptor pair and average number of each receptor per target cell and either additive or synergistic binding according to a crosslink multivalent binding model.
-
FIG. 1 provides a schematic of monovalent receptor-ligand binding. Ligand (Lg) binds to receptor (R) to form a ligand/receptor complex (CLg). -
FIGS. 2A and 2B show a schematic of the crosslink multivalent binding model of multivalent nanoparticles to monovalent receptors. Let Ci be the concentration of a nanoparticle bound to the cell surface via i of its v (valence) available surface-attached ligands (i=0, 1, 2, . . . , f) where f is the effective valence. InFIG. 2A , a free nanoparticle binds to a single receptor on the cell surface. Subsequently, as shown inFIG. 2B at left, the nanoparticle binds to a second receptor, and then to a third, as shown inFIG. 2B at right. Simultaneous crosslink multivalent binding continues until the nanoparticle reaches f bounds. It is assumed that the nanoparticle can only form monovalent bounds with single receptors and receptor dimers. The crosslink association and dissociation constants are assumed to be constant for successive bindings. -
FIG. 3 provides a cell association of F5 scFv-conjugated immunoliposomes (ILS) with increasing valence in MCF-7/HER2 cells. Cells were incubated with liposomes (LS) labeled with DiD (75 uM PL) at 37° C. for 1 hr and analyzed by flow cytometry (mean fluorescent intensity [MFI] with a tight spread of 5*103 cells). -
FIGS. 4A, 4B and 4C provide crosslink multivalent binding model predictions in high receptor expressing cells. Plots of nanoparticle cell association (CBeq) and/or free receptors (Req) as a function of valence (v) in high receptor expressing cells (RT=106 #/cell) with an effective valence (f) ofFIG. 4A . f=10 ligands per nanoparticle,FIG. 4B . f=7, 10, 17, 50, & 100, andFIG. 4C . f=v. Values were evaluated in Mathcad® with the additional parameters: 106 nanoparticles per cell in solution (Lo), 100 nM equilibrium constant (KD), 1/(70*103 #/cells) crosslinking equilibrium constant (KX). It is assumed that there are no nanoparticle and receptor depletion effects, and since f≤v, if. v<f then v=f. -
FIGS. 5A and 5B provide crosslink multivalent binding model predictions for all plausible valence and effective valence (f≤v) in high receptor expressing cells.FIGS. 5A and 5B provide different views of a surface plot of nanoparticle cell association (CBeq, nanoparticles/cell) as a function of valence and effective valence (ligands/nanoparticle) in high receptor expressing cells (RT=106 #/cell). Values were evaluated in Mathcad® with the additional parameters: 106 nanoparticles per cell in solution (Lo), 100 nM equilibrium constant (KD), 1/(70*103 #/cells) crosslinking equilibrium constant (KX). It is assumed that there are no nanoparticle and receptor depletion effects, and since f≤v, if v<f then v=f. -
FIGS. 6A and 6B provide crosslink multivalent binding model predictions in moderate (FIG. 6A ) and low (FIG. 6B ) receptor expressing cells. Plots of nanoparticle cell association (CBeq) and free receptors (Req) as a function of valence (v) in moderate receptor expressing cells (105 #/cell) (FIG. 6 a ) and low receptor expressing cells (104 #/cell) (FIG. 6B ) with an effective valence (f) of 10 or v ligands per nanoparticle. Values were evaluated in Mathcad® with the additional parameters: 106 nanoparticles per cell in solution (Lo), 100 nM equilibrium constant (KD), 1/(10*103 #/cells) and 1/(3*103 #/cells) crosslinking equilibrium constant (KX) for moderate and low receptors model, respectively. It is assumed that there are no nanoparticle and receptor depletion effects, and since f≤v, if v<f then v=f. -
FIG. 7 provides a crosslink multivalent binding model prediction for increased affinity. The equilibrium dissociation constant was decreased from 100 nM to 100*10−5 nM in the high reception expression model with f=v, resulting in approximately only 2-fold increase in cell association. -
FIG. 8 provides a plot of optimal calculated valence for a single ligand (#ligands/particle) against equilibrium dissociation constant for ligand-receptor binding under both high receptor expression (on the order of 106) or moderate receptor expression (on the order of 105) models. Additional data based on this curve may be found in Table 1 below. -
FIG. 9A provides a plot of optimal calculated valence for a single ligand (# ligands/particle) against equilibrium dissociation constant for ligand-receptor binding under several different receptor expression levels.FIG. 9B provides the relationship of optimal valence against receptor expression level (# receptors/cell) at different ligand-receptor equilibrium dissociation constants. Additional data based onFIGS. 9A and 9B may be found in Table 2 below. -
FIGS. 10A, 10B, 10C and 10D show a schematic of steps in a synthesis of a Fab′-PEG-DSPE linkage, for example, as means of attaching a Fab′ ligand to a lipid surface layer of a ligand-drug particle. -
FIGS. 11A and 11B show a schematic of steps in a synthesis of a peptide or protein ligand (such as EGF or TGFα) to PEG-DSPE as a means of attaching the ligand to a lipid surface layer of a ligand-drug particle. -
FIGS. 12A and 12B provide schematics showing how a ligand-PEG-DSPE compound can be incorporated into a lipid surface layer of a liposome particle, by a micelle transfer method (FIG. 12A ) or by a sequential micelle transfer-conjugation method (FIG. 12B ). As shown inFIG. 12A , Liposome+Ligand-PEG-DSPE produce a Ligand-Liposome. InFIG. 12B , Liposome+Mal-PEG-DSPE first yield Mal-Liposome, which is then subject to a further reaction to yield Ligand-Liposome (where Mal stands for maleimide). -
FIGS. 13A and 13B provide schematics of constructing two antibody ligand dual-targeted ligand-drug liposome particles via a micelle transfer-conjugation method. As shown inFIG. 13A , Liposome+Mal-PEG-DSPE first yields Mal-Liposome, and then Mal is replaced by a Fab′ ligand (cetuximab Fab′) to yield Fab′-Liposome. InFIG. 13B a second scFv ligand (F5 scFv) is added to the liposome. -
FIGS. 14A-14F show concentration profile examples of the cell associated particle concentration at equilibrium (CBeq) as a function of CBeq(v,fx,RT,KD,KX) under different conditions. Plots of cell associated particle concentration at equilibrium (CBeq) against valency (ligands/particle) are provided. For optimal cell association, of design interest, for example, are the peak CBeq and its corresponding valences.FIG. 14A shows a High Receptor Expression Model (KD=0.1 nM; RT=4*10{circumflex over ( )}5-3*10{circumflex over ( )}6 receptors/cell).FIG. 14B shows a High Receptor Expression Model (KD=1 nM; RT=4*10{circumflex over ( )}5-3*10{circumflex over ( )}6 receptors/cell).FIG. 14C shows a High Receptor Expression Model (KD=10 nM; RT=4*10{circumflex over ( )}5-3*10{circumflex over ( )}6 receptors/cell).FIG. 14D shows a High Receptor Expression Model (KD=100 nM; RT=4*10{circumflex over ( )}5-3*10{circumflex over ( )}6 receptors/cell).FIG. 14E shows a High Receptor Expression Model (KD=0.001-1000 nM; RT=10{circumflex over ( )}6 receptors/cell).FIG. 14F shows a High Receptor Expression Model (KD=0.001-1000 nM; RT=5*10{circumflex over ( )}5 receptors/cell). -
FIGS. 15A-15D show plots of cell associated particle concentration at equilibrium (CBeq) against valency (ligands/particle) for a multi-targeted multi-valent crosslink binding model under different conditions. These examples depict dual-targeted multi-valent nanoparticles to dual receptors where each ligand/receptor may have unique RT, KD, and/or KX. Additive and synergetic binding benefits were explored. For optimal cell association, of design interest are, for example, the peak CBeq and its corresponding valences.FIG. 15A shows a model where the KDS of the receptor-ligand interactions are both 0.1 nM under additive binding.FIG. 15B shows a model where the KDS of the receptor-ligand interactions are both 0.1 nM under synergistic binding.FIG. 15C shows a model where the KDS of the receptor-ligand interactions are both 1 nM under additive binding.FIG. 15D shows a model where the KDS of the receptor-ligand interactions are both 01 nM under synergistic binding. CBeqHH indicates that the cell highly expresses both receptors while CBeqMM indicates that the cell moderately expresses both receptors and CBeqHM indicates that the cell highly expresses one receptor and moderately expresses the other. The CBeqH and CBeqM curves show cell association for a corresponding highly expressed and moderately expressed single ligand. - The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All references cited herein, including patent applications and publications, are incorporated herein by reference in their entireties for any purpose.
- Unless otherwise defined, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.
- In this application, the use of “or” means “and/or” unless stated otherwise. In the context of a multiple dependent claim, the use of “or” refers back to more than one preceding independent or dependent claim in the alternative only. Also, terms such as “element” or “component” encompass both elements and components comprising one unit and elements and components that comprise more than one subunit unless specifically stated otherwise.
- As described herein, any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated.
- Units, prefixes, and symbols are denoted in their Système International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range. Measured values are understood to be approximate, taking into account significant digits and the error associated with the measurement.
- The headings provided herein are not limitations of the various aspects of the disclosure, which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety.
- As utilized in accordance with the present disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:
- The term “consisting essentially of” when referring to a mixture of ingredients or a ligand-drug particle herein indicates that, while ingredients other than those expressly listed may be present, such ingredients are found only in trace amounts or in amounts otherwise low enough that the fundamental characteristics of the particle including its cellular uptake properties.
- A “conjugate particle” or “ligand-drug particle” or “particle” herein refers to a composition, generally in the form of an organized particle, comprising one or more lipids, at least one ligand, and at least one drug. In some embodiments, a “ligand drug particle” is a liposomal particle comprising at least one lipid surface layer into which at least one ligand may be incorporated or to which a ligand may be attached. The at least one drug may be incorporated in the interior of a particle, or embedded in a lipid surface layer, or otherwise coated with lipid particles, or may otherwise be attached to the surface of a particle. A ligand may be attached to the surface of a particle or interspersed between lipids of a lipid bilayer so that it is sufficiently exposed on the surface of the particle to interact with its intended receptor on a target cell. A “particle” may have any shape, but in the case of a lipid-coated particle, is often roughly spherical.
- In some embodiments, a particle may be a “liposome” particle. A liposome comprises a particle with an aqueous interior that is surrounded by a lipid surface layer. The lipid surface layer may be a lipid bilayer or lipid monolayer depending upon which types of lipids are present.
- A “ligand” herein refers to a molecule located in a ligand-drug particle that binds to a receptor molecule on the surface of a target cell. A ligand herein is generally a protein, such as an antibody. In some embodiments, a ligand is an antibody, such as an antigen binding fragment of an antibody. A “ligand” herein may merely function to target a ligand-drug particle to a target cell, but in some embodiments, may also itself have biological or therapeutic activity.
- A “drug” as used in the context of a ligand drug particle herein, includes any chemical compound that has a therapeutic effect on a disease or condition or that can be used as a diagnostic compound, for example inside an animal cell. Drugs include small organic molecules as well as macromolecular therapeutics such as nucleic acid and protein therapeutics. Some drugs are hydrophilic, and thus may be located in an aqueous compartment in a particle such as in the interior, while some drugs are hydrophobic and may be found surrounded by lipids or other hydrophobic molecules, for example, in a lipid surface layer.
- A “target cell” herein refers to a cell to which a ligand-drug particle is intended to bind, such as a tumor cell or an infectious cell or an inflammatory cell. In some embodiments, for example, a ligand on a ligand-drug particle may bind to a component of a target cell such as a receptor protein, allowing the contents of the particle to enter the cell through endocytosis.
- In referring to ligand-drug particles herein, the term “valence” refers to the number of ligands per particle. The “effective valence” refers to the number of ligands per particle that are assumed to be able to bind to a target cell. An effective valence might differ from the valence, for instance, due to steric hindrance or other limitations of a particular ligand's ability to bind to its target.
- When referring to a numerical quantity such as the number of receptors per cell or a dissociation constant, herein, the term “on the order of” followed by a number means that the actual reported or measured quantity rounds up or down to the numerical quantity provided. For example, 8×105 and 2×106 are each on the order of 106 or 1×106, and 20 nM and 8 nM are each on the order of 10 nM.
- As used herein to refer to the binding of two molecules, a “binding affinity” or “equilibrium dissociation constant” or “dissociation constant” or “KD” are used interchangeably. The binding is generally measured in vitro such as in aqueous solution or in cell culture unless specified otherwise. The dissociation constant of a binding pair can be assessed using various scientific and surface-based methods including surface plasmon resonance (SPR), biolayer interferometry (BLI), enzyme linked immunosorbent assays (ELISA), affinity capillary electrophoresis (ACE), electrophoretic mobility shift assay (EMSA), and microarray-based platform.
- The terms “polypeptide” and “protein” are used interchangeably to refer to a polymer of amino acid residues, and are not limited to a minimum length. Such polymers of amino acid residues may contain natural or non-natural amino acid residues, and include, but are not limited to, peptides, oligopeptides, dimers, trimers, and multimers of amino acid residues. Both full-length proteins and fragments thereof are encompassed by the definition. The terms also include post-expression modifications of the polypeptide, for example, glycosylation, sialylation, acetylation, phosphorylation, and the like. Furthermore, for purposes of the present invention, a “polypeptide” refers to a protein which includes modifications, such as deletions, additions, and substitutions (generally conservative in nature), to the native sequence, as long as the protein maintains the desired activity. These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts which produce the proteins or errors due to PCR amplification.
- The term “antibody” as used herein refers to a molecule comprising at least complementarity-determining region (CDR) 1, CDR2, and CDR3 of a heavy chain and at least CDR1, CDR2, and CDR3 of a light chain, wherein the molecule is capable of binding to antigen. The term “antibody” includes, but is not limited to, fragments that are capable of binding antigen (i.e., “antigen binding fragments”), such as Fv, single-chain Fv (scFv), Fab, Fab′, and (Fab′)2. In some embodiments, the antibody is an Fab′ fragment. In some embodiments, an antibody comprises a heavy chain variable region and a light chain variable region. In some embodiments, an antibody comprises at least one heavy chain comprising a heavy chain variable region and at least a portion of a heavy chain constant region, and at least one light chain comprising a light chain variable region and at least a portion of a light chain constant region. In some embodiments, the antibody comprises a full length light chain (i.e. a complete variable region and a complete constant region). In some embodiments, the antibody comprises a full length heavy chain. In some embodiments, the antibody comprises both a full length light chain and a full length heavy chain. As used herein, a single-chain Fv (scFv), or any other antibody that comprises, for example, a single polypeptide chain comprising all six CDRs (three heavy chain CDRs and three light chain CDRs) is considered to have a heavy chain and a light chain. In some such single-chain embodiments, the heavy chain is the region of the antibody that comprises the three heavy chain CDRs and the light chain in the region of the antibody that comprises the three light chain CDRs.
- Ligand-drug particles herein may, for example, comprise liposomal particles. Liposomal particles are artificial particles that typically comprise an aqueous interior surrounded by a lipid surface layer such as a lipid bilayer or lipid monolayer. The aqueous interior is favorable to entrap water-soluble drug agents while lipid-soluble hydrophobic drug agents can be partitioned into the lipid bilayer. Liposomes may also comprise polyethylene glycol (PEG), for example, to provide a protective layer. Ligands may be incorporated into the lipid surface layer, for example, if they are hydrophobic. Excipients may also be included in the particles, for example, to help stabilize or solubilize a drug in the particle or to help maintain a particular pH.
- Liposomes as a drug delivery system may alter the pharmacokinetic profile of the drug encapsulated to the profile of liposomal carrier. Some chemotherapeutic drugs that may be encapsulated in the aqueous core or incorporated in the lipid surface layer of a liposome, for instance, include daunomycin, doxorubicin (e.g., Doxil®), cisplatin, vinorelbine, topotecan, AraC, vinblastine, vincristine, PALA, methotrexate, paclitaxel, and irinotecan. Doxil® (Janssen Products, Johnson & Johnson) is a sterically stabilized liposome-encapsulated form of doxorubicin used for the treatment of ovarian cancer, multiple myeloma, and Kaposi's sarcoma, for example. The surface of the Doxil® particle, for example, is pegylated.
- Ligand-drug particles herein, such as liposomes, may be taken up by target cells either passively or actively. For example, solid tumors are supported by a discontinuous microvasculature and may have pore sizes varying between 100-780 nm, which allows the passage of large molecules and nanoparticles such as liposomes. The accumulation of large molecules and liposomes in tumors, the result of a leaky microvasculature and impaired lymphatics supporting the tumor area, is a phenomenon known as the enhanced permeability and retention effect (EPR). EPR is limited to pathological sites with affected and leaky vasculature such as solid tumors, sites of inflammations, and infarcted areas. Large molecules or particles 10-500 nm like liposomes can extravasate through the endothelium and localize in the tumor interstitium. Because free cytotoxic agents are small, they are localized in the tumor rapidly, but may also be cleared rapidly, resulting in considerable lower tumor AUC for free drug than liposomal drugs. Despite the increased in tumor accumulation, distribution of liposomes within the tumor interstitium is still limited, resulting from high interstitial pressure and a large interstitial space. Liposomes in the interstitium space are not usually found within tumor cells but are found inside tumor macrophages. Ideally once in the interstitium space, drug leaks at sufficient rate to become bioavailable at the tumor. Drug may leak due to instabilities from conditions in the interstitium, plasma protein, enzymes, or liposomal degradation by macrophages. Released drug can act on neighboring cells via a bystander effect. Passive targeting is limited to pathological sites susceptible to the EPR. In addition, it relies on the diffusion of drugs from the liposomes into the cells of interest. As a result, the delivery of drugs that are prone to degradation from the plasma environment may not be ideal for delivery.
- Ligands that induce receptor-mediated endocytosis upon binding can be engineered onto liposomes for the delivery of drugs intracellularly to tumors. Liposomes delivered for solid tumors, for example, may first benefit from passive targeting, accumulating in the tumor interstitium due to the EPR. But ligand targeting also allows for uptake via endocytosis into target cells. Ligand targeting also allows for delivery to other types of target cells such as endothelial cells, infectious cells, and the like.
- All eukaryotic cells exhibit some form of endocytosis to maintain homeostasis, at the cellular level by recovering protein and lipid components and at the organismal level by controlling activities including transmission of neuronal, metabolic, and proliferative signals, nutrient uptake, and defense preparation. Multiple types of endocytosis exist including phagocytosis, clathrin-independent endocytosis, and clathrin-dependent endocytosis. The endocytosis of many signaling receptors is stimulated by ligand-induced activation, with virtually every signaling receptor family undergoing clathrin-dependent endocytosis. To ensure the internalization of lipid-containing particles into targeted cells, attached high affinity ligands may internalize to induce receptor-mediated clathrin-dependent endocytosis upon binding.
- Endocytosis is typically initiated by the binding of transmembrane receptors and their extracellular ligands into cytoplasmic vesicles that are pinched off from the plasma membrane. Receptor-ligand complexes are recruited to clathrin-coated pits and invaginate inwards to form clathrin-coated vesicles. Endocytosed vesicles fuse with early endosomes, and subsequently receptor-ligand complexes can dissociate and traffic to the recycling
compartment containing Rab 11 or to the late endosomal compartment containing Rab7. Many receptor-ligand complexes dissociate in the early endosomes due to the slightly acidic pH (pH ˜6.0-6.8). While receptors and ligands in recycling endosomes are returned to the plasma membrane, fusion of late endosomes with lysosomes (pH ˜4.0-5.5) carrying proteolytic enzymes results in cargo degradation. - Endosomal trafficking is controlled by several Rab proteins, small guanosine triphosphate-binding proteins. The Rab family is the largest branch of the Ras superfamily with more than 60 members found in mammalian cells. Rab proteins reside in particular types of endosomes and function by recruiting specific effector proteins. Rab proteins distinguish certain intracellular compartments and are involved in vesicle budding, vesicular movement, membrane tethering, membrane docking, and membrane fusion. Rab7 is primarily localized on the late endosomes and has been shown to be essential for lysosomes biogenesis. Rab11 is primarily localized on the recycling endosomes and has been extensively studied for its involvement in transferrin receptor recycling. Tagged Rab proteins as markers are useful for the isolation and localization of nanoparticles within the late endosomes and the recycling endosomes.
- Exemplary Components of Liposomal Ligand-Drug Particles
- In some embodiments, herein, the ligand-drug particle is a liposome. In some embodiments, liposomes may be, for example, 10 nm to 500 nm in diameter, such as 50-150 nm in diameter, such as 70-120 nm, 80-110 nm, or 90-110 nm, or 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, or 120 nm. In some embodiments, liposomes are charge-neutral. In some embodiments, liposomes comprise a lipid monolayer while in others they comprise a lipid bilayer as a lipid surface layer. In some embodiments, liposomes comprise a lipid surface layer comprising both one or more phospholipids as well as PEG and/or cholesterol. In some embodiments, the liposome comprises a PEG coating. In others, it does not. In some embodiments, phospholipids may be neutral or charged, and may be selected from phosphatidylcholine, soybean phosphatidylcholine, hydrogenated soybean phosphatidylcholine, egg phosphatidylcholine, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dioleoyl phosphatidylcholine, distearoyl phosphatidylcholine, palmitoyl oleoyl phosphatidylcholine, phosphatidylethanolamine, distearoyl phosphoethanolamine, dimyristoyl phosphatidylethanolamine, dipalmitoyl phosphatidylethanolamine, dioleoyl phosphatidylethanolamine, phosphatidylserine, dimyristoyl phosphatidylserine, dipalmitoyl phosphatidylserine, dioleoyl phosphatidylserine, phosphatidic acid, phosphatidylinositol, phosphatidylglycerol, dimyristoyl phosphatidylglycerol, dipalmitoyl phosphatidylglycerol, dioleoyl phosphatidylglycerol, distearoyl phosphatidylglycerol, egg sphingomyelin, cholesterol, glycerophospholipids, sphingomyelins, and dioleoyl trimethylammonium propane. In some embodiments, for example, they may be selected from phosphatidyl choline, phosphatidylserine, phosphatidylinositol, phosphatidylethanolamine, sphingomyelin, HSPC (hydrogenated soybean phosphatidylcholine), DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), and PLPC (1-palmitoyl-2-lauroyl-sn-glycero-3-phosphocholine). In some embodiments, the lipid surface layer may comprise one or more lipids or carriers such as phosphatidylcholine, soybean phosphatidylcholine, hydrogenated soybean phosphatidylcholine, egg phosphatidylcholine, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dioleoyl phosphatidylcholine, distearoyl phosphatidylcholine, palmitoyl oleoyl phosphatidylcholine, phosphatidylethanolamine, distearoyl phosphoethanolamine, dimyristoyl phosphatidylethanolamine, dipalmitoyl phosphatidylethanolamine, dioleoyl phosphatidylethanolamine, phosphatidylserine, dimyristoyl phosphatidylserine, dipalmitoyl phosphatidylserine, dioleoyl phosphatidylserine, phosphatidic acid, phosphatidylinositol, phosphatidylglycerol, dimyristoyl phosphatidylglycerol, dipalmitoyl phosphatidylglycerol, dioleoyl phosphatidylglycerol, distearoyl phosphatidylglycerol, egg sphingomyelin, cholesterol, glycerophospholipids, sphingomyelins, dioleoyl trimethylammonium propane, polyethylene glycol (PEG), and albumin, among others.
- In embodiments herein, drugs that may be incorporated into the aqueous interior or lipid surface layer of a liposomal particle include, for example, small molecule chemotherapy agents, kinase inhibitors, nucleic acid-based therapeutics, peptide therapeutics and the like. Drugs may also include diagnostic agents, for example, fluorescent or radio-labeled molecules. In some embodiments, liposomal particles may encapsulate, for example 1-5×104 drug molecules per liposome, such as 1.5-4×104 drug molecules, or 2-3×104 drug molecules. In some embodiments, a drug is enclosed in the interior space or is embedded in the lipid surface layer of a ligand-drug particle comprising a ligand, and is not covalently attached to a ligand or otherwise covalently attached to the surface of the particle or exposed on the surface of the particle.
- In embodiments herein, ligands exposed on the lipid surface layer of the particle may be covalently attached to another surface molecule or may be otherwise associated on the surface of the particle, for example, through attachment to a trans-membrane peptide domain that spans a lipid bilayer. In some embodiments, the ligand is an antibody. In some such embodiments, the ligand is an antigen binding fragment of an antibody. In some such embodiments, the antigen binding fragment is an Fv, scFv, Fab, Fab′, or (Fab′)2 fragment. In some embodiments, it is an scFv or Fab′ fragment.
- In some embodiments, the antibody may be selected from abciximab, adalimumab, adecatumumab, alacizumab, alemtuzumab, alirocumab, aprutumab, atezolizumab, avelumab, basiliximab, batuzumab, belimumab, bemarituzumab, benralizumab, bevacizumab, bezlotoxumab, blinatumomab, brentuximab, brodalumab, brolucizumab, canakinumab, capromab, catumaxomab, certolizumab, cetuximab, citatuzumab, cixutumumab, daclizumab, dalotuzumab, daratumumab, denosumab, depatuxizumab, dinutuximab, duligotuzumab, dupilumab, durvalumab, eculizumab, edrecolomab, elgemtumab, elotuzumab, emibetuzumab, emicizumab, ertumaxomab, evolocumab, faricimab, fibatuzumab, figitumumab, futuximab, ganitumab, gemtuzumab, golimumab, guselkumab, ibritumomab, icrucumab, idarucizumab, ifabotuzumab, imgatuzumab, infliximab, inotuzumab, ipilimumab, istiratumab, ixekizumab, laprituximab, losatuxizumab, lumretuzumab, margetuximab, mepolizumab, modotuximab, natalizumab, necitumumab, nimotuzumab, nivolumab, obiltoxaximab, obinutuzumab, ocrelizumab, ofatumumab, olaratumab, omalizumab, oportuzumab, palivizumab, panitumumab, patritumab, pembrolizumab, pertuzumab, ramucirumab, ranibizumab, raxibacumab, reslizumab, rinucumab, rituximab, robatumumab, sarilumab, secukinumab, seribantumab, siltuximab, solitomab, tanibirumab, telisotuzumab, teprotumumab, timigutuzumab, tocilizumab, tomuzotuximab, trastuzumab, tucotuzumab, ustekinumab, varisacumab, vedolizumab, xentuzumab, zalutumumab, zatuximab, and zenocutuzumab, and antigen binding fragments of the above-listed antibodies. In some embodiments, a ligand may be selected from: Orthoclone® OKT3 (muromonab-CD3), ReoPro® (abciximab), Zenapax® (daclizumab), Rituxan/Mabthera® (rituximab), Simulect® (basiliximab), Remicade® (infliximab), Synagis® (palivizumab), Herceptin® (trastuzumab), Campath® (alemtuzumab), Humira® (adalimumab), Raptiva® (efalizumab), Zevalin® (ibritumomab tiuxetan), Bexxar® (tositumomab), Avastin® (bevacizumab), Erbitux® (cetuximab), Xolair® (omalizumab), Tysabri® (natalizumab), Vectibix® (panitumumab), Lucentis® (ranibizumab), Soliris® (eculizumab), Cimzia® (certolizumab pegol), Ilaris® (canakinumab), Simponi® (golimumab), Arzerra® (ofatumumab), Prolia/Xgeva® (denosumab), Actemra/RoActemra® (tocilizumab/atlizumab), Benlysta® (belimumab), Yervoy® (ipilimumab), Stelara® (ustekinumab), Opdivo® (nivolumab), Keytruda® (Pembrolizumab), Entyvio® (vedolizumab), and Darzalex® (daratumumab). In some embodiments, the ligand may be derived from the antibody component of Mylotarg® (gemtuzumab ozogamicin), Adcetris® (brentuximab vedotin), or Kadcyla® (trastuzumab emtansine).
- In some embodiments, the ligand may be selected from: 3f8, 8h9, abagovomab, abciximab, abituzumab, abrezekimab, abrilumab, actoxumab, adalimumab, adecatumumab, adrenomedullin, aducanumab, afasevikumab, afelimomab, afutuzumab, alacizumab, alemtuzumab, alirocumab, altumomab, amatuximab, amphiregulin, anatumomab, andecaliximab, anetumab, angiopoietin, anifrolumab, anrukinzumab, anti-apoptotic survival factor, apolizumab, aprutumab, arcitumomab, artemin, ascrinvacumab, aselizumab, atezolizumab, atidortoxumab, atinumab, atorolimumab, autocrine motility factor, avelumab, azintuxizumab, bapineuzumab, basiliximab, bavituximab, bcd-100, bectumomab, begelomab, belantamab, belimumab, bemarituzumab, benralizumab, berlimatoxumab, bersanlimab, bertilimumab, besilesomab, betacellulin, bevacizumab, bezlotoxumab, biciromab, bimagrumab, bimekizumab, birtamimab, bivatuzumab, bivv009, bleselumab, blinatumomab, blontuvetmab, blosozumab, bococizumab, bone morphogenetic proteins, brazikumab, brentuximab, briakinumab, brodalumab, brolucizumab, brontictuzumab, burosumab, cabiralizumab, camidanlumab, camrelizumab, canakinumab, cantuzumab, caplacizumab, capromab, carlumab, carotuximab, catumaxomab, cbr96, cedelizumab, cemiplimab, cergutuzumab, certolizumab, cetrelimab, cetuximab, cibisatamab, ciliary neurotrophic factor family, citatuzumab, cixutumumab, clazakizumab, clenoliximab, clivatuzumab, codrituzumab, cofetuzumab, colony-stimulating factors, coltuximab, conatumumab, concizumab, cosfroviximab, cr6261, crenezumab, crizanlizumab, crotedumab, cusatuzumab, cytokine, dacetuzumab, daclizumab, dalotuzumab, dapirolizumab, daratumumab, dectrekumab, demcizumab, denintuzumab, denosumab, depatuxizumab, derlotuximab, detumomab, dezamizumab, dinutuximab, diridavumab, domagrozumab, dorlimomab, drozitumab, ds-8201, duligotuzumab, dupilumab, durvalumab, dusigitumab, duvortuxizumab, ecromeximab, eculizumab, edobacomab, edrecolomab, efalizumab, efungumab, eldelumab, elezanumab, elgemtumab, elotuzumab, elsilimomab, emactuzumab, emapalumab, emibetuzumab, emicizumab, enapotamab, enavatuzumab, enfortumab, enlimomab, enoblituzumab, enokizumab, enoticumab, ensituximab, ephrin a2, ephrin a3, ephrin a4, ephrin a5, ephrin b1, ephrin b2, ephrin b3, ephrins, epidermal growth factor, epigen, epiregulin, epitumomab, epratuzumab, eptinezumab, erenumab, erlizumab, ertumaxomab, erythropoietin, etaracizumab, etigilimab, etrolizumab, evinacumab, evolocumab, exbivirumab, fanolesomab, faralimomab, faricimab, farletuzumab, fasinumab, fbta05, felvizumab, fezakinumab, fibatuzumab, fibroblast growth factor 1-23, fibroblast growth factors, ficlatuzumab, figitumumab, firivumab, flanvotumab, fletikumab, flotetuzumab, foetal bovine somatotrophin, fontolizumab, foralumab, foravirumab, fremanezumab, fresolimumab, frunevetmab, fulranumab, futuximab, galcanezumab, galiximab, gancotamab, ganitumab, gantenerumab, gatipotuzumab, gavilimomab, gdnf family of ligands glial cell line-derived neurotrophic factor, gedivumab, gemtuzumab, gevokizumab, gilvetmab, gimsilumab, girentuximab, glembatumumab, golimumab, gomiliximab, gosuranemab, granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, growth differentiation factor-9, growth factors, growth factor receptors, guselkumab, heparin-binding epidermal growth factor, heparin-binding growth factor, hepatocyte growth factor, hepatocyte growth factor-like protein, hepatoma-derived growth factor, heregulin, hormones, ianalumab, ibalizumab, ibi308, ibritumomab, icrucumab, idarucizumab, ifabotuzumab, igovomab, iladatuzumab, imab362, imalumab, imaprelimab, imciromab, imgatuzumab, inclacumab, indatuximab, indusatumab, inebilizumab, infliximab, inolimomab, inotuzumab, insulin, insulin-like growth factor-2, insulin-like growth factors, interleukin-6, interleukins, intetumumab, iomab-b, ipilimumab, iratumumab, isatuximab, iscalimab, istiratumab, itolizumab, ixekizumab, keliximab, keratinocyte growth factor, labetuzumab, lacnotuzumab, ladiratuzumab, lampalizumab, lanadelumab, landogrozumab, laprituximab, larcaviximab, lebrikizumab, lemalesomab, lendalizumab, lenvervimab, lenzilumab, lerdelimumab, leronlimab, lesofavumab, letolizumab, leukemia inhibitory factor, lexatumumab, libivirumab, lifastuzumab, ligelizumab, lilotomab, lintuzumab, lirilumab, lodelcizumab, lokivetmab, loncastuximab, lorvotuzumab, losatuxizumab, lucatumumab, lulizumab, lumiliximab, lumretuzumab, lupartumab, lutikizumab, mabp1, macrophage colony-stimulating factor, macrophage-stimulating protein, mapatumumab, margetuximab, marstacimab, maslimomab, matuzumab, mavrilimumab, mepolizumab, metelimumab, migration-stimulating factor, milatuzumab, minretumomab, mirikizumab, mitumomab, modotuximab, mogamulizumab, monalizumab, morolimumab, mosunetuzumab, motavizumab, moxetumomab, muromonab, myostatin, nacolomab, namilumab, naptumomab, naratuximab, narnatumab, natalizumab, navicixizumab, navivumab, naxitamab, nebacumab, necitumumab, nemolizumab, neod001, nerelimomab, nerve growth factors, nesvacumab, netakimab, neuregulin 1-4, neuregulins, neuropilin-1, neurotrophin-3, neurotrophin-4, neurotrophins, neurotrophins brain-derived neurotrophic factor, neurturin, nimotuzumab, nirsevimab, nivolumab, nofetumomab, obiltoxaximab, obinutuzumab, ocaratuzumab, ocrelizumab, odulimomab, ofatumumab, olaratumab, oleclumab, olendalizumab, olokizumab, omalizumab, oms721, onartuzumab, ontuxizumab, onvatilimab, opicinumab, oportuzumab, oregovomab, orf viral vascular endothelial growth factor homologs, orticumab, otelixizumab, otilimab, otlertuzumab, oxelumab, ozanezumab, ozoralizumab, pagibaximab, palivizumab, pamrevlumab, panitumumab, pankomab, panobacumab, parsatuzumab, pascolizumab, pasotuxizumab, pateclizumab, patritumab, pdr001, pembrolizumab, pemtumomab, peptides, perakizumab, persephin, pertuzumab, pexelizumab, pidilizumab, pinatuzumab, pintumomab, placenta growth factor, placental growth factor, placulumab, platelet-derived growth factor, platelet-derived growth factor-alpha polypeptide, plozalizumab, pogalizumab, polatuzumab, ponezumab, porgaviximab, prasinezumab, prezalizumab, priliximab, pritoxaximab, pritumumab, pro 140, proteins, quilizumab, racotumomab, radretumab, rafivirumab, ralpancizumab, ramucirumab, ranevetmab, ranibizumab, ravagalimab, ravulizumab, raxibacumab, refanezumab, regavirumab, remtolumab, reslizumab, rilotumumab, rinucumab, risankizumab, rituximab, rivabazumab, rmab, robatumumab, roledumab, romilkimab, romosozumab, rontalizumab, rosmantuzumab, rovalpituzumab, rovelizumab, rozanolixizumab, ruplizumab, sa237, samalizumab, samrotamab, sapelizumab, sarilumab, satralizumab, secukinumab, selicrelumab, seribantumab, setoxaximab, setrusumab, sevirumab, sgn-cd19a, shp647, sibrotuzumab, sifalimumab, siltuximab, simtuzumab, siplizumab, sirtratumab, sirukumab, sofituzumab, solanezumab, solitomab, sonepcizumab, sontuzumab, spartalizumab, stamulumab, sulesomab, suptavumab, sutimlimab, suvizumab, suvratoxumab, tabalumab, tacatuzumab, tadocizumab, talacotuzumab, talizumab, tamtuvetmab, tanezumab, tanibirumab, taplitumomab, tarextumab, tavolimab, t-cell growth factor, tefibazumab, telimomab, telisotuzumab, tenatumomab, teneliximab, teplizumab, tepoditamab, teprotumumab, tesidolumab, tetulomab, tezepelumab, tgn1412, thrombopoietin, tibulizumab, tigatuzumab, tildrakizumab, timigutuzumab, timolumab, tiragotumab, tislelizumab, tisotumab, tnx-650, tocilizumab, tomuzotuximab, toralizumab, tosatoxumab, tositumomab, tovetumab, tralokinumab, transforming growth factor alpha, transforming growth factor beta, transforming growth factors, trastuzumab, trbs07, tregalizumab, tremelimumab, trevogrumab, tucotuzumab, tumor necrosis factor-alpha, tuvirumab, ublituximab, ulocuplumab, urelumab, urtoxazumab, ustekinumab, utomilumab, vadastuximab, vanalimab, vandortuzumab, vantictumab, vanucizumab, vapaliximab, varisacumab, varlilumab, vascular endothelial growth factor a-f, vascular endothelial growth factors, vascular permeability factor, vatelizumab, vedolizumab, veltuzumab, vepalimomab, vesencumab, visilizumab, vobarilizumab, volociximab, vonlerolizumab, vopratelimab, vorsetuzumab, votumumab, vunakizumab, xentuzumab, xmab-5574, zalutumumab, zanolimumab, zatuximab, zenocutuzumab, ziralimumab, zolbetuximab, and zolimomab. In some embodiments, the ligand comprises an RNA aptamer, peptide aptamer, polypeptide, such as a cell surface receptor, or a sugar, folic acid, or folate.
- In some embodiments, a ligand may be attached to a lipid molecule in a particle through a polymer linkage. For example, amphiphilic particles of targeting ligands comprising a hydrophilic polymer spacer between a lipid anchor and a ligand group can be attached to the surface of liposomes to offer receptor-specific targeting. The particle can be synthesized with three main conjugation methods: reaction between activated carboxyl groups and amino groups yielding an amide bond, reaction between pyridyldithiols and thiols yielding disulfide bonds, and reaction between maleimide derivatives and thiols yielding thioether bonds. With the later, conjugation of ligands such as antibody fragments with maleimide chemistry using naturally occurring cysteine residue, engineered C-terminal cysteine, or thiolated with Traut's reagent may provide strong stable bonds. Reactions with the cysteine on antibody fragments can offer ideal orientation, distant from antibody binding site, minimizing interference with binding. A polymer linker like PEG also helps with the orientation, extending the ligand far enough from the PEG shielding so the ligand is accessible to receptors on cells.
- In some embodiments, a micelle transfer method may be used to construct particles herein. In the micelle transfer method, micellar conjugates of the ligand and an amphiphilic lipid co-incubated with preformed liposomes spontaneously insert themselves into liposome bilayers without the loss of the liposome integrity, providing a rapid and simple method for transforming non-targeted liposomes into antibody-targeted liposomes. Insertion is performed at 55-60° C., so the denaturation of protein ligands is a concern, but longer overnight incubation at 37° C. is also possible. Liposomes may remain mostly unaltered through conjugations.
- In some embodiments, the ligand targets a specific cell surface receptor on a target cell, for example, a receptor that is overexpressed on a particular target cell such as a tumor cell. In some embodiments, the receptor may comprise one or more of: CD44, GD2, folate receptor, transferrin receptor, CD3, glycoprotein IIb/IIIa, IL-2Rα receptor (CD25), CD20, IL-2Rα receptor (CD25), TNFα, RSV F protein, ErbB2/HER2, CD52, CD11a, VEGF, VEGFR, EGFR, immunoglobulin E (IgE), alpha-4 (α4) integrin, complement system protein C5, IL-1β, IL-6R, BAFF, CD30, CTLA-4, IL-12, IL-23, PD-1, α4β7, CD38, or a receptor tyrosine kinase. In some embodiments, the ligand targets one or more members of the ErbB family of receptor tyrosine kinases. The ErbB family consists of four structurally related transmembrane receptor tyrosine kinases EGFR/HER1 (epidermal growth factor receptor/human EGFR 1), HER2 (human EGFR 2), HER3 (human EGFR 3), and HER4 (human EGFR 4). For example, HER2 overexpression is also known to occur in ovarian, stomach, prostrate, lung, uterine, pancreas, and thyroid carcinomas. For example, EGFR overexpression occurs in many human cancers including breast, lung, colorectal and brain cancers and can result in poor prognosis. In such embodiments, the ligand may be derived from one or more of cetuximab, panitumumab, zalutumumab, nimotuzumab, and matuzumab. In some embodiments, the ligand does not target HER2 or EGFR, but may target one of the other above receptor proteins.
- In some embodiments, the ligand targets a molecule such as one or more of the following: 1-40-β-amyloid, 4-1BB, SAC, 5′-nucleotidase, 5T4, activated F9, F10, activin receptor-like kinase 1, ACVR2B, adenocarcinoma antigen, adrenomedullin, alpha-4 integrin, alpha-fetoprotein, amphiregulin, amyloid, angiopoietin, angiopoietin 2, angiopoietin 3, anthrax toxin, anti-apoptotic survival factor, AOC3, artemin, autocrine motility factor, AXL, B7-H3, Bacillus anthracis anthrax, BAFF, BAFF-R, BCMA, beta amyloid, betacellulin, B-lymphoma cell, BLyS, bone morphogenetic proteins, C1s, C242 antigen, C5, CA-125, calcitonin, calcitonin gene-related peptide, calcitonin related polypeptide alpha, Canis lupus familiaris IL31, carbonic anhydrase 9, cardiac myosin, CCL11, CCR2, CCR4, CCR5, CD11, CD11a, CD123, CD125, CD134, CD137, CD140a, CD147, CD15, CD152, CD154, CD18, CD184, CD19, CD2, CD20, CD200, CD22, CD221, CD23, CD25, CD27, CD276, CD279, CD28, CD3, CD3 epsilon, CD30, CD319, CD33, CD37, CD38, CD3E, CD4, CD40, CD40L, CD41, CD44 v6, CD45, CD49b, CD5, CD51, CD52, CD54, CD56, CD6, Cd62L, CD70, CD74, CD79B, CD80, CD97B, CEA, CEACAM5, CEA-related antigen, CFD, CGRP, ciliary neurotrophic factor family, CLDN18, CLDN18.2, Clostridium difficile, Clostridium difficile toxin B, clumping factor A, c-Met, coagulation factor III, colony-stimulating factors, complement C5a, Complement component 5, CSF1, CSF1R, CSF2, CTGF, CTLA-4, CXCR4, cytokine, cytomegalovirus, cytomegalovirus glycoprotein B, dabigatran, dendritic cell-associated lectin 2, DLL3, DLL4, DPP4, DRS, E. coli shiga toxin type-1, E. coli shiga toxin type-2, ebolavirus glycoprotein, EGFL7, EGFR, EGFR 1-4, EGFR extracellular domain III, endoglin, endotoxin, eotaxin-1, EpCAM, EPHA3, ephrin a2, ephrin a3, ephrin a4, ephrin a5, ephrin b1, ephrin b2, ephrin b3, ephrin receptor A3, ephrins, epidermal growth factor, epigen, epiregulin, episialin, erythropoietin, Escherichia coli, F protein of respiratory syncytial virus, F protein of RSV, Factor Ixa, Factor X, FAP, FCGRT, FGF 23, FGFR2, fibrin II beta chain, fibroblast growth factor 1-23, fibroblast growth factors, fibronectin extra domain-B, foetal bovine somatotrophin, folate hydrolase, folate receptor, folate receptor 1, folate receptor alpha, Frizzled receptor, GCGR, GD2, GD2 ganglioside, GD3 ganglioside, GDF-8, gdnf family of ligands glial cell line-derived neurotrophic factor, gelatinase B, glycoprotein 75, glypican 3, GMCSF, GMCSF receptor α-chain, GPIIb/IIIa, GPNMB, granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, growth differentiation factor 8, growth differentiation factor-9, growth factors, growth factor receptors, GUCY2C, hemagglutinin, hemagglutinin HA, heparin-binding epidermal growth factor, heparin-binding growth factor, hepatitis B surface antigen, hepatitis B surfage antigen, hepatitis B virus, hepatocyte growth factor, hepatocyte growth factor-like protein, hepatoma-derived growth factor, HER, HER 1-4, HER2, HER3, HER4, heregulin, HGF, HGFR, HHGFR, histone complex, HIV-1, HLA-DR, HNGF, hormones, Hsp90, human beta-amyloid, human scatter factor receptor kinase, human TNF, ICAM-1, ICOS, ICOSL, IFN-α, IFN-γ, IgE, IgE Fc region, IGF1, IGF-1 receptor, IGF2, IGHE, IL-1, IL-12, IL-12R, IL-13, IL-13R, IL-17, IL-17A, IL-17F, IL-17R, IL-17RA, IL-1A, IL-1B, IL-1R, IL-1β, IL-2, IL-20, IL-20R, IL-22, IL-22R, IL-23, IL-23A, IL-23R, IL-2R, IL-2RA, IL-31, IL-31RA, IL-4, IL-4RA, IL-5, IL-5RA, IL-6, IL-6R, IL-9, IL-9R, IL-GF2, Influenza A hemagglutinin, influenza A virus hemagglutinin, influenza A virus hemagglutinin HA, insulin, insulin-like growth factor-2, insulin-like growth factors, integrin receptor, integrin α4, integrin α4β7, integrin α5β1, integrin αIIbβ3, integrin αvβ3, integrin β7, interferon gamma, interferon gamma-induced protein, interferon receptor, interferon α/β receptor, interleukin receptors, interleukins, ITGA2, ITGB2, kallikrein, keratinocyte growth factor, KIR2D, leukemia inhibitory factor, Lewis-Y antigen, LFA-1, LINGO-1, lipoteichoic acid, LIV-1, LOXL2, LRRC15, L-selectin, LTA, LYPD3, macrophage colony-stimulating factor, macrophage-stimulating protein, MASP-2, MCAM, MCP-1, MCSF, mesothelin, MIF, migration-stimulating factor, MS4A1, MSLN, MUC1, mucin CanAg, mucosal addressin cell adhesion molecule, myelin-associated glycoprotein, myostatin, NACP, NCA-90, nectin-4, nerve growth factors, neural apoptosis-regulated proteinase 1, neuregulin 1-4, neuregulins, neuropilin-1, neurotrophin-3, neurotrophin-4, neurotrophins, neurotrophins brain-derived neurotrophic factor, neurturin, NGF, NGNA ganglioside, NKG2A, NOGO-A, Notch 1, Notch receptor, NRP1, orf viral vascular endothelial growth factor homologs, OX-40, oxLDL, PCDC1, PCSK9, PD-1, PDCD1, PDGF-R α, PDGFRA, PD-L1, peptides, persephin, phosphate-sodium co-transporter, phosphatidylserine, placenta growth factor, placental growth factor, platelet-derived growth factor, platelet-derived growth factor receptor beta, platelet-derived growth factor-alpha polypeptide, programmed cell death 1, prostatic carcinoma cells, Protective antigen of Bacillus anthracis, Protective antigen of the Anthrax toxin, proteins, Pseudomonas aeruginosa, Pseudomonas aeruginosa type III secretion system, PSMA, PTK7, rabies virus G glycoprotein, rabies virus glycoprotein, RANKL, respiratory syncytial virus, RGMA, RHD, Rhesus factor, RON, root plate-specific spondin 3, RSVFR, RTN4, sclerostin, SDC1, selectin P, serum amyloid A protein, serum amyloid P component, SLAMF7, SLITRK6, SOST, sphingosine-1-phosphate, Staphylococcus aureus, Staphylococcus aureus alpha toxin, Staphylococcus aureus bi-component leukocidin, STEAP1, TAG-72, tau protein, t-cell growth factor, T-cell receptor, TEM1, tenascin C, TFPI, TGF beta 1, TGF beta 2, TGF-β, thrombopoietin, TIGIT, TNF, TNF alpha, TNFR superfamily member 4, TNFRSF8, TRAIL-R1, TRAIL-R2, transforming growth factor alpha, transforming growth factor beta, transforming growth factors, TRAP, TROP-2, TSLP, tumor antigen CTAA16.88, tumor necrosis factor-alpha, tumor specific glycosylation of MUC1, TWEAK receptor, TYRP1, VAP-1, vascular endothelial growth factor a-f, vascular endothelial growth factors, vascular permeability factor, VEGF, VEGF A-F, VEGFR, VEGFR1, VEGFR2, VEGFR3, vimentin, VSIR, VWF, Zaire ebolavirus glycoprotein, among others.
- In some embodiments, the target cell is a tumor cell, such as a solid tumor cell or a lymphoma or leukemia cell. In some embodiments, the target tumor or tumor-associated cell is selected from a solid tumor cell, a tumor stem cell, or a tumor-associated macrophage. In other embodiments, the target cell is an infectious cell, such as a bacterial cell, fungal cell such as a yeast cell, or a eukaryotic infectious cell. In some embodiments, the target cell is an epithelial cell. In some embodiments, the target cell is an inflammatory cell such as a monocyte or macrophage cell.
- Drugs that can be incorporated into particles herein may comprise any drug molecule capable of inhabiting the interior of a liposome particle or associating with the lipid surface layer of a particle. Drugs may include small molecule chemicals as well as peptide or protein drugs and nucleic acid drugs, for example. In some embodiments, the drug or drugs included in a particle may be anti-cancer drugs, anti-inflammatory agents, chemotherapy drugs, or kinase inhibitors. In some embodiments, drugs may comprise compounds intended for diagnostic purposes, including dyes or fluorescent or radio-labeled molecules.
- Therapeutic agents compatible with embodiments of ligand-drug particles herein (for example, as incorporated drugs or ligands or in the case of liposomal drugs or other types of particle drugs, that may be modified into a ligand-drug particle, such as by adding a ligand as described herein) may include agents such as 5-FU (Fluorouracil), Abemaciclib, Abiraterone Acetate, Abitrexate® (Methotrexate), Abraxane® (Paclitaxel Albumin-stabilized Nanoparticle Formulation), ABVD, ABVE, ABVE-PC, AC, Acalabrutinib, AC-T, Actigall®, Actos®, Adcetris® (Brentuximab Vedotin), ADE, Ado-Trastuzumab Emtansine, Adriamycin (Doxorubicin Hydrochloride), Afatinib Dimaleate, Afinitor® (Everolimus), Akynzeo® (Netupitant and Palonosetron Hydrochloride), Aldara® (Imiquimod), Aldesleukin, Alecensa® (Alectinib), Alectinib, Alemtuzumab, Alimta® (Pemetrexed Disodium), Aliqopa® (Copanlisib Hydrochloride), Alkeran® for Injection (Melphalan Hydrochloride), Alkeran® Tablets (Melphalan), Aloxi® (Palonosetron Hydrochloride), Alunbrig® (Brigatinib), amadotin, Ambochlorin® (Chlorambucil), Amboclorin® (Chlorambucil), Amifostine, Aminolevulinic Acid, Anastrozole, Apalutamide, Aprepitant, Aredia® (Pamidronate Disodium), Arimidex® (Anastrozole), aritox, Aromasin® (Exemestane), Arranon® (Nelarabine), Arsenic Trioxide, Arzerra® (Ofatumumab), Asparaginase Erwinia chrysanthemi, Atezolizumab, Avandia, Avastin® (Bevacizumab), Avelumab, Axicabtagene Ciloleucel, Axitinib, Azacitidine, azathioprine, Bavencio® (Avelumab), BEACOPP, Becenum® (Carmustine), Beleodaq® (Belinostat), Belinostat®, Bendamustine Hydrochloride, BEP, Besponsa® (Inotuzumab Ozogamicin), betaine, Bevacizumab, Bexarotene, Bicalutamide, BiCNU® (Carmustine), Bleomycin, Blinatumomab, Blincyto® (Blinatumomab), bogatox, Bortezomib, Bosulif® (Bosutinib), Bosutinib, Brentuximab Vedotin, Brigatinib, BuMel, Busulfan, Busulfex® (Busulfan), Cabazitaxel, Cabometyx® (Cabozantinib-S-Malate), Cabozantinib-S-Malate, CAF, Calquence® (Acalabrutinib), Campath® (Alemtuzumab), Camptosar® (Irinotecan Hydrochloride), Capecitabine, CAPDX, Carac® (Fluorouracil—Topical), Carboplatin, CARBOPLATIN-TAXOL, Carfilzomib,® (Carmustine), Carmustine, Carmustine Implant, Casodex® (Bicalutamide), CEM, Ceritinib, Cerubidine (Daunorubicin Hydrochloride), Cervarix® (Recombinant HPV Bivalent Vaccine), Cetuximab, CEV, Chlorambucil, CHLORAMBUCIL-PREDNISONE, Cholbam, cholic acid, CHOP, Cisplatin, cituxetan, Cladribine, Clafen® (Cyclophosphamide), Clofarabine, Clofarex® (Clofarabine), Clolar® (Clofarabine), CMF, Cobimetinib, colchicine, Cometriq® (Cabozantinib-S-Malate), Copanlisib Hydrochloride, COPDAC, COPP, COPP-ABV, Cosmegen® (Dactinomycin), Cotellic® (Cobimetinib), Creon, Crizotinib, CVP, Cyclophosphamide, Cyfos® (Ifosfamide), Cyramza® (Ramucirumab), Cystadane, Cytarabine, Cytarabine Liposome, Cytosar-U® (Cytarabine), Cytoxan® (Cyclophosphamide), Dabrafenib, Dacarbazine, Dacogen® (Decitabine), Dactinomycin, Daratumumab, Darzalex® (Daratumumab), Dasatinib, Daunorubicin Hydrochloride, Daunorubicin Hydrochloride and Cytarabine Liposome, Decitabine, Defibrotide Sodium, Defitelio® (Defibrotide Sodium), Degarelix, Denileukin Diftitox, Denosumab, DepoCyt® (Cytarabine Liposome), Dexamethasone, Dexrazoxane Hydrochloride, Dinutuximab, Docetaxel, Doxil® (Doxorubicin Hydrochloride Liposome), doxorubicin, Doxorubicin Hydrochloride, Doxorubicin Hydrochloride Liposome, Dox-SL (Doxorubicin Hydrochloride Liposome), DTIC-Dome® (Dacarbazine), Durvalumab, Efudex® (Fluorouracil—Topical), Elitek® (Rasburicase), Ellence® (Epirubicin Hydrochloride), Elotuzumab, Eloxatin® (Oxaliplatin), Eltrombopag Olamine, Emend® (Aprepitant), Empliciti® (Elotuzumab), emtansine, Enasidenib Mesylate, Enzalutamide, Epirubicin Hydrochloride, EPOCH, Erbitux® (Cetuximab), Eribulin Mesylate, Erivedge® (Vismodegib), Erleada® (Apalutamide), Erlotinib Hydrochloride, Erwinaze® (Asparaginase Erwinia chrysanthemi), Ethyol® (Amifostine), Etopophos® (Etoposide Phosphate), Etoposide, Etoposide Phosphate, Evacet® (Doxorubicin Hydrochloride Liposome), Everolimus, Evista® (Raloxifene Hydrochloride), Evomela® (Melphalan Hydrochloride), Exemestane, Fareston® (Toremifene), Farydak® (Panobinostat), Faslodex® (Fulvestrant), FEC, Femara® (Letrozole), Filgrastim, floxuridine, Fludara® (Fludarabine Phosphate), Fludarabine Phosphate, Fluoroplex® (Fluorouracil—Topical), Fluorouracil Injection, Fluorouracil—Topical, Flutamide, Folex® (Methotrexate), Folex® PFS (Methotrexate), one or more components of FOLFIRI, FOLFIRI-BEVACIZUMAB, FOLFIRI-CETUXIMAB, FOLFIRINOX, FOLFOX, Folotyn® (Pralatrexate), FUDR, FU-LV, Fulvestrant, Gardasil® (Recombinant HPV Quadrivalent Vaccine), Gardasil 9® (Recombinant HPV Nonavalent Vaccine), Gazyva® (Obinutuzumab), Gefitinib, Gemcitabine Hydrochloride, GEMCITABINE-CISPLATIN, GEMCITABINE-OXALIPLATIN, Gemtuzumab Ozogamicin, Gemzar® (Gemcitabine Hydrochloride), Gilotrif® (Afatinib Dimaleate), Gleevec (Imatinib Mesylate), Gliadel® (Carmustine Implant), Gliadel wafer (Carmustine Implant), Glucarpidase, Goserelin Acetate, govitecan, Halaven® (Eribulin Mesylate), Hemangeol® (Propranolol Hydrochloride), Herceptin® (Trastuzumab), HPV Bivalent Vaccine, Recombinant, HPV Nonavalent Vaccine, Recombinant, HPV Quadrivalent Vaccine, Recombinant, Humatin, Hycamtin® (Topotecan Hydrochloride), Hydrea® (Hydroxyurea), Hydroxyurea, Hyper-CVAD, Ibrance® (Palbociclib), Ibritumomab Tiuxetan, Ibrutinib, ICE, Iclusig® (Ponatinib Hydrochloride), Idamycin® (Idarubicin Hydrochloride), Idarubicin Hydrochloride, Idelalisib, Idhifa® (Enasidenib Mesylate), Ifex® (Ifosfamide), Ifosfamide, Ifosfamidum® (Ifosfamide), IL-2 (Aldesleukin), Imatinib Mesylate, Imbruvica® (Ibrutinib), Imfinzi® (Durvalumab), Imiquimod, Imlygic® (Talimogene Laherparepvec), Inlyta® (Axitinib), Inotuzumab Ozogamicin, Interferon Alfa-2b, Recombinant, Interleukin-2 (Aldesleukin), Intron A (Recombinant Interferon Alfa-2b), Ipilimumab, Iressa® (Gefitinib), Irinotecan Hydrochloride, Irinotecan Hydrochloride Liposome, Istodax® (Romidepsin), Ixabepilone, ixadotin, Ixazomib Citrate, Ixempra® (Ixabepilone), Jakafi® (Ruxolitinib Phosphate), JEB, Jevtana® (Cabazitaxel), Kadcyla® (Ado-Trastuzumab Emtansine), Keoxifene® (Raloxifene Hydrochloride), Kepivance® (Palifermin), Keytruda® (Pembrolizumab), Kisqali® (Ribociclib), Kymriah® (Tisagenlecleucel), Kyprolis® (Carfilzomib), Lanreotide Acetate, Lapatinib Ditosylate, Lartruvo® (Olaratumab), Lenalidomide, Lenvatinib Mesylate, Lenvima (Lenvatinib Mesylate), Letrozole, Leucovorin Calcium, Leukeran® (Chlorambucil), Leuprolide Acetate, Leustatin® (Cladribine), Levulan® (Aminolevulinic Acid), Linfolizin® (Chlorambucil), LipoDox® (Doxorubicin Hydrochloride Liposome), Lomustine, Lonsurf® (Trifluridine and Tipiracil Hydrochloride), Luminal, Lupron® (Leuprolide Acetate), Lupron® Depot (Leuprolide Acetate), Lupron® Depot-Ped (Leuprolide Acetate), Lutathera® (Lutetium Lu 177-Dotatate), Lutetium® (Lu 177-Dotatate), Lynparza® (Olaparib), mafenatox, mafodotin, Marqibo® (Vincristine Sulfate Liposome), Matulane® (Procarbazine Hydrochloride), Mechlorethamine Hydrochloride, Megestrol Acetate, Mekinist (Trametinib), Melphalan, Melphalan Hydrochloride, Mercaptopurine, merpentan, mertansine, Mesna, Mesnex® (Mesna), Methazolastone® (Temozolomide), Methotrexate, Methotrexate LPF (Methotrexate), Methylnaltrexone Bromide, Mexate® (Methotrexate), Mexate®-AQ (Methotrexate), Midostaurin, Mitomycin C, Mitoxantrone Hydrochloride, Mitozytrex® (Mitomycin C), monatox, MOPP, Mozobil® (Plerixafor), Mustargen (Mechlorethamine Hydrochloride), Mutamycin® (Mitomycin C), Myleran® (Busulfan), Mylosar® (Azacitidine), Mylotarg® (Gemtuzumab Ozogamicin), nadolol, Nanoparticle Paclitaxel (Paclitaxel Albumin-stabilized Nanoparticle Formulation), Navelbine® (Vinorelbine Tartrate), Necitumumab, Nelarabine, Neo-Fradin, neomycin, Neosar® (Cyclophosphamide), Neo-Tab, Neratinib Maleate, Nerlynx® (Neratinib Maleate), Netupitant and Palonosetron Hydrochloride, Neulasta® (Pegfilgrastim), Neupogen® (Filgrastim), Nexavar® (Sorafenib Tosylate), Nilandron® (Nilutamide), Nilotinib, Nilutamide, Ninlaro® (Ixazomib Citrate), Niraparib Tosylate Monohydrate, Nivolumab, Nolvadex® (Tamoxifen Citrate), Nplate® (Romiplostim), obeticholic acid, Obinutuzumab, Ocaliva, Odomzo® (Sonidegib), OEPA, Ofatumumab, OFF, Olaparib, Olaratumab, Omacetaxine Mepesuccinate, Oncaspar® (Pegaspargase), Ondansetron Hydrochloride, Onivyde® (Irinotecan Hydrochloride Liposome), Ontak® (Denileukin Diftitox), Opdivo, Opdivo® (Nivolumab), OPPA, orlistat, Osimertinib, Oxaliplatin, ozogamicin, Paclitaxel, Paclitaxel Albumin-stabilized Nanoparticle Formulation, PAD, Palbociclib, Palifermin, Palonosetron Hydrochloride, Palonosetron Hydrochloride and Netupitant, Pamidronate Disodium, Pancreaze, pancrelipase, Pangestyme EC, Panitumumab, Panobinostat, Panocaps, paptox, Paraplat® (Carboplatin), Paraplatin® (Carboplatin), paromomycin, pasudotox, Pazopanib Hydrochloride, PCV, PEB, Pegaspargase, Pegfilgrastim, Peginterferon Alfa-2b, PEG-Intron® (Peginterferon Alfa-2b), pelidotin, Pembrolizumab, Pemetrexed Disodium, pendetide, pentetate, Perjeta® (Pertuzumab), Pertuzumab, Pertzye, phenobarbital, pioglitazone, Platinol® (Cisplatin), Platinol-®AQ (Cisplatin), Plerixafor, Pomalidomide, Pomalyst® (Pomalidomide), Ponatinib Hydrochloride, Portrazza® (Necitumumab), Pralatrexate, Prednisone, Procarbazine Hydrochloride, Proleukin® (Aldesleukin), Prolia (Denosumab), Promacta® (Eltrombopag Olamine), propranolol, Propranolol Hydrochloride, Provenge® (Sipuleucel-T), Purinethol® (Mercaptopurine), Purixan® (Mercaptopurine), Radium 223 Dichloride, Raloxifene Hydrochloride, Ramucirumab, Rasburicase, ravtansine, R-CHOP, R-CVP, Recombinant Human Papillomavirus (HPV) Bivalent Vaccine, Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine, Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine, Recombinant Interferon Alfa-2b, Regorafenib, Relistor® (Methylnaltrexone Bromide), R-EPOCH, Revlimid® (Lenalidomide), Rheumatrex® (Methotrexate), Ribociclib, R-ICE, Rituxan (Rituximab), Rituxan Hycela (Rituximab and Hyaluronidase Human), Rituximab, Rituximab and Hyaluronidase Human, Rolapitant Hydrochloride, Romidepsin, Romiplostim, rosiglitazone, Rubidomycin (Daunorubicin Hydrochloride), Rubraca® (Rucaparib Camsylate), Rucaparib Camsylate, Ruxolitinib Phosphate, Rydapt® (Midostaurin), satetraxetan, Sclerosol Intrapleural Aerosol (Talc), Siltuximab, Sipuleucel-T, Somatuline® Depot (Lanreotide Acetate), Sonidegib, Sorafenib Tosylate, soravtansine, Sprycel® (Dasatinib), STANFORD V, Sterile Talc Powder (Talc), Steritalc® (Talc), Stivarga® (Regorafenib), Sunitinib Malate, Sutent® (Sunitinib Malate), Sylatron® (Peginterferon Alfa-2b), Sylvant® (Siltuximab), Synribo® (Omacetaxine Mepesuccinate), Tabloid® (Thioguanine), TAC, tafenatox, Tafinlar® (Dabrafenib), Tagrisso® (Osimertinib), Talc, Talimogene Laherparepvec, talirine, Tamoxifen Citrate, Tarabine® PFS (Cytarabine), Tarceva® (Erlotinib Hydrochloride), Targretin® (Bexarotene), Tasigna® (Nilotinib), Taxol (Paclitaxel), Taxotere® (Docetaxel), Tecentriq® (Atezolizumab), Temodar® (Temozolomide), Temozolomide, Temsirolimus, tesirine, tetraxetan, Thalidomide, Thalomid® (Thalidomide), Thioguanine, Thiotepa, Tisagenlecleucel, tiuxetan, Tolak® (Fluorouracil—Topical), Topotecan Hydrochloride, Toremifene, Torisel® (Temsirolimus), Totect® (Dexrazoxane Hydrochloride), TPF, Trabectedin, Trametinib, Trastuzumab, Treanda® (Bendamustine Hydrochloride), Trifluridine and Tipiracil Hydrochloride, Trisenox® (Arsenic Trioxide), Tykerb® (Lapatinib Ditosylate), Ultresa, Unituxin® (Dinutuximab), Uridine Triacetate, Urso, Urso Forte, ursodiol, VAC, Valrubicin, Valstar® (Valrubicin), VAMP, Vandetanib, Varubi® (Rolapitant Hydrochloride), Vectibix® (Panitumumab), vedotin, VeIP, Velban® (Vinblastine Sulfate), Velcade® (Bortezomib), Velsar® (Vinblastine Sulfate), Vemurafenib, Venclexta® (Venetoclax), Venetoclax, Verzenio® (Abemaciclib), Viadur (Leuprolide Acetate), Vidaza® (Azacitidine), Vinblastine Sulfate, Vincasar® PFS (Vincristine Sulfate), Vincristine Sulfate, Vincristine Sulfate Liposome, Vinorelbine Tartrate, Viokace, Viokase, VIP, Vismodegib, Vistogard® (Uridine Triacetate), Voraxaze® (Glucarpidase), Vorinostat, Votrient® (Pazopanib Hydrochloride), Vyxeos® (Daunorubicin Hydrochloride and Cytarabine Liposome), Wellcovorin (Leucovorin Calcium), Xalkori® (Crizotinib), XELIRI, Xeloda® (Capecitabine), XELOX, Xgeva® (Denosumab), Xofigo® (Radium 223 Dichloride), Xtandi® (Enzalutamide), Yervoy® (Ipilimumab), Yescarta® (Axicabtagene Ciloleucel), Yondelis® (Trabectedin), Zaltrap® (Ziv-Aflibercept), Zarxio® (Filgrastim), Zejula® (Niraparib Tosylate Monohydrate), Zelboraf® (Vemurafenib), Zenpep, Zevalin® (Ibritumomab Tiuxetan), Zinecard® (Dexrazoxane Hydrochloride), Ziv-Aflibercept, Zofran® (Ondansetron Hydrochloride), Zoladex® (Goserelin Acetate), Zoledronic Acid, Zolinza® (Vorinostat), Zometa® (Zoledronic Acid), Zydelig® (Idelalisib), Zykadia® (Ceritinib), and Zytiga® (Abiraterone Acetate), among others.
- Uptake of Particles
- To optimize the uptake of ligand-conjugated liposomes to cells, ligands should have high affinity binding to the targeted receptors. The rapid screening and identifying of tumor-specific high affinity internalizing human antibodies and antibody fragments from phage and yeast display of non-immune phage antibody libraries may be used for ligand selection. Access of the ligand to the receptor may also be important. A polymer linker such as PEG, for example, may be helpful to distance low molecular weight ligands such as folate from the liposomal surface and to allow receptor binding. Coupling of ligands to polymer linkers of various lengths to the distal terminals of antibody fragments and other ligands may improve binding, internalizing, and overall bioactivity in the delivery of drugs.
- The affinity of soluble ligands for their receptors in vitro may not differ drastically from the affinity of ligands conjugated to liposomes for their receptors. The conjugation of anti-HER2 F5 scFv to liposomes has been shown to not significantly affect the ligand interaction with HER2 in HER2-overexpressing cell lines since the KD for the binding of monovalent F5 scFv conjugated liposomes (KD=111 nM) and of soluble F5 scFv (K6=160 nM) are comparable, for example. In addition, it has been shown that the high affinity binding of Fab′-conjugated immunoliposomes derived from antibody fragments of trastuzumab is comparable to that of free Fab′ and intact antibody. Increasing the surface valency of ligands per liposomes correlates to increased targeted uptake in cells until a plateau, however, after which additional ligands may decrease binding and internalization. In HER2-overexpressing human breast cancer cells, it has been documented that the cell binding and internalization of anti-HER2 immunoliposomes increased at higher surface valency of conjugated ligands, reaching a plateau, depending on ligand, at ˜40 trastuzumab-Fab′/liposome and a plateau at ˜30 F5 scFv/liposome. Similarly, in EGFR-overexpressing human breast cancer cells, a plateau was reached, depending on ligand, at ˜30-40 cetuximab-Fab′/liposome. Apparently, the limit on the binding and uptake of ligand-conjugated liposomes may be dependent on ligand valency per liposome and receptor expression level rather than on the cells than to ligand affinity.
- In some embodiments herein, a particle comprises more than one targeting ligand. For example, a particle may comprise anti-HER2 and anti-EGFR dual-targeted ligands. Dual-targeted particles may allow for the examination of the antagonistic effects of a non-specific ligand possibly from steric hindrance on cells expressing only one of the receptors. Dual-targeting liposomes against HER2 and EGFR may improve the delivery of immunoliposomes to cell lines expressing both receptors by increasing the receptor density, but can also serve to simplify the formulation of ligand-targeted lipid particles that can target a larger array of cells, similar to a cocktail-targeting approach.
- Determining Ligand Valency of a Ligand-Drug Particle
- In some embodiments, the efficiency of uptake of a ligand-drug particle into a cell increases with the number of ligands found on the particle up to an optimum valency, and then plateaus or decreases as more ligands are added to the particle. The present disclosure provides results of mathematical modeling experiments conducted to predict the optimal valency for ligand-drug particles based on the dissociation constant for the ligand and its receptor on the target cell and on the expression level of the receptor by the target cell. For example, as described in the Examples below, an optimal valency for a ligand-drug particle may be determined where the target cell expresses on the order of from 103 to 107 receptors per cell. When a value is provided for the number of receptors expressed in a target cell, it is understood that the value is an average number for cells of that type as determined experimentally. Generally such values are rounded to one significant figure. A value that is “on the order of,” for instance, 105 or 106 means a value that would round closest to 1×105 or 1×106 (for example 9×105 would round closest to 1×106 while 3×105 would round closest to 1×105).
- When referring to valency determination herein, a cell providing “high expression” or cell “highly expressing” a particular receptor means a cell that expresses on the order of 106 receptor molecules per cell. A “moderate expression” cell expresses on the order of 105 receptor molecules per cell, while a “low expression” cell expresses on the order of 104 receptor molecules per cell.
- Particles with One Ligand Species
- Table 1 below (also in the Examples below) provides calculated optimal valence for particles with a single ligand species specific for a receptor with high expression or moderate expression in the target cell, the valence also depending on the in vitro equilibrium dissociation constant of the ligand and receptor.
-
TABLE 1 Optimal valency for single ligand, single receptor under high and moderate average receptor expression levels Optimal Multi-Valent Binding: Mono-Targeted Valence (Ligands/Particle) KD (nM) High Moderate 1000 19 23 100 17 21 10 16 19 1 14 17 0.1 13 15 0.01 11 13 0.001 10 12 - Optimal valence for a more specific range of receptor expression levels are provided in Table 2.
-
TABLE 2 Optimal valency for single ligand, single receptor under specific average receptor expression levels (RT) and receptor-ligand KD Optimal Multi Valent Binding Mono Targeted/High Expression Valence (Ligands/Particle) RT (#/cell) KD (nM) 4*10{circumflex over ( )}5 5*10{circumflex over ( )}5 6*10{circumflex over ( )}5 7*10{circumflex over ( )}5 8*10{circumflex over ( )}5 9{circumflex over ( )}10{circumflex over ( )}5 10{circumflex over ( )}6 3*10{circumflex over ( )}6 1000 36 29 25 23 21 20 19 12 100 33 27 23 21 19 18 17 11 10 30 24 21 19 18 16 16 10 1 27 22 19 17 16 15 14 9 0.1 24 19 17 15 14 13 13 8 0.01 21 17 15 13 12 12 11 7 0.001 18 15 13 12 11 10 10 6 - As can be seen from Tables 1 and 2, ligand-drug particles comprising one ligand may have specific ligand valencies or ranges of ligand valencies depending upon the KD of the ligand-receptor interaction measured in vitro and on the average receptor expression level for the target cells, for example, measured in tissue culture. Actual chosen valencies where the RT and KD are on the order of the numbers shown in the two above tables may vary by plus or minus one. For example, for a KD on the order of 10 nM and an RT on the order of 5×105, the valency may be 24+/−1 or 23-25.
- For example, in some embodiments, if the target cell highly expresses the receptor according to high expression as defined above, then the ligand-drug particle may have a valency of 10-19 ligands per particle, based on Table 1 above. If the target cell moderately expresses the receptor, then the ligand-drug particle may have a valency of 12-23 ligands per particle, based on Table 1 above. The specific valency or valency range may depend further on the KD of the ligand for its receptor. For example, from Table 1, if the ligand-receptor KD is on the order of 10 nM (i.e., a value rounding closest to 10 nM), and the receptor is highly expressed as defined above, then the particle may have a valency of 15-17, or may have a valency of 15, 16, or 17, or of 16. From Table 1, if the ligand-receptor KD is on the order of 1 nM (i.e., a value rounding closest to 1 nM), and the receptor is moderately expressed as defined above, then the particle may have a valency of 16-18, or may have a valency of 16, 17 or 18, or of 17. From Table 2, if the ligand-receptor KD is on the order of 0.1 nM (i.e., a value rounding closest to 0.1 nM), and the receptor is expressed at an average on the order of 7×105, then the particle may have a valency of 14-16, or may have a valency of 14, 15, or 16, or of 15. Similar valencies may be determined for a ligand-drug particle embodiment herein for all of the other combinations of RT and KD shown in Tables 1 and 2.
- Thus, in some embodiments, where the receptor-ligand equilibrium dissociation constant, measured in vitro, is 0.001 to 1000 nM, the particle has a ligand valency as follows: (a) a valency of 6-12 where the target cell has an average on the order of 3×106 receptors per cell; (b) a valency of 10-19 where the target cell has an average on the order of 1×106 receptors per cell; (c) a valency of 10-20 where the target cell has an average on the order of 9×105 receptors per cell; (d) a valency of 11-21 where the target cell has an average on the order of 8×105 receptors per cell; (e) a valency of 12-23 where the target cell has an average on the order of 7×105 receptors per cell; (f) a valency of 13-25 where the target cell has an average on the order of 6×105 receptors per cell; (g) a valency of 15-29 where the target cell has an average on the order of 5×105 receptors per cell; or (h) a valency of 18-36 where the target cell has an average on the order of 4×105 receptors per cell. In some such embodiments, the ligand-receptor equilibrium dissociation constant, measured in vitro, is 0.1 to 10 nM and the particle has a ligand valency as follows: (a) a valency of 8-10 where the target cell has an on the order of 3×106 receptors per cell; (b) a valency of 13-16 where the target cell has an average on the order of 9×105 to 1×106 receptors per cell; (c) a valency of 14-18 where the target cell has an average on the order of 8×105 receptors per cell; (d) a valency of 15-19 where the target cell has an average on the order of 7×105 receptors per cell; (e) a valency of 17-21 where the target cell has an average on the order of 6×105 receptors per cell; (f) a valency of 19-24 where the target cell has an average on the order of 5×105 receptors per cell; or (g) a valency of 24-30 where the target cell has an average on the order of 4×105 receptors per cell.
- In some such embodiments, the ligand-receptor equilibrium dissociation constant, measured in vitro, is 0.01 to 0.1 nM and the particle has a ligand valency as follows: (a) a valency of 7-8 where the target cell has an on the order of 3×106 receptors per cell; (b) a valency of 11-13 where the target cell has an average on the order of 9×105 receptors per cell; (c) a valency of 12-13 where the target cell has an average on the order of 1×106 receptors per cell; (d) a valency of 12-14 where the target cell has an average on the order of 8×105 receptors per cell; (e) a valency of 13-15 where the target cell has an average on the order of 7×105 receptors per cell; (f) a valency of 15-17 where the target cell has an average on the order of 6×105 receptors per cell; (g) a valency of 17-19 where the target cell has an average on the order of 5×105 receptors per cell; or (h) a valency of 21-24 where the target cell has an average on the order of 4×105 receptors per cell. In some embodiments, the ligand-receptor equilibrium dissociation constant, measured in vitro, is 0.1 to 1 nM and the particle has a ligand valency as follows: (a) a valency of 8-9 where the target cell has an on the order of 3×106 receptors per cell; (b) a valency of 13-14 where the target cell has an average on the order of 9×105 receptors per cell; (c) a valency of 13-15 where the target cell has an average on the order of 1×106 receptors per cell; (d) a valency of 14-16 where the target cell has an average on the order of 8×105 receptors per cell; (e) a valency of 15-17 where the target cell has an average on the order of 7×105 receptors per cell; (f) a valency of 17-19 where the target cell has an average on the order of 6×105 receptors per cell; (g) a valency of 19-22 where the target cell has an average on the order of 5×105 receptors per cell; or (h) a valency of 24-27 where the target cell has an average on the order of 4×105 receptors per cell. In some embodiments, the ligand-receptor equilibrium dissociation constant, measured in vitro, is 1 to 10 nM and the particle has a ligand valency as follows: (a) a valency of 9-10 where the target cell has an on the order of 3×106 receptors per cell; (b) a valency of 14-16 where the target cell has an average on the order of 9×105 receptors per cell; (c) a valency of 15-16 where the target cell has an average on the order of 1×106 receptors per cell; (d) a valency of 16-18 where the target cell has an average on the order of 8×105 receptors per cell; (e) a valency of 17-19 where the target cell has an average on the order of 7×105 receptors per cell; (f) a valency of 19-21 where the target cell has an average on the order of 6×105 receptors per cell; (g) a valency of 22-24 where the target cell has an average on the order of 5×105 receptors per cell; or (h) a valency of 27-30 where the target cell has an average on the order of 4×105 receptors per cell. In some embodiments, the ligand-receptor equilibrium dissociation constant, measured in vitro, is 10 to 100 nM and the particle has a ligand valency as follows: (a) a valency of 10-11 where the target cell has an on the order of 3×106 receptors per cell; (b) a valency of 16-17 where the target cell has an average on the order of 9×105 receptors per cell; (c) a valency of 16-18 where the target cell has an average on the order of 1×106 receptors per cell; (d) a valency of 18-19 where the target cell has an average on the order of 8×105 receptors per cell; (e) a valency of 19-21 where the target cell has an average on the order of 7×105 receptors per cell; (f) a valency of 21-23 where the target cell has an average on the order of 6×105 receptors per cell; (g) a valency of 24-27 where the target cell has an average on the order of 5×105 receptors per cell; or (h) a valency of 30-33 where the target cell has an average on the order of 4×105 receptors per cell.
- In further embodiments, the ligand-drug particle has a ligand-receptor in vitro binding affinity is 0.001 to 0.1 nM and the particle has a ligand valency as follows, depending on the number of receptors per cell: (a) a valency of 15-24 where the target cell has an average on the order of 4×105 to 5×105 receptors per cell; (b) a valency of 13-19 where the target cell has an average on the order of 5×105 to 6×105 receptors per cell; (c) a valency of 12-17 where the target cell has an average on the order of 6×105 to 7×105 receptors per cell; (d) a valency of 11-15 where the target cell has an average on the order of 7×105 to 8×105 receptors per cell; (e) a valency of 10-14 where the target cell has an average on the order of 8×105 to 9×105 receptors per cell; (f) a valency of 10-13 where the target cell has an average on the order of 9×105 to 1×106 receptors per cell; or (g) a valency of 6-13 where the target cell has an average on the order of 1×106 to 3×106 receptors per cell. In additional embodiments, the ligand-receptor in vitro binding affinity is 0.1 to 10 nM and the particle has a ligand valency as follows: (a) a valency of 19-30 where the target cell has an average on the order of 4×105 to 5×105 receptors per cell; (b) valency of 17-24 where the target cell has an average on the order of 5×105 to 6×105 receptors per cell; (c) a valency of 15-21 where the target cell has an average on the order of 6×105 to 7×105 receptors per cell; (d) a valency of 14-19 where the target cell has an average on the order of 7×105 to 8×105 receptors per cell; (d a valency of 13-18 where the target cell has an average on the order of 8×105 to 9×105 receptors per cell; (f) a valency of 13-16 where the target cell has an average on the order of 9×105 to 1×106 receptors per cell; or (g) a valency of 8-16 where the target cell has an average on the order of 1×106 to 3×106 receptors per cell. In yet other embodiments, the ligand-receptor in vitro binding affinity is 10 to 1000 nM and the particle has a ligand valency as follows: (a) valency of 24-36 where the target cell has an average on the order of 4×105 to 5×105 receptors per cell; (b) a valency of 21-29 where the target cell has an average on the order of 5×105 to 6×105 receptors per cell; (c) a valency of 19-25 where the target cell has an average on the order of 6×105 to 7×105 receptors per cell; (d) a valency of 18-23 where the target cell has an average on the order of 7×105 to 8×105 receptors per cell; (e) a valency of 16-21 where the target cell has an average on the order of 8×105 to 9×105 receptors per cell; (f) a valency of 16-20 where the target cell has an average on the order of 9×105 to 1×106 receptors per cell; or (g) a valency of 10-19 where the target cell has an average on the order of 1×106 to 3×106 receptors per cell.
- In embodiments where the expression level of the receptor is such that there is an average of on the order of 4×105 receptors per cell, then, based on Table 2, the ligand valency may be (a) 35-37; or 35, 36, or 37; or 36 if the ligand-receptor KD is on the order of 1000 nM; (b) 32-34; or 32, 33, or 34; or 33 if the ligand-receptor KD is on the order of 100 nM; (c) 29-31; or 29, 30, or 31; or 30 if the ligand-receptor KD is on the order of 10 nM; (d) 26-28; or 26, 27, or 28; or 27 if the ligand-receptor KD is on the order of 1 nM; (e) 23-25; or 23, 24, or 25; or 24 if the ligand-receptor KD is on the order of 0.1 nM; (f) 20-22; or 20, 21, or 22; or 21 if the ligand-receptor KD is on the order of 0.01 nM; or (g) 17-19; or 17, 18, or 19; or 18 if the ligand-receptor KD is on the order of 0.001 nM.
- In embodiments where the expression level of the receptor is such that there is an average of on the order of 5×105 receptors per cell, then, based on Table 2, the ligand valency may be (a) 28-30; or 28, 29, or 30; or 29 if the ligand-receptor KD is on the order of 1000 nM; (b) 26-28; or 26, 27, or 28; or 27 if the ligand-receptor KD is on the order of 100 nM; (c) 23-25; or 23, 24, or 25; or 24 if the ligand-receptor KD is on the order of 10 nM; (d) 21-23; or 21, 22, or 23; or 22 if the ligand-receptor KD is on the order of 1 nM; (e) 18-20; or 18, 19, or 20; or 19 if the ligand-receptor KD is on the order of 0.1 nM; (f) 16-18; or 16, 17, or 18; or 17 if the ligand-receptor KD is on the order of 0.01 nM; or (g) 14-16; or 14, 15, or 16; or 15 if the ligand-receptor KD is on the order of 0.001 nM.
- In embodiments where the expression level of the receptor is such that there is an average of on the order of 6×105 receptors per cell, then, based on Table 2, the ligand valency may be (a) 24-26; or 24, 25, or 26; or 25 if the ligand-receptor KD is on the order of 1000 nM; (b) 22-24; or 22, 23, or 24; or 23 if the ligand-receptor KD is on the order of 100 nM; (c) 20-22; or 20, 21, or 22; or 21 if the ligand-receptor KD is on the order of 10 nM; (d) 18-20; or 18, 19, or 20; or 19 if the ligand-receptor KD is on the order of 1 nM; (e) 16-18; or 16, 17, or 18; or 17 if the ligand-receptor KD is on the order of 0.1 nM; (f) 14-16; or 14, 15, or 16; or 15 if the ligand-receptor KD is on the order of 0.01 nM; or (g) 12-14; or 12, 13, or 14; or 13 if the ligand-receptor KD is on the order of 0.001 nM.
- In embodiments where the expression level of the receptor is such that there is an average of on the order of 7×105 receptors per cell, then, based on Table 2, the ligand valency may be (a) 22-24; or 22, 23, or 24; or 23 if the ligand-receptor KD is on the order of 1000 nM; (b) 20-22; or 20, 21, or 22; or 21 if the ligand-receptor KD is on the order of 100 nM; (c) 18-20; or 18, 19, or 20; or 19 if the ligand-receptor KD is on the order of 10 nM; (d) 16-18; or 16, 17, or 18; or 17 if the ligand-receptor KD is on the order of 1 nM; (e) 14-16; or 14, 15, or 16; or 15 if the ligand-receptor KD is on the order of 0.1 nM; (f) 12-14; or 12, 13, or 14; or 13 if the ligand-receptor KD is on the order of 0.01 nM; or (g) 11-13; or 11, 12, or 13; or 12 if the ligand-receptor KD is on the order of 0.001 nM.
- In embodiments where the expression level of the receptor is such that there is an average of on the order of 8×105 receptors per cell, then, based on Table 2, the ligand valency may be (a) 20-22; or 20, 21, or 22; or 21 if the ligand-receptor KD is on the order of 1000 nM; (b) 18-20; or 18, 19, or 20; or 19 if the ligand-receptor KD is on the order of 100 nM; (c) 17-19; or 17, 18, or 19; or 18 if the ligand-receptor KD is on the order of 10 nM; (d) 15-17; or 15, 16, or 17; or 16 if the ligand-receptor KD is on the order of 1 nM; (e) 13-15; or 13, 14, or 15; or 14 if the ligand-receptor KD is on the order of 0.1 nM; (f) 11-13; or 11, 12, or 13; or 12 if the ligand-receptor KD is on the order of 0.01 nM; or (g) 10-12; or 10, 11, or 12; or 11 if the ligand-receptor KD is on the order of 0.001 nM.
- In embodiments where the expression level of the receptor is such that there is an average of on the order of 9×105 receptors per cell, then, based on Table 2, the ligand valency may be (a) 19-21; or 19, 20, or 21; or 20 if the ligand-receptor KD is on the order of 1000 nM; (b) 17-19; or 17, 18, or 19; or 18 if the ligand-receptor KD is on the order of 100 nM; (c) 15-17; or 15, 16, or 17; or 16 if the ligand-receptor KD is on the order of 10 nM; (d) 14-16; or 14, 15, or 16; or 15 if the ligand-receptor KD is on the order of 1 nM; (e) 12-14; or 12, 13, or 14; or 13 if the ligand-receptor KD is on the order of 0.1 nM; (f) 11-13; or 11, 12, or 13; or 12 if the ligand-receptor KD is on the order of 0.01 nM; or (g) 9-11; or 9, 10, or 11; or 10 if the ligand-receptor KD is on the order of 0.001 nM.
- In embodiments where the expression level of the receptor is such that there is an average of on the order of 1×106 receptors per cell, then, based on Table 2, the ligand valency may be (a) 18-20; or 18, 19, or 20; or 19 if the ligand-receptor KD is on the order of 1000 nM; (b) 16-18; or 16, 17, or 18; or 17 if the ligand-receptor KD is on the order of 100 nM; (c) 15-17; or 15, 16, or 17; or 16 if the ligand-receptor KD is on the order of 10 nM; (d) 13-15; or 13, 14, or 15; or 14 if the ligand-receptor KD is on the order of 1 nM; (e) 12-14; or 12, 13, or 14; or 13 if the ligand-receptor KD is on the order of 0.1 nM; (f) 10-12; or 10, 11, or 12; or 11 if the ligand-receptor KD is on the order of 0.01 nM; or (g) 9-11; or 9, 10, or 11; or 10 if the ligand-receptor KD is on the order of 0.001 nM.
- In embodiments where the expression level of the receptor is such that there is an average of on the order of 3×106 receptors per cell, then, based on Table 2, the ligand valency may be (a) 11-13; or 11, 12, or 13; or 12 if the ligand-receptor KD is on the order of 1000 nM; (b) 10-12; or 10, 11, or 12; or 11 if the ligand-receptor KD is on the order of 100 nM; (c) 9-11; or 9, 10, or 11; or 10 if the ligand-receptor KD is on the order of 10 nM; (d) 8-10; or 8, 9, or 10; or 9 if the ligand-receptor KD is on the order of 1 nM; (e) 7-9; or 7, 8, or 9; or 8 if the ligand-receptor KD is on the order of 0.1 nM; (f) 6-8; or 6, 7, or 8; or 7 if the ligand-receptor KD is on the order of 0.01 nM; or (g) 5-7; or 5, 6, or 7; or 6 if the ligand-receptor KD is on the order of 0.001 nM.
- Particles with Two Ligands, Each Recognizing a Different Receptor
- Also contemplated herein are ligand-drug particles that comprise two different ligands, specific for two different receptors on a target cell. Such ligand-drug particles may comprise a lipid surface layer, at least one drug in the interior of the particle or embedded in the lipid surface layer, and two ligands specific for two different cell surface receptors on a target cell, wherein the ligands are exposed on the lipid surface layer; the ligands bind to their receptors with in vitro binding affinity of 0.1 to 100 nM; the target cell that the particle targets comprises an average on the order of 103 to 10′ of each receptor; and the particle has a ligand valency that depends upon the ligand-receptor in vitro binding affinity or each receptor-ligand pair, the average number of each receptor per target cell, and whether ligand-receptor binding is additive or synergistic.
- In some embodiments, in a dual-ligand particle, at least one ligand is an antibody, or both ligands are antibodies. In some embodiments, at least one ligand is an antigen binding fragment of an antibody, or both ligands are antigen binding fragments of antibodies, such as an Fv, scFv, Fab′, or F(ab′)2 fragment.
- Table 3 below (also in the Examples below) provides calculated optimal valence of each ligand for particles with two different ligand species specific for two different receptors with high expression or moderate expression in the target cell, the valence also depending on the in vitro equilibrium dissociation constant of the ligand and receptor, and on whether the interaction between the ligands and receptors on the target cell is observed to be additive or synergistic. The valence, in Table 3 below refers to the valence of each ligand per particle. Thus, for example, if the table indicates an optimal valency of, say, 16, the valency would be 16 for each of the two ligands for a total ligand valency of 32.
-
TABLE 3 Optimal Valance for Each Ligand on Particles with Two Ligands under Different Receptor Expression and Ligand-Receptor Affinity Conditions Optimal Multi-Valent Binding: Dual-Targeted KD (nM) Valence (Ligands/Particle) Ligand 1Ligand 2HHa HMa MMa HHs HMS MMS 100 100 17 17 21 13 10 15 100 10 16 17 20 13 10 15 100 1 16 17 19 13 10 15 100 0.1 15 17 19 13 10 15 10 10 16 16 19 12 9 13 10 1 15 16 18 12 9 13 10 0.1 14 16 17 12 9 13 1 1 14 14 17 10 8 1 1 0.1 13 14 16 10 8 12 0.1 0.1 13 13 15 9 7 11 - Table 3, which is also provided in the Examples below, provides optimal valence for each ligand calculated based on particular sets of ligand equilibrium dissociation constants and the expression levels of each receptor (high (H) on the order of 1×106 or moderate (M) on the order of 1×105) and whether the binding is additive (a) or synergistic (s).
- In some embodiments where a particle has two ligands, the particle has a ligand valency as follows: (a) a valency of 13-17 where each receptor is highly expressed by the target cell and where binding of the two receptors by the two ligands is additive (HHa in Table 3); (b) valency of 9-13 where each receptor is highly expressed by the target cell and where binding of the two receptors by the two ligands is synergistic (HHs); (c) a valency of 13-17 where one receptor is highly expressed by the target cell and the other receptor is moderately expressed, and where binding of the two receptors by the two ligands is additive (HMa); (d) a valency of 7-10 where one receptor is highly expressed by the target cell and the other receptor is moderately expressed, and where binding of the two receptors by the two ligands is synergistic (HMs); (e) a valency of 15-21 where each receptor is moderately expressed by the target cell and where binding of the two receptors by the two ligands is additive (MMa); or (f) a valency of 11-15 where each receptor is moderately expressed by the target cell and where binding of the two receptors by the two ligands is synergistic (MMs).
- In some embodiments, the dual-ligand particle has a ligand valency as follows: (a) a valency of 17-21 where the in vitro binding affinity for each ligand-receptor pair is on the order of 100 nM and binding is additive; (b) a valency of 16-20 where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 10 nM and binding is additive; (c) a valency of 16-19 where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 1 nM and binding is additive; (d) a valency of 15-19 where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is additive; (e) a valency of 16-19 where the in vitro binding affinity for each ligand-receptor pair is on the order of 10 nM and binding is additive; (f) a valency of 15-18 where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 1 nM and binding is additive; (g) a valency of 14-17 where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is additive; (h) a valency of 14-17 where the in vitro binding affinity for each ligand-receptor pair is on the order of 1 nM and binding is additive; (i) a valency of 13-16 where the in vitro binding affinity for one ligand-receptor pair is on the order of 1 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is additive; (j) a valency of 13-15 where the in vitro binding affinity for each ligand-receptor pair is on the order of 0.1 nM and binding is additive; (k) a valency of 10-15 where the in vitro binding affinity for each ligand-receptor pair is on the order of 100 nM and binding is synergistic; (l) a valency of 10-15 where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 10 nM and binding is synergistic; (m) a valency of 10-15 where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 1 nM and binding is synergistic; (n) a valency of 10-15 where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is synergistic; (o) a valency of 9-13 where the in vitro binding affinity for each ligand-receptor pair is on the order of 10 nM and binding is synergistic; (p) a valency of 9-13 where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 1 nM and binding is synergistic; (q) a valency of 9-13 where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is synergistic; (r) a valency of 8-12 where the in vitro binding affinity for each ligand-receptor pair is on the order of 1 nM and binding is synergistic; (s) a valency of 8-12 where the in vitro binding affinity for one ligand-receptor pair is on the order of 1 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is synergistic; or (t) a valency of 7-11 where the in vitro binding affinity for each ligand-receptor pair is on the order of 0.1 nM and binding is synergistic.
- In some embodiments, the dual-ligand particle has a ligand valency as follows, where the target cell highly expresses both receptors: (a) a valency of 16-18; or 16, 17, or 18; or 17, where the in vitro binding affinity for each ligand-receptor pair is on the order of 100 nM and binding is additive; (b) a valency of 15-17; or 15, 16, or 17; or 16, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 10 nM and binding is additive; (c) a valency of 15-17; or 15, 16, or 17; or 16, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 1 nM and binding is additive; (d) a valency of 14-16; or 14, 15, or 16; or 15, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is additive; (e) a valency of 15-17; or 15, 16, or 17; or 16, where the in vitro binding affinity for each ligand-receptor pair is on the order of 10 nM and binding is additive; (f) a valency of 14-16; or 14, 15, or 16; or 15, where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 1 nM and binding is additive; (g) a valency of 13-15; or 13, 14, or 15; or 14, where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is additive; (h) a valency of 13-15; or 13, 14, or 15; or 14, where the in vitro binding affinity for each ligand-receptor pair is on the order of 1 nM and binding is additive; (i) a valency of 12-14; 12, 13, or 14; or 13, where the in vitro binding affinity for one ligand-receptor pair is on the order of 1 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is additive; (j) a valency of 12-14; 12, 13, or 14; or 13, where the in vitro binding affinity for each ligand-receptor pair is on the order of 0.1 nM and binding is additive; (k) a valency of 12-14; 12, 13, or 14; or 13, where the in vitro binding affinity for each ligand-receptor pair is on the order of 100 nM and binding is synergistic; (l) a valency of 12-14; 12, 13, or 14; or 13, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 10 nM and binding is synergistic; (m) a valency of 12-14; 12, 13, or 14; or 13, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 1 nM and binding is synergistic; (n) a valency of 12-14; 12, 13, or 14; or 13, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is synergistic; (o) a valency of 11-13; 11, 12, or 13; or 12, where the in vitro binding affinity for each ligand-receptor pair is on the order of 10 nM and binding is synergistic; (p) a valency of 11-13; 11, 12, or 13; or 12, where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 1 nM and binding is synergistic; (q) a valency of 11-13; 11, 12, or 13; or 12, where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is synergistic; (r) a valency of 9-11; 9, 10, or 11; or 10, where the in vitro binding affinity for each ligand-receptor pair is on the order of 1 nM and binding is synergistic; (s) a valency of 9-11; 9, 10, or 11; or 10, where the in vitro binding affinity for one ligand-receptor pair is on the order of 1 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is synergistic; or (t) a valency of 8-10; 8, 9, or 10; or 9, where the in vitro binding affinity for each ligand-receptor pair is on the order of 0.1 nM and binding is synergistic.
- In some embodiments, the dual-ligand particle has a ligand valency as follows, where the target cell moderately expresses both receptors: (a) a valency of 20-22; or 20, 21, or 22; or 21, where the in vitro binding affinity for each ligand-receptor pair is on the order of 100 nM and binding is additive; (b) a valency of 19-21; or 19, 20, or 21; or 20, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 10 nM and binding is additive; (c) a valency of 18-20; or 18, 19, or 20; or 19, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 1 nM and binding is additive; (d) a valency of 18-20; or 18, 19, or 20; or 19, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is additive; (e) a valency of 18-20; or 18, 19, or 20; or 19, where the in vitro binding affinity for each ligand-receptor pair is on the order of 10 nM and binding is additive; (f) a valency of 17-19; or 17, 18, or 19; or 18, where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 1 nM and binding is additive; (g) a valency of 16-18; or 16, 17, 18; or 17, where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is additive; (h) a valency of 16-18; or 16, 17, 18; or 17, where the in vitro binding affinity for each ligand-receptor pair is on the order of 1 nM and binding is additive; (i) a valency of 15-17; or 15, 16, or 17; or 16, where the in vitro binding affinity for one ligand-receptor pair is on the order of 1 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is additive; (j) a valency of 14-16; or 14, 15, or 16; or 15; where the in vitro binding affinity for each ligand-receptor pair is on the order of 0.1 nM and binding is additive; (k) a valency of 14-16; or 14, 15, or 16; or 15; where the in vitro binding affinity for each ligand-receptor pair is on the order of 100 nM and binding is synergistic; (l) a valency of 14-16; or 14, 15, or 16; or 15; where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 10 nM and binding is synergistic; (m) a valency of 14-16; or 14, 15, or 16; or 15; where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 1 nM and binding is synergistic; (n) a valency of 14-16; or 14, 15, or 16; or 15; where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is synergistic; (o) a valency of 12-14; or 12, 13, or 14; or 13, where the in vitro binding affinity for each ligand-receptor pair is on the order of 10 nM and binding is synergistic; (p) a valency of 12-14; or 12, 13, or 14; or 13, where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 1 nM and binding is synergistic; (q) a valency of 12-14; or 12, 13, or 14; or 13, where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is synergistic; (r) a valency of 11-13; or 11, 12, or 13; or 12, where the in vitro binding affinity for each ligand-receptor pair is on the order of 1 nM and binding is synergistic; (s) a valency of 11-13; or 11, 12, or 13; or 12, where the in vitro binding affinity for one ligand-receptor pair is on the order of 1 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is synergistic; or (t) a valency of 10-12; or 10, 11, or 12; or 11, where the in vitro binding affinity for each ligand-receptor pair is on the order of 0.1 nM and binding is synergistic.
- In some embodiments, the dual-ligand particle has a ligand valency as follows, where the target cell highly expresses one receptor and moderately expresses the other: (a) a valency of 16-18; or 16, 17, or 18; or 17, where the in vitro binding affinity for each ligand-receptor pair is on the order of 100 nM and binding is additive; (b) a valency of 16-18; or 16, 17, or 18; or 17, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 10 nM and binding is additive; (c) a valency of 16-18; or 16, 17, or 18; or 17, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 1 nM and binding is additive; (d) a valency of 16-18; or 16, 17, or 18; or 17, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is additive; (e) a valency of 15-17; or 15, 16, or 17; or 16, where the in vitro binding affinity for each ligand-receptor pair is on the order of 10 nM and binding is additive; (f) a valency of 15-17; or 15, 16, or 17; or 16, where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 1 nM and binding is additive; (g) a valency of 15-17; or 15, 16, or 17; or 16, the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is additive; (h) a valency of 13-15; or 13, 14, or 15; or 14, where the in vitro binding affinity for each ligand-receptor pair is on the order of 1 nM and binding is additive; (i) a valency of 13-15; or 13, 14, or 15; or 14, where the in vitro binding affinity for one ligand-receptor pair is on the order of 1 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is additive; (j) a valency of 12-14; 12, 13, or 14; or 13, where the in vitro binding affinity for each ligand-receptor pair is on the order of 0.1 nM and binding is additive; (k) a valency of 9-11; or 9, 10, or 11; or 10, where the in vitro binding affinity for each ligand-receptor pair is on the order of 100 nM and binding is synergistic; (l) a valency of 9-11; or 9, 10, or 11; or 10, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 10 nM and binding is synergistic; (m) a valency of 9-11; or 9, 10, or 11; or 10, where the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 1 nM and binding is synergistic; (n) a valency of 9-11; or 9, 10, or 11; or 10, the in vitro binding affinity for one ligand-receptor pair is on the order of 100 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is synergistic; (o) a valency of 8-10; or 8, 9, or 10; or 9, where the in vitro binding affinity for each ligand-receptor pair is on the order of 10 nM and binding is synergistic; (p) a valency of 8-10; or 8, 9, or 10; or 9, where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 1 nM and binding is synergistic; (q) a valency of 8-10; or 8, 9, or 10; or 9, where the in vitro binding affinity for one ligand-receptor pair is on the order of 10 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is synergistic; (r) a valency of 7-9; or 7, 8, or 9; or 8, where the in vitro binding affinity for each ligand-receptor pair is on the order of 1 nM and binding is synergistic; (s) a valency of 7-9; or 7, 8, or 9; or 8, where the in vitro binding affinity for one ligand-receptor pair is on the order of 1 nM for the second ligand-receptor pair is on the order of 0.1 nM and binding is synergistic; or (t) a valency of 6-8; or 6, 7, or 8; or 7, where the in vitro binding affinity for each ligand-receptor pair is on the order of 0.1 nM and binding is synergistic.
- In some embodiments, the equilibrium dissociation constant for a particular ligand will have been previously measured in vitro, and this information may be used to obtain an optimal ligand valence for a particle comprising that ligand. For instance, some reported equilibrium dissociation constants for potential ligand molecules include: abciximab 5 nM, adalimumab 0.05-0.1 nM, alemtuzumab 3-10 nM, atezolizumab 0.4 nM, avelumab 0.7 nM, basiliximab 0.1 nM, belimumab 0.1-0.3 nM, benralizumab 0.016 nM, bevacizumab 0.5-20 nM, bezlotoxumab 0.02-0.04 nM, blinatumomab 1.5 nM, brentuximab 0.2 nM, brodalumab 0.24 nM, canakinumab 0.02-1.3 nM, certolizumab 0.09 nM, cetuximab 0.1-0.4 nM, daclizumab 0.3-0.5 nM, daratumumab 4.4 nM, denosumab 0.003 nM, dinutuximab 11-12 nM, dupilumab 0.01-0.03 nM, durvalumab 0.022 nM, eculizumab 0.12 nM, elotuzumab 30-45 nM, emicizumab 900-1800 nM, evolocumab 0.016 nM, golimumab 0.018 nM, ibritumomab 17 nM, idarucizumab 0.0021 nM, infliximab 0.1-0.45 nM, inotuzumab 0.12-0.15 nM, ipilimumab 1-10 nM, ixekizumab 0.0018 nM, mepolizumab 0.0042 nM, natalizumab 0.3 nM, necitumumab 0.32 nM, nivolumab 2-3 nM, obiltoxaximab 0.33 nM, obinutuzumab 4 nM, ocrelizumab 0.47-1.2 nM, ofatumumab 3-6 nM, olaratumab 0.33 nM, omalizumab 2-8 nM, palivizumab 1 nM, panitumumab 0.05 nM, pembrolizumab 0.029 nM, pertuzumab 9-15 nM, ramucirumab 0.05 nM, ranibizumab 0.19 nM, raxibacumab 1-4 nM, reslizumab 0.081 nM, rituximab 5-11 nM, sarilumab 0.054 nM, secukinumab 0.06-0.37 nM, siltuximab 0.034 nM, tocilizumab 1-3 nM, trastuzumab 1-14 nM, and EGF & TGFα 2-3 nM.
- In addition, cell lines from disease models may be used to estimate the expression level of target cells in a human patient, for example. For example, for ligand-drug particles with one or more ligands specific for the epidermal growth factor receptor (EGFR), one can obtain cancer cell lines such as MDA-MB-468, MB-MB-231, and MCF-7 with published 1-1.3*10{circumflex over ( )}6 EGFR/cell, 1-1.3*10{circumflex over ( )}5 EGFR/cell, and 1-1.5*10{circumflex over ( )}4 EGFR/cell respectively. For ligand-drug particles specific for human epidermal growth factor receptor (HER2), for example, one can obtain HER2-overexpressing cancer cell lines such as BT474 (10{circumflex over ( )}6 HER2/cell), SK-BR-3 (3*10{circumflex over ( )}6 HER2/cell), etc. Similarly, one can obtain well characterized cell lines that overexpress other potential receptor proteins. Alternatively, one can transfect cell lines to express those antigen/receptors if necessary such as HER2-overexpressing MCF-7/HER2 and VEGFR2-overexpressing PAE/KDR (2.5*10{circumflex over ( )}5 VEGFR2/cell) and 293/KDR (2.5*10{circumflex over ( )}6 VEGFR2/cell).
- It is understood that the valencies given herein are average valencies for the particle and that due to manufacturing methods, actual individual particle valencies may vary somewhat from one particle to the next. Valency (number of ligands per particle) may be measured experimentally, for example, from the ratio of protein to phospholipid (see
references 35, 36, 38, 42, 44 below). For example, phospholipid concentration of a ligand-drug particle can be measured by a phosphate assay (ref. 118) or high performance liquid chromatography (HPLC). Ligand concentration of a ligand-drug particle can be determined by ImageJ® (National Institutes of Health) from SDS-PAGE stained with SYPRO® Ruby. Other protein quantification methods are possible such as BCA Protein Assay Kit (Thermo Scientific), Quant-iT® Protein Assay Kit (Life Technologies), SDS-PAGE (Bio-Rad), UV spectrometry, and HPLC. All measurements are against a phosphate or protein standard. For example, for a liposome size of 100 nm in diameter and an average area per phospholipid molecule of 75 {circumflex over ( )}2, this gives an average of 80,000 phospholipid molecules per liposome. Antibodies have an average molecular weight of 150-160 kDa, Fab′ of ˜50 kDa, and scFv of ˜25 kDa. Protein concentration to phospholipid concentration provides the protein to phospholipid ratio, which with the phospholipid per particle and protein per ligand correction factors, determine the valency. Other techniques are also possible such as dual measurements of protein and lipid through HPLC, labeling the ligands and/or lipids with a fluorescent marker for quantification, or secondary component measurements such as quantification of encapsulated drug or embedded cholesterol or PEG. - Systems and Methods for Optimizing Ligand Valence
- This disclosure also contemplates systems for determining ligand valency for a ligand-drug particle, wherein the particle comprises a lipid surface layer, at least one drug in the interior of the particle or embedded in the lipid surface layer, and a ligand specific for a receptor on a target cell, the ligand exposed on the lipid surface layer, the system comprising software capable of determining ligand valency from in vitro ligand-receptor dissociation constant and average number of receptors per target cell according to a crosslink multivalent binding model. The disclosure also contemplates systems for determining ligand valency for a ligand-drug particle, wherein the particle comprises a lipid surface layer, at least one drug in the interior of the particle or embedded in the lipid surface layer, and two ligands each specific for a receptor on a target cell, the ligands exposed on the lipid surface layer, the system comprising software capable of determining ligand valency from in vitro ligand-receptor dissociation constants for each ligand-receptor pair and average number of each receptor per target cell and either additive or synergistic binding according to a crosslink multivalent binding model. In such systems, software may be used, for example, to determine an optimal valency based on methods described in Example 1 below.
- For example, in some embodiments, one may determine ligand valence by obtaining or determining a ligand-receptor KD and a receptor expression level (e.g., number of receptors per target cell; RT) and then determining a plot or relationship of the number of cell-associated particles per cell at equilibrium (CBeq) to valence, where the peak of the plot curve comprises the maximium cellular uptake and an optimal valence. (See for example
FIGS. 14-15 .) Briefly, with known or determined KD, RT, and assumed equilibrium and steady-state constants, one would apply the crosslink binding model (equations 5-3b and 5-3d) to solve simultaneously for a function of CBeq to valence. The examples below were conducted in Mathcad®, solving a system of differential equations for a plot of CBeq to valence. The maximium calculated cell association (CBeq) and its respective valence (rounded to an integer) provide an optimum valence for ligand-drug particle uptake. A working range of KD and RT were examined and disclosed as examples. For dual-targeted ligand-drug particles, additive binding can be calculated based upon the sum of the CBeq of each individual particle cell association calculated separately. For dual-targeted ligand-drug particles, synergetic binding can be calculated based upon a singular dissociation constant and crosslinking equilibrium constant for the ligand-receptor binding combination with higher affinity. As examples, valences ratios of 1:1 for each ligand duals were accessed; other combinations can also be examined. A working range of KD and RT were examined and disclosed as examples. Through the cell association plots, these calculations also display the cellular uptake levels of ligand-drug particles. Other mathematical software are possible to assist in the calculations such as Mathcad®, Matlab®, Maple®, Mathematica®, Python®, R, etc. - In the equations 5-3b and 5-3d, Req is the number of free receptors per cell at equilibrium, CBeq is the number of cell-associated particles per cell at equilibrium, RT is the total number of receptors per cell, Lo, which is the free particle concentration in solution, KD is the equilibrium dissociation constant of the ligand for its receptor on the cell, v=valence, f is the effective valence, which is essentially the effective number of ligands per particle that can bind to a cell out of the total valence (v), and KX=kx/k−x is the crosslinking equilibrium constant. Ci is the concentration of a particle bound to the cell surface via i of its v available surface-attached ligands (i=0, 1, 2, . . . , f).
- To better capture the dynamics between ligands and receptors on cells, many models for the cell surface receptor binding and trafficking of both ligands and receptors have been proposed (133-140). Translating the kinetic models of ligands with receptors to multivalent nanoparticles with receptors may provide insight to the experimental data and as well as observations in the literature. To begin, one may start with a base case of the monovalent binding of ligand (Lg) to receptor (R) to form a ligand/receptor complex (CLg) (
FIG. 1 ). Through mass action kinetics, the kinetics of ligand, receptor, and complex with time can be described as equation 5-1 with association and dissociation rate constants kf and kr, respectively. Unlike many ligands, nanoparticles such as ligand-drug particles are multivalent. Nanoparticles are nanometers in size, for example 10-500 nm in length or diameter. The first bond of a single ligand on a nanoparticle to a single receptor on the cell surface can still be applied with the base model, but subsequent interactions should be considered and adjusted to more accurately model the avidity. -
- In regards to the receptor, the receptor can interact with other receptors and proteins, forming ternary complexes. The ErbB family of receptor tyrosine kinases such as EGFR and HER2 are known to form dimers, for example. The affinity of ligands to single receptors compared to dimers, whether with one or more binding sites occupied, can greatly change the binding and internalizing kinetics, with the later, dimerization with higher binding site occupancy usually associated with higher affinity(133, 138, 141). For immunoglobulin receptors, the separation distance between the sites of a bivalent antibody is between 9 and 20 nm(135, 142, 143). For a liposome particle with 20 surface ligands and an average diameter of 100 nm, the separation between ligands is approximately 40 nm assuming equal distribution. This distance can be slightly greater through a polymer linker attached to the ligand. Due to the spacing of the targeting groups on a nanoparticle such as a ligand-drug liposome particle, it is unlikely for a single nanoparticle to occupy both sites of a bivalent receptor or even occupy both dimerized receptors. Hence, it is assumed that nanoparticles with functional monovalent ligands can only occupy one site per single receptor or set of dimerized receptors. This simplifies the model, treating the receptors as monovalent. Keep in mind that higher valence nanoparticles, smaller multivalent nanoparticles, and ligand-drugs are in the realms of possibility of bivalent receptor binding. Other ternary complex possibilities that receptors can interact with are G-proteins, coated-pit binding proteins, and cytoskeletal elements(133). It is assumed that none of these are rate-limiting or saturated in the model.
- Relative to a ligand, nanoparticles are large, increasing interaction with multiple components on a cell such as additional receptors, proteins, lipids, and macromolecules that may induce binding. Non-specific binding can skew a binding model. Immunoliposomes are coated with a layer of polyethylene glycol, providing sterical stabilization that limits the non-specific binding and interaction with cells. Therefore, it is assumed that non-specific binding is minimal, as also evident by low cell association for non-targeted liposomes. The experimental studies mainly focused on targeting cancer cells that overexpressed receptors, specifically EGFR and HER2, and likewise, these may be used as targets of the model. Assuming an average cell diameter of 10 μm with 106 receptors and an average liposome particle diameter of 100 nm with 20 ligands, the receptor to ligand per surface area ratio is 5, meaning that for every ligand there are 5 receptors available to bind. Crosslink multivalent binding of liposomes to multiple receptors is a possible and plausible outcome.
- The crosslink multivalent binding model for multivalent ligands to monovalent receptors, developed and reviewed by a number of investigators(134-136, 139, 140), was applied to model the cell association of nanoparticles (
FIG. 2A-2B ). The general idea is that a free nanoparticle (L=C0) first binds to a single receptor (R) as described by the base monovalent binding model. Subsequently, a second ligand on the nanoparticle binds to a second receptor with forward and reverse crosslinking constants (kx and k−x), resulting in a complex consisting of a nanoparticle bound to the surface by 2 ligands. Additional ligands simultaneously bind to the cell surface until the number of ligand-receptor bounds reach the effective valence (f), essentially the effective number of ligands per nanoparticle that can bind to a cell out of the total valence (v). Consequently, the multivalent nanoparticle with f crosslinked receptors is internalized into the cell by receptor-mediated endocytosis. It is assumed that f≤v due to sterical hindrance with the bound receptor and suboptimal positioning and spacing of the ligands(135). Let Ci be the concentration of a nanoparticle bound to the cell surface via i of its v available surface-attached ligands (i=0, 1, 2, . . . , f), equations by mass action kinetics to describe the crosslink multivalent binding model building upon the monovalent binding model are as follows: -
- At steady-state, solutions for the number of free receptors per cell at equilibrium (Req) and the number of cell associated nanoparticles per cell at equilibrium (CBeq) can be symbolic solved with the additional parameters (total receptors per cell (RT), free nanoparticle concentration in solution (L=Lo), equilibrium dissociation constant (KD=kr/kf), and the crosslinking equilibrium constant (KX=kx/k−x)):
-
- All parameters in the model are based on experimental data and from the literature, particularly for studies pertaining to anti-HER2 F5 scFv-conjugated immunoliposomes and BT-474 cells in the high receptor expression model. For analysis at equilibrium (time <4 hr), assume a constant free nanoparticle concentration in solution (L=Lo), no nanoparticle and receptor depletion effects, and constant forward and reverse crosslinking constants (kx and k−x) for additional receptor binding. The total receptors per cell (RT) is 106 for high receptor expressing cells (ie, BT-474 cells; adjusted to 105 and 104 for the moderate and low receptor expression models, respectively). The free nanoparticle concentration in solution (Lo) is 106 nanoparticles per cell (˜70-100 μM PL), which is approximately the saturating concentration observed at the optimal cell association. The equilibrium dissociation constant (KD=kr/kf) is 100 nM (111 nM for monovalent F5 scFv-ILS, 160 nM for F5 scFv)(34). The crosslinking equilibrium constant (KX=kx/k−x) is 1/(70K #/cell) for high receptor expressing cells, estimated from the maximum uptake of nanoparticles in dose-uptake studies assuming high crosslinking. For the moderate and low receptor expression models, KX of 1/(10K #/cell) and 1/(3K #/cell) were estimated, respectively. Valence and effective valence in the range of 1-200 ligands per nanoparticle were evaluated since that is the maximum Fab′ valence per nanoparticle stably construct in experiments. Since f≤v, assume that if v<f, then f=v (equation 5-4). The number of free receptors per cell at equilibrium (Req) and the number of cell associated nanoparticles per cell at equilibrium (CBeq) as a function of v and f were evaluated and plotted using Mathcad®.
-
- Predictions calculated from the crosslink multivalent binding model on the cell association of multivalent nanoparticles to cells overall quite accurately describe experimental data. For example, optimal cell association of liposome particles to cells, depending on ligand, has been observed at v=15-40 antibody fragments per liposome(4, 33-37), as demonstrated with EGF-LS and TGFα-LS and F5 scFv-ILS in
FIG. 3 . Since binding and uptake saturate in that range, an effective valence off=10<v was initially predicted (FIGS. 4A-C ). Increasing the surface valency of ligands per nanoparticle with f=10 correlated to increased targeted association in the high receptor expression model until a plateau. Complementarily, the concentration of free receptors decreased as the concentration of nanoparticles was receptor-associated. These results fit quite in line with the observations. - Various effective valences were also analyzed (
FIGS. 4A-4C ). At f≤7 (ie, f=7), the binding is reasonably linear, increasing, and negligible in comparison to higher effective valences. This is similar to monovalent ligand binding and low receptor expressing models discussed later (FIG. 6A-6B ). At f=8-17 (ie, f=10), the overall bound concentration increases significantly, curves to saturation, and then maxes at f=17. For f higher than 17 (ie, f=50 or 100), cell association subsequently decreases. A peak at f=17 supports that v=15-40 observed. When v>f=17, the overall binding starts to decrease. - The effective valence was initially assumed to be constant and much lower than v as observed for models of multivalent ligands. What if f is not constant, but increases as v increases? As previously mentioned, at v=20, there are 5 receptors available in a given surface area per ligand, reducing to a reasonable 1:1 at v=100. Hence, it is plausible that nanoparticles can have a high f/v ratio. A scenario where f=v and that assumes that every ligand on the nanoparticle efficiently binds to a receptor iis plotted in
FIGS. 4A-4C . The graph displays a familiar observation seen with experimental data, where increasing the valence beyond the optimal valence can decrease cell association (FIG. 5A-5B ). This will hold true not only for a model where f=v, but when v>f=17 (ie, f=50 & 100,FIG. 4A-4C ) or when f increases with v. In addition, at a high effective valence like when f≈v, it supports the data where roughly a 1:1 ratio of ligands to expressed receptors was observed internalized at optimal valence. Plots of the cell association as a function of the full f and v range (f≤v) were also analyzed in the model (FIG. 5A-5B ), indicating that the optimal cell association can be no further optimized based purely on ligand surface valency. - Moderate and low receptor expression models were also considered (
FIG. 6A-6B ). The total receptors per cell availability was reduced, and likewise KX lowered and adjusted to match the empirical data. It is expected that f will be much lower than cases for the high expression model and hence mainly examined f=10. For the moderate receptor expression model, when f=10, binding was observed to increase with v reaching a steady plateau as free receptors concentration decreased. These results support the cell association of a HER2/EGFR moderately expressing cell line MKN-7. The scenario where f=v was also considered, but may not be realistic due to the lower receptor availability. In reality, f will most likely have a lower limit than for cases of the high receptor expression model. In the case of the low receptor expression model, the cell association behavior appropriately resembles monovalent ligand binding, showing a linear non-crosslinking, non-cooperative binding with very low binding, similar to f=1 for the high receptor expression model. - Concentrations of the calculated cell association closely approximate the dose-uptake experimental data at comparable liposomal incubation concentrations (L at 89 μM). For HER2 high-expressing BT-474 cells (RT=106 receptors per cell), the model calculated the bound liposomes per cell concentration of 5.9*104 for v=15, where in the dose-uptake studies I observed cellular uptake at 6.8*104±7*103 for v=15. The estimated uptake is within 85% accuracy of empirical data. When the high receptor expression model was adjusted for SK-BR-3 cells (increasing to 3*106 receptors per cell), the calculated concentration again appropriately increased. For SK-BR-3 cells, the model calculated bound liposomes per cell concentrations of 2.3*105 for v=10 and 2.2*105 for v=15, where in the dose-uptake studies I observed cellular uptakes at 2.3*105±4*10 3 for v=10 and 2.3*105±9*10 3 for v=15. The estimated values are within 95% accuracy of empirical data. Since v for optimum binding was calculated to be v=11 for SK-BR-3 cells, it is appropriate that the observed uptake in the dose-uptake studies was slightly higher for v=10 than for v=15, as predicted from the model. Suitably, it also suggests that the optimum v decreases as the number of available receptor increases as expected. When RT was lowered to 5*105 receptors per cell, the optimum ligand valence was observed at −30 ligands per liposome, which would account for the full 15-40 ligands per liposome range observed for optimal uptake.
- Assuming the equilibrium dissociation constants for monovalent nanoparticles and their respective attached ligand are comparable as in the real example of F5 scFv, the crosslink multivalent binding model allows researchers to estimate the optimum valence and cell association by knowing the dissociation constants of the ligand and the receptor expression level of a cell. However, based on the crosslink multivalent binding model for the cell association of multivalent nanoparticles to high receptor expressing cells, the current systems may have already been optimized purely from experimental data. Varying monovalent ligand valency beyond the 10+v range will not significantly alter the binding and uptake of nanoparticles.
- In addition, the model also predicted the limitations of ligand affinity as experimentally observed by Zhou and associates, where ultrahigh affinity anti-EGFR scFv is unnecessary for optimal nanoparticle targeting(93). Zhou empirically detected an increase of 24% in targeted liposomal cell association when comparing surface attached C10 scFv (264 nM KD) to 224 scFv (0.94 nM KD). Using the listed KD's, the model precisely predicted a 23.7% increase at v=74 (valence evaluated by the paper). Based on the model for F5 scFv, the affinity must be improved by an order of 5 magnitudes to merely increase cell association by 2-fold (
FIG. 7 ). - How can cell association be increased? As evidence by equations 5-3b and 5-3d, CBeq is exponentially proportional to Req which is exponentially proportional to RT. Hence, increasing the total receptor will in effect increase the concentration of bound nanoparticles. This hypothesis was experimentally examined with dual-targeted immunoliposomes, showing additive uptake effects. In addition, quite simply, the liposomal uptake in cells directly correlates with expression level, ie SK-BR-3 cells>BT-474 cells. Still, the overall uptake, despite being higher, is not quite valuable in applications that rely mainly on increased accumulation for bioactivity since the increase is marginal. However, applications where the receptor expression level is uncertain, such as drug delivery to tumors since expressed receptors can be both heterogeneous and transient, may still be an avenue worth pursing for dual-targeted systems.
- In addition to examples targeting cells expressing HER2 or EGFR, the model has been expanded to design and optimize the uptake efficiency of ligand-based drugs and nanomedicines relative to ligand surface valency, receptor expression level, mono-targeting as well as dual-targeting to multiple receptors, multi-targeted and multi-valent, and ultimately the consequential biological activity in the delivery of drugs for any ligand and to any antigen target.
- Cell association, drug uptake, and cytotoxicity experiments have validated aspects of the model for HER2-targeted lipid nanoparticles to HER2-expressing cells. Likewise, the model may be applied to any ligand and to any antigen target. Equilibrium dissociation constants and total receptors on a cell are measurable parameters through various quantification assays. These parameters are often disclosed in the literature, especially for antibodies and established cell lines. For example, ranges of equilibrium dissociation constants in the literature are abciximab 5 nM, adalimumab 0.05-0.1 nM, alemtuzumab 3-10 nM, atezolizumab 0.4 nM, avelumab 0.7 nM, basiliximab 0.1 nM, belimumab 0.1-0.3 nM, benralizumab 0.016 nM, bevacizumab 0.5-20 nM, bezlotoxumab 0.02-0.04 nM, blinatumomab 1.5 nM, brentuximab 0.2 nM, brodalumab 0.24 nM, canakinumab 0.02-1.3 nM, certolizumab 0.09 nM, cetuximab 0.1-0.4 nM, daclizumab 0.3-0.5 nM, daratumumab 4.4 nM, denosumab 0.003 nM, dinutuximab 11-12 nM, dupilumab 0.01-0.03 nM, durvalumab 0.022 nM, eculizumab 0.12 nM, elotuzumab 30-45 nM, emicizumab 900-1800 nM, evolocumab 0.016 nM, golimumab 0.018 nM, ibritumomab 17 nM, idarucizumab 0.0021 nM, infliximab 0.1-0.45 nM, inotuzumab 0.12-0.15 nM, ipilimumab 1-10 nM, ixekizumab 0.0018 nM, mepolizumab 0.0042 nM, natalizumab 0.3 nM, necitumumab 0.32 nM, nivolumab 2-3 nM, obiltoxaximab 0.33 nM, obinutuzumab 4 nM, ocrelizumab 0.47-1.2 nM, ofatumumab 3-6 nM, olaratumab 0.33 nM, omalizumab 2-8 nM, palivizumab 1 nM, panitumumab 0.05 nM, pembrolizumab 0.029 nM, pertuzumab 9-15 nM, ramucirumab 0.05 nM, ranibizumab 0.19 nM, raxibacumab 1-4 nM, reslizumab 0.081 nM, rituximab 5-11 nM, sarilumab 0.054 nM, secukinumab 0.06-0.37 nM, siltuximab 0.034 nM, tocilizumab 1-3 nM, trastuzumab 1-14 nM, and EGF & TGFα 2-3 nM.
- To design multi-targeted multi-valent nanoparticles with optimal cell association, drug delivery, and efficacy, data discloses concentration profile examples of the cell associated particle concentration at equilibrium (CBeq) as a function of CBeq(v,fx,RT,KD,KX). Examples depict dual-targeted multi-valent nanoparticles to dual receptors where each ligand/receptor may have unique RT, KD, and/or KX. For multi-targeting such as dual-targeting nanoparticles, additive and synergetic binding benefits were explored. For optimal cell association, of design interest are the peak CBeq and its corresponding valences. Table 3 below shows the optimal valencies from application of the model to particles with two ligands binding to two different receptors on a target cell.
-
TABLE 3 Optimal Multi-Targeted Multi-Valent Binding: For Any Ligand and to Any Antigen Target Optimal Multi-Valent Binding: Dual-Targeted KD (nM) Valence (Ligands/Particle) Ligand 1Ligand 2HHa HMa MMa HHs HMs MMs 100 100 17 17 21 13 10 15 100 10 16 17 20 13 10 15 100 1 16 17 19 13 10 15 100 0.1 15 17 19 13 10 15 10 10 16 16 19 12 9 13 10 1 15 16 18 12 9 13 10 0.1 14 16 17 12 9 13 1 1 14 14 17 10 8 12 1 0.1 13 14 16 10 8 12 0.1 0.1 13 13 15 9 7 11 - An array of anti-HER2, anti-EGFR, and dual-targeted lipid nanoparticles at varying ligand valencies were formulated with receptor-specific targeting against cell lines expressing HER2 and/or EGFR. For HER2-targeting, liposomes were functionalized with an antigen-binding fragment (Fab′) derived from trastuzumab or F5 single-chain variable fragment (scFv). For EGFR-targeting, liposomes were functionalized with a Fab′ derived from cetuximab, or with epidermal growth factor (EGF), or transforming growth factor alpha (TGFα). The surface attachment of ligand conjugates onto liposomes was achieved by the micelle transfer method or a novel sequential micelle transfer-conjugation method. Through a combination of both the sequential micelle transfer-conjugation and the micelle transfer methods, dual-targeted immunoliposomes of various ligand ratios of anti-HER2 F5 scFv and anti-EGFR cetuximab-Fab′ were constructed. (See
FIGS. 10A to 13B .) EGF and TGFα were investigated as potential targeting groups for liposomal delivery to EGFR-expressing cell lines. Cell association, uptake, and cytotoxicity studies were performed on a panel of human breast cancer cell lines that express either or both HER2 and EGFR at different expression levels. - For HER2-overexpessing and EGFR-overexpressing cell lines, the receptor-mediated uptake studies confirmed the observation that increasing ligand valency per liposome increases targeted uptake until saturation (trastuzumab, F5 scFv, and cetuximab). For ligand surface valencies at optimum binding and higher, as well as high liposomal concentration in incubation, there is roughly a 1:1 ratio of ligands to expressed receptors for MCF-7/HER2, BT-474, SK-BR-3, and MDA-468 cells. In addition, the accumulation of liposomes and ligands for anti-HER2 and anti-EGFR dual-targeted immunoliposomes were roughly additive of their mono-targeted counterparts in BT-474 and MKN-7 cells. No antagonistic effects were observed from the additional of a non-targeted ligand in all cell lines except for SK-BR-3 cells unless beyond 10 anti-EGFR ligand per liposome, where anti-EGFR ligands decreased overall uptake. Despite the additive uptake effect, dual-targeted liposomal delivery of doxorubicin to cell lines expressing HER2 and EGFR was only slightly better in the inhibition of cell proliferation.
- To study the receptor-specific targeted drug delivery of liposomes against cells lines expressing HER2 and/or EGFR, an array of anti-HER2, anti-EGFR, and dual-targeted lipid nanoparticles at varying ligand valencies (trastuzumab, F5 scFv, cetuximab, EGF and TGFα) were formulated. The various engineered liposomal formulations served as probes to help understand the uptake efficiency of liposomes relative to ligand surface valency and receptor expression level, mono-targeting as well as dual-targeting to multiple receptors, intracellular trafficking, and ultimately the consequential biological activity in the delivery of drugs. For receptor-specific targeting, sterically stabilized liposomes were functionalized with the attachment of anti-HER2 and/or anti-EGFR ligands. Liposomes were approximately 80-120 nm in diameter, composed of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), and a fluorescent
lipophilic tracer - Amphiphilic targeting ligand conjugates synthesized by maleimide chemistry consisting of a hydrophilic polymer spacer PEG between a lipid anchor DSPE and a ligand group were attached to the surface of liposomes to offer receptor-specific targeting. The conjugation of ligands such as antibody fragments by reactions between maleimide derivatives and thiols using naturally occurring cysteine residue, engineered C-terminal cysteine, or thiolated with Traut's reagent provide strong stable thioether bonds. Reactions with the cysteine on antibody fragments can offer ideal orientation, distant from antibody binding site, minimizing interference with binding. A polymer linker like PEG also helps with the orientation, extending the ligand far enough from the PEG shielding so the ligand are accessible to receptors on cells.
- Fab′ conjugates of cetuximab and trastuzumab with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000]) (Mal-PEG-DSPE) were synthesized as previously described(35, 36), taking advantage of the naturally occurring cysteine residue of Fab′. Briefly, cetuximab and trastuzumab IgG were cleaved with pepsin to two antigen-binding fragments connected by disulfide bonds (Fab2), reduced with cysteamine to Fab′, and conjugated to Mal-PEG-DSPE (
FIG. 10A-10D ). The yielded efficiency of Fab′-PEG-DSPE confirmed by size-exclusion chromatography and SDS-PAGE was a reasonable 25-50%. Unfortunately, Fab′ conjugates derived from Mal-PEG-DSPE manufactured by Avanti Polar Lipids poorly incorporated to the surface of liposomes by the micelle transfer method. - Due to the lack of free cysteine residues, EGF and TGFα were thiolated with Traut's reagent before conjugation to Mal-PEG-DSPE (
FIG. 11A-11B ). Similar to the conjugation with Fab′, the yielded growth factor-PEG-DSPE was 25-50% efficient as confirmed by size-exclusion chromatography and SDS-PAGE. 100% conjugation efficiency was achievable when the growth factors were reacted with higher concentrations of Traut's reagent (>500 fold), but the ligand conjugates were prone to crosslink resulting in poor receptor binding. F5 scFv conjugated to Mal-PEG-DSPE was manufactured by the National Cancer Institute as previously described(38, 42). The surface attachment of ligand conjugates onto liposomes was achieved by the micelle transfer method or the sequential micelle transfer-conjugation method. - Ligand Conjugation onto Liposomes by the Micelle Transfer Method and Sequential Micelle Transfer—Conjugation Method
- Through the micelle transfer method(35, 44), micellar conjugates of the ligand and an amphiphilic lipid co-incubated with preformed liposomes spontaneously insert themselves into liposome bilayers without the loss of the liposome integrity(47), providing a rapid and simple method for transforming non-targeted liposomes into antibody-targeted liposomes(48, 49) (
FIG. 12A-12B ). Insertion is performed at 50-60° C., so the denaturation of protein ligands is a concern, but longer overnight incubation at 37° C. is also possible(34, 48). Liposomes remain mostly unaltered through conjugations, and the techniques have shown to be simple and reproducible. - In the experiments, insertion efficiency for ligand conjugates of F5 scFv-PEG-DSPE, EGF-PEG-DSPE and TGFα-PEG-DSPE onto liposomes via the micelle transfer method(35, 44) was highly efficient (90-100%). Unfortunately, the insertion efficiency of Fab′-PEG-DSPE from trastuzumab and cetuximab onto liposomes was low (5-10%). No more than 10 Fab′ per liposome was possible despite an excessive concentration of Fab′-PEG-DSPE incubation, and receptor-specific cell association was low. Previously attempts of the micelle transfer of Fab′-PEG-DSPE were more successful using Mal-PEG-DSPE manufactured by Shearwaters Polymers(35, 36) instead of the current available stock from Avanti Polar Lipids, but they are no longer in production.
- Due to the low transfer of Fab′-PEG-DSPE synthesized from Mal-PEG-DSPE by Avanti Polar Lipids onto liposomes by the micelle transfer method, a novel sequential micelle transfer-conjugation method was developed. IgG (cetuximab & trastuzumab) were cleaved with pepsin, reduced with cysteamine, and conjugated to liposomes micelle transferred with Mal-PEG-DSPE (
FIG. 13A-13B ). Through this method, a range of 0-200 Fab′ per liposome at approximately 25-50% efficiency was achieved. Approximately 50 Fab′ per liposome was conjugated for every 0.25% Mal-PEG-DSPE transferred. Attempts of higher valencies (ie, >1% Mal-PEG-DSPE transferred) often resulted in liposomal precipitation. - Hence, Mal-PEG-DSPE available from Avanti Polar Lipids conjugated to small ligands (F5 scFv, EGF, and TGFα) is effective for liposomal insertion by the micelle transfer method, but is also effective for Fab′ if Mal-PEG-DSPE is sequential micelle transfer-onto liposomes prior to Fab′ conjugation. Another benefit of the sequential micelle transfer-conjugation method is the reduced exposure of the ligands to high temperature incubations required of micelle transfer. This may help with protein stability. Compared to constructing liposomes pre-consisting of Mal-PEG-DSPE, this method allows for a more controlled means to functionalized pre-existing liposomes. Finally, the method also allows for the serial addition of a second targeting group in the case of anti-HER2 and anti-EGFR dual-targeted.
- Through a combination of both the sequential micelle transfer-conjugation and the micelle transfer methods, dual-targeted immunoliposomes of various ligand ratios of anti-HER2 F5 scFv and anti-EGFR cetuximab-Fab′ were achieved. Liposomes were functionalized with cetuximab-Fab′ via the sequential micelle transfer-conjugation method, followed by insertion of F5 scFv-PEG-DSPE via the micelle transfer method (
FIG. 13A-13B ). Based on the optimum ligand valencies for the cell association of mono-targeted immunoliposomes as previously determined by flow cytometry, liposomes of varying ligand valencies of anti-HER2 F5 scFv (0-40 ligands/liposomes), anti-EGFR cetuximab-Fab′ (0-60 ligands/liposomes), and combinations of both for dual-targeting were constructed. - Conjugate incorporation efficiency was measured and determined by ImageJ (National Institutes of Health) from SDS-PAGE (Bio-Rad) stained with SYPRO Ruby. Because the conjugation efficiency of cetuximab-Fab′ to Mal-PEG-DSPE sequential micelle transfer-conjugated liposomes was variable at 25-50%, lower than the ˜100% insertion efficiency of F5 scFv-PEG-DSPE, a range of cetuximab-Fab′ conjugated immunoliposomes were first constructed and quantified for ligand valency. From these, cetuximab-Fab′ conjugated liposomes of desired ligand valencies were selected for F5 scFv-PEG-DSPE micelle transfer. Cell association studies showed ligand valency dependent binding of liposomes with cells overexpressing HER2 and/or EGFR, and were further investigated for dose-uptake and cytotoxicity studies.
- As mentioned previously, EGF and TGFα were thiolated with Traut's reagent, conjugated to Mal-PEG-DSPE, and micelle transferred onto liposomes. An array of liposomes with up to 50 growth factors of either EGF or TGFα per liposome was constructed. Although the cell association and trafficking of EGF and TGFα are well characterized, little has been documented for their EGFR-targeting capabilities as functional groups on liposomes in EGFR-overexpressing cells. Cell association studies of EGF-conjugated and TGFα-conjugated liposomes in EGFR-overexpressing MDA-468 cells were conducted to determine optimum ligand valencies, incubation times, and phospholipid concentrations. MDA-468 cells were incubated with EGFR-targeted liposomes labeled with DiD of varying ligand valencies of EGF (0-50 ligands/liposomes) and TGFα (0-50 ligands/liposomes) at 37° C. for 1-24 hr, 0-750 μM PL, and analyzed by flow cytometry and fluorometry.
- Increasing the valency of EGF and TGFα ligands per liposomes correlated to amplified targeted binding in MDA-468 cells until a plateau. Similar to the binding results of other anti-HER2 and anti-EGFR targeted immunoliposomes, maximum binding was achieved at −20 ligand per liposome for both EGF-conjugated and TGFα-conjugated liposomes. Although the ligand valency ratio dependent uptake was similar for 0-50 ligands per liposomes, the binding of EGF-conjugated liposomes was 10-fold higher than that of TGFα-conjugated liposomes. By increasing the incubation times from 1-11 hr, binding also increased but saturation was not reached. Increasing the phospholipid concentration from 0-750 μM PL showed evidence of a possible plateau. There was a less than a magnitude difference in binding between EGF-conjugated and TGFα-conjugated liposomes at higher incubation times and concentration.
- In addition to the cell association analysis by flow cytometry, the uptake of anti-EGFR liposomes encapsulated with doxorubicin in MDA-468 cells was also evaluated by fluorometry. Results correlated with the binding experiments where maximum binding was achieved at −20 ligands per liposome in a ligand valency ratio dependent uptake fashion, and that EGF-conjugated liposomes had a magnitude of higher binding than TGFα-conjugated liposomes. Because the equilibrium dissociation constants for both ligands are close (KD 2.2-2.6 nM)(77), one hypothesis that may explain the difference in uptake is due to the sterical hindrance resulting from binding to different epitopes on EGFR(115). Unlike F5 scFv, there binding and internalizing abilities may also be altered by surface attachment to liposomes.
- EGF-conjugated and TGFα-conjugated liposomes also exhibited 1-2 magnitude lower cell association than cetuximab-conjugated immunoliposomes as expected since the equilibrium dissociation constant for cetuximab (0.1-0.4 nM)(116) is one magnitude lower than that of the growth factors. With the lower binding of EGF-conjugated and TGFα-conjugated liposomes, it may explain why the plateau is harder to reach despite higher concentrations and incubation times. EGFR is not depleted, insuring a constant stream of binding and uptake. EGF-conjugated and TGFα-conjugated liposomes proved effective in cell association with MDA-468 cells. In addition, the modeling of crosslink multivalent binding of lipid nanoparticles to monovalent receptors can offer some insights on the relationship of equilibrium dissociation constant and cell association.
- To determine the optimum ligand valencies and ligand combinations for HER2-targeted, EGFR-targeted, and dual-targeted immunoliposomes in HER2-expressing and EGFR-expressing cell lines, the targeted binding of immunoliposomes labeled with DiD was evaluated by flow cytometry. Cells were incubated with liposomes of varying ligand valencies of anti-HER2 F5 scFv (0-40 ligands/liposomes), anti-EGFR cetuximab-Fab′ (0-40 ligands/liposomes), and combinations of both for dual-targeting at 37° C. for 4 hr (75 μM phospholipid (PL)). The mean fluorescent intensity with a tight spread of 5*103 cells was recorded per liposomal formulation.
- In EGFR-overexpressing MDA-468 cells, maximum binding was confirmed at ˜20-40 anti-EGFR cetuximab-Fab′ per liposome (˜500 fold>non-targeted liposomes, NT). There was negligible binding for anti-HER2 F5 scFv-conjugated immunoliposomes (ILS) at all ligand valencies (=NT), and correspondingly no additive binding effects for dual-targeted immunoliposomes (˜500 fold>NT). In HER2-overexpressing BT-474 cells, maximum binding was confirmed at −15-20 F5 scFv per liposome (˜400 fold>NT). Binding was low but significant for cetuximab-ILS (˜20-40 fold>NT). EGFR has been documented to be moderately expressed in BT-474 cells(123). In comparison to mono-targeted immunoliposomes, dual-targeted immunoliposomes offered no additive binding effects for combinations with 15+F5 scFv per liposome (˜400 fold>NT), but appeared to be additive for combinations with 5 F5 scFv per liposome (˜300 fold vs. ˜200 fold>NT).
- In HER2 and EGFR moderately expressing MKN-7 cells, binding was low but significant for HER2-targeted and EGFR-targeted immunoliposomes in comparison to non-targeted liposomes (˜300 fold>NT). Similar to liposomal cell association in MDA-468 and BT-474 cells, maximum binding was observed at −20 cetuximab-Fab′ per liposome for EGFR-targeted immunoliposomes and ˜15-20 F5 scFv per liposome for HER2-targeted immunoliposomes in MKN-7 cells. Dual-targeted immunoliposomes resulted in higher binding than their mono-targeted counterparts (˜500 fold>NT), indicating possible synergistic or additive effects. The cell association studies were quick preliminary tests for targeted functionality and were further investigated in the dose-uptake studies.
- For mono-targeted immunoliposomes against HER2 and EGFR, the optimum ligand valencies for maximum binding were in line with previous research(34-37), ˜20-40 cetuximab-Fab′ per liposome for EGFR-targeted immunoliposomes and ˜15-20 F5 scFv per liposome for HER2-targeted immunoliposomes. At maximum cell association, these results also provide a baseline to compare to dual-targeted immunoliposomes for potential additive, synergistic, or antagonistic effects. Because MDA-468 cells overexpress EGFR but negligible HER2, binding was only observed with EGFR-targeted immunoliposomes. Dual-targeted immunoliposomes resulted in similar cell association as EGFR-targeted immunoliposomes, confirming negligible HER2 binding as well as a lack of antagonistic effects from additional non-targeted functional groups or sterical hindrance.
- Although BT-474 cells overexpress HER2, they also moderately express EGFR, corroborating with the results for high HER2-targeted and low EGFR-targeted cell association. Interestingly, potential additive effects were observed with dual-targeted liposomes only with low F5 scFv valencies. Again, no antagonistic binding effects were observed for dual-targeted immunoliposomes. MKN-7 cells express moderate levels of both HER2 and EGFR, and accordingly moderate cell association with immunoliposomes targeting either receptor was observed. Dual-targeted immunoliposomes resulted in higher cell association than all mono-targeted counterparts. Hence, immunoliposomes with dual-targeting to HER2 and EGFR may increase cell association with targeted cells when conditions are not optimum, in the case of low F5 scFv valencies in BT-474 cells and moderately HER2-expressing and EGFR-expressing MKN-7 cells. Based on these results, ligand valencies were chosen for uptake studies for further investigation.
- To investigate whether the accumulation of trastuzumab is higher when attached to immunoliposomes or as a free antibody in HER2-overexpressing cell lines, an uptake study was conducted and evaluated by fluorometry. MCF-7/HER2 and BT-474 cells were oversaturated with trastuzumab labeled with Alexa Fluor 488 (40 nM) or immunoliposomes labeled with DiD (23 trastuzumab-Fab′ per liposome, 375 μM PL). After a 4 hr incubation, the total accumulation of trastuzumab as an IgG and trastuzumab-Fab′ from the immunoliposomes were comparable in MCF-7/HER2 cells, 5-7*105 ligands per cell (P<0.1). Although the accumulation was significantly different in BT-474 cells, 0.8-1.2*106 trastuzumab ligands per cell (P<0.002), they were in the same range. Results from a dose-uptake study in BT-474 cells for F5 scFv-ILS in the next section also yielded similar uptake levels, 1.0*106 ligands per cell at valence of 15 ligands per liposomes, which is comparable to the amount of ligands delivered from trastuzumab-ILS (P<0.14) and free trastuzumab (P<0.07). These results suggest that multiple ligands on the liposomes may contribute the uptake of the lipid nanoparticles. If only a few ligands are required for uptake, it is more likely that the accumulation of liposomes would be closer to the free trastuzumab accumulation range and hence the ligands delivered from the liposomes would be many folds higher (up to 15-20 fold).
- HER2 is overexpressed in the human breast cancer cell lines BT-474 (106 HER2/cell)(44, 124) and MCF-7/HER2 (106 HER2/cell)(44, 125). Regardless as a free antibody or conjugated as an antibody fragment onto liposomes, the total accumulation of the trastuzumab ligands is close to a 1:1 ratio of ligands to HER2 expressed on BT-474 and MCF-7/HER2 cells. This raises an interesting question in the targeted delivering of drugs, whether it is more efficient as an antibody-ligand-drug such as trastuzumab emtansine (Roche) or drug-encapsulated liposomal formulations? Typical immunoliposomes (100 nm) can encapsulate 15-40*103 drug molecules per liposome, but may require 15-40 ligands per liposome for optimum delivery(4). Hence, the total maximum accumulation of liposomal particles compared to antibody-drug particles can be 1-2 magnitudes less due to the rate limiting 1:1 ratio of ligands to HER2 expressed. However, in a controlled environment in vitro, immunoliposomes still offer roughly a 3 magnitude advantage in drug delivery over antibody-ligand-drugs (assuming 1:1 ratio) due to the high drug-loading efficiency and large payload of liposomal delivery. The advantage may be even higher in vivo due to other benefits from liposomal delivery compared to antibody-bound delivery, such as increased drug stability, prolonged circulation, and enhanced permeability and retention effect.
- Dose-Uptake of HER2-Targeted and EGFR-Targeted Immunoliposomes of Varying Ligand Valence
- To evaluate the targeted uptake of HER2-targeted and EGFR-targeted immunoliposomes relative to ligand valency, ligand combinations, and lipid concentration, dose-uptake studies were performed with increasing concentrations of liposomes labeled with DiO at 37° C. for 4 hr. Immunoliposomes consisted of varying ligand valencies of anti-HER2 F5 scFv (0-15 ligands/liposomes), anti-EGFR cetuximab-Fab′ (0-20 ligands/liposomes), and combinations of both for dual-targeting. Similar studies using immunoliposomes labeled with DiD, loaded with doxorubicin, and slightly different ligand combinations were also evaluated and yielded comparable results (data not shown).
- In MDA-468 cells, immunoliposomes with higher cetuximab-Fab′ per liposome valencies correlated with higher targeted uptake. 20 cetuximab-Fab′ per liposome reached a plateau at ˜300 μM PL, resulting in ˜5*105 liposomes and ˜106 cetuximab-Fab′ per cell (Table 4). Similarly, there was an accumulation of ˜106 cetuximab-Fab′ per cell in all cases for dual-targeted immunoliposomes with 20 cetuximab-Fab′ and 0-15 F5 scFv per liposome. Immunoliposomes with varying F5 scFv valencies had no significant uptake compared to non-targeted liposomes.
- In HER2-overexpressing SK-BR-3 cells, immunoliposomes with high F5 scFv per liposome valencies correlated with high targeted uptake. 10-15 F5 scFv per liposome reached a plateau at ˜200 μM PL, resulting in ˜2-3*105 liposomes and ˜3*106 F5 scFv per cell. Similarly, there was an accumulation of ˜2-3*106 F5 scFv per cell in all cases for dual-targeted immunoliposomes with 10-15 F5 scFv and 0-20 cetuximab-Fab′ per liposome. Immunoliposomes with varying cetuximab-Fab′ valencies had no significant uptake compared to non-targeted liposomes. There is higher uptake of anti-HER2 targeted immunoliposomes in SK-BR3 cells than in BT-474 cells.
- The MDA-468 human breast cancer cell line overexpresses roughly 106 EGFR per cell(126, 127) but negligible HER2, and the SK-BR-3 human breast cancer cell line overexpresses 2-3*106 HER2 per cell(128, 129) but negligible EGFR. At the plateau, there is roughly a 1:1 ratio of ligands to receptors for both cell lines with their respective overexpressed receptors. Similar to the cell association studies in MDA-468 cells, non-specific anti-HER2 ligands did not interfere with targeted uptake. In the case of anti-HER2 and anti-EGFR dual-targeted immunoliposomes, uptake was not significantly different compared to anti-EGFR immunoliposomes of similar cetuximab-Fab′ valencies (P<0.95 for E20Hy; P<0.53 for E10Hy).
- Interestingly in SK-BR-3 cells, non-specific anti-EGFR ligands can interfere with targeted uptake in an antagonistic manner beyond 10 anti-EGFR ligands per liposome. At 10 anti-EGFR ligands per liposome, there is no significant effect. Although mono-targeted cetuximab-immunoliposomes had no significant uptake compared to non-targeted liposomes, in the case of anti-HER2 and anti-EGFR dual-targeted immunoliposomes with 20 cetuximab-Fab′ per liposome, uptake was lower for all combinations with F5 scFv compared to mono-targeted counterparts. These results provide evidence that the addition of non-specific ligands may interfere with the uptake of some cell lines such as SK-BR-3, but not others like MDA-468, at high enough of ligand valence. It could also be due to the larger size of Fab′ compared to scFv.
- To investigate the effects of true dual-targeting, dose-uptake studies were continued on cell lines expressing moderate to high levels of both HER2 and EGFR. In BT-474 cells (106 HER2 per cell and moderate levels of EGFR(44, 124)), F5 scFv-ILS reached a plateau at ˜100-200 μM PL, resulting in ˜7*104 liposomes and ˜1*106 F5 scFv per cell. At the plateau, there is again roughly a 1:1 ratio of ligands to receptors, similar ratios seen from trastuzumab as an IgG and trastuzumab-Fab′ from the immunoliposomes. Immunoliposomes with varying cetuximab-Fab′ valencies exhibited low uptake (˜2*104 liposomes/cell), but significantly higher compared to non-targeted liposomes. In the case of anti-HER2 and anti-EGFR dual-targeted immunoliposomes, uptake was significantly higher compared to anti-HER2 immunoliposomes of similar F5 scFv valencies (P<4*10−3 for ExH15; P<8*10−5 for ExH10; P<9*10−5 for ExH5).
- The accumulation of liposomes and ligands for dual-targeted immunoliposomes was roughly additive of their mono-targeted counterparts in BT-474 cells (Table 4). Dual-targeted immunoliposomes with 15 F5 scFv and 20 cetuximab-Fab′ resulted in 8.3*104 liposomes per cell, which is also the additive accumulation of mono-targeted 15 F5 scFv-ILS (6.8*104 liposomes/cell) and 20 cetuximab-ILS (1.5*104 liposomes/cell). Similarly, dual-targeted immunoliposomes resulted in 1.2*106F5 scFv per cell, which is also the additive accumulation of mono-targeted F5 scFv (1*106F5 scFv/cell) and cetuximab-ILS (2*105F5 scFv/cell, extrapolated from 3*105 cetuximab-Fab′ assuming 15:20 ratio). The additive accumulation of liposomes and ligands for dual-targeted immunoliposomes from their mono-targeted counterparts were close for all ratios, 0-15 F5 scFv and 0-20 cetuximab-Fab′ per liposome.
- In MKN-7 cells (moderate levels of both HER2 and EGFR), HER2-targeted and EGFR-targeted immunoliposomes did not reach an uptake plateau for any ligand valencies. Immunoliposomes exhibited low uptake (<2*104 liposomes/cell), but significantly higher compared to non-targeted liposomes, except for 10 cetuximab-Fab′ per liposome. In the case of dual-targeted immunoliposomes, uptake was significantly higher compared to anti-EGFR or anti-HER2 immunoliposomes of similar ligand valencies, in line with previous cell association studies (P<10−6 for ExH15, ExH10, ExH5, E20Hy, & E10Hy). Similar to the BT-474 cell line, the accumulation of liposomes and ligands for dual-targeted immunoliposomes were roughly additive of their mono-targeted counterparts (Table 4). Dual-targeted immunoliposomes with 15 F5 scFv and 20 cetuximab-Fab′ resulted in ˜9*103 liposomes per cell, which is the additive accumulation of mono-targeted 15 F5 scFv-ILS (4*103 liposomes/cell) and 20 cetuximab-ILS (4*103 liposomes/cell). Similarly, dual-targeted immunoliposomes resulted in ˜1.3*105F5 scFv per cell, which is the additive accumulation of mono-targeted F5 scFv (6.1*105F5 scFv/cell) and cetuximab-ILS (5.4*105F5 scFv/cell, extrapolated from 7.2*105 cetuximab-Fab′ assuming 15:20 ratio). The additive accumulation of liposomes and ligands for dual-targeted immunoliposomes from their mono-targeted counterparts were close for all ratios, 0-15 F5 scFv and 0-20 cetuximab-Fab′ per liposome.
-
TABLE 4 LS/Cell Anti-EGFR Lg/Cell Anti-HER2 Lg/Cell Max Sum Max Sum Max Sum BT-474 E0H0/NT 1.7E3 ± 3.6E2 E10H0 2.0E4 ± 6.6E3 2.0E5 ± 6.6E4 E20H0 1.5E4 ± 4.8E3 3.0E5 ± 9.6E4 E0H5 4.0E4 ± 6.0E2 2.0E5 ± 3.0E3 E0H10 7.2E4 ± 8.0E3 7.2E5 ± 8.0E4 E0H15 6.8E4 ± 7.3E3 1.0E6 ± 1.1E5 E10H5 6.1E4 ± 2.8E3 5.9E4 6.1E5 ± 2.8E4 5.9E5 3.1E5 ± 1.4E4 3.0E5 E10H10 9.9E4 ± 8.4E3 9.1E4 9.9E5 ± 8.4E4 9.1E5 9.9E5 ± 8.4E4 9.1E5 E20H5 5.6E4 ± 1.8E3 5.5E4 1.1E6 ± 3.5E4 1.1E6 2.8E5 ± 8.8E3 2.7E5 E20H10 9.7E4 ± 4.6E3 8.7E4 1.9E6 ± 9.2E4 1.7E6 9.7E5 ± 4.6E4 8.7E5 E20H15 8.3E4 ± 1.4E3 8.3E4 1.7E6 ± 2.7E4 1.7E6 1.2E6 ± 2.1E4 1.2E6 MKN-7 E0H0/NT 1.8E3 ± 4.7E2 E10H0 2.1E3 ± 2.5E2 2.1E4 ± 2.5E3 E20H0 3.6E3 ± 7.8E2 7.2E4 ± 1.6E4 E0H5 8.1E3 ± 4.5E2 4.1E4 ± 2.3E3 E0H10 4.9E3 ± 2.2E2 4.9E4 ± 2.2E3 E0H15 4.1E3 ± 3.3E2 6.1E4 ± 5.0E3 E10H5 9.8E3 ± 3.4E2 1.0E4 9.8E4 ± 3.4E3 1.0E5 4.9E4 ± 1.7E3 5.1E4 E10H10 7.9E3 ± 3.3E2 7.0E3 7.9E4 ± 3.3E3 7.0E4 7.9E4 ± 3.3E3 7.0E4 E20H5 1.3E4 ± 6.9E2 1.2E4 2.5E5 ± 1.4E4 2.3E5 6.3E4 ± 3.4E3 5.9E4 E20H10 5.5E3 ± 3.4E2 8.5E3 1.1E5 ± 6.8E3 1.7E5 5.5E4 ± 3.4E3 8.5E4 E20H15 8.5E3 ± 5.7E2 7.7E3 1.7E5 ± 1.1E4 1.5E5 1.3E5 ± 8.5E3 1.2E5 MDA-468 E0H0/NT 1.4E4 ± 8.6E3 E10H0 2.0E4 ± 5.8E2 2.0E5 ± 5.8E3 E20H0 5.3E4 ± 2.3E3 1.1E6 ± 4.6E4 E0H5 5.3E3 ± 2.0E2 2.6E4 ± 1.0E3 E0H10 1.1E3 ± 2.2E2 1.1E4 ± 2.2E3 E0H15 8.0E3 ± 2.0E2 1.2E5 ± 2.0E3 E10H5 2.7E4 ± 8.5E2 2.5E4 2.7E5 ± 8.5E3 2.5E5 1.4E5 ± 4.2E3 1.3E5 E10H10 2.2E4 ± 1.6E3 2.1E4 2.2E5 ± 1.6E4 2.1E5 2.2E5 ± 1.6E4 2.1E5 E20H5 6.1E4 ± 2.0E3 5.8E4 1.2E6 ± 4.1E4 1.2E6 3.1E5 ± 1.0E4 2.9E5 E20H10 5.3E4 ± 2.6E3 5.4E4 1.1E6 ± 5.2E4 1.1E6 5.3E5 ± 2.6E4 5.4E5 E20H15 5.9E4 ± 2.2E3 6.1E4 1.2E6 ± 4.3E4 1.2E6 8.8E5 ± 3.2E4 9.1E5 - Table 4 above shows the accumulation of liposomes (LS) and ligands (Lg) from HER2-targeted, EGFR-targeted, and dual-targeted immunoliposomes (ILS) in BT-474, MKN-7, and MDA-468 cells from dose-uptake studies. Max is the maximum measured accumulation; Sum is the total calculated accumulation from mono-targeted immunoliposomes counterparts. For ExHy ILS, x and y specify the number of ligands per liposome against EGFR (cetuximab-Fab′) and HER2 (F5 scFv), respectively, while NT stands for non-targeted (i.e., no ligands).
- The dose-uptake experiments were also evaluated on Scatchard plots for cooperativity, which compares the binding affinity with the extent of receptor occupancy. Although Scatchard plots are traditionally used to assess binding, uptake and binding for lipid nanoparticles are directly and proportionally linked with internalizing surface ligands. For all cases where mono-targeted immunoliposomes were incubated with a receptor overexpressing cell line (ie, anti-EGFR in MDA-468, anti-HER2 in BT-474, & anti-HER2 in SK-BR-3), the plot concave downwards indicating positive cooperativity. This implies that the equilibrium dissociation constant increases with occupancy. For all cases where mono-targeted immunoliposomes were incubated with a receptor moderately expressing cell line (ie, anti-EGFR in BT-474, both anti-EGFR and anti-HER2 in MKN-7, lesser extent with anti-EGFR in SK-BR-3), the plot concave upwards indicating negative cooperativity. The equilibrium dissociation constant hence decreases with occupancy. Interestingly, for BT-474 cells, dual-targeted immunoliposomes changes the curvilinear profile, with cooperativity being negative at low concentrations and linear to positive at higher concentrations. The cooperativity for all the liposomal samples is apparent, indicating other possible associating interactions such as multivalent binding.
- In HER2-overexpressing and EGFR-overexpressing human breast cancer cell lines, increasing the valency of ligands per liposomes increased targeted uptake until saturation. After which point, increased ligand valency may decrease uptake, maintaining a 1:1 ratio of ligands to receptors. The equal ligands to receptors ratio may be explained by multivalent binding and receptor crosslinking. In such ideal situations with both high receptor expression on the cells and high affinity constants for ligands to receptors, it may be possible that multiple ligands are binding to multiple receptors during the process of receptor-mediated endocytosis. In essence, a liposome is behaving as a multivalent ligand that can multivalent bind and crosslink monovalent receptors expressed on the cells. HER2 have been shown to form clusters in cell membranes which may even increase the chances of crosslink binding(130, 131). In addition, per surface area, there are more receptors available per ligand. Assuming an average cell diameter of 10 μm with 106 receptors and an average liposome diameter of 100 nm with 20 ligands, the receptor to ligand per surface area ratio is 5, meaning that for every ligand there are 5 receptors available to bind. Crosslink multivalent binding of liposomes to clustered receptors is a possible and plausible outcome.
- For cell lines that express both receptors such as BT-474 and MKN-7, anti-HER2 and anti-EGFR dual-targeted immunoliposomes can increase the overall accumulation of liposomes and ligands beyond the saturation point of mono-targeted immunoliposomes. In addition, the uptake is roughly additive of their mono-targeted counterparts. Because the uptake of dual-targeted immunoliposomes appears to be additive instead of synergistic, the overall accumulation is only marginally higher (folds, not magnitudes), and hence may result only in marginally increased benefits from increased accumulation. The main advantage may be more of a simplified multi-targeting formulation, where the immunoliposomes can target multiple receptors, and hence effective with more cell lines and accordingly heterogeneous receptor expressing tumors. Only in the SK-BR-3 cell line that the addition of a non-targeting functional group may be antagonistic to uptake at high anti-EGFR ligand valence. Despite that, uptake was only marginally lower.
- In parallel to the dose-uptake studies, cytotoxicity studies with doxorubicin-encapsulated HER2-targeted, EGFR-targeted, and dual-targeted immunoliposomes were also examined for any correlations between increased targeted uptake and toxicity benefits of dual-targeted drug delivery. In MDA-468 cells, immunoliposomes with higher cetuximab-Fab′ per liposome ligand valencies (0-60 ligands/liposome) correlated with higher cell death. Immunoliposomes with varying F5 scFv valencies (0-15 ligands/liposome) had no significant cytotoxicity compared to non-targeted liposomes. In the case of anti-HER2 and anti-EGFR dual-targeted immunoliposomes, cell viability was not significantly lower to anti-EGFR immunoliposomes of similar cetuximab-Fab′ valencies (P<0.6 for E10Hy; P<0.99 for E60Hy). Results were in agreement with the dose-uptake studies, higher uptake resulting in higher toxic effect in cells.
- In BT-474 cells, immunoliposomes with varying F5 scFv per liposome valencies (5-15 ligands/liposome) yielded significant cytotoxicity compared to non-targeted liposomes, but no significant difference among each other. Immunoliposomes with varying cetuximab-Fab′ valencies (0-60 ligands/liposome) resulted in no significant cell viability. In the case of anti-HER2 and anti-EGFR dual-targeted immunoliposomes, cell growth inhibition was significantly better compared to anti-HER2 immunoliposomes of similar F5 scFv only in two cases where cetuximab was also high: E60H10 (P<10−6) and E60H15 (P<9*10−4). Compared to the dose-uptake studies, the degree of toxic effect is not as pronounced as targeted uptake.
- In MKN-7 cells, immunoliposomes with varying cetuximab-Fab′ per liposome ligand valencies (10−60 ligands/liposome) yielded higher cytotoxicity compared to non-targeted liposomes (P<10−4), but no significant difference among each other (Error! Reference source not found). Immunoliposomes with varying F5 scFv valencies (0-15 ligands/liposome) resulted in no significant cell growth inhibition (P<1). In the case of anti-HER2 and anti-EGFR dual-targeted immunoliposomes, cell viability was not significant compared to any mono-targeted immunoliposomes (0.01<P<1). Compared to the dose-uptake studies, the degree of toxic effect again is not as pronounced as targeted uptake. In OVCA-420 cells which moderately express both EGFR and HER2, immunoliposomes with varying F5 scFv per liposome (0-15 ligands/liposome) and cetuximab-Fab′ per liposome (0-60 ligands/liposome) ligand valencies for mono-targeting had no significant cytotoxicity compared to non-targeted liposomes. However, similar to BT-474 cells, anti-HER2 and anti-EGFR dual-targeted immunoliposomes yielded enhanced cytotoxicity for a few cases cases: E60H10, E60H15, & E10F15; P<10−6). Results were in agreement with the dose-uptake studies (data not shown).
- For these cytotoxicity studies in vitro, free doxorubicin is the most effective since it easily and quickly penetrate the cell membrane and internalized into the nucleus, the site of action. On the contrary, free doxorubicin is not as effective as liposomal doxorubicin in vivo since free doxorubicin has a fast clearance rate and liposomal doxorubicin are passively targeted to the tumors through the enhanced permeability and retention effect. Cytotoxicity studies in vitro with less membrane diffusible drugs such as topotecan and vinorelbine are more effective in a targeted liposomal formulation compared to free form. Cytotoxicity studies were conducted with doxorubicin as it is the staple drug for liposomal delivery. Changing to more membrane less permeable drugs will likely increase the resolution for the cytotoxicity studies.
- In comparison to the cytotoxicity studies with doxorubicin, the targeted uptake studies with anti-HER2 and anti-EGFR immunoliposomes resulted in higher resolution, showing differences between ligand valencies and the additive effects of using dual-targeted immunoliposomes. The additive and possible synergistic effects of using dual-targeting ligands only significantly enhanced the cell growth inhibition with doxorubicin for a few formulations where both anti-EGFR and anti-HER2 ligands were of high valency in the BT-474 and OVA-420 cell lines. As discussed earlier, the uptake of dual-targeted immunoliposomes appears to be additive instead of synergistic where the accumulation is only marginally higher, and hence it is expected that the biological effect of drug delivery was only marginally better if at all. The main advantage was evident in the cocktail-targeting approach, where the immunoliposomes can target multiple receptors, and hence effective with more cell lines. The same dual-targeting liposomal formulations were used with all the cell lines with no observed antagonistic effects with cell viability, even in the case of SK-BR-3 cells (data not shown). Hence, the dozen formulations can be reduced to one.
- Anti-HER2, anti-EGFR, and dual-targeted lipid nanoparticles at varying ligand valencies (trastuzumab, F5 scFv, cetuximab, EGF and TGFα) were formulated with receptor-specific targeting against cells lines expressing HER2 and/or EGFR. For HER2-targeting, liposomes were functionalized with Fab′ reduced from trastuzumab or F5 scFv. For EGFR-targeting, liposomes were functionalized with Fab′ reduced from cetuximab, EGF, or TGFα. Although the surface attachment of F5 scFv, EGF, and TGFα conjugates onto liposomes was effective with the micelle transfer method, Fab′ of trastuzumab and cetuximab benefited from the sequential micelle transfer-conjugation method where Fab′ is directly conjugated to maleimide micelle transferred onto the liposomes. Through a combination of both the sequential micelle transfer-conjugation and the micelle transfer methods, dual-targeted immunoliposomes of various ligand ratios of anti-HER2 F5 scFv and anti-EGFR cetuximab-Fab′ were made possible for further studies.
- For HER2-overexpessing and EGFR-overexpressing cell lines, the receptor-mediated cell association studies confirmed the observation where increasing ligand valency per liposome increases targeted uptake until saturation (trastuzumab, F5 scFv, and cetuximab). At the optimum ligand valency and higher valence, there is roughly a 1:1 ratio of ligands (F5 scFv and cetuximab-Fab′) to receptor for MCF-7/HER2, BT-474, SK-BR-3, and MDA-468 cells. There was also comparable accumulation of free trastuzumab as trastuzumab-Fab′ delivered from immunoliposomes in MCF-7/HER2 and BT-474 cells.
- In addition, the accumulation of liposomes and ligands for anti-HER2 and anti-EGFR dual-targeted immunoliposomes were roughly additive of their mono-targeted counterparts in BT-474 and MKN-7 cells. No antagonistic effects were observed from the additional of a non-targeted ligand in all cell lines except for SK-BR-3 at high anti-EGFR ligand valence, where anti-EGFR ligands decreased overall uptake. Despite the additive uptake effect, dual-targeted liposomal delivery of doxorubicin to cell lines expressing HER2 and EGFR only significantly enhanced the cell growth inhibition compared to mono-targeted liposomal delivery for a few liposomal formulations where both anti-EGFR and anti-HER2 ligands were of high valency. Although significant, the improvement was minimal and hence not valuable on a purely increased of cellular drug accumulation standpoint. Dual-targeting lipid nanoparticles can still be beneficial as a system to target heterogeneous cancers.
- 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (Mal-PEG-DSPE) were purchased from Avanti Polar Lipids (Alabaster, AL). 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine perchlorate (DiD) and 3,3′-dioctadecyloxacarbocyanine perchlorate (DiO), and Alexa Fluor 488 carboxylic acid succinimidyl ester mixed isomers were purchased from Life Technologies (Grand Island, NY). Cholesterol was obtained from Calbiochem (San Diego, CA).
- Trastuzumab/Herceptin® (Roche) and cetuximab/Erbitux® (ImClone LLC) were donated for research purposes. F5 single-chain variable fragment (scFv) conjugated to Mal-PEG-DSPE was manufactured by the National Cancer Institute as previously described(38, 42). EGF and TGFα were purchased from Millipore (Billerica, MA) and Peprotech (Rocky Hill, NJ). Doxorubicin (Dox; Bedford Laboratories) was purchased from the UCSF Pharmacy (San Francisco, CA). Pepsin, cysteamine, 2-iminothiolane, glycine, and thiazolyl blue tetrazolium bromide were purchased from Sigma-Aldrich (St. Louis, MO). Cell culture media, fetal calf serum, penicillin-streptomycin, trypsin, and phosphate buffered saline (PBS) were purchased from the UCSF Cell Culture Facility (San Francisco, CA).
- MDA-468 and BT-474 human breast cancer cell lines were obtained from the American Type Culture Collection (Rockville, MD), MKN-7 and SK-BR-3 human breast cancer cell lines from the UCSF Cell Culture Facility (San Francisco, CA), and MCF-7/HER2(125) human breast cancer cell line from the UCSF Preclinical Therapeutics Core (San Francisco, CA). MDA-468 cells were maintained in Leibovitz's L-15 medium without NaHCO3, BT-474 and MKN-7 cells in RPMI-1640 medium, SK-BR-3 in McCoy's 5A medium, and MCF-7/HER2 in DEM H-21 medium with gentamycin (200 μg/ml). All media were supplemented with 10% fetal calf serum and 1% penicillin-streptomycin. All cells were cultured as monolayer at 37° C. in 5% CO2 except in the absence of CO2 for MDA-468 cells.
- Liposomes were prepared by the lipid film hydration-extrusion method(117). Lipid solution of DSPC, cholesterol, PEG-DSPE (3:2:0.3), and a fluorescent lipophilic tracer (DiD or DiO, 0.5%) were dissolved in chloroform with a few drops of methanol, and dried under reduced pressure at 60° C. using rotary evaporation. Lipid films were hydrated in HEPES buffered saline (HBS 6.5; 5 mM HEPES, 135 mM NaCl, pH 6.5), and liposomes were prepared according to the repeated freeze-thawing method (6 cycles). Liposomes were subsequently extruded 10 times through 100 nm polycarbonate membrane filters using an extruder, resulting in liposomes of 80-120 nm diameter as determined by dynamic light scattering. Liposome concentration was measured using a standard phosphate assay(118).
- For encapsulation of doxorubicin, the remote-loading method using ammonium sulfate was performed(119, 120). Lipid films were hydrated in ammonium sulfate (250 mM, pH 6), followed by the freeze-thawing method and extrusion as described. Free ammonium sulfate was removed by size-exclusion chromatography using a Sephadex G75 column eluted with HEPES buffered saline (20 mM HEPES, 135 mM NaCl, pH 5.5). Liposomes were then incubated with doxorubicin (150 μg Dox/μmol PL) at 60° C. for 1 hr. Unencapsulated drugs were removed by size-exclusion chromatography using a Sephadex G75 column eluted with HBS 6.5. Loading efficiencies were typically in the range of 95-100% as determined by fluorometry (485/20:590/35 nm). Final liposomal formulations were all filtered through a 0.2 μm Nalgene® polyethersulfone membrane (Thermo Scientific) before cellular experiments.
- IgG (trastuzumab or cetuximab) was cleaved and reduced to Fab′(35, 36), but incorporated onto liposomes via a modified version of the micelle transfer method(35, 44). IgG was cleaved with pepsin (weight ratio 1:20) in sodium acetate (0.1 M, pH 3.7) at 37° C. for 2 h under argon, followed by dialysis against MES buffered saline (5 mM MES, 135 mM NaCl, pH 6.0). The Fab2 was reduced with cysteamine (16 mM) at 37° C. for 1 h under argon, followed by size-exclusion chromatography on a Sephadex G25 column eluted with MOPS buffered saline (5 mM MOPS, 135 mM NaCl, pH 7.0). For standards, the resulting Fab′ was conjugated with a 5:1 excess of Mal-PEG-DSPE at room temperature for 2 hr under argon. The mixture was quenched with 1 mM 2-mercaptoethanol at room temperature for 15 min under argon. Unbound Fab′ was removed by size-exclusion chromatography on an AcA34 column eluted with HBS (5 mM HEPES, 135 mM NaCl, pH 7.4) in 1 ml fractions. The fraction of Fab′ conjugated to micellar lipids was measured and determined by UV absorbance (280 nm) and SDS-PAGE (Bio-Rad).
- EGF and TGFα were thiolated with Traut's reagent(121), conjugated to Mal-PEG-DSPE, and incorporated onto liposomes via the micelle transfer method(35, 44). EGF or TGFα at 0.2-0.5 g/l in Traut's buffer (50 mM triethanolamine, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, pH 8) was modified with a 7:1 excess of 2-iminothiolane at room temperature for 1 hr under argon. Excess reagent was removed by size-exclusion chromatography on a Sephadex G25 column eluted with sodium phosphate buffer (0.1 M sodium phosphate, 0.1 M NaCl, pH 7.5) in 200 ul fractions. The thiolated EGF or TGFα was conjugated with a 5:1 excess of Mal-PEG-DSPE at room temperature for 2 hr under argon. The mixture was quenched with 1 mM 2-mercaptoethnaol (200 mM stock in 5 mM MES, 135 mM NaCl, pH 6.0) at room temperature for 15 min under argon. Unbound growth factor was removed by size-exclusion chromatography on a Sephadex G75 column eluted with HBS (20 mM Hepes, 150 mM NaCl, pH 7.4) in 200 ul fractions. The fraction of growth factor conjugated to micellar lipids was measured and determined by BCA Protein Assay Kit (Thermo Scientific), Quant-iT Protein Assay Kit (Life Technologies), and SDS-PAGE (Bio-Rad).
- Ligand Conjugation onto Liposomes by the Micelle Transfer Method and Sequential Micelle Transfer—Conjugation Method
- Ligands were incorporated onto liposomes either by the micelle transfer method(35, 44) or the sequential micelle transfer-conjugation method. For the micelle transfer method, conjugates of F5 scFv-PEG-DSPE, EGF-PEG-DSPE or TGFα-PEG-DSPE were incubated with liposomes at 50° C. for 40 min under argon (0-100 ligands per liposome, assuming 8*104PL per liposome)(35, 122). Unincorporated conjugates were removed by size-exclusion chromatography on a Sepharose 4B column eluted with HBS 6.5. For the sequential micelle transfer-conjugation method, Mal-PEG-DSPE (0-1%) was first incubated with liposomes at 50° C. for 40 min under argon, followed by incubation with freshly reduced Fab′ (trastuzumab or cetuximab) at room temperature for 2 hr under argon (1:1 Fab′:Mal-PEG-DSPE). Unbound Fab′ was removed by size-exclusion chromatography on a Sepharose 4B eluted with HBS 6.5. Conjugate incorporation efficiency was measured and determined by ImageJ (National Institutes of Health) from SDS-PAGE (Bio-Rad) stained with SYPRO Ruby.
- Dual-targeted immunoliposomes of various ligand ratios were achieved by a combination of both the sequential micelle transfer-conjugation and the micelle transfer methods. For anti-HER2 and anti-EGFR dual-targeted immunoliposomes, Mal-PEG-DSPE (0-1%) was first incubated with liposomes at 50° C. for 40 min under argon, followed by incubation with cetuximab-Fab′ at room temperature for 2 hr under argon (1:1 Fab′:Mal-PEG-DSPE). Unbound Fab′ was removed by size-exclusion chromatography on a Sepharose® 4B eluted with HBS 6.5. Subsequently, F5 scFv-PEG-DSPE (0-1%) was incubated with cetuximab-ILS at 50° C. for 40 min under argon. Unincorporated conjugates were again removed by size-exclusion chromatography on a Sepharose® 4B column eluted with HBS 6.5. Alternatively, F5 scFv-PEG-DSPE (0-1%) and Mal-PEG-DSPE (0-1%) can simultaneously be incubated with liposomes at 50° C. for 40 min under argon, followed by incubation with cetuximab-Fab′ at room temperature for 2 hr under argon. Conjugate incorporation efficiency was measured and determined by ImageJ (National Institutes of Health) from SDS-PAGE (Bio-Rad) stained with SYPRO Ruby following each conjugation step. F5 scFv conjugation was assumed to be 100% as previously determined.
- For ligand trafficking experiments, ligands were fluorescently labeled with Alexa Fluor 488 or 546. Trastuzumab, F5 scFv, cetuximab, EGF, and TGFα were conjugated with Alexa Fluor 488 carboxylic acid succinimidyl ester (Life Technologies) as described by vendor, yielding 1-2 fluorophores per ligand. Alexa Fluor 546 carboxylic acid succinimidyl ester (Life Technologies) yielded 3-4 fluorophores per ligand. The relative efficiency of labeling was determined by measurements on the
NanoDrop 1000 spectrophotometer and Quant-iT Protein Assay Kit (Life Technologies). - For the assessment of targeted binding by flow cytometry, cells cultured overnight in 24-well plates (75-100*103 cells/well) were incubated with liposomes labeled with DiD or DiO (0-750 μM PL) at 37° C. for 1-11 hr, washed with
PBS 3×, detached with trypsin, resuspended in PBS, and immediately subjected to flow cytometry (BD FACSCalibur). Detached cells were analyzed on fluorescence channels FL4 and FL1 for liposomes labeled with DiD and DiO, respectively. The mean fluorescent intensity with a tight spread of 5*103 cells was recorded per liposomal formulation. - For the assessment of targeted uptake by fluorometry, cells cultured overnight in 96-well plates (80*103 cells/well) were incubated with liposomes labeled with DiD (400 μM PL) at 37° C. for 24 hr, washed with
PBS 3×, freeze-thawed 3×, and lysed with 80% isopropyl alcohol (IPA) and 1% Triton X-100. Lysed samples along with standards using labeled liposomes added to the plates were read on a fluorescent microplate reader (Wallac Victor). Measurements were read with excitation and emission band-pass filters as follow: DiD 644:665 nm and doxorubicin 485/20:590/35 nm. Cell count was estimated based on a hemacytometer and MTT assay ((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), showing negligible cell detachment or toxicity under these conditions between groups. - For the assessment of targeted uptake by fluorometry, cells cultured overnight in 96-well plates (50*103 cells/well) were incubated with liposomes labeled with DiD (75 or 375 μM PL) or ligands labeled with Alexa Fluor 488 (40 nM) at 37° C. for 4 hr, stripped with an acid wash (50 mM glycine, 150 mM NaCl, pH 3) at 4° C. for 5 min, washed with
PBS 2×, freeze-thawed 3×, and lysed with 80% isopropyl alcohol (IPA) and 1% Triton X-100. For the assessment of targeted dose-uptake by fluorometry, cells cultured overnight in 96-well plates (50*103 cells/well) were incubated with liposomes labeled with DiD or DiO (800 μM PL with 1/3 dilutions) at 37° C. for 4 hr, washed withPBS 3×, freeze-thawed 3×, and lysed with 80% IPA and 1% Triton X-100. Lysed samples along with standards using labeled liposomes and ligands added to the plates were read on a fluorescent microplate reader (Biotek Synergy HT or Wallac Victor). Measurements were read with excitation and emission band-pass filters as follow: DiO 485/20:528/20 nm, DiD 644:665 nm, Alexa Fluor 488 485/20:528/20 nm, and doxorubicin 485/20:590/35 nm. Cell count was estimated based on a hemacytometer and MTT assay ((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), showing negligible cell detachment or toxicity under these conditions between groups. - For cytotoxicity studies, cells cultured overnight in 96-well plates (10*103 cells/well) were incubated with doxorubicin-load liposomes (100 μg/ml with 1/3 dilutions) at 37° C. for 4 hr, washed with PBS, and grown in medium for 3 additional days. Cell viability was analyzed by MTT assay. Bars of standard deviations were adjusted for the error of propagation.
- For dose-uptake studies, the uptake of liposomes was analyzed by two-way ANOVA via SPSS Statistics 20 (IBM) using two factors, liposomal formulation and incubated liposomal concentration. For cytotoxicity studies, cell growth inhibition was analyzed by two-way ANOVA via SPSS Statistics 20 (IBM) using two factors, liposomal formulation and incubated drug concentration. For group comparisons, the largest P value was selected to generalize the overall group. For mean comparisons, student's t-test was applied.
- The following abbreviations are used herein:
-
- Ab Antibody
- ADC Antibody drug conjugate
- API Active pharmaceutical ingredient
- CBeq Cell associated particle concentration at equilibrium (#/cell)
- CBeq(v,fx,RT,KD,KX) CBeq as a function of 5 parameters; Order of function as listed
- CBeq(v,fx) CBeq as a function of 2 parameters; Order of function as listed
- CBeq(v) CBeq as a function of 1 parameters; Order of function as listed
- Ci Concentration of a particle bound to the cell surface via I of its available surface-attached ligands
- CLg Ligand/receptor complex
- DiD 1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine perchlorate
-
DiO - Dox Doxorubicin
-
DSPC 1,2-Distearoyl-sn-glycero-3-phosphocholine -
DSPE 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine - EDTA Ethylenediaminetetraacetic acid
- EGF Epidermal growth factor
- EGFR Epidermal growth factor receptor
- EPR Enhanced permeability and retention effect
- Eq Equilibrium
- Equiv. Equivalent
- ExHy Immunoliposomes with x anti-EGFR ligands and y anti-HER2 ligands per liposome
- f or fx Effective valence (#/particle)
- F5 scFv F5 single-chain variable fragment that binds HER2
- Fab′ Antigen-binding fragment
- Fab2 Two antigen-binding fragments connected by disulfide bonds
- Fc Crystallizable fragment
- GF Growth factor
- HBS HEPES-buffered saline
- HEPES 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid
- HER1 Human epidermal
growth factor receptor 1 - HER2 Human epidermal
growth factor receptor 2 - HER3 Human epidermal
growth factor receptor 3 - HER4 Human epidermal
growth factor receptor 4 - HHa Dual-targeted against cells with dual High/High; Additive binding
- HHs Dual-targeted against cells with dual High/High; Synergetic binding
- High or H High receptor expression (RT=˜10{circumflex over ( )}6)
- HMa Dual-targeted against cells with dual High/Moderate; Additive binding
- HMs Dual-targeted against cells with dual High/Moderate; Synergetic binding
- i Number of bounds
- IC50 Half maximal inhibitory concentration
- IgG Immunoglobulin G
- ILS Immunoliposome
- KD Equilibrium dissociation constant (nM)
- kd Dissociation rate constant
- kf Associating rate constant
- KX Crosslinking equilibrium constant (1/(#/cell))
- kx Receptor crosslinking rate constant
- k−x Receptor decrosslinking rate constant
- L Particle concentration in solution per cell (#/cell)
- LDC Ligand drug conjugate
- Lo Particle concentration in solution per cell (˜1M #/cell); initial
- Lg Ligand
- Low Low receptor expression (RT=˜10{circumflex over ( )}4)
- LS Liposome
- mAb Monoclonal antibody
- Mal Maleimide
- Mal-PEG-
DSPE 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] - MES 2-(N-Morpholino)ethanesulfonic acid
- MFI Mean fluorescent intensity
- MMa Dual-targeted against cells with dual Moderate/Moderate; Additive binding
- MMs Dual-targeted against cells with dual Moderate/Moderate; Synergetic binding
- Moderate or M Moderate receptor expression (RT=˜10{circumflex over ( )}5)
- MOPS 3-(N-Morpholino)propanesulfonic acid
- MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- NA Avogadro's number
- NaCl Sodium chloride
- NE Not evaluable
- NT Non-targeted (liposome)
- PBS Phosphate-buffered saline
- PEG Polyethylene glycol
- PEG-
DSPE 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] - PL Phospholipid
- Q Pertaining to receptor or nanoparticle
- R Receptor concentration
- Req or ReqF Free receptors per cell at equilibrium (#/cell)
- ReqF(v,fx,RT,KD,KX) ReqF as a function of 5 parameters; Order of function as listed
- Req(v,fx) ReqF as a function of 2 parameters; Order of function as listed
- Req(v) ReqF as a function of 1 parameters; Order of function as listed
- RES Reticuloendothelial system
- RhuMAb Recombinant humanized monoclonal antibody
- RT Room temperature
- RT Total receptors per cell (#/cell)
- scFv Single-chain variable fragment
- SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
- SE Standard error
- SH Sulfhydryl group
- TEA Triethanolamine
- TGFα Transforming growth factor receptor alpha
- TNFα Tumor necrosis factor alpha
- Tras Trastuzumab
- UCSF University of California San Francisco
- UV Ultraviolet
- VEGF Vascular endothelial growth factor
- VEGFR Vascular endothelial growth factor receptor
- v Ligand valence per particle (#/particle)
- The references below are cited by number in the text of the Examples above:
- 1. D. C. Drummond, O. Meyer, K. Hong, D. B. Kirpotin, D. Papahadjopoulos, Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacological reviews 51, 691 (December, 1999).
- 2. D. Papahadjopoulos, A. Gabizon, Sterically stabilized (Stealth®) liposomes: Pharmacological properties and drug carrying potential in cancer. J. R. Philippot, F. Schuber, Eds., Liposomes as Tools in Basic Research and Industry (CRC Press, Boca Raton, F L, 1995), pp. 177-188.
- 3. P. A. Speth, Q. G. van Hoesel, C. Haanen, Clinical pharmacokinetics of doxorubicin.
Clinical pharmacokinetics 15, 15 (July, 1988). - 4. C. O. Noble, D. B. Kirpotin, M. E. Hayes, C. Mamot, K. Hong, J. W. Park, C. C. Benz, J. D. Marks, D. C. Drummond, Development of ligand-targeted liposomes for cancer therapy. Expert opinion on therapeutic targets 8, 335 (August, 2004).
- 5. T. M. Allen, L. Murray, S. MacKeigan, M. Shah, Chronic liposome administration in mice: effects on reticuloendothelial function and tissue distribution. The Journal of pharmacology and experimental therapeutics 229, 267 (April, 1984).
- 6. G. Storm, C. Oussoren, P. J. Peters, Y. Barenholz, Tolerability of liposomes in vivo. G. Gregoriadis, Ed., Liposome Technology (CRC Press, Inc., Boca Raton, F L, 1993).
- 7. C. P. Carpenter, M. D. Woodside, E. R. Kinkead, J. M. King, L. J. Sullivan, Response of dogs to repeated intravenous injection of polyethylene glycol 4000 with notes on excretion and sensitization. Toxicology and applied pharmacology 18, 35 (January, 1971).
- 8. T. M. Allen, C. Hansen, J. Rutledge, Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochimica et biophysica acta 981, 27 (May 19, 1989).
- 9. D. Liu, A. Mori, L. Huang, Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochimica et biophysica acta 1104, 95 (Feb. 17, 1992).
- 10. M. C. Woodle, K. K. Matthay, M. S. Newman, J. E. Hidayat, L. R. Collins, C. Redemann, F. J. Martin, D. Papahadjopoulos, Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochimica et biophysica acta 1105, 193 (Apr. 13, 1992).
- 11. T. Allen, C. Hansen, D. E. Lopes de Menezes, Pharmacokinetics of long-circulating liposomes. Advanced drug delivery reviews 16, 267 (September, 1995).
- 12. T. M. Allen, Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends in
pharmacological sciences 15, 215 (July, 1994). - 13. T. M. Allen, C. Hansen, Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochimica et biophysica acta 1068, 133 (Sep. 30, 1991).
- 14. M. S. Webb, D. Saxon, F. M. Wong, H. J. Lim, Z. Wang, M. B. Bally, L. S. Choi, P. R. Cullis, L. D. Mayer, Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochimica et biophysica acta 1372, 272 (Jul. 17, 1998).
- 15. M. S. Webb, T. O. Harasym, D. Masin, M. B. Bally, L. D. Mayer, Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. British journal of cancer 72, 896 (October, 1995).
- 16. A. Gabizon, D. Papahadjopoulos, The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochimica et biophysica acta 1103, 94 (Jan. 10, 1992).
- 17. J. Senior, J. C. Crawley, G. Gregoriadis, Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection. Biochimica et biophysica acta 839, 1 (Mar. 29, 1985).
- 18. J. H. Senior, Fate and behavior of liposomes in vivo: a review of controlling factors. Critical reviews in therapeutic
drug carrier systems 3, 123 (1987). - 19. F. M. Muggia, J. D. Hainsworth, S. Jeffers, P. Miller, S. Groshen, M. Tan, L. Roman, B. Uziely, L. Muderspach, A. Garcia, A. Burnett, F. A. Greco, C. P. Morrow, L. J. Paradiso, L. J. Liang, Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. Journal of clinical oncology: official journal of the American Society of
Clinical Oncology 15, 987 (March, 1997). - 20. O. Lyass, B. Uziely, R. Ben-Yosef, D. Tzemach, N. I. Heshing, M. Lotem, G. Brufman, A. Gabizon, Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89, 1037 (Sep. 1, 2000).
- 21. F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D. A. Berk, V. P. Torchilin, R. K. Jain, Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer research 55, 3752 (Sep. 1, 1995).
- 22. S. K. Hobbs, W. L. Monsky, F. Yuan, W. G. Roberts, L. Griffith, V. P. Torchilin, R. K. Jain, Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proceedings of the National Academy of Sciences of the United States of America 95, 4607 (Apr. 14, 1998).
- 23. Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer research 46, 6387 (December, 1986).
- 24. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of controlled release: official journal of the Controlled Release Society 65, 271 (Mar. 1, 2000).
- 25. S. K. Huang, K. D. Lee, K. Hong, D. S. Friend, D. Papahadjopoulos, Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer research 52, 5135 (Oct. 1, 1992).
- 26. V. P. Torchilin, Passive and active drug targeting: drug delivery to tumors as an example. Handbook of experimental pharmacology, 3 (2010).
- 27. A. Gabizon, M. Chemla, D. Tzemach, A. T. Horowitz, D. Goren, Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. Journal of drug targeting 3, 391 (1996).
- 28. L. D. Mayer, P. Cullis, M. Bally, Medical Applications of Liposomes. D. Lasic, D. Papahadjopoulos, Eds., (Elsevier Science, B.V., New York, 1998).
- 29. P. Sapra, T. M. Allen, Ligand-targeted liposomal anticancer drugs. Progress in lipid research 42, 439 (September, 2003).
- 30. T. M. Allen, Ligand-targeted therapeutics in anticancer therapy. Nature reviews.
Cancer 2, 750 (October, 2002). - 31. G. A. Niehans, T. P. Singleton, D. Dykoski, D. T. Kiang, Stability of HER-2/neu expression over time and at multiple metastatic sites. Journal of the National Cancer Institute 85, 1230 (Aug. 4, 1993).
- 32. D. S. Salomon, R. Brandt, F. Ciardiello, N. Normanno, Epidermal growth factor-related peptides and their receptors in human malignancies. Critical reviews in oncology/hematology 19, 183 (July, 1995).
- 33. S. Zalipsky, B. Puntambekar, P. Boulikas, C. M. Engbers, M. C. Woodle, Peptide attachment to extremities of liposomal surface grafted PEG chains: preparation of the long-circulating form of laminin pentapeptide, YIGSR.
Bioconjugate chemistry 6, 705 (November-December, 1995). - 34. U. B. Nielsen, D. B. Kirpotin, E. M. Pickering, K. Hong, J. W. Park, M. Refaat Shalaby, Y. Shao, C. C. Benz, J. D. Marks, Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochimica et biophysica acta 1591, 109 (Aug. 19, 2002).
- 35. D. Kirpotin, J. W. Park, K. Hong, S. Zalipsky, W. L. Li, P. Carter, C. C. Benz, D. Papahadjopoulos, Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36, 66 (Jan. 7, 1997).
- 36. C. Mamot, D. C. Drummond, U. Greiser, K. Hong, D. B. Kirpotin, J. D. Marks, J. W. Park, Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer research 63, 3154 (Jun. 15, 2003).
- 37. K. Maruyama, T. Takizawa, T. Yuda, S. J. Kennel, L. Huang, M. Iwatsuru, Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochimica et biophysica acta 1234, 74 (Mar. 8, 1995).
- 38. M. A. Poul, B. Becerril, U. B. Nielsen, P. Morisson, J. D. Marks, Selection of tumor-specific internalizing human antibodies from phage libraries. Journal of molecular biology 301, 1149 (Sep. 1, 2000).
- 39. B. Becerril, M. A. Poul, J. D. Marks, Toward selection of internalizing antibodies from phage libraries. Biochemical and biophysical research communications 255, 386 (Feb. 16, 1999).
- 40. M. D. Sheets, P. Amersdorfer, R. Finnern, P. Sargent, E. Lindquist, R. Schier, G. Hemingsen, C. Wong, J. C. Gerhart, J. D. Marks, Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proceedings of the National Academy of Sciences of the United States of America 95, 6157 (May 26, 1998).
- 41. E. T. Boder, K. S. Midelfort, K. D. Wittrup, Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proceedings of the National Academy of Sciences of the United States of America 97, 10701 (Sep. 26, 2000).
- 42. U. B. Nielsen, J. D. Marks, Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries. Pharmaceutical science &
technology today 3, 282 (August, 2000). - 43. D. Goren, A. T. Horowitz, S. Zalipsky, M. C. Woodle, Y. Yarden, A. Gabizon, Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. British journal of cancer 74, 1749 (December, 1996).
- 44. J. W. Park, K. Hong, D. B. Kirpotin, G. Colbern, R. Shalaby, J. Baselga, Y. Shao, U. B. Nielsen, J. D. Marks, D. Moore, D. Papahadjopoulos, C. C. Benz, Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clinical cancer research: an official journal of the American Association for Cancer Research 8, 1172 (April, 2002).
- 45. D. Aragnol, L. D. Leserman, Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proceedings of the National Academy of Sciences of the United States of America 83, 2699 (April, 1986).
- 46. J. A. Harding, C. M. Engbers, M. S. Newman, N. I. Goldstein, S. Zalipsky, Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochimica et biophysica acta 1327, 181 (Jul. 25, 1997).
- 47. S. Zalipsky, Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates.
Bioconjugate chemistry 6, 150 (March-April, 1995). - 48. T. Ishida, D. L. Iden, T. M. Allen, A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS letters 460, 129 (Oct. 22, 1999).
- 49. D. L. Iden, T. M. Allen, In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochimica et biophysica acta 1513, 207 (Aug. 6, 2001).
- 50. D. Kirpotin, J. W. Park, K. Hong, Y. Shao, R. Shalaby, G. Colbern, C. C. Benz, D. Papahadjopoulos, Targeting of Liposomes to Solid Tumors: The Case of Sterically Stabilized Anti-Her2 Immunoliposomes. Journal of
liposome research 7, 391 (1997). - 51. C. Mamot, D. C. Drummond, C. O. Noble, V. Kallab, Z. Guo, K. Hong, D. B. Kirpotin, J. W. Park, Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer research 65, 11631 (Dec. 15, 2005).
- 52. J. W. Park, K. Hong, D. B. Kirpotin, O. Meyer, D. Papahadjopoulos, C. C. Benz, Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer letters 118, 153 (Oct. 14, 1997).
- 53. J. N. Moreira, R. Gaspar, T. M. Allen, Targeting Stealth liposomes in a murine model of human small cell lung cancer. Biochimica et biophysica acta 1515, 167 (Dec. 1, 2001).
- 54. C. Mamot, D. C. Drummond, K. Hong, D. B. Kirpotin, J. W. Park, Liposome-based approaches to overcome anticancer drug resistance. Drug resistance updates reviews and commentaries in antimicrobial and
anticancer chemotherapy 6, 271 (October, 2003). - 55. D. Sadava, A. Coleman, S. E. Kane, Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. Journal of
liposome research 12, 301 (November, 2002). - 56. C. Mamot, R. Ritschard, A. Wicki, W. Kung, J. Schuller, R. Herrmann, C. Rochlitz, Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. Journal of drug targeting 20, 422 (June, 2012).
- 57. I. Mellman, Endocytosis and molecular sorting. Annual review of cell and
developmental biology 12, 575 (1996). - 58. A. Sorkin, M. von Zastrow, Endocytosis and signalling: intertwining molecular networks. Nature reviews.
Molecular cell biology 10, 609 (September, 2009). - 59. S. L. Schmid, Clathrin-coated vesicle formation and protein sorting: an integrated process. Annual review of biochemistry 66, 511 (1997).
- 60. Q. Al-Awqati, Proton-translocating ATPases. Annual review of
cell biology 2, 179 (1986). - 61. I. Mellman, R. Fuchs, A. Helenius, Acidification of the endocytic and exocytic pathways. Annual review of biochemistry 55, 663 (1986).
- 62. M. Forgac, Structure and properties of the coated vesicle proton pump. Annals of the New York Academy of Sciences 671, 273 (Nov. 30, 1992).
- 63. A. Alexander, Endocytosis and intracellular sorting of receptor tyrosine kinases. Frontiers in bioscience: a journal and
virtual library 3, d729 (Jul. 26, 1998). - 64. A. Spang, Vesicle transport: a close collaboration of Rabs and effectors. Current biology: CB 14, R33 (Jan. 6, 2004).
- 65. M. Zerial, H. McBride, Rab proteins as membrane organizers. Nature reviews.
Molecular cell biology 2, 107 (February, 2001). - 66. C. Bucci, P. Thomsen, P. Nicoziani, J. McCarthy, B. van Deurs, Rab7: a key to lysosome biogenesis. Molecular biology of the
cell 11, 467 (February, 2000). - 67. M. Ren, G. Xu, J. Zeng, C. De Lemos-Chiarandini, M. Adesnik, D. D. Sabatini, Hydrolysis of GTP on
rab 11 is required for the direct delivery of transferrin from the pericentriolar recycling compartment to the cell surface but not from sorting endosomes. Proceedings of the National Academy of Sciences of the United States of America 95, 6187 (May 26, 1998). - 68. M. Trischler, W. Stoorvogel, O. Ullrich, Biochemical analysis of distinct Rab5- and Rab11-positive endosomes along the transferrin pathway. Journal of cell science 112 (Pt 24), 4773 (December, 1999).
- 69. D. Duan, Y. Yue, Z. Yan, P. B. McCray, Jr., J. F. Engelhardt, Polarity influences the efficiency of recombinant adenoassociated virus infection in differentiated airway epithelia.
Human gene therapy 9, 2761 (Dec. 10, 1998). - 70. C. R. Hopkins, I. S. Trowbridge, Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells. The Journal of cell biology 97, 508 (August, 1983).
- 71. C. R. Hopkins, Intracellular routing of transferrin and transferrin receptors in epidermoid carcinoma A431 cells.
Cell 35, 321 (November, 1983). - 72. M. Karin, B. Mintz, Receptor-mediated endocytosis of transferrin in developmentally totipotent mouse teratocarcinoma stem cells. The Journal of biological chemistry 256, 3245 (Apr. 10, 1981).
- 73. J. N. Octave, Y. J. Schneider, R. R. Crichton, A. Trouet, Transferrin uptake by cultured rat embryo fibroblasts. The influence of temperature and incubation time, subcellular distribution and short-term kinetic studies. European journal of biochemistry/FEBS 115, 611 (April, 1981).
- 74. J. D. Bleil, M. S. Bretscher, Transferrin receptor and its recycling in HeLa cells. The
EMBO journal 1, 351 (1982). - 75. C. Harding, J. Heuser, P. Stahl, Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. The Journal of cell biology 97, 329 (August, 1983).
- 76. A. R. French, G. P. Sudlow, H. S. Wiley, D. A. Lauffenburger, Postendocytic trafficking of epidermal growth factor-receptor complexes is mediated through saturable and specific endosomal interactions. The Journal of biological chemistry 269, 15749 (Jun. 3, 1994).
- 77. R. Ebner, R. Derynck, Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes.
Cell regulation 2, 599 (August, 1991). - 78. M. Perez-Tones, M. Guix, A. Gonzalez, C. L. Arteaga, Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. The Journal of biological chemistry 281, 40183 (Dec. 29, 2006).
- 79. C. D. Austin, A. M. De Maziere, P. I. Pisacane, S. M. van Dijk, C. Eigenbrot, M. X. Sliwkowski, J. Klumperman, R. H. Scheller, Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Molecular biology of the
cell 15, 5268 (December, 2004). - 80. T. Yoshida, I. Okamoto, T. Okabe, T. Iwasa, T. Satoh, K. Nishio, M. Fukuoka, K. Nakagawa, Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. International journal of cancer. Journal international du cancer 122, 1530 (Apr. 1, 2008).
- 81. D. Patel, A. Lahiji, S. Patel, M. Franklin, X. Jimenez, D. J. Hicklin, X. Kang, Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer research 27, 3355 (September-October, 2007).
- 82. W. S. Chen, C. S. Lazar, M. Poenie, R. Y. Tsien, G. N. Gill, M. G. Rosenfeld, Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature 328, 820 (Aug. 27-Sep. 2, 1987).
- 83. E. Kornilova, T. Sorkina, L. Beguinot, A. Sorkin, Lysosomal targeting of epidermal growth factor receptors via a kinase-dependent pathway is mediated by the receptor carboxyl-terminal residues 1022-1123. The Journal of biological chemistry 271, 30340 (Nov. 29, 1996).
- 84. S. J. Kil, M. Hobert, C. Carlin, A leucine-based determinant in the epidermal growth factor receptor juxtamembrane domain is required for the efficient transport of ligand-receptor complexes to lysosomes. The Journal of biological chemistry 274, 3141 (Jan. 29, 1999).
- 85. S. J. Kil, C. Carlin, EGF receptor residues leu(679), leu(680) mediate selective sorting of ligand-receptor complexes in early endosomal compartments. Journal of cellular physiology 185, 47 (October, 2000).
- 86. J. Bao, I. Alroy, H. Waterman, E. D. Schejter, C. Brodie, J. Gruenberg, Y. Yarden, Threonine phosphorylation diverts internalized epidermal growth factor receptors from a degradative pathway to the recycling endosome. The Journal of biological chemistry 275, 26178 (Aug. 25, 2000).
- 87. K. A. Lund, C. S. Lazar, W. S. Chen, B. J. Walsh, J. B. Welsh, J. J. Herbst, G. M. Walton, M. G. Rosenfeld, G. N. Gill, H. S. Wiley, Phosphorylation of the epidermal growth factor receptor at threonine 654 inhibits ligand-induced internalization and down-regulation. The Journal of biological chemistry 265, 20517 (Nov. 25, 1990).
- 88. L. K. Opresko, C. P. Chang, B. H. Will, P. M. Burke, G. N. Gill, H. S. Wiley, Endocytosis and lysosomal targeting of epidermal growth factor receptors are mediated by distinct sequences independent of the tyrosine kinase domain. The Journal of biological chemistry 270, 4325 (Mar. 3, 1995).
- 89. W. Ding, L. N. Zhang, C. Yeaman, J. F. Engelhardt, rAAV2 traffics through both the late and the recycling endosomes in a dose-dependent fashion. Molecular therapy: the journal of the American Society of Gene Therapy 13, 671 (April, 2006).
- 90. R. J. Lee, P. S. Low, Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. The Journal of biological chemistry 269, 3198 (Feb. 4, 1994).
- 91. A. Gabizon, A. T. Horowitz, D. Goren, D. Tzemach, F. Mandelbaum-Shavit, M. M. Qazen, S. Zalipsky, Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies.
Bioconjugate chemistry 10, 289 (March-April, 1999). - 92. G. Blume, G. Cevc, M. D. Crommelin, I. A. Bakker-Woudenberg, C. Kluft, G. Storm, Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochimica et biophysica acta 1149, 180 (Jun. 18, 1993).
- 93. Y. Zhou, D. C. Drummond, H. Zou, M. E. Hayes, G. P. Adams, D. B. Kirpotin, J. D. Marks, Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. Journal of molecular biology 371, 934 (Aug. 24, 2007).
- 94. J. W. Park, K. Hong, P. Carter, H. Asgari, L. Y. Guo, G. A. Keller, C. Wirth, R. Shalaby, C. Kotts, W. I. Wood, et al., Development of anti-p185HER2 immunoliposomes for cancer therapy. Proceedings of the National Academy of Sciences of the United States of America 92, 1327 (Feb. 28, 1995).
- 95. D. Ye, J. Mendelsohn, Z. Fan, Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 18, 731 (Jan. 21, 1999).
- 96. K. Laginha, D. Mumbengegwi, T. Allen, Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity. Biochimica et biophysica acta 1711, 25 (Jun. 1, 2005).
- 97. S. Grant, L. Qiao, P. Dent, Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Frontiers in bioscience: a journal and
virtual library 7, d376 (Feb. 1, 2002). - 98. S. A. Eccles, The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. The International journal of developmental biology 55, 685 (2011).
- 99. E. M. Bublil, Y. Yarden, The EGF receptor family: spearheading a merger of signaling and therapeutics. Current opinion in cell biology 19, 124 (April, 2007).
- 100. R. I. Nicholson, J. M. Gee, M. E. Harper, EGFR and cancer prognosis. Eur J Cancer 37
Suppl 4, S9 (September, 2001). - 101. J. J. Laskin, A. B. Sandler, Epidermal growth factor receptor: a promising target in solid tumours. Cancer treatment reviews 30, 1 (February, 2004).
- 102. T. Heitner, A. Moor, J. L. Garrison, C. Marks, T. Hasan, J. D. Marks, Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. Journal of immunological methods 248, 17 (Feb. 1, 2001).
- 103. S. Paik, C. Park, HER-2 and choice of adjuvant chemotherapy in breast cancer. Seminars in oncology 28, 332 (August, 2001).
- 104. N. Prenzel, O. M. Fischer, S. Streit, S. Hart, A. Ullrich, The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocrine-related cancer 8, 11 (March, 2001).
- 105. D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, W. L. McGuire, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177 (Jan. 9, 1987).
- 106. D. J. Slamon, W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, W. J. Levin, S. G. Stuart, J. Udove, A. Ullrich, et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707 (May 12, 1989).
- 107. A. D. Santin, S. Bellone, J. J. Roman, J. K. McKenney, S. Pecorelli, Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 102, 128 (August, 2008).
- 108. J. Baselga, D. Tripathy, J. Mendelsohn, S. Baughman, C. C. Benz, L. Dantis, N. T. Sklarin, A. D. Seidman, C. A. Hudis, J. Moore, P. P. Rosen, T. Twaddell, I. C. Henderson, L. Norton, Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 14, 737 (March, 1996).
- 109. M. A. Cobleigh, C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, J. M. Wolter, V. Paton, S. Shak, G. Lieberman, D. J. Slamon, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 17, 2639 (September, 1999).
- 110. D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, L. Norton, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England journal of medicine 344, 783 (Mar. 15, 2001).
- 111. R. M. Neve, U. B. Nielsen, D. B. Kirpotin, M. A. Poul, J. D. Marks, C. C. Benz, Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. Biochemical and biophysical research communications 280, 274 (Jan. 12, 2001).
- 112. M. Sznol, J. Holmlund, Antigen-specific agents in development. Seminars in oncology 24, 173 (April, 1997).
- 113. P. Carter, M. L. Rodriguez, J. W. Park, G. Zapata, Preparation and uses of Fab′ fragments from E. coli. J. G. McCaffrey, H. R. Hoogenboom, D. J. Chiswell, Eds., Antibody Engineering: A Practical Approach (IRL Press, Oxford, 1996).
- 114. R. Schier, J. D. Marks, E. J. Wolf, G. Apell, C. Wong, J. E. McCartney, M. A. Bookman, J. S. Huston, L. L. Houston, L. M. Weiner, et al., In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology: an international journal of
immunological engineering 1, 73 (May, 1995). - 115. A. E. Lenferink, A. D. De Roos, M. J. Van Vugt, M. L. Van de Poll, E. J. Van Zoelen, The linear C-terminal regions of epidermal growth factor (EGF) and transforming growth factor-alpha bind to different epitopes on the human EGF receptor. The Biochemical journal 336 (Pt 1), 147 (Nov. 15, 1998).
- 116. N. I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, J. Mendelsohn, Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clinical cancer research: an official journal of the American Association for
Cancer Research 1, 1311 (November, 1995). - 117. F. Szoka, Jr., D. Papahadjopoulos, Comparative properties and methods of preparation of lipid vesicles (liposomes). Annual review of biophysics and
bioengineering 9, 467 (1980). - 118. G. R. Bartlett, Phosphorus assay in column chromatography. The Journal of biological chemistry 234, 466 (March, 1959).
- 119. D. D. Lasic, P. M. Frederik, M. C. Stuart, Y. Barenholz, T. J. McIntosh, Gelation of liposome interior. A novel method for drug encapsulation. FEBS letters 312, 255 (Nov. 9, 1992).
- 120. G. Haran, R. Cohen, L. K. Bar, Y. Barenholz, Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochimica et biophysica acta 1151, 201 (Sep. 19, 1993).
- 121. E. Bohl Kullberg, N. Bergstrand, J. Carlsson, K. Edwards, M. Johnsson, S. Sjoberg, L. Gedda, Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents. Bioconjugate chemistry 13, 737 (July-August, 2002).
- 122. D. A. Marsh, CRC Handbook of Lipid Bilayers. CRC Press, Boca Raton, FL., 163 (1990).
- 123. K. Subik, J. F. Lee, L. Baxter, T. Strzepek, D. Costello, P. Crowley, L. Xing, M. C. Hung, T. Bonfiglio, D. G. Hicks, P. Tang, The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast cancer: basic and
clinical research 4, 35 (2010). - 124. G. D. Lewis, I. Figari, B. Fendly, W. L. Wong, P. Carter, C. Gorman, H. M. Shepard, Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer immunology, immunotherapy: CII 37, 255 (September, 1993).
- 125. C. C. Benz, G. K. Scott, J. C. Sarup, R. M. Johnson, D. Tripathy, E. Coronado, H. M. Shepard, C. K. Osborne, Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast cancer research and treatment 24, 85 (1992).
- 126. J. Filmus, M. N. Pollak, R. Cailleau, R. N. Buick, MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochemical and biophysical research communications 128, 898 (Apr. 30, 1985).
- 127. J. Filmus, J. M. Trent, M. N. Pollak, R. N. Buick, Epidermal growth factor receptor gene-amplified MDA-468 breast cancer cell line and its nonamplified variants. Molecular and
cellular biology 7, 251 (January, 1987). - 128. S. Yang, M. A. Raymond-Stintz, W. Ying, J. Zhang, D. S. Lidke, S. L. Steinberg, L. Williams, J. M. Oliver, B. S. Wilson, Mapping ErbB receptors on breast cancer cell membranes during signal transduction. Journal of cell science 120, 2763 (Aug. 15, 2007).
- 129. D. L. Costantini, K. Bateman, K. McLarty, K. A. Vallis, R. M. Reilly, Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 49, 1498 (September, 2008).
- 130. P. Nagy, A. Jenei, A. K. Kirsch, J. Szollosi, S. Damjanovich, T. M. Jovin, Activation-dependent clustering of the erbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy. Journal of cell science 112 (Pt 11), 1733 (June, 1999).
- 131. R. Kaufmann, P. Muller, G. Hildenbrand, M. Hausmann, C. Cremer, Analysis of Her2/neu membrane protein clusters in different types of breast cancer cells using localization microscopy. Journal of microscopy 242, 46 (April, 2011).
- 132. B. J. Woodcroft, L. Hammond, J. L. Stow, N. A. Hamilton, Automated organelle-based colocalization in whole-cell imaging. Cytometry. Part A: the journal of the International Society for Analytical Cytology 75, 941 (November, 2009).
- 133. D. A. Lauffenburger, J. J. Linderman, Receptors Models for Binding, Trafficking, and Signaling. (Oxford University Press, New York, New York, 1993), pp. 365.
- 134. A. S. Perelson, Receptor Clustering on a Cell Surface. I. Theory of Receptor Cross-linking by Ligands Rearing Two Chemically Identical Functional Groups. Mathematical Biosciences 48, 71 (1980).
- 135. A. S. Perelson, Receptor clustering on a cell surface. III. Theory of receptor cross-linking by multivalent ligands: description by ligand states. Mathematical Biosciences 53, 1 (1981).
- 136. A. S. Perelson, Receptor Clustering on a Cell Surface. II. Theory of Receptor Cross-linking by Ligands Bearing Two Chemically Distinct Functional Groups. Mathematical Biosciences 49, 87 (1980).
- 137. C. M. Waters, K. C. Oberg, G. Carpenter, K. A. Overholser, Rate constants for binding, dissociation, and internalization of EGF: effect of receptor occupancy and ligand concentration. Biochemistry 29, 3563 (Apr. 10, 1990).
- 138. C. Wofsy, B. Goldstein, K. Lund, H. S. Wiley, Implications of epidermal growth factor (EGF) induced egf receptor aggregation. Biophysical journal 63, 98 (July, 1992).
- 139. A. Gandolfi, M. A. Giovenco, Reversible binding of multivalent antigen in the control of B lymphocyte activation. Journal of theoretical biology 74, 513 (Oct. 21, 1978).
- 140. C. DeLisi, The biophysics of ligand-receptor interactions. Quarterly reviews of biophysics 13, 201 (May, 1980).
- 141. B. S. Hendriks, L. K. Opresko, H. S. Wiley, D. Lauffenburger, Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels. The Journal of biological chemistry 278, 23343 (Jun. 27, 2003).
- 142. T. C. Werner, J. R. Bunting, R. E. Cathou, The shape of immunoglobulin G molecules in solution. Proceedings of the National Academy of Sciences of the United States of America 69, 795 (April, 1972).
- 143. R. E. Cathou, D. A. Holowka, Evolution of conformational flexibility of immunoglobulin M. Advances in experimental medicine and biology 64, 207 (1975).
- The foregoing written specification and the claims that follow are considered to be sufficient to enable one skilled in the art to practice the embodiments. The foregoing description and Examples detail certain embodiments and describes the best mode contemplated by the inventors. It will be appreciated, however, that no matter how detailed the foregoing may appear in text, the embodiment may be practiced in many ways and should be construed in accordance with the appended claims and any equivalents thereof.
Claims (20)
1.-34. (canceled)
35. A ligand-drug particle comprising a lipid surface layer, at least one drug in the interior of the particle or embedded in the lipid surface layer, and a ligand specific for a cell surface receptor on a target cell, wherein:
a. the ligand is exposed on the lipid surface layer;
b. the ligand binds to its receptor with an in vitro binding affinity of 0.001 to 1000 nM;
c. the target cell that the particle targets comprises an average number of receptors per cell ranging from 105 to 107 receptors per cell; and
d. the particle has a ligand valency that depends upon the ligand-receptor in vitro binding affinity and the average number of receptors per target cell, wherein the ligand valency is as follows:
i. a valency of 6-10 where the target cell has an average number of receptors per cell on the order of 3×106 receptors per cell;
ii. a valency of 10-16 where the target cell has an average number of receptors per cell on the order of 1×106 receptors per cell;
iii. a valency of 10-20 where the target cell has an average number of receptors per cell on the order of 9×105 receptors per cell;
iv. a valency of 11-21 where the target cell has an average number of receptors per cell on the order of 8×105 receptors per cell;
v. a valency of 12-23 where the target cell has an average number of receptors per cell on the order of 7×105 receptors per cell;
vi. a valency of 13-25 where the target cell has an average number of receptors per cell on the order of 6×105 receptors per cell;
vii. a valency of 15-29 where the target cell has an average number of receptors per cell on the order of 5×105 receptors per cell;
viii. a valency of 18-36 where the target cell has an average number of receptors per cell on the order of 4×105 receptors per cell;
ix. a valency of 15-36 where the target cell has an average number of receptors per cell on the order of 4×105 to 5×105 receptors per cell;
x. a valency of 13-29 where the target cell has an average number of receptors per cell on the order of 5×105 to 6×105 receptors per cell;
xi. a valency of 12-25 where the target cell has an average number of receptors per cell on the order of 6×105 to 7×105 receptors per cell;
xii. a valency of 11-23 where the target cell has an average number of receptors per cell on the order of 7×105 to 8×105 receptors per cell;
xiii. a valency of 10-21 where the target cell has an average number of receptors per cell on the order of 8×105 to 9×105 receptors per cell;
xiv. a valency of 10-16 or 18-20 where the target cell has an average number of receptors per cell on the order of 9×105 to 1×106 receptors per cell; or
xv. a valency of 6-10, 12-16, or 19 where the target cell has an average number of
receptors per cell on the order of 1×106 to 3×106 receptors per cell, and wherein the drug is a macromolecular therapeutic molecule.
36. The ligand-drug particle according to claim 35 , wherein the ligand-receptor in vitro binding affinity is 0.1 to 10 nM and the particle has a ligand valency as follows:
a. a valency of 8-10 where the target cell has an average number of receptors per cell on the order of 3×106 receptors per cell;
b. a valency of 13-16 where the target cell has an average number of receptors per cell on the order of 9×105 to 1×106 receptors per cell;
c. a valency of 14-18 where the target cell has an average number of receptors per cell on the order of 8×105 receptors per cell;
d. a valency of 15-19 where the target cell has an average number of receptors per cell on the order of 7×105 receptors per cell;
e. a valency of 17-21 where the target cell has an average number of receptors per cell on the order of 6×105 receptors per cell;
f. a valency of 19-24 where the target cell has an average number of receptors per cell on the order of 5×105 receptors per cell; or
g. a valency of 24-30 where the target cell has an average number of receptors per cell on the order of 4×105 receptors per cell.
37. The ligand-drug particle according to claim 35 , wherein the ligand-receptor in vitro binding affinity is 0.001 to 0.1 nM and the particle has a ligand valency as follows:
a. a valency of 15-24 where the target cell has an average number of receptors per cell on the order of 4×105 to 5×105 receptors per cell;
b. a valency of 13-19 where the target cell has an average number of receptors per cell on the order of 5×105 to 6×105 receptors per cell;
c. a valency of 12-17 where the target cell has an average number of receptors per cell on the order of 6×105 to 7×105 receptors per cell;
d. a valency of 11-15 where the target cell has an average number of receptors per cell on the order of 7×105 to 8×105 receptors per cell;
e. a valency of 10-14 where the target cell has an average number of receptors per cell on the order of 8×105 to 9×105 receptors per cell;
f. a valency of 10-13 where the target cell has an average number of receptors per cell on the order of 9×105 to 1×106 receptors per cell; or
g. a valency of 6-13 where the target cell has an average number of receptors per cell on the order of 1×106 to 3×106 receptors per cell.
38. The ligand-drug particle according to claim 35 , wherein the ligand-receptor in vitro binding affinity is 0.1 to 10 nM and the particle has a ligand valency as follows:
a. a valency of 19-30 where the target cell has an average number of receptors per cell on the order of 4×105 to 5×105 receptors per cell;
b. a valency of 17-24 where the target cell has an average number of receptors per cell on the order of 5×105 to 6×105 receptors per cell;
c. a valency of 15-21 where the target cell has an average number of receptors per cell on the order of 6×105 to 7×105 receptors per cell;
d. a valency of 14-19 where the target cell has an average number of receptors per cell on the order of 7×105 to 8×105 receptors per cell;
e. a valency of 13-18 where the target cell has an average number of receptors per cell on the order of 8×105 to 9×105 receptors per cell;
f. a valency of 13-16 where the target cell has an average number of receptors per cell on the order of 9×105 to 1×106 receptors per cell; or
g. a valency of 8-16 where the target cell has an average number of receptors per cell on the order of 1×106 to 3×106 receptors per cell.
39. The ligand-drug particle according to claim 35 , wherein the ligand-receptor in vitro binding affinity is 10 to 1000 nM and the particle has a ligand valency as follows:
a. a valency of 24-36 where the target cell has an average number of receptors per cell on the order of 4×105 to 5×105 receptors per cell;
b. a valency of 21-29 where the target cell has an average number of receptors per cell on the order of 5×105 to 6×105 receptors per cell;
c. a valency of 19-25 where the target cell has an average number of receptors per cell on the order of 6×105 to 7×105 receptors per cell;
d. a valency of 18-23 where the target cell has an average number of receptors per cell on the order of 7×105 to 8×105 receptors per cell;
e. a valency of 16-21 where the target cell has an average number of receptors per cell on the order of 8×105 to 9×105 receptors per cell;
f. a valency of 16 or 18-20 where the target cell has an average number of receptors per cell on the order of 9×105 to 1×106 receptors per cell; or
g. a valency of 10, 12-16, or 18-19 where the target cell has an average on the order of 1×106 to 3×106 receptors per cell.
40. The ligand-drug particle according to claim 35 , wherein the ligand is an antibody, an antigen binding fragment of an antibody, or an Fv, scFv, Fab′, or F(ab′)2 fragment.
41. The ligand-drug particle according to claim 35 , wherein the lipid surface layer is a lipid bilayer or a lipid monolayer.
42. The ligand-drug particle according to claim 35 , wherein the particle further comprises a coating comprising polyethylene glycol (PEG).
43. The ligand-drug particle of claim 35 , wherein the particle is 70-120 nm, 80-110 nm, 90-110 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, or 120 nm in diameter.
44. The ligand-drug particle of claim 35 , wherein the drug comprises a hydrophobic, hydrophilic, cationic, and/or anionic interaction with the lipid layer or aqueous compartment.
45. The ligand-drug particle of claim 35 , wherein the drug is a protein or nucleic acid molecule.
46. A ligand-drug particle comprising a lipid surface layer, at least one drug in the interior of the particle or embedded in the lipid surface layer, wherein the drug is a macromolecular therapeutic molecule, a first ligand specific for a first cell surface receptor on a target cell, and a second ligand specific for a second cell surface receptor on the target cell, wherein:
a. the first and second ligands are exposed on the lipid surface layer;
b. the first and second ligands bind to their respective first and second receptors with in vitro binding affinity of 0.1 to 100 nM;
c. the target cell that the particle targets comprises (i) an average number of the first receptor per target cell ranging from 103 to 107 and (ii) an average number of the second receptor per target cell ranging from 103 to 107; and
d. the particle has a ligand valency that depends on the in vitro binding affinity for each of the first receptor and the second receptor and their respective ligands, the average number of the first receptor per target cell, the average number of the second receptor per target cell, and whether ligand-receptor binding is additive or synergistic; wherein the ligand valency for each of the first and second ligands is as follows:
i. a valency of 13-17 where each of the first and the second receptors is highly expressed by the target cell, and where binding of the first and the second receptors by the first and the second ligands, respectively, is additive;
ii. a valency of 9-13 where each of the first and the second receptors is highly expressed by the target cell, and where binding of the first and the second receptors by the first and the second ligands, respectively, is synergistic;
iii. a valency of 13-17 where one receptor of the first and the second receptors is highly expressed by the target cell and the other receptor of the first and the second receptors is moderately expressed by the target cell, and where binding of the first and the second receptors by the first and the second ligands, respectively, is additive;
iv. a valency of 7-10 where one receptor of the first and the second receptors is highly expressed by the target cell and the other receptor of the first and the second receptors is moderately expressed by the target cell, and where binding of the first and the second receptors by the first and the second ligands, respectively, is synergistic;
v. a valency of 15-21 where each receptor of the first and the second receptors is moderately expressed by the target cell, and where binding of the first and the second receptors by the first and the second ligands, respectively, is additive; or
vi. a valency of 11-15 where each receptor of the first and the second receptors is moderately expressed by the target cell, and where binding of the first and the second receptors by the first and the second ligands, respectively, is synergistic.
47. The ligand-drug particle according to claim 46 , wherein the particle has a ligand valency for each of the first and second ligands as follows:
a. a valency of 17-21 where the in vitro binding affinity for each of the first and the second receptors and their respective ligands is on the order of 100 nM, and binding is additive;
b. a valency of 16-20 where the in vitro binding affinity for one of the first and the second receptors and their respective ligands is on the order of 100 nM, the in vitro binding affinity for another of the first and the second receptors and their respective ligands is on the order of 10 nM, and binding is additive;
c. a valency of 16-19 where the in vitro binding affinity for one of the first and the second receptors and their respective ligands is on the order of 100 nM, the in vitro binding affinity for another of the first and the second receptors and their respective ligands is on the order of 1 nM, and binding is additive;
d. a valency of 15-19 where the in vitro binding affinity for one of the first and the second receptors and their respective ligands is on the order of 100 nM, the in vitro binding affinity for another of the first and the second receptors and their respective ligands is on the order of 0.1 nM, and binding is additive;
e. a valency of 16-19 where the in vitro binding affinity for each of the first and the second receptors and their respective ligands is on the order of 10 nM, and binding is additive;
f. a valency of 15-18 where the in vitro binding affinity for one of the first and the second receptors and their respective ligands is on the order of 10 nM, the in vitro binding affinity for another of the first and the second receptors and their respective ligands is on the order of 1 nM, and binding is additive;
g. a valency of 14-17 where the in vitro binding affinity for one of the first and the second receptors and their respective ligands is on the order of 10 nM, the in vitro binding affinity for another of the first and the second receptors and their respective ligands is on the order of 0.1 nM, and binding is additive;
h. a valency of 14-17 where the in vitro binding affinity for each of the first and the second receptors and their respective ligands is on the order of 1 nM, and binding is additive;
i. a valency of 13-16 where the in vitro binding affinity for one of the first and the second receptors and their respective ligands on the order of 1 nM, the in vitro binding affinity for another of the first and the second receptors and their respective ligands is on the order of 0.1 nM, and binding is additive;
j. a valency of 13-15 where the in vitro binding affinity for each of the first and the second receptors and their respective ligands is on the order of 0.1 nM, and binding is additive;
k. a valency of 10-15 where the in vitro binding affinity for each of the first and the second receptors and their respective ligands is on the order of 100 nM, and binding is synergistic;
l. a valency of 10-15 where the in vitro binding affinity for one of the first and the second receptors and their respective ligands is on the order of 100 nM, the in vitro binding affinity for another of the first and the second receptors and their respective ligands is on the order of 10 nM, and binding is synergistic;
m. a valency of 10-15 where the in vitro binding affinity for one of the first and the second receptors and their respective ligands is on the order of 100 nM, the in vitro binding affinity for another of the first and the second receptors and their respective ligands is on the order of 1 nM, and binding is synergistic;
n. a valency of 10-15 where the in vitro binding affinity for one of the first and the second receptors and their respective ligands is on the order of 100 nM, the in vitro binding affinity for another of the first and the second receptors and their respective ligands is on the order of 0.1 nM, and binding is synergistic;
o. a valency of 9-13 where the in vitro binding affinity for each of the first and the second receptors and their respective ligands is on the order of 10 nM, and binding is synergistic;
p. a valency of 9-13 where the in vitro binding affinity for one of the first and the second receptors and their respective ligands is on the order of 10 nM, the in vitro binding affinity for another of the first and the second receptors and their respective ligands is on the order of 1 nM, and binding is synergistic;
q. a valency of 9-13 where the in vitro binding affinity for one of the first and the second receptors and their respective ligands is on the order of 10 nM, the in vitro binding affinity for another of the first and the second receptors and their respective ligands is on the order of 0.1 nM, and binding is synergistic;
r. a valency of 8-12 where the in vitro binding affinity for each of the first and the second receptors and their respective ligands is on the order of 1 nM, and binding is synergistic;
s. a valency of 8-12 where the in vitro binding affinity for one of the first and the second receptors and their respective ligands is on the order of 1 nM, the in vitro binding affinity for another of the first and the second receptors and their respective ligands is on the order of 0.1 nM, and binding is synergistic; or
t. a valency of 7-11 where the in vitro binding affinity for each of the first and the second receptors and their respective ligands is on the order of 0.1 nM, and binding is synergistic.
48. The ligand-drug particle according to claim 46 , wherein at least one of the first and second ligands is an antibody, an antigen binding fragment of an antibody, an Fv fragment, a scFv fragment, an Fab′ fragment, or F(ab′)2 fragment, or wherein both ligands are antibodies, antigen binding fragments of antibodies, Fv fragments, scFv fragments, Fab′ fragments, or F(ab′)2 fragments.
49. The ligand-drug particle according to claim 46 , wherein the lipid surface layer is a lipid bilayer or a lipid monolayer.
50. The ligand-drug particle according to claim 46 , wherein the particle further comprises a coating comprising polyethylene glycol (PEG).
51. The ligand-drug particle of claim 46 , wherein the particle is 70-120 nm, 80-110 nm, 90-110 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, or 120 nm in diameter.
52. The ligand-drug particle according to claim 46 , wherein the drug comprises a hydrophobic, hydrophilic, cationic, and/or anionic interaction with the lipid layer or aqueous compartment.
53. A system for determining ligand valency for a ligand-drug particle, wherein the particle comprises a lipid surface layer, at least one drug in the interior of the particle or embedded in the lipid surface layer, and a ligand specific for a receptor on a target cell, the ligand exposed on the lipid surface layer, the system comprising software capable of determining ligand valency from in vitro ligand-receptor dissociation constant and average number of receptors per target cell according to a crosslink multivalent binding model.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/172,843 US20230310628A1 (en) | 2017-04-28 | 2023-02-22 | Multi-Targeted Multi-Valent Ligand Drug Particles for the Treatment and Prevention of Diseases and Conditions |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762492085P | 2017-04-28 | 2017-04-28 | |
PCT/US2018/029790 WO2018200951A1 (en) | 2017-04-28 | 2018-04-27 | Multi-targeted multi-valent ligand-drug particles for the treatment and prevention of diseases and conditions |
US201916607711A | 2019-10-23 | 2019-10-23 | |
US18/172,843 US20230310628A1 (en) | 2017-04-28 | 2023-02-22 | Multi-Targeted Multi-Valent Ligand Drug Particles for the Treatment and Prevention of Diseases and Conditions |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/607,711 Continuation US11617797B2 (en) | 2017-04-28 | 2018-04-27 | Multi-targeted multi-valent ligand drug particles for the treatment and prevention of diseases and conditions |
PCT/US2018/029790 Continuation WO2018200951A1 (en) | 2017-04-28 | 2018-04-27 | Multi-targeted multi-valent ligand-drug particles for the treatment and prevention of diseases and conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230310628A1 true US20230310628A1 (en) | 2023-10-05 |
Family
ID=63918787
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/607,711 Active 2039-05-08 US11617797B2 (en) | 2017-04-28 | 2018-04-27 | Multi-targeted multi-valent ligand drug particles for the treatment and prevention of diseases and conditions |
US18/172,843 Abandoned US20230310628A1 (en) | 2017-04-28 | 2023-02-22 | Multi-Targeted Multi-Valent Ligand Drug Particles for the Treatment and Prevention of Diseases and Conditions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/607,711 Active 2039-05-08 US11617797B2 (en) | 2017-04-28 | 2018-04-27 | Multi-targeted multi-valent ligand drug particles for the treatment and prevention of diseases and conditions |
Country Status (2)
Country | Link |
---|---|
US (2) | US11617797B2 (en) |
WO (1) | WO2018200951A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220096382A1 (en) * | 2019-01-07 | 2022-03-31 | Ucl Business Ltd | Polymersomes functionalised with multiple ligands |
EP3986481A2 (en) * | 2019-06-20 | 2022-04-27 | Takeda Pharmaceutical Company Limited | Method of treatment with viral-based gene therapy |
US20210299272A1 (en) * | 2020-03-31 | 2021-09-30 | The Trustees Of The University Of Pennsylvania | Methods and compositions for drug delivery |
CN112763714B (en) * | 2020-12-31 | 2022-07-01 | 徐州市中心医院 | Biomarker for liver cancer diagnosis and detection method thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004512258A (en) * | 2000-03-21 | 2004-04-22 | ウィスコンシン アルムニ リサーチ ファンデイション | Methods and reagents for modulating cellular responses in biological systems |
US6676963B1 (en) * | 2000-10-27 | 2004-01-13 | Barnes-Jewish Hospital | Ligand-targeted emulsions carrying bioactive agents |
US6696243B2 (en) | 2001-01-23 | 2004-02-24 | Coulter International Corp. | Method for the analysis of soluble analytes |
NZ574093A (en) * | 2006-06-12 | 2011-03-31 | Symphogen As | Pan-cell surface receptor- specific therapeutics |
US8980908B2 (en) | 2009-01-16 | 2015-03-17 | Virginia Commonwealth University | Non-peptidyl, potent, and selective mu opioid receptor antagonists and their use in treating opioid addiction and opioid induced constipation |
-
2018
- 2018-04-27 US US16/607,711 patent/US11617797B2/en active Active
- 2018-04-27 WO PCT/US2018/029790 patent/WO2018200951A1/en active Application Filing
-
2023
- 2023-02-22 US US18/172,843 patent/US20230310628A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20200306384A1 (en) | 2020-10-01 |
WO2018200951A1 (en) | 2018-11-01 |
US11617797B2 (en) | 2023-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230310628A1 (en) | Multi-Targeted Multi-Valent Ligand Drug Particles for the Treatment and Prevention of Diseases and Conditions | |
US20240033376A1 (en) | Systems and methods for nucleic acid expression in vivo | |
US20240075101A1 (en) | Combination therapies for treating cancer | |
US20190290585A1 (en) | Ev-mediated delivery of binding protein-small molecule conjugates | |
US20180360881A1 (en) | Compositions and Methods for Treatment of Her2 Positive Metastatic Breast Cancer | |
TWI677506B (en) | Bi-specific antibodies and use thereof | |
EP3483180A1 (en) | Multi specific molecules | |
EP3416691A1 (en) | Nucleic acid carriers and therapeutic methods of use | |
AU2019253681A1 (en) | Combination of near infrared photoimmunotherapy targeting cancer cells and host-immune activation | |
US20220363779A1 (en) | Combination therapies for treating cancer | |
Chen et al. | Bispecific antibody (HER2× mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes | |
JPWO2003009870A1 (en) | Breast cancer treatment | |
US20240018211A1 (en) | Exosome comprising overexpressed fc receptor or portion thereof, and method for preparing same | |
WO2010103118A1 (en) | Chemotherapeutic composition for the treatment of cancer | |
WO2006030602A1 (en) | Diagnostic and/or remedy for ovary cancer | |
US20240052012A1 (en) | Platelet alpha-granules for delivery of multiple proteins | |
WO2024040195A1 (en) | Conditioning for in vivo immune cell engineering | |
WO2023223307A1 (en) | Multifunctional delivery system and uses thereof | |
CA3148394A1 (en) | Platelet-facilitated delivery of therapeutic compounds | |
Tran | Receptor-Mediated Uptake and Intracellular Sorting of Multivalent Lipid Nanoparticles against the Epidermal Growth Factor Receptor (EGFR) and the Human EGFR 2 (HER2) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |